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In the last decade the immunological studies in diabetes have
substantially modified some of the basic aspects of diabetology and
specifically the classification of the disease itself.
The aim of the thesis is to investigate further some of the
immune phenomena present in diabetes focussing attention on the
immunological factors in the pathogenesis of type I diabetes, the
immunological consequences of insulin treatment,the immunological
phenomena in diabetic vascular complications and the
physiopathological immune correlations between diabetic women and
their neonates.
The immune phenomena investigated include organ specific auto¬
antibodies (among others islet cell antibodies),insulin antibodies,
insulin-anti-insulin complexes,T cells subsets and activated T cells.
Furthermore, circulating specific islet cell antigens were sought by
an immunological approach.A wide range of monoclonal antibodies
against islet cell antigens and T cell surface antigens have been
used.In most of the techniques used,there have been personal technical
modifications or developments.
The studies on the pathogenesis of type I diabetes were performed
on a large group of insulin dependent diabetics at diagnosis and at
regular intervals thereafter and in an uncommon and interesting group
of diabetics with islet cell antibodies but not requiring insulin at
diagnosis. Islet cell antibodies, and complement-fixing islet cell
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antibodies, appear to be important markers in monitoring the islet
cell damage, in detecting patients with other subclinical autoimmune
disorders and in finding those diabetics, initially not requiring
insulin, rapidly developing an insulin failure.Immune complexes have
been found in circulation in newly diagnosed type I diabetic patients.
In addition to the antibodies to islet cell and the immune complexes,
some islet cell antigens also seem to be in circulation in type I
diabetics, as determined by a new technical approach involving anti-
islet monoclonal antibodies.
Studies on the consequences of insulin treatment were performed
in type I diabetic patients within the first year of the insulin
treatment and in long standing diabetics.They have shown that
conventional heterologous insulin treatment has immunological conse¬
quences as determined by insulin antibodies, insulin-anti-insulin
complexes and antigen non specific immune complexes and that human
insulin is the least immunogenic of the currently available insulins.
The investigation on diabetic vascular complications has shown
the presence of circulating immune complexes in patients with severe
microangiopathy. The correlation has been demonstrated between this
increase and an impairment of macroaggregate clearance by macrophages.
A potentially important finding was the correlation between the
increased levels of immune complexes and/or insulin-anti-insulin
complexes and abnormalities of platelet specific proteins in diabetics
with proliferative retinopathy. An inverse correlation was found
between the presence of complexes and the levels of the T lymphocytes
with the T8 phenotype.
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The findings of the studies on the immunology of diabetic pre¬
gnancy have suggested a role for insulin antibodies and immune com¬
plexes in some maternal and neonatal clinical complications. Insulin-
anti-insulin complexes were first described in the cord blood of
neonates with characteristics different from those found in the
diabetic mothers at the end of pregnancy. An interesting finding in
pregnant diabetics was a higher increase in mononuclear cells ex¬
pressing the 4F2 antigen than in those expressing MHC class II an¬
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Al.l EARLY STUDIES ON IMMUNITY IN DIABETES
Immunology developed from the study of resistance factors to
infections.lt has recently been proved that these defence mechanisms,
instead of serving as a protection against disease, may give rise to
serious disorders.From this fact,wide overlaps between immunology and
other disciplines have become apparent.The influence of hormones or
metabolic conditions on the immune system and of immune factors on
the endocrine system in a healthy or diseased condition has received
a great deal of attention.
Much of this attention has centered on diabetes.
Immunopathological phenomena have been described in various
situations connected with diabetes.Treatment with heterologous
insulin induces immune responses with potentially dangerous consequ¬
ences (Page Faulk et al 1971;Jayarao et al 1974). Immunological
changes are believed to play some role in late complications (Berns
et al, 1962;Ortved-Andersen 1976).In the pregnant diabetic(insulin
antibodies crossing the placenta may have untoward effects on the
fetus (Fallucca et al;1980) .On the other hand,metabolic disturbances
can seriously impair the immune defence mechanisms,facilitating
aggression by exogenous agents (Bagdade et al,1974).
Over the past ten years attention has been focused on the
immunological events involved in the early stages of type I diabetes.
Epidemiological studies have shown that this type of diabetes is
associated with organ-specific autoimmunity (Irvine 1974; Irvine et
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al,1970). A round-cell infiltration of pancreatic islets has been
described in some juvenile diabetics who died shortly after the onset
of diabetes (Gepts 1965) . A modification of cell-mediated immunity
has been found in several juvenile onset diabetics using different
methodological approaches (Nerup et al 1971;Nerup et al 1974;MacCuish
et al 1975).Circulating antibodies directed towards islet antigen
determinants have been revealed both in diabetics with other
autoimmune endocrine disorders (Bottazzo et al 1974;MacCuish et al
1974) and in most insulin dependent diabetics in the early stages of
the disease (Lendrum et al 1975;Irvine et al 1977).
While evidence has been accumulating on the presence of several
concomitant immunological changes close to the clinical onset of
insulin dependent diabetes,other clinical and experimental work
indicates both that some genetically determined disturbances of
immune responses exist in this type of diabetes and that evironmental
agents are often involved in the immunological alterations
observed.The study of the mutual influence of genetic,environmental
and immunological factors has become the key to an understanding of
the mechanisms leading to this disease.
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A1.2 CLASSIFICATION OF DIABETES: A REAPPRAISAL
In order to group patients for clinical and research purposes.it
is of paramount importance to try to subdivide this syndrome ac¬
cording to some features which,with the present state of our know¬
ledge, seem highly relevant.In the past, differences were between
forms of diabetes secondary to other well-known disorders.mainly
endocrinopathies, and forms that have no clear correlation with other
diseases and,for this reason,are called primary or idiopathic diabe¬
tes.Within the latter forms of diabetes there are clinical diffe¬
rences in the onset and evolution of the disease that have been more
clearly assessed.More recently,studies on the families of diabetic
patients, studies on identical twins,the evaluation of autoimmune
phenomena, particularly of antibodies against islet cell cytoplasm,
the study of cell-mediated immunity,and genetic findings have clearly
separated at least two substantially different forms within primary
diabetes.In the past,these two forms were divided,principally,
according to the age at onset of disease, the limit of division being
arbitrarily around 25-30 years.The criterion of the age at onset,
however,is not now considered satisfactory.In the last few years
different classifications of diabetes have been reported (Bottazzo &
Doniach,1976;Cudworth & Woodrow,1976;Irvine, 1977;Cudworth,1978). A
major problem at present is that no classification is satisfactory to
both the clinician and the researcher.In 1979,the National Diabetes
Data Group, together with the main associations for the study of
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diabetes, developed a new classification of the disease (National
Diabetes Data Group,1979). Their aim was to give diabetologists a
uniform framework in which to conduct clinical and epidemiological
research or follow therapeutic guidelines.This classification divides
primary diabetes according to insulin dependence.Nevertheless,the
sole criterion of insulin dependence may be misleading because there
are many non-insulin-dependent subjects that are treated with insulin
for various reasons. Furthermore.among the non-insulin-dependent
diabetic patients, there is a small group which,within a few months
or years of diagnosis, develops a clear insulin dependence.To
overcome these and other limits the National Diabetes Data Group
proposed a parallel classification for research purposes.The main
criteria of this classification are the detection of islet cell
antibodies (ICA),an association with organ- specific autoimmune
disorders,HLA typing and the mode of inheritance (Table Al.2/1).But
this classification also has many theoretical and practical limits:
the most important of which being that only a few diabetic clinics
are able to perform genetic and immunological studies.In addition,
these classifications reflect the state of knowledge on diabetes in
Europe and North America.The possibility exists that among other
populations the characteristics of these types of diabetes may be
somehow different, or that certain ethnic groups may have peculiar
forms of diabetes. In any event, irrespective of the criteria chosen
to subdivide the diabetic syndrome,there is a proportion of patients
that do not fit neatly into any group.
TABLEAl.2/1
Provisionalre earchsubclassificationType1dia t s (NationalDiabetesatGr up1979,modified) Diabetesmellitus Associationw thorgan specificautoimmune diseaseorautoimmune phenomenaPresenceofisl tc ll antibodies(inrelation toonsetfinsulin dependency)
Othercharacteristics thatofferpromisef beingusedtosub- classifydiabetes
Insulin-dependent type(IDDM) Subclassa Subclassb bueta99<-
Positive Negative Negative
Usuallypersistent Usuallytransient Undetected
Possibleviralaetiology prevalenceofHLAtyp s (elevatedorreduced lativetohegen ral population),suchasSubclass DR2,DR3,DR4,B8,B15 etc.;antibodyrespo se toex genousinsulin
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A1.3 FACTORS INVOLVED IN THE PATHOGENESIS OF TYPE I DIABETES
Considering the complexity of the problem, the discussion on the
aetiology and the pathogenesis of diabetes remains quite speculative
and attention should be especially focused on those aspects in which
convincing findings have been reported.
Indirect and direct evidence of the presence of immunopatholog¬
ical phenomena in diabetes has been accumulated.An association
between diabetes (primarily of the juvenile-onset type) and other
diseases of autoimmune etiology has been described (Perlman,1961;
Solomon et al,1965;Irvine, 1974;Nerup,1974). Moreover, the presence
of some organ-specific humoral antibodies has been observed in
insulin-dependent diabetes mellitus (IDDM)(Landing et al,1963;
Blizzard et a'l, 1967; Irvine et al, 1970;Goldstein et al,1970) as have
alterations of cell-mediated immunity (MacCuish and Irvine,1975;
MacCuish et al, 1974;Nerup et al,1974),and antibodies to pancreatic
islet cells (Bottazzo et al,1974;Irvine et al,1977). The latter are
also found in diabetics with other autoimmune disorders (Lendrum et
al,1975; MacCuish et al,1974).More recently a series of abnormalities
has been noted in the early stages of IDDM,including an increase in
circulating immune complexes (Irvine et al,1978),the presence of
antibodies to surface antigens of pancreatic islets (Lernmark et
al,1978),an increased number of killer cells (Pozzilli et al,1979)
and circulating la-positive T cells (Rowley and Eisenbarth,1982).On
the other hand,suppressor T lymphocytes have been found to be
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depressed (Buschard et al,1980;Galluzzo et al,1980). Type I diabetes,
defined according to recently stated criteria (National Diabetes Data
Group,1979),is heterogeneous, and may include adult females with a
general trait towards autoimmunity, with characteristics very
different from those found in young subjects with an acute severe
onset of the disease (Table Al.3/1).
Three factors are at present known to be involved in the pa¬
thogenesis of type I diabetes:genetic susceptibility.environmental
agents and immunological factors.



























A1.3a The genetic factor
The main data on genetic factors involved in type 1 diabetes
derive from studies on the Human Leucocyte Antigens (HLA) of the
major histo-compatibility system and from epidemiological research
conducted using different approaches: population,family and twin
studies (Nerup et al,1974;Wolf et al,1983;Srikanta et al,1983).
The histocompatibility system genes located in the short arm of
the sixth chromosome have been shown to be of paramount importance in
a few disorders, including diabetes.In the same chromosomal area are
the genes that control many aspects of the immune response, including
the cell-mediated immune response and part of the antibody
production. The HLA system is the most polymorphic system described
in man with the genes at each locus encoding a different cell surface
antigen. However, between HLA-A-B-C and-D there is a marked linkage
disequilibrium,i.e..certain antigens tend to occur together more
frequently than expected from their individual frequencies.The HLA
genes present on one chromosome constitute the HLA haplotype and each
individual inherits two alleles for each locus, one from the father
and one from the mother.
* Population studies
Population studies have demonstrated that a number of histo¬
compatibility antigens are more frequently found in insulin-dependent
diabetics than in the normal population.Others.however,are rarer
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(Nerup et al,1974;Morris et al, 1976). DR3 and DR4, both in linkage
disequilibrium with other antigens on A,B and C loci, are more
frequently present.DR2,however, seems to have no association with
diabetes.The presence of DR3 or DR4, therefore means an increased
risk of developing type 1 diabetes and the simultaneous presence of
both of these confers an additive risk.Conversely,DR2 seems somehow
to afford protection against diabetes.lt is now clear,however,that
the strongest associations with the disease lie with the DR antigens,
HLA DR3 (Sachs et al, 1980;Deschamps et al,1980) and HLA DR4
(Deschamps et al,1980). Current evidence suggests that the findings
reported originally regarding the HLA-A and HLA-B series antigens are
secondary to those findings regarding the HLA DR series. In other
words, the association of HLA-A,-B and -C antigens with diabetes
comes about because of linkage disequilibrium with DR3 and DR4. Thus,
HLA B8,B18,and Al are in linkage disequilibrium with DR3 while HLA A2
and B15 are in linkage disequilibrium with DR4.Similarly, the appar¬
ent decrease in frequency of HLA B7 is due to the decrease of DR2
(Singal & Blajchman, 1973; Nerup et al,1974; Thomsen et al,1975;
Morris et al,1976;Cudworth & Woodrow,1976). Direct evidence of
heterogeneity within Type 1 diabetic patients comes from genetic
studies showing that DR3 and DR4 seem to confer additive risk of type
I diabetes. In Caucasians,the relative risk to heterozygote DR3/DR4
patients is considerably increased when compared with DR3/X and DR4/X
patients even when they are homozygotes (Nerup et al,1980;Sachs et
al,1980;Deschamps et al,1980).
Indirect evidence of differences between DR3 and DR4 diabetic
patients derives from other studies (Table A1.3/2).In some cases,DR3
diabetic patients tend to have a persistent presence of ICA and
TABLEAl.3/2





Relativeriskfor diabetes Linkage disequilibrium Insulinantibodies Isletc ll Antipancreaticcell Ageofns t Seasonalv riation LevelsofC-peptide ResidualB-cell Canpresenta TypeIIdiabetes
-Additive-
B8.A1 Non/Lowresponder (lowantibody levels) Persistent Increased Anyage No High Yes
B15,Cw3 Highresponder (producehighanti¬ bodylevels) Transient Notincreased Youngage Yes Low No
t relativeisk,excess ofpatients
f occurrenceinconcordant MZtwins trisktosibling f occurrencein familialcases Youngest Lowest
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occurrences of other subclinical or overt organ-specific autoimmune
diseases.They also tend to form low titres of insulin antibodies
following insulin treatment.The risk of diabetes is increased in all
age groups and in DR3 diabetic patients autoimmune mechanisms appear
to be relevant in the pathogenesis. On the other hand,DR4 patients
tend to have an increased production of antibodies to viruses and to
heterologous insulin but there is no tendency towards autoimmunity.
DR4- positive subjects seem to have an increased risk of developing
the disease before the age of 16 (Ludwig et al, 1976;Irvine et al,
1978a; Irvine et al,1978b; Bottazzo et al,1978;Nerup et al,1980;
Cudworth,1981).The decrease in frequency of DR2 antigens in diabetics
may be secondary to the increases in DR3 and DR4 (Sachs et al,1980)
or subjects may be protected against type 1 diabetes possibly because
their immune system can cope with adverse factors in the environment.
These data were obtained from population studies of Caucasian
people. Different human races show substantial differences in the HLA
system. Of relevance is also the fact that data presently available
demonstrate different characteristics and prevalences of ketosis-
prone diabetes in many African and Asian populations (Wakisaka et
al,1976). Properdin (complement factor B;Bf) polymorphism has
received considerable attention in recent years.Raum et al(1979)
suggested that the BfFl allele was in strong linkage disequilibrium
with a specific susceptibility gene associated with a disease of
younger age at onset. BfFl is a good example of racial differences in
distribution of alleles occurring relatively commonly in Southern
Europeans, as a component of the DR3-B18-Cw5-Aw30 or A25 haplotype
(Deschamps et al,1979;De Mouzon et al,1979).
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Combining the findings in two large studies in the British
Isles, Wolf et al(1982) found that 21 out of 22 patients studied with
the B18 haplotype possessed BfFl in association with Cw5.All were DR3
positive.They were unable to confirm a younger age of onset. DR3-
negative subjects were not associated with BfFl but were associated
with BfF or BfS.They concluded that the increase in frequency of the
rare BfFl allele occurred almost exclusively in haplotypes possessing
B18 and Cw5 in linkage disequilibrium with DR3.They concluded that
the rare BfFl allele was increased in frequency and this occurred
almost exclusively in haplotypes possessing B18 and Cw5 in linkage
disequilibrium with DR3.
* Family studies
Family studies have shown that in siblings of type I diabetics
there is a statistically significant association between the sharing
of an identical haplotype and the developement of type I diabetes
(Nerup et al,1977;Cudworth,1980). Moreover,siblings of type I and
type II diabetics tend to show the same type of diabetes as the
propositi. This would support the existence of HLA-linked
predisposing genes (Cudworth & Woodrow, 1976;Nerup et al,1977;Barbosa
et al,1977; Cudworth,1981;Deschamps et al,1980).On the other hand,
studies on type II diabetics have shown no association with HLA.Thus,




Twin studies have confirmed a genetic susceptibility in type I
diabetes but have shown that the importance given to the genetic
factor alone in the development of the disease has perhaps been
overstressed (Barnett et al,1981). In fact,in identical twins the
concordance is near to 100% when the age at onset is above 45 years
(Pyke,Nelson,1978) while the concordance is around 50% when the age
at onset is less than 45 years.
HLA studies in twins have shown that HLA B8 was increased only
in the concordant pairs while HLA B15 was equally increased in the
concordant and in the discordant pairs.This finding reinforces the
possibility of the presence of two different diabetogenic genes in
linkage disequilibrium with HLA B8 and B15 respectively (Nelson et
al, 1975; Cudworth,1981).
* Discussion
The risk of developing diabetes conferred by DR3 and DR4 seems
to be related to the peculiar immunoresponsiveness found in these
individuals.HLA-DR genes seem to be in linkage disequilibrium with
other genes which regulate some immune responses (more generally
termed Ir genes) and are present on the same chromosome.DR3 patients
tend to show a pathological immune response towards autoantigens,
while DR4 seems associated with an abnormal immune response to some
exogenous agents (Bertrmas et al,1976;Irvine et al,1978).Thus,it
seems that at least two HLA-linked diabetogenic genes,acting through
27
different mechanisms,may be inherited.The presence of these genes
does not seem sufficient for the development of diabetes in
individual patients. Other superimposed acquired factors must also be
present.
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A1.3b The environmental factor
Clinical observations have shown that diabetes may appear
shortly after a viral infection or after the ingestion of chemical
products (Gundersen,1927;Craighead,1978;Cahill and McDevitt,1981). A
variety of environmental events are thought to play a role in
triggering the onset of type I diabetes.At present, the harmful agent
has been found and described only in a few situations.
* Viruses
Viruses appear to be the most likely agents to be involved in
the development of many cases of diabetes.There is mounting evidence
of their role in the aetiology of the disease but definite proof is
lacking.Circumstantial evidence for the role of viruses has come from
two distinct investigative processes. Interest in viral infections
was aroused many years ago by the clinical observations in Scandin¬
avian communities that a number of patients had suffered from a
mumps infection some weeks or months before the clinical onset of
diabetes (Gundersen,1927).
Epidemiological studies have shown that the onset of diabetes is
more common in the cold months (Cudworth et al,1977;MacMillan et
al,1977;Gamble 1977),coinciding with the peak incidence of some viral
infections. Interestingly,this seasonal phenomenon is remarkably
constant from year to year and it might also be concluded that in
view of the epidemic nature of viral infections a single virus is
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unlikely to be the sole pathogen.Studies have also shown an increased
frequency and has elevated titres of antibodies to Coxsackie B4 virus
in some type 1 diabetic patients at diagnosis (Gamble et al,
1969;Cudworth et al,1977;El Hagrassy et al,1980). Of interest is the
incidence of diabetes in patients with congenital rubella
infection,which Menser et al(1978) observed to be 20%.
Studies on animals have shown that a diabetic-like disease can
be produced in some mice by the M variant of the encephalomyocarditis
(EMC) virus (Craighead,1981), while reovirus (Onodera et al,1978),
Venezualan equine encephelitis virus (Rayfield et al,1979)and Group B
coxsackie viruses (Yoon et al,1978) all produce a diabetic-like
disease in rodents.lt is relevant that only a few strains of mice
develop hyperglycaemia after viral infections whereas other strains
seem to be resistant.This finding stresses the role of a genetically
determined abnormal immunoresponsiveness. The two lines of evidence
come together when considering the histology of the islet of exper¬
imental diabetes in animals and of autopsy specimens in man. In mice
infected with the encephalomyocarditis virus, insulitis occurs with a
macrophage and lymphocyte infiltration (Craighead,1977), and in
animals infected with reovirus, virus particles can be identified in
the B cells (Onodera et al,1978). These findings are similar to those
found in autopsy material from patients with type I diabetes (Gepts &
De May,1978;Gepts & LeCompte, 1981).
Following their obervation of an association between diabetes
mellitus and congenital rubella infection, Menser et al,1978
reported that experimental congenital rubella infection in rabbits
produced histological changes in the B cells similar to those prod¬
uced by the M variant of the encephalomyocarditis virus. Yoon et
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al(1979) linked the clinical and experimental findings in a patient
who died from a viraemia associated with acute diabetes mellitus.
They observed that homogenates of the patient's pancreas added to
mouse, monkey,or human cell culture allowed recovery of the virus.
Evidence that this was not a laboratory contaminant lay in the
finding of an increase in titre of neutralising antibody in the
patient before death. Furthermore, inoculation of mice resulted in
hyperglycaemia and histology of the mouse islets showed B cell
necrosis with an inflammatory cell infiltrate.The virus was iden¬
tified as being similar to Coxsackie B4.
* Chemicals
Chemicals may be responsible for diabetes (Craighead,1978).A
satisfactory assessment of their role is very difficult because of
the extremely•high number of substances potentially involved.In a few
cases,a clear cause/effect relationship of chemical and disease has
made identification of the substance possible (Notkins,1979).
The mechanism through which chemicals may lead to islet cell
damage is obscure.Of interest is the observation that repeated sub-
diabetogenic injections of streptozotocin in some strains of mice
produced hyperglycaemia and diabetes,and,surprisingly,an insulitis




More intriguing are the mechanisms via which environmental
agents may lead to islet destruction.lt is likely that a wide range
of combinations exist.Severe viral infections or a high dose of a
chemical agent may result in direct damage of the islets, but this
seems unusual.On the other hand,viruses may interact with the host
defence mechanisms in several ways.A prolonged virus infection may
induce the production of antibodies to the islets through a mechanism
of cross reactivity or by a direct modification of cytoplasmic or
surface antigens; a modification of T cell subsets with a failure in
the regulation of the host immune response may also be a consequence.
Alternatively,the persistent antigenic stimulation may induce an
abnormal proliferation of B lymphocytes and production of a wide
range of organ-specific autoantibodies directed not only towards
islets but also towards other cells (Onodera et al,1983). For
chemicals the mechanisms were thought to be different but it is
noteworthy that,after repeated subdiabetogenic injections of
streptozotocin in mice,there was a mononuclear cell infiltration of
pancreatic islets simultaneous with insulin deficiency (Appel et
al,1978).
In any case environmental agents seem to produce diabetes only
in individuals with a genetically abnormal immune response; further¬
more, in most cases these agents seem only to trigger the immune
mechanisms ultimately responsible for islet damage.
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Al. 3c The immune factor
From basic immunology it is known that cells can be damaged in
different ways by immune mechanisms(Eisen,1982;Roitt,1980). In other
words,cytotoxic antibodies, immune complexes and cell mediated
immunity are the main tissue damaging factors.The possible invol¬
vement of these mechanisms in the early stages of type I diabetes is
here discussed.
* Cell damaging antibodies
Circulating antibodies may lead to a tissue lesion in a number
of different ways. They may lead to phagocytosis by opsonization or
by immune adherence, they may activate the complement system and lyse
the cell or they may arm K cells and so predispose the target to be
killed.There is no evidence that these mechanisms are actually
operating in diabetes but,in any case,different kinds of antibodies
are present in diabetes (Charles et al,1983).
Islet cell antibodies (ICA) have been found so far in several
conditions (Irvine,1980;Bottazzo et al,1981;Brogren & Lernmark,1982).
They tend to decline soon after diagnosis in type la patients. ICA
have also been found in a few non-insulin-dependent diabetics,in
patients with other autoimmune disorders but without diabetes, in
subjects with an impaired glucose tolerance test, in gestational
diabetics, in first degree relatives of type I diabetics and in a few
normals (Irvine,1980).There is a significant association between ICA
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and thyrogastric antibodies.This associaton is much stronger in ICA
persistently positive subjects (Irvine,1980).The role of ICA in the
pathogenesis of type I diabetes is still not clear;nor is the
significance of their presence in non diabetic subjects. There is no
clear evidence,so far,of a cell destructive effect of the antibodies
in diabetes mellitus (Madsbad et al,1980). ICA,crossing the placenta
from a diabetic mother to the fetus (Gamlen et al,1977),do not cause
diabetes in the newborn. The fact that these antibodies react with
all cell types present in the islet does not support a direct
role for ICA on Beta cells. No significant difference was found
between ICA positive and negative diabetics in plasma glucagon and
insulin responses to an intravenous arginine infusion (Rubenstein et
al,1980; Tiengo et al,1977). So far,the presence of ICA in diabetics
is considered a valuable marker in separating type I from type II
diabetics,selecting diabetics with subclinical autoimmune disorders
when the antibodies persist for years and in selecting from NIDD
those with the tendency to progress to insulin dependency.In fact,in
these patients the presence of ICA has been shown to be a good
indicator of the probability of becoming insulin dependent (Irvine et
al,1977;Irvine et al,1979). In subjects without diabetes mellitus,ICA
are important in the selection of those apparently normal subjects at
risk of developing diabetes. In these cases,the presence of ICA
precedes the impairment of glucose tolerance (IGT)(Gorsuch et
al,1981; Gorsuch et al, 1982).In gestational diabetes (GDM),ICA
increase the probability of developing overt diabetes in the fol¬
lowing years (Bottazzo et al,1980;Steel et al,1980).
It is not clear whether complement fixing islet cell antibodies
(CF ICA) are a separate group of ICA or simply one immunoglobulin G
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(IgG) subclass that avidly fixes complement (Bottazzo et al,1980;
Bottazzo et al,1981). CF ICA seem to be present shortly before the
clinical onset of the disease and rapidly disappear thereafter.CF ICA
positivity is lower than that of ICA and almost all the CF ICA
positive diabetics are also ICA positive (Chapter B1.3). CF ICA seem
to be a good marker for an early clinical onset of diabetes in
subjects at risk of developing the disease (Sai et al,1981;Bottazzo
et al,1981).
A more interesting pathogenic significance seems to be held by
antibodies reacting with the surface of islet cells (ICSA)(Lernmark
et al,1978;Baekkeskov et al,1982). They are present in about two
thirds of newly diagnosed type I diabetics and their presence
declines thereafter (Lernmark et al,1981; Pujol-Borell et
al,1982).There is a significant,but not very strong, correlation
between the presence of ICA and that of ICSA in the same patients.lt
is still not clear whether ICSA react with all the cells in the islet
or only with beta cells.ICSA have been found in some normals
and,interestingly enough, also in subjects who developed overt
diabetes after the ingestion of chemicals (Karam et al,1980). ICSA
were found to be able to impair the function of islets in a
perifusion system. It is of relevance that ICSA positive sera showed
a complement dependent cytotoxic effect in cultures of dispersed rat
islet cells; this effect was not found with ICA positive ICSA ne¬
gative diabetic sera (Dobersen et al,1980).
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* Immune complexes
Other possible tissue damaging mechanisms acting in diabetes
involve circulating immune complexes (AgAb).Immune complexes may
produce a tissue lesion through different mechanisms.They may in¬
teract with platelets.inducing a platelet aggregation,they may
activate the complement system,leading to inflammation and they can
interact with cells bearing complement(C) or Fc receptors.This
phenomenon is very interesting because of the numerous effects of
this interaction: the activity of the C-or-Fc bearing cells may be
modulated in different ways and,in extreme conditions,may be either
blocked or armed with a potential cytotoxicity.The formation and the
properties of AgAb also differ substantially for a given antigen and
antibody.The Ag/Ab ratio, the size of complexes,the lattice formation
and the rate of formation disappearance deeply influence the patho¬
genetic potential of complexes.Increased levels of immune complexes
have been found in newly diagnosed diabetics(using the solid phase
Clq binding test, the Conglutinin radioimmunoassay and the Raji
cell-binding assay)( Chapters B1.2.B1.3). The levels of immune
complexes tend to decline soon after diagnosis,and within a few
months of the onset of disease to reach levels not significantly
different from those of normals. Whether AgAb are really involved in
islet cell damage in type I diabetes is not clear.The most in¬
teresting aspect is the study of all the possible interactions
between AgAb and cells bearing receptors for the Fc of immuno¬
globulins or for C3 and,in particular,the possible modulation of T




A major role for this type of immune response in the early
stages of IDDM has been suggested by pancreatic histopathological
findings.A round-cell infiltration of the hyperactive islet is well
in accordance with the possibility of cellular immune defence against
a viral infection (Gepts,1965;Gepts,1980;LeCompte & Legge,1972). When
it was confirmed that these cells were small lymphocytes mostly
directed towards beta cells and that plasma cells were not present,
these concepts were reinforced. Cell-mediated immunity comprises
immune mechanisms in which the specific recognition of the antigen is
due to receptors on T lymphocytes.At present T cells are divided into
regulators and effectors and there are two substantially different
forms of effector T cells: those mediating delayed type hypersen¬
sitivity (DHT) and those that lyse target cells bearing the stimul¬
ating alloantigen (CTL). Cytotoxic properties are also retained by
cells with Fc- surface receptors other than B and T lymphocytes. The
activity of part of these cells is dependent on the presence of
specific antibodies and immune complexes, the so called antibody
dependent cellular cytotoxicity (ADCC).
Cell-mediated immunity has been investigated in different ways
(Buschard et al,1980;Selam et al,1979;Sensi & Pozzilli,1979;Orita et
all980;Buschard et al,1980;Boitard et al,1980).
The measurement of total T cells and the study of their
functional capacity have received attention in many research works.
When metabolic control is taken into account,there seems to be no
substantial difference between the T cell number in diabetics and
controls nor was the PHA stimulation of diabetic lymphocytes
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significantly abnormal when the patients were studied in good
metabolic control. A positive lymphocyte migration inhibition was
found in several newly diagnosed insulin dependent diabetics when a
bovine, porcine and human pancreatic antigen was used(lrvine et
al,1976). Lymphocytes from type I diabetics were found to be toxic to
cultured human insulinoma cells (Huang & MacLaren,1976).
More recently,new sophisticated techniques of identification,
isolation and functional characterization of T-cell subsets have
become available.T cells spontaneously form rosettes with ery¬
throcytes and the measurement of this phenomenon under high affinity
or low affinity experimental conditions has been developed. It is
accepted that the low affinity E-rosette-forming cells have receptors
for the Fc portion of immunoglobulin G and are capable of mediating
the antibody dependent cellular cytotoxicity (West et al,1977).In a
recent study,about half of the IDD studied at diagnosis had raised
levels of these cells.This increase was no longer found at a distance
from diagnosis of more than 1 year (Pozzilli et al,1980;Sensi et al,
1981). At present,the availability of monoclonal antibodies against
antigens present in the lymphocytes has given further impulse to
understanding the modification of the cell-mediated immune response.
It is also rather interesting that an increased number of activated
T cells were found,using monoclonal antibodies against antigens




The most obvious question is still unresolved: are these
immunopathological mechanisms the cause of type 1 diabetes?
It is possible to say that a genetic, an enviromental and an
immunological factor are interacting in a wide spectrum of ways to
produce the islet cell damage. In one extreme,the genetic susceptibi¬
lity to organ specific autoimmunity leading to islet cell damage
through immune mechanisms is probably different from those operating
when a genetic predisposition modifies the immune defence mechanisms
towards an aggression by exogenous agents, such as viruses or che¬
micals. In another extreme,an overwhelming viral infection or a che¬
mical toxic to the pancreas may lead directly to islet destruction.
The possible immune mechanisms operating in the beta cell destruction
may involve cytotoxic T lymphocyte, killer cells armed by either
specific antibodies or immune complexes in antibody excess and
cytotoxic antibodies (Figure Al. 3/1). The intervention of these
effector immune cells and the increase of these cytotoxic antibodies
are probably secondary to a primary modification of the T regulator
cells. In genetically susceptible individuals the environmental agent
may act in a wide variety of ways, slowly modifying the host self
antigens and interfering with helper/suppressor regulatory mechanisms
or derepressing B cell clones towards self antigens. Certainly we are
far from full elucidation of the pathogenesis of type I diabetes; the
mounting evidence from recent research at least suggests we are on
the right lines.
FICURE Al.3/1
Possible immune mechanisms involved in the beta cell destruction
in type 1 diabetes
• = Antigen
Y = Antibody


















A1.4 IMMUNOLOGICAL CONSEQUENCES OF INSULIN TREATMENT
Although insulin has been known to have antigenic properties for
60 years (Joslin et al,1922;Tuft,1928,Lewis,1937), only in the
sixties did the immunological aspects of insulin treatment receive
the attention that it deserved (Federlin,1971).
It is known at present that the spatial configuration and the
presence of contaminants are mostly responsible for the
immunogenicity of commercial insulins. Insulin antibody formation is
genetically influenced and the presence of insulin antibodies and of
insulin-anti-insulin complexes are responsible for several clinical
manifestations of immunological reactions, such as localized and
diffuse allergy, insulin resistance, lipodystrophy, anaphylactic




The main cause of insulin antigenicity is the species hetero¬
geneity (Maloney & Coval,1955;Berson and Yalow,1959;Lockwood &
Prout,1965; Renold et al,1966; Page Faulk et al,1971). Both bovine
and porcine insulins, the most commonly used in therapy,are
immunogenic but bovine insulin seems to produce more antibodies then
porcine insulin. When a patient is switched from treatment with
bovine,or a mixture,of bovine-porcine insulin to porcine insulin
(Andreani et al, 1972) a reduction in insulin antibody levels is
usually observed. Bovine insulin,purified by sequential
recrystallization,is more immunogenic than the equivalent form of
porcine insulin (Kurtz and Nabarro, 1980;Reeves,1980;Reeves and
Kelly,1982).This difference is likely due to the fact that bovine
insulin presents three aminoacids different from the human
molecule,namely,those in position 8 and 10 in the A chain and in
position 30 in the B chain, whereas porcine insulin has only the
amminoacid in position 30 in the B chain different from human
insulin. Thus,generally speaking,insulin antibody levels seem related
to the number of different aminoacids in the therapeutic insulin
molecule.
The spatial configuration of the molecule also accounts for the
antigenicity of heterologous insulin.The disulphuric bridges, the
disposition of C-terminal aminoacids and the spatial configuration of
insulin are important in establishing immunogenic determinants
(Lockwood and Prout, 1965;Levin, 1969;Arquilla et al,1976; Keck, 1975;-
Berson and Yalow,1961). But there are, in fact differences in insulin
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antibody binding between porcine and whale insulins with identical
aminoacid sequences (Levin,1969).
Pancreatic contaminants, such as a-component,b-component,
glucagon, somatostatin,pancreatic and proinsulin may be important, in
addition to insulin itself,in evoking an immune response against
therapeutic insulin preparations (Schlichtkrull,1974;Schlichtkrull et
al,1972;Bruni et al,1978;Kawazu et al,1979;Fizpatrick & Patel, 1981;
Bloom et al,1979; Kurtz et al,1980; Kurtz et al,1983).
Physico-chemical factors are another cause of insulin antige¬
nicity.The pH of insulin, the polymerization of the molecule,
molecular changes such as arginine insulin,ethylester of insulin,
monodesamino-insulin the presence of Zn,etc. may be responsibile for
the immunogenicity even when human insulins are used (Neubauer &
Scone,1978;Deckert et al,1972;llangen et al,1981;Wilson et al, 1962).
Some of these factors induce changes in structure when insulin is
already injected in tissues so that,even if the original preparations
of insulin are almost pure, these physico-chemical changes may
enhance an immune response (Hangen et al,1981;Wilson et al,1962;
Deckert et al,1972;Renold et al,1964). The two aminoacidic chains
have different immunogenic properties. The A chain appears to be more
immunogenic than the B chain. (Wilson et al,1962;Berson and Yalow,
1963;Kumar,1979; Lockwood and Prout,1965). A few experimental studies
have shown that, provided the A chain is not modified, the B-chain
modifications of insulin do not substantially change the antigenicity
but may modify its linkage with antibodies of different affinity
(Federlin,1971;Wilson,1969;Faulk et al,1974; Kerp and Kasemir,1976).
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A1.4b Insulin antibody formation
In the last two decades particular attention has been focused on
insulin antigenicity mainly to obtain less antigenic insulin
preparations and thus to avoid some inconveniences which are related
to antibody formation in insulin treated diabetics.
Though a weak immunogen, insulin is able to elicit antibody
formation both in the experimental animal and in humans treated with
heterologous insulin (Berson et al,1956; Berson,1958; Root et al,
1972; Kumar et al,1975; Dixon et al,1975; Arquilla et al,1976; Baxter
et al,1976; Davidson & Debra,1976; Gerbitz & Kenner,1978; Kurtz et
al,1978; Kurtz et al,1979; Kurtz & Nabarro,1980; Ramila et al,1981;
Arquilla et al,1981; Karlsson et al,1982).
Insulin antibody levels, easily detectable with common methods,
are reached within a few weeks. In diabetics submitted to insulin
treatment the level of antibodies increases progressively up to a
year,thereafter it remains substantially the same at least as long as
antigen is administered.Environmental conditions,i.e. infectious
diseases, however, may interfere with antibody production and cause a
sharp increase in circulating antibody. All the classes of anti¬
bodies, with known different properties, have been detected during
insulin treatment and the affinity to antigen varies within the same
class (Kerp and Kasimir,197b;Kumar, 1977) but the most clinically
relevant are IgE and IgG antibodies (Berson and Yalow,1959).
In a few conditions insulin antibodies have been found in
circulation irrespective of the injection of heterologous or exo¬
genous insulin. Insulin antibodies have been found in newly diagnosed
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insulin dependent diabetics before insulin treatment (Palmer et
al,1982).If this finding is confirmed the presence of these antibo¬
dies may be explained as an autoimmune reaction towards partially
modified insulin released by the damaged beta cells.Insulin anti¬
bodies were also found spontaneously present in a few diabetics with
the so-called "insulin-auto-immune syndrome" (Kembo and Hirata,1974;
Kawazu et al,1975).
There is evidence that insulin antibody formation is under
genetic control in animals (Arquilla et al,1969;Barcinski &
Rosenthal,1977;Keck,1977;Rosenwasser et al,1979; Scoer et al,1979;
Spaeth et al,1981). Several research contributions have shown that in
humans there is also a correlation between certain HLA types and the
levels of insulin antibodies (Chapter B2.2b)(Bertrams et al,1976;
Keck,1977; Schernthaner et al,1979; Kapp & Bucy,1981; Zeidler et
al,1982; Schernthaner et al,1983). The genetic data indicate an
association between low antibody responses and HLA-B8-DR3 as well as
an association between B15- DR4.DR7 and high antibody responses.lt
seems that the Gm genes regulating the IgG-allotype determinants also
have a remarkable influence on the immune response to insulin
(Robbins and Kapp,1980; Nakao et al,1981).
Insulin antibodies usually found in circulation are an hetero¬
geneous family of antibodies,some with a high affinity to insulin but
the majority with a low affinity to the antigen.
The presence of insulin-anti-insulin complexes is expected in
insulin treated diabetics with circulating insulin antibodies. In
effect, these complexes comprised of insulin have been described in
many diabetics (Jayarao et al,1974).
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The insulin-anti-insulin complexes are usually of small size and
they do not precipitate.lt is doubful whether insulin-anti- insulin
complexes near the equivalence point may fix complement. These
complexes are usually of small size.In antigen excess they show the
structure Ag^Ab and their molecular weight is roughly about 165.000
dalton (Kerp et al,1976;Folling,1976).At present there is no truly
reliable and highly sensitive method to detect them.
Highly purified or human insulins have greatly reduced the
production of insulin antibodies, as discussed in other parts of the
work (Andreani et al,1972; Andreani,1973; Andreani 1974; Andreani et
al,1974; Yue & Turtle,1977; Andreani et al,1977; Weber et
al,1978;Wright et al,1979).
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A1.4c Clinical consequences of
insulin immunogenicity
Therapheutic insulin and insulin antibodies may be responsible
for many clinical and pathological effects (Karr et al,1931; Leslie,
1977). The main ones are allergic reactions,lipodystrophy,insulin
resistance, reduction of bioavailability of insulin,prolonged insulin
action and apparently there are effects on the clinical complications
of infants of diabetic mothers and on the development of
microangiopathy.
Insulin allergy is mainly caused by multiple factors,among which
IgE, IgG antibodies and the activity of T lymphocytes are in-Din
volved. It seems also to be influenced by genetic factors (Bertrams &
Grunekle,1977). Furthermore, many studies have reported that diabetic
subjects affected by insulin allergy present elevated levels of
circulating IgG-IAb and that after desensitization and treatment with
highly purified insulin there is a decrease both in the allergy and
the IgG-IAb levels (Andreani et al,1974;Teutscher,1975;Bruni et
al,1975; Kawanishi et al,1977; Lunetta,1982). Even highly purified
insulins may occasionally induce insulin allergy (Goldman et al,1976;
Andreani et al,1977; Bachmann et al,1979; Carini et al,1982). In
these cases a previous transitory insulin therapy with conventional
insulin is usually reported.
A possible role for IgG-IAb in lipoatrophy (Teutscher,1974) and
in lipohypertrophy (Andreani et al,1974) was suggested in 1974 and
subsequent research has confirmed that lipoatrophy may be reduced or
eliminated by purified insulins (Teutscher,1975;Hulst, 1976;Poulsen
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and Deckert, 1977) .However, it should be pointed out that in a few
subjects purified insulins may also induce lipoatrophy. Recently,
Reeves et al.(1980) confirmed elevated levels of IgG-IAb in insulin-
treated diabetic patients with lipoatrophy and made relevant findings
to support the immune pathogenesis of lipoatrophy.
The presence of antibodies is responsible for some specific
metabolic conditions (Gonen et al,1979; Gray et al,1981; Vaughan et
al,1983). Since the insulin activity is dependent upon the free form
of the hormone, one of the effects of the antibodies binding circu¬
lating insulin is the delay in its action and in some circumstances
antibodies may even hinder the activity of insulin so that a resis¬
tance to the hormonal action derives.This resistance very rarely is
absolute but may reach a high degree.From time to time occasional
cases occur in which enormous amounts of insulin are needed to
overcome resistance.
Another condition which has been studied more recently and in
which insulin antibodies may play an important role,is pregnancy in
insulin treated diabetic women. In effect, maternal antibodies cross
the placenta, while insulin does not.Insulin antibodies in fetal
cord blood are of the same level as in the mother's blood (Spellancy
& Goetz,1963; Exon et al,1974; Kalhan et al,1975). Elevated insulin
antibody levels have been correlated with newborn hypoglycaemia
(Nagawa et al,1973). Indeed increased insulin and/or C peptide levels
have been reported in the circulation of infants of diabetic mothers
having high levels of circulating insulin antibodies (Sosenko et
al,1979; Fallucca et al,1980).
Since insulin antibodies were first described there have been
numerous investigations on the possible influence of prolonged
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heterologous insulin treatment on the course of diabetic microang¬
iopathy.This question is still unresolved.So far there have been
conflicting indications from studies that have correlated the amount
of insulin antibodies with the severity of microangiopathy (Page
Faulk et al,1971;Andersen,1976).These mainly negative results are
somehow expected.If insulin treatment has any influence on the course
of complications through immune mechanisms, the study of free
antibodies to insulin is not the best way to investigate this
problem. These aspects will be discussed in details in chapter A1.5.
In the early seventies highly purified insulins were introduced
in therapy (Andreani et al, 1973; Peacock et al, 1983) and in the early
eighties human insulins were made available. Whereas highly purified
and monospecies insulins have been proven to be of great utility in
the treatment of allergic reactions,of lipodystrophy and other side
effects, there is no evidence so far that purified insulins can
substantially modify the course of microangiopathy. It must be said
however that .there are single cases which do not respond favourably
to the purified insulin. In these cases it is presumed that the newly
introduced human insulin may be useful. The newly prepared human
insulins, both those developed by DNA recombinant technique and by
semisynthesis, seem to have an immunogenicity similar or may be lower
than that of purified porcine insulins.No significant difference has
been observed in the insulin dose and in the biological effects on
glucose metabolism at least after 6 months of follow up when patients
previously treated with porcine monocomponent insulins were shifted
to human insulins (Andreani et al,1984; Iavicoli et al,1983).
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A1.5 IMMUNOLOGICAL ASPECTS OF DIABETIC MICROANGIOPATHY
A1.5a Pathogenetic Mechanisms of
Diabetic Microvascular Disease
Most aspects of the pathogenesis of diabetic microvascular
disease remain unknown despite the great deal of research work in
this area. Nevertheless,some factors or mechanisms responsible for
the development of vascular damage have already been described. They
can be divided into functional, biochemical, morphological and
immunological changes.
* Functional changes of small
blood vessels
Modifications of haemodynamics
Intermittent vasodilatation of venules and capillaries,both in
the retina and in the conjunctiva,are among the earliest changes in
the microcirculation of diabetic patients (Ditzel,1980;Ditzel et al,
1960).This is problably due to hypoxia, increased blood flow and
increased blood viscosity.
Increased blood flow has been demonstrated by many studies,
mainly in insulin-dependent diabetic patients. It is present in the
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retinal circulation (Kohner,1976), in the kidney even at the onset of
diabetes (Mogensen,1971) and in other tissues (Gundersen,1974).This
increased blood flow is present in patients with a poor metabolic
control and may be a consequence of a decrease in vascular resist¬
ance. In fact,several studies indicate an altered reactivity of
vessels to vasoactive substances which can lead to decreased vascular
resistance,which in turn may lead to an increased blood flow (Sieker
et al,1955; Rhie et al,1982; Szentivanyi et al,1973; Cseuz et al,
1973; Sullivan et al,1979; Brody et al,1964; Ditzel et al,1972;
Hostetter et al, 1981; Kreisberg 1982).Furthermore, the production of
vasoactive hormones, and in particular of prostacyclin, is altered in
diabetes (Christlieb,1976; Schernthaner et al,1981; Harrison et
al,1981) .
The increased blood viscosity may be a consequence of abnor¬
malities of red blood cells (Ditzel 1980; Mc Millan et al,1981),
plasma proteins (Mc Millan 1975),platelets (Colwell et al,1981) etc.
Modification of permeability
The permeability changes are rather complicated. In diabetics an
increased permeation of small blood vessels by albumin has been
described (Williamson et al,1981).apparently as a consequence of an
increased blood flow. On the other hand, inflammatory agents do not
induce a substantially higher increase of albumin permeation in
experimental diabetic animals in comparison with normal animals
(Garcia-Leme et al,1974;Llorach et al,1976).perhaps because of the
impaired vascular response to vasoactive substances found in
diabetes. Furthermore,a change in electrical charge is found in
diabetics and this can contribute to the loss of albumin in the first
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stages of nephropathy while structural changes with the appearance of
large pores may explain the massive proteinuria in the advanced
stages (Myers et al,1982; Cohen et al,1977).
* Biochemical changes
/
Some biochemical modifications are relevant in the deployment of
immunological phenomena (Spiro,1976; Kijlstra et al,1978).
Biochemical studies of the permeability of the glomerular
capillary wall have pointed out the importance of the positively or
negatively fixed charged sites in the GBM in binding or trapping
other penetrating macromolecules (Bohrer et al,1978; Brownlee &
Spiro,1979; Gallo et al,1981). This permselectivity of the glomerular
barrier is impaired in diabetic microangiopathy with a loss of
glomerular electrostatic charge, a loss of ability to discriminate
between macr'omolecules and with an increase in their transglomerular
passage. The loss of glomerular fixed negative charges leads to an
enhanced mesangial accumulation of circulating aggregates, a reduced
affinity for cationic stains, a reduced restriction to filtration of
circulating polyanions, a fusion of foot processes and eventually to
an enhanced mesangial matrix production and albuminuria (Carrie and
Myers 1980). Thus, among macromolecules, a few types of immune
complexes, some of them potentially tissue destructive, may be more
easily trapped or bound in the diabetic capillary walls (Barcelli et
al,1981;Meade et al, 1981; Melato et al,1982). The fact that most of
the glomerular electrostatic charges that are lost are negative seems
to be due to a decrease in the basement membrane of sialic acid
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residues and of glycosaminoglycans, that are negatively charged. In
fact,a decrease in both sialic acid residues (Westberg et al,1973;
Kefalides,1974; Canivet et al, 1979) and in glycosaminoglycans in
diabetic kidney tissues (Farquhar,1981; Williamson et al,1983;
Parthasarathy et al,1982) has been reported.
Apart from the changes in electrostatic charges other important
biochemical modifications have been observed in diabetes.The main
finding has been an increase in type IV collagen in the basemement
membranes in the glomerulus,as a result of both an increased syn¬
thesis and a decreased degradation (Cohen et al,1982;Brownlee et
al,1981). What is still not known is the reason for these abnor¬
malities. In order to explain the increased synthesis of type IV
collagen,it has been suggested that insulin deficiency,by causing an
increased utilization of the alternate metabolic pathways of glucose,
such as the polyol pathway, may mainly damage those cells which do
not require insulin for the uptake of glucose and so are directly in¬
fluenced by glucose levels (Williamson et al,1981; Gabbay,1975).
Another possible explanation links together biochemical and fun¬
ctional changes of diabetic microangiopathy.The increases in blood
flow and glomerular filtration rate may lead to an intravascular
hyperpressure,thus accelerating the blood vessel damage (Hostetter et
al, 1981; Williamson et al,1977). In order to explain the reduced
degradation of type IV collagen,the theory of increased glycosylation
of proteins has been invoked. The increased glycosylation of collagen
may indeed decrease its proteolysis,leading to an increased ac¬
cumulation in the basement membrane (Uitto et al,1982).This increase
in circulation is mainly due to non-enzymatic mechanisms.
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* Morphological changes
The main morphological modifications of blood vessels in dia¬
betes are the retinal microaneurysms, the degeneration of pericytes,
the segmental loss of endothelial lining cells, the capillary base¬
ment membrane thickening and the accumulation of proteins in the
vascular basement membranes. Even if none of these changes is patho¬
gnomonic of diabetic microangiopathy,their contemporary presence is
found only in diabetes. Very little is known about the causes of
retinal microaneurysms, of pericyte degeneration,and of seemingly
associated segmental loss of endothelial lining cells (Cogan et
al,1961; Kuwabara et al,1963; Tilton et al,1981).However.numerous
researchers have investigated the capillary basement membrane
thickening. Research on diabetic twins has shown an increase in width
of the basement membrane in the gastrocnemius but not in the qua¬
driceps muscle (Ganda et al 1983). This is obscure and differences in
membrane width in the two muscles may be explained by differences in
intravascular pressure. The blood pressure in the small vessels seems
to be an important element (Gay et al,1966; Berkman et al,1973;
Williamson et al, 1977; Mauer et al,1978).
The accumulation of proteins, including immune factors, is of
great relevance in diabetic microangiopathy (Mauer et al,1976; Mauer
et al,1978; Cohn et al,1978; Steffes et al,1978; Jeraj et al, 1983).
The presence of albumin among these proteins and their increased
accumulation after unilateral nephrectomy or in the presence of
hypertension, suggest that their presence is a result of an increased
filtration of proteins with a consequent higher binding or trapping
in the basement membrane. Nevertheless, the presence of some of these
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proteins and,in particular,of the immunological proteins and macromo-
lecules in the basement membrane may he harmful and contribute to the
small blood vessel wall damage.
* Immunological changes
These aspects are extensively discussed in A1.5b.
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A1.5b Immunological aspects of
microangiopathy
* Evidence for non-metabolic
factors
The causes and the sequence of events of the lesions in small
blood vessels in diabetics are still a matter of controversy. At
present, it is widely accepted that metabolic abnormalities play a
major role in inducing and accelerating the microangiopathic changes
(Cudworth et al,1982). Nevertheless, there are many aspects of the
pathogenesis of microangiopathy that cannot be explained only by
metabolic derangements.
The occurrence and the progression of diabetic microangiopathy
presents a wide individual variability.
- Microangiopathy may occur rather soon after the clinical on¬
set of diabetes in patients with fairly good metabolic
control and with a mild form of the disease. On the other
hand, in some patients with an average unsatisfactory
control, the late complications may not be recognizable even
a few decades after diagnosis.
- Metabolic factors have been proved relevant in the initia¬
tion of nephropathy but they do not seem to have the same
value when a fall in the glomerular filtration rate has
taken place (Keen and Viberti,1981).
- From studies on diabetic twins, it has become apparent that
there is a surprising concordance in the progression and
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severity of retinopathy in type 2 (non-insulin dependent)
diabetic twins (Pyke & Tattersall,1973; Leslie and Pyke,1982).
- A heterogeneity within type 1 diabetes,with respect to
susceptibility to microvascular disease and related to
particular HLA antigens,has been suggested by several
authors, though not confirmed by others. In any case, the
assumption that the development of, or the protection from,
microangiopathy may be influenced by inherited constitu¬
tional factors, either linked to HLA genes or not, is widely
accepted (Marks et al,1981; Bodansky et al, 1.982; Gray et al,1982).
- To some extent, there is a difference between tvpes I and II
diabetes in the severity and rate of progression of micro¬
angiopathic lesions,which is apparently related to factors
other than metabolic events.
- Other factors, including growth hormone and other hormonal
factors,seem to play a role in controlling the insurgence
and development of microangiopathy.
These and other considerations suggest that the pathogenesis of
diabetic microangiopathy is multifactorial and an individual
variability on a genetic basis may be expected. Furthermore, it is
likely that different factors act at different stages of the
pathogenetic sequence.
Rather than trying to postulate a single theory capable of
explaining all the aspects of the small vessel damage, it may be more
useful to orientate the research towards the individual aspects so
far proved to be present in diabetic microangiopathy and try to
understand their significance in the general multifactorial context.
Of these aspects, only the immune phenomena will be discussed here.
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* Immunological phenomena
Evidence is accumulating that a few potentially harmful immune
factors are both in the circulation and in the blood vessel walls in
diabetic patients with microangiopathy (Blumenthal,1962; Blumenthal
et al,1962; Mohos et al,1963; Blumenthal et al,1964; Bloodworth,1965;
Zampa & Mancini,1969; Andreani et al,1971).
In the sixties, interest in immunological mechanisms in late
diabetic complications mounted after several researchers had reported
immunohistopathological findings in the diabetic vascular lesions
(Bloodworth,1968;Coleman et al,1962), as well as the possibility of
inducing diabetic-like microangiopathy in normal animals through
immune mechanisms and even with insulin treatment (Andreev et
al,1970;McVerry et al,1980).
In the early seventies, this interest declined. Data available
at that time suggested that the immunological abnormalities found
could be merely secondary to other events and without a specific and
destructive potentiality (Westberg and Michael,1972). Moreover, it
was pointed out that exogenous heterologous insulin was not essential
to the development of small blood vessel disease in diabetes.
In the late seventies, several different studies on circulating
immune factors (Ortved Andersen,1976;Irvine et al,1977), on the
interaction between soluble immune factors and other cellular systems
(Iavicoli et al,1982), on the phagocytic function (Bagdade et
al,1972) and on the physiopathology of the vascular basement membrane
(Cruz & Moreau Lalande,1978; Cohen et al,1980) contributed new
evidence on the immunological events in diabetic microangiopathy, at
the same time revitalising interest in the subject.
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Histopathological findings in man
The results of histological studies may be summarized as fol¬
lows :
- immunoglobulins, albumin, fibrin, complement, insulin and other
proteins are deposited in the small blood vessel walls;
- deposits of immunoglobulins have been found in the ocular and
dermal as well as glomerular vessels;
- in the diabetic kidney, serum proteins are present in the glo¬
merular and tubular basement membrane and in mesangial nodules;
serum proteins are deposited in most cases in a continuous
linear pattern and sometimes also in a granular aspect along the
capillary walls;
- immunoglobulins have no antibody activity to the glomerular
basement membrane and added heterologous complement is not fixed;
- there are morphological similarities between the diabetic vascular
lesions and those seen in other disorders of known immunological
origin.
Animal models
Studies on diabetic animals and experimental models capable of
inducing microangiopathy in normal animals led to these main results:
- in diabetic animals, there is an increase in the glomerular
basement membrane thickness, in the mesangial area and in
immunological deposits; - in normal animals, the injection of insulin
together with Freund's adjuvant induces a diabetic-like vasculopathy;
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- insulin injections produce microangiopathy only when insulin
antibodies are formed;
- microangiopathy is experimentally induced in animals either
sensitized with insulin/albumin or after injections of glucosylated
plasma proteins.
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A1.5c Insulin antibodies and
immune complexes
Insulin antibodies
Because of the species heterogeneity of therapeutic insulin,
insulin antibodies, following exogenous insulin administration, were
among the first immunological factors thought to play a role in
vascular damage. As reported above, studies on animals supported this
hypothesis. A few clinical studies have added some evidence of a role
for insulin antibodies in subjects with severe diabetic complications
(Ortved Andersen,1976;Jayarao et al,1974). Other research works have
not been able to confirm an association between increased levels of
insulin antibodies and the occurrence of microangiopathy (Bodansky et
al,1982; chapter B3.2c).
This lack of a significant correlation between insulin antibody
levels and clinical signs of microangiopathy was somehow to be
expected. Most of the available methods of detecting insulin
antibodies give a value related mainly to the free part of the
antibody. If insulin has any role in the vessel wall damage, it is
more likely brought about by the insulin anti-insulin complexes.
Whereas this kind of complex in antibody or antigen excess is small
in size because of the bivalency of insulin, insulin anti-insulin
complexes near the equivalence point are of larger size and might
activate complement components or induce the release of vasoactive
substances when trapped in the vessel walls. Studies in this
direction have recently been performed but no clear evidence for an
influence of insulin anti-insulin complexes on the genesis of the
microangiopathic lesion has so far been established (Kilkpatrick &
Virella,1980)(Chapter B3.4).
Immune complexes
The discovery of diabetic microangiopathy before the insulin era
and its occurrence in insulin-treated as well as non-insulin-treated,
diabetics suggest that immunological abnormalities,other than those
simply related to therapeutic insulin,are involved in diabetic
microangiopathy. More recently, attention has been focused on cir¬
culating and deposited immune complexes. In several different re¬
search works, an increase in immune complexes in circulation has been
reported in a significant proportion of diabetics (Jayarao et al,
1974; Kumar and Quismorio, 1978; Bodansky et al,1982; Abrass and
Lieberman,1983; Virella et al,1983). A few of these studies have
reported an increase in complexes in diabetic patients with severe
microangiopathy but not in those free of vessel wall lesions
(Bodansky et al,1982)(Chapter B3.2c). This increase was found both in
patients with proliferative retinopathy and advanced nephropathy but
no substantial difference was found between insulin-treated and non-
insulin-treated patients. The increase in immune complexes was even
higher in diabetic patients with early retinopathy, also referred to
as malignant microangiopathy (Andreani, 1980); the clinical
manifestations in these cases have been referred to as an immune
complex disease by some authors. From these studies, the presence of
immune complexes seems to be closely related to the occurrence of
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microangiopathic changes rather than the duration of the disease or
the type of treatment.
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A1.6 IMMUNOLOGY IN DIABETIC PREGNANCY
A1. 6a Immunology in normal pregnangy
Diabetic pregnancy is a very interesting model to study in order
to further understand the significance of several immune phenomena.
In the present state of knowledge the immune system in normal
pregnancy is considered to be in a state of "activation" rather than
"depression" (Gleicher and Siegel,1983) and in many immunological
aspects there is a strict interrelationship between mother and fetus,
both in physiological and in pathological events.
In normal pregnancy, interesting modifications of the immune
response are faced. An elevated production of counterregulatory hor¬
mones, which has been reported throughout the 9-months period,may
influence the immune system. A decrease in both humoral and cellular
immunoresponsiveness has been described (Gusdon,1976; Kaye,1973;
Froelich et al,1980). The interrelations between mother and fetus are
highly significant.The placental barrier selectively allows the
passage of several molecules, including immunoglobulin G, whereas it
blocks the passage of others (Vahquist,1958;Brambell,1974).
Furthermore in pregnancy, the maternal immune system faces an
antigenically non-self organism through the placental barrier. On the
other hand, the fast growing immune system of the fetus is somehow
protected and stimulated by the immune system of the host.
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Several explanations have been proposed for this maternal immune
protection.
The first hypothesis is based upon an immunological difference
of the uterus.Thus allogenic spermatozoa are not recognized as
foreign and promptly rejected by the immunocompetent system.On the
other hand, since intrauterine graft of tissues other than fetal
tissues are normally rejected, it is conceivable that human seminal
plasma contains an immunosuppressive activity (Beer & Billingham,
1974; Lord et al,1977; Stites et al,1979; Denman,1982).
The second theory invokes a decrease in the expression of HLA
antigens on the trophoblast (Page Faulk,1981). Whether the expression
of transplantation antigens is really decreased is still a matter of
controversy.lt seems that HLA antigens, and both the maternal and
paternal components of fetal transplantation antigens, are expressed
on the placenta but in low density at the beginning of pregnancy and
then they progressively increase and become detectable near the end
of pregnancy.,
A third possibility is based on the separation of maternal and
fetal circulation. In clear contrast with this theory is the finding
that fetal red cells, fetal lymphocytes and syncytiotrophoblast cells
may cross the placenta during gestation.
At present the active immunosuppression found in pregnancy seems
due both to humoral and to cellular immune factors.
Circulating factors such as hormones,alpha-fetoprotein,alfa2
pregnancy associated globulin,immune complexes, anti-HLA antibodies,
etc. are thought to have an immunosuppressive effect(Lord et al,1977;
Masson et al,1977; Stites et al,1979; Whyte and Loke,1979; Stimson,
1980; Denman,1982).
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More recently the intervention of soluble suppressor factors,
released by fetal suppressor T lymphocytes that then reach the
maternal circulation, has been hypothesized (Olding and Olstone,
1975; Zuccarini et al,1983).
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A1. 6b Immunology in diabetic
pregnant women
In the diabetic syndrome, several immune abnormalities have been
found to be involved in the pathogenesis of type 1 diabetes (Bottazzo
et al,1974; MacCuish et al,1974; Lernmark et al,1978; Pozzilli et
al,1979)(Chapters B1.2a, B1.2b,B1.3), in the development of diabetic
microangiopathy (Freedman et al,1960; Westberg & Michael,1972)
(Chapters B3.2a, B3.2b, B3.2c, B3.2d), and as a consequence of
heterologous insulin administration (Jayarao et al,1974; Andreani,
1974; Andersen,1976)(Chapters B2.3, B2.4, B2.5, B2.6).
In diabetic pregnancy, all these immunological phenomena are
further complicated by the variable metabolic situation which in¬
fluences several aspects of the immune response both in the mother
and probably in the fetus (Barns and Morgans,1949; Macourt,1974;
Pedersen,1975; Essex & Pyke,1979). Moreover, all the immunological
factors or the defects antedating pregnancy have to be considered.
It is now well established that insulin antibodies, following
heterologous insulin administration, cross the placenta and may be
found for months in the newborn blood (Spellacy & Goetz,1963;
Thorell,1966; Exon et al,1974; Mylvaganam et al,1983). On the other
hand, maternal insulin does not reach the fetal circulation in
significant amounts (Kalhan et al,1975).
Soluble immune complexes, found to be present in a good number
of long-standing diabetics, have been reported to be present in the
diabetic pregnant, but not, so far, in the neonatal circulation
(Jorgensen et al,1966;Tamas et al,1975). Deposits of immune complexes
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have been reported in placental vessels and into the basement
membrane of the trophoblast. The presence of circulating immune
complexes binding to placental Fc receptors seems responsible for the
pre-eclamptic toxaemia. The hypothesis that immune complexes may
interact with immunocompetent cells bearing Fc receptors on their
surface, thus modulating or favouring an immunosuppressive effect, is
stimulating .
Islet cell antibodies are present in some type 1 diabetic
pregnant women. These antibodies may cross the placenta,as discussed
in Al.6c.More important is the presence of islet cell antibodies in
gestational diabetics.Here the presence of ICA predicts a probable
insulin failure in the near future (Tingle et al,1979; Mylvaganam et
al,1980; Steel et al,1980; Ginsberg-Felner et al,1980).Gestational
diabetes with ICA shows a high association with HLA DR3 and/or
DR4.The contemporary presence of these histocompatibility antigens
and of islet cell antibodies suggests that a subgroup of gestational
diabetics has many similarities with type 1 diabetes mellitus.
It is very likely that both the metabolic and the immunological
factors present in diabetic pregnancy may have an influence on the
course of pregnancy, on the function of the placenta and on the nor¬
mal development of the fetus.
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A1.6c Immunology in the infants of
diabetic mothers
* Humoral immunity
Insulin antibodies and islet cell antibodies easily cross the
placenta and are found in the circulation in neonates of antibody
positive,diabetic mothers.
The pathological significance of the presence of insulin anti¬
bodies in the neonatal circulation has not yet been elucidated but
theoretically they may be responsible for fetal hyperinsulinism and,
thus,for the macrosomic and/or hypoglycaemic reactions in the
neonate. In particular,the maternal insulin antibodies,on reaching
the fetal circulation,face an immunological situation different from
that of the mother. In diabetic pregnant women,the antigen is a
heterologous' therapeutic insulin, partially purified or of low
immunogenicity, administered as a bolus,usually twice a day. Since
maternal insulin does not cross the placenta in significant amounts,
in the fetal circulation maternal insulin antibodies encounter the
antigenically different endogenous foetal insulin continuously
secreted throughout the day. Furthermore,in the fetal circulation the
antigen/antibody molar ratio varies with the progression of
pregnancy, so, from a condition of antibody excess in early
pregnancy, a more balanced antigen antibody ratio is reached in late
pregnancy.
Islet cell antibodies which have been passively transferred from
the mother, may be found in the neonatal circulation but they do not
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seem to have any specific deleterious effect on the fetus. They
usually remain in the circulation for some months after birth but no
correlation between their presence and glucose metabolism abnor¬
malities or other neonatal clinical complications has so far been
found.Circulating immune complexes have not yet been described so far
in the circulation of infants of diabetic mothers. It is likely that
the immune complexes described in some diabetic pregnancies may be
passively trapped,or actively bound to Fc receptors of the placenta
and this produces local damage with indirect pathological conse¬
quences for the mother and the fetus.
* Cell-mediated immunity
Eosinophilic infiltration of the pancreas of infants of diabetic
mothers has been described (Silverman,1963).It is likely that this
infiltration■is due to alterations in the immune response.The thymus
of infants of diabetic mothers shows signs of involution in contrast
to the generalized macrosomia (Horger et al,1975).
Using monoclonal antibodies it has been shown that neonatal T
lymphocytes do not express class II antigens on their surface after
prolonged pokweed mitogenic stimulation (Miyawaki et al,1982). The
percentage of T suppressor lymphocytes in the cord blood appears to
be surprisingly decreased thus suggesting that the immunosuppressive
effect described in the neonatal circulation is not correlated to the
number of cells but probably to other factors,possibly secreted by
the immunocompetent cells themselves (Hayward and Kurnick,1981).
CHAPTER A 2
PLAN OF THE STUDIES
INCLUDED IN THE THESIS
Chapter A2 PLAN OF THE STUDIES INCLUDED IN THE THESIS
A2.1 Background of the studies
A2.2 Aims of the studies
A2.3 General design of the studies
72
A2.1 BACKGROUND OF THE STUDIES
The present study is concerned with the immunological aspects of
diabetes mellitus.
The personal scientific interest of the author has been, and
continues to be, on the overlap between immunology and diabetes, that
area that is in more general terms referred to as immunoendocrinology.
The interest in the immunology of diabetes has developed only two
decades ago. The detection of insulin antibodies after heterologous
insulin treatment, the severe problem of microangiopathy, and the
suspicion of aggravating immunological factors, and epidemiological
and histopathological studies on the juvenile form of diabetes slowly
raised interest in the role of immunological events in diabetes. At
the end of 1974, however, the discovery of antibodies directed to the
pancreatic islet in newly diagnosed insulin dependent diabetics by
Bottazzo and Doniach in London and by Irvine's group in Edinburgh
convinced all those in the field of the importance of immunity in
diabetes.
This work started from the author's original observation that
circulating immune complexes are present in diabetic patients. Their
presence was described in different diabetic conditions: in some newly
diagnosed insulin dependent diabetics, in long standing insulin-
treated diabetics and in some patients with microangiopathy (B1.2a,
B2.2a, B3.2a).
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The finding of increased circulating amounts of antigen-antibody
complexes, not only confirmed the occurrence of immunological
phenomena in diabetes, but suggested their possible role in still
obscure pathological events.
Since complexes were found to be increased in such different
diabetic conditions, they were thought to be heterogeneous. The pre¬
liminary observation of a possible correlation of immune complexes
with islet cell antibodies, insulin antibodies and vascular
complications respectively in newly diagnosed diabetics, in long
standing insulin treated diabetics and in diabetics with
microangiopathy stimulated the author to pursue research in a number
of directions.
Thus three main lines of research were begun.
The first was on the pathogenesis of type 1 diabetes (subchapter
B1.2). The presence of circulating immune complexes needed to be con¬
firmed in a substantial number of newly diagnosed insulin dependent
diabetics (B1.2c). The possible correlation between the presence of
immune complexes and the occurrence of circulating antibodies reacting
with pancreatic antigen was analyzed both at diagnosis (B1.2c) and in
an interesting minority of diabetics, the so-called islet cell anti¬
body persisters (B1.2d), who were also genetically and immunologically
better defined (B1.2b).These studies confirmed the increased presence
of some types of complexes in newly diagnosed diabetics, and in islet
cell antibody persisters, and their correlation with the occurrence of
islet cell antibodies.
The second was on the consequences of insulin treatment
f.
(subchapter B2.2). The possible correlation between insulin antibodies
and the presence of islet cell antibodies was investigated in type 1
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diabetics at the same time after diagnosis and in islet cell antibody
persister diabetics (B2.2b). The genetic influence on the immune
response, as evaluated by HLA phenotypes, was also studied (B2.2b).
The production of antibodies to exogenous insulin was found to be
linked to particular HLA types whereas no correlation was found
between insulin and islet cell antibodies.
The third was on the immunological phenomena in diabetic vascular
complications (subchapter B3.2). In order to assay the possible
pathogenetic role of circulating immune complexes in patients with
microangiopathy, their presence needed firstly to be confirmed in a
larger group of patients with different degrees of microangiopathy
(B3.2b). Following this, selected patients with severe microangiopathy
and others with no apparent sign of microangiopathy were studied
(B3.2c). Since an increase in circulating complexes can be the result
of an increased formation or of a decreased clearance, the function of
fixed phagocytes was analyzed in vivo in patients with microangiopathy
and correlated with the presence of complexes (B3.2d). This showed
that some types of immune complexes are increased in both type 1 and 2
diabetics with severe microangiopathy and that such an increase is
likely to be due to a reduced phagocytic clearance.
Following on from this earlier work - done mainly in Edinburgh in
the years 1976-1981 - a more general plan of study has been designed
which follows the three lines detailed above. A fourth line has been
added, the immunology of diabetic pregnancy, to better understand the
role of immunity in diabetes.
The cultural and theoretical background of the study have already
been discussed in chapter A1.
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A2.2 AIMS OF THE STUDIES
The aims of the studies included in this thesis are:
1. To investigate the role of humoral immune factors in the patho¬
genesis of type 1 diabetes. Circulating islet cell antibodies, pan¬
creatic specific antigens and immune complexes are evaluated and
correlated with other immunological and genetic parameters in an
attempt to monitor the islet cell damage in the early stages of type 1
diabetes and to better understand the pathogenetic phenomena.
2. To evaluate the immunogenicity of insulin preparations differing
in purity and in their sources, i.e. semisynthetic human insulins or
insulins extracted from animal pancreases. The host immune response to
exogenous insulin is evaluated through the humoral immunological
consequences of the treatment.
3. To study the possible role of humoral immune factors in the
development of diabetic microangiopathy and their correlation with
other abnormalities likely to be present in the same condition, i.e.
platelet, coagulation and lymphocyte changes.
4. To better understand the immunological aspects of the feto-
maternal relationship in diabetic pregnancy. In this particular
condition the sum of the abnormalities related to diabetes and of the
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modifications of the immune response characteristic in pregnancy may
have physiopathological consequences on the outcome of pregnancy and
on the neonate, that are largely unexplored.
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A2.3 GENERAL DESIGN OF THE STUDIES
This study follows four different lines in the field of immunity
in diabetes.
This division into four lines is somewhat artificial, there being
many areas of overlap. Such a division, however, best describes how
the research has been planned and certainly simplifies its discussion.
i) Pathogenesis of type 1 diabetes (Chapter Bl)
Attention is focussed on humoral immunological phenomena in
prospective studies on type 1 insulin dependent diabetics and on that
interesting minority of diabetics who show immune abnormalities but
initially do not require insulin.
Immune complexes are studied prospectively in a large number of
type 1 insulin dependent diabetics and correlated with the presence of
islet cell antibodies, complement fixing islet cell antibodies, viral
antibodies, insulin antibodies and HLA types (B1.3).
Immune complexes, islet cell antibodies, complement fixing islet
cell antibodies and autoantibodies to thyroid and gastric-parietal
cells are studied prospectively in newly diagnosed diabetics, initial¬
ly treated with diet or oral agents but showing islet cell antibodies
in their serum (B1.4).
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Since circulating antibodies to islet cells and soluble
antigen-antibody complexes were found to be present and in correlation
in the early stages of type 1 diabetes, it has been decided to search
for circulating specific pancreatic antigens as possible early markers
of islet cell damage. Thus monoclonal antibodies against pancreatic
antigens are used, in specifically designed techniques, to try to
reveal circulating pancreatic antigens in the early stages of type 1
diabetes (B1.5).
ii) Immunological consequences of insulin treatment (chapter B2)
The main objectives Qjl&> to correlate the presence of soluble
immune complexes with the type of treatment and with the presence of
insulin antibodies and also to compare the immunogenicity of different
insulin preparations.
The presence of immune complexes is evaluated in a large number
of insulin and non-insulin treated diabetics and correlated with the
type of treatment and other variables, such as age and sex, and
duration of the disease (B2.3).
The correlation between immune complexes and insulin antibodies
in randomly selected insulin treated diabetics is analyzed (B2.4).
The immunogenicity of conventional and highly purified hetero¬
logous insulins, as far as insulin antibodies and immune complexes are
concerned, is investigated in a one year prospective study on newly
diagnosed type 1 diabetics (B2.5).
Finally the immunogenicity of conventional, monocomponent and
semisynthetic human insulins is studied in type 1 and 2 diabetics at
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the beginning of their insulin treatment and in the following six
months (B2.6).
iii) Immunology of diabetic vascular complications (chapter B3)
After having established the increase in the circulation of some
types of immune complexes and the impairment of phagocytic function
with a decreased clearance of macromolecules in diabetics with severe
microangiopathy, the relationship between insulin antibodies and
different kinds of immune complexes in patients with and without
microangiopathy is investigated (B3.3).
The presence of humoral immune factors, such as immune
complexes,insulin antibodies and insulin complexes, is investigated
and the possible correlation with other abnormalities reported to be
present in diabetics with severe retinopathy,i.e. the modification of
platelet and' coagulation factors is evaluated (B3.4).
The possible modification of T lymphocyte subsets and their
correlation with immune complexes are investigated in long standing
diabetics with various degrees of microangiopathy (B3.5).
iv) Immunology of diabetic pregnancy (chapter B4)
Attention is focussed on both the humoral and cellular phenomena
in insulin treated diabetic pregnant women and on the possible
physiopathological consequences of these factors on the outcome of
pregnancy and on the neonate.
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Insulin antibodies,immune complexes and islet cell antibodies are
studied in a large group of insulin treated diabetic pregnant women.
The possible correlation between these immune factors and the type of
insulin treatment and the maternal metabolic control are considered.
The main objective is to investigate the possible role of immune
factors in clinical complications in the mother and/or neonate (B4.2).
Insulin antibodies and insulin-anti-insulin complexes is
evaluated in both the maternal circulation during pregnancy and in
neonatal cord blood. The placental transfers of insulin, of insulin
antibody and of insulin-anti-insulin complexes and their physio-
pathological consequences have received particular attention (B4.3).
Since pregnancy is a unique condition as far as cellular immunity
is concerned, and diabetic pregnancy is likely to be further
complicated by cell-mediated phenomena related to diabetes, it is
considered to be of some importance to study T cell subsets in dia¬
betic pregnant women (B4.4) and to search for activated T cells by the
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pancreatic islet cell antigens




A3.1 CIRCULATING IMMUNE COMPLEXES
A great deal of useful information has accumulated over the past
ten years on the composition, biological activities and detection of
immune complexes in human disease. This period has also seen an
increase in the number of variable techniques for the detection of
complexes (WHO Scientific Group Report,1977;Thompson RA 1980). Almost
all of the tests for immune complexes are antigen non-specific since
they depend upon the various biological properties of complexed IgG,
which are in turn expressions of activity of altered Fc domains. An
inevitable consequence of this non-specific expression of activity is
the failure of available techniques to distinguish between complexes
arising from specific disease processes and those which are the
result of a' natural encounter with environmental agents or perhaps
expressions of altered autoimmunity with increasing age. This is of
more than academic importance and requires that the possible physio¬
logical roles of immune complexes be more fully explored. A better
understanding of the mechanisms by which immune complexes are detec¬
ted and a further refinement and development of immune complex
technology will hopefully facilitate a greater comprehension of their
potential physiological and undoubted pathological roles.
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A3, la Methods of detection:
general lines
Although the pathological importance of the formation of soluble
immune complexes has been recognised for almost seventy years, only
recently have apparently suitable techniques for their detection been
developed and refined. At this time there are about thirty such tech¬
niques which depend upon one or another of the variety of physical or
biological properties displayed by immune complexes. Of this large
number of techniques,only a few appear sufficiently sensitive for
clinical or experimental purposes in human disease (WHO Scientific
Group Report,1977;Fust et al,1981).None of these methods
distinguishes between non-specifically aggregated immunoglobulins and
immune complexes. They are based on the properties of complexed
immunoglobulins, which differ from those of monomeric immunoglobu¬
lins. Depending on the principle of the method,they may be broadly
divided into those revealing complexes through the physical
properties of complexes and those through the biological properties.
a) Methods based on the physical properties of the complexes:
Among this group are those methods based on size changes of
aggregated immunoglobulins and those based on solubility changes. The
increase in size may be analyzed by sucrose density gradients, by gel
filtration or ultrafiltration and by analytical ultracentrifugation.
These methods are more important in the purification of complexes
than in routine evaluations of serum immune complex levels in pa¬
tients. The solubility changes of aggregated immunoglobulins may be
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revealed by low temperature or by polyethylene glycol, molecular
weight 6000. This latter method has been extensively used for routine
assays but its very low specificity recommends its use only as an
initial step in the further purification of complexes.
b) Methods based on the biological properties of complexes:
The reactivity of immune complexes with receptors, either on
free molecules or on the surface of cells,is the basis of numerous
techniques.
Among the methods utilizing receptors on free molecules,there is
a large group based on the properties of the first component of
complement (Clq). Clq avidly binds the Fc portion of complexed
immunoglobulins and different techniques have been devised to reveal
this binding. Among these,the most commonly used are the fluid phase
Clq radioimmune assay and the solid phase Clq binding test (see
below).The direct measurement of anticomplementary activity or the
interaction of complexes with complement is also used as the basis
of several other tests. Other free molecules used to bind complexes
are the rheumatoid factor, low affinity IgM antibodies and a bovine
protein, conglutinin,which binds complex-bound C3. The conglutinin
binding test is now widely used(see below).
Among the methods based on the reactivity of complexes with cel¬
lular receptors,the Raj i cell radioimmune assay must be mentioned.
This human lymphoblastoid cell line, derived from Burkitt's lymphoma
patients, presents both Fc and complement receptors on the cell
surface (see later). Other cellular tests include those using pla¬
telets or macrophages.
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None of the methods described above is sufficiently specific,
reproducible or sensitive enough to detect circulating immune
complexes with precision.
* Comparison between different
techniques
At present it is widely accepted that different methods usually
detect different types of immune complexes. Of course,the types of
complex detected depend on the antigen(s) or antibody(s) involved.
But,for a given antigen and antibody, the valency of the antigen,the
class of the antibody and the antigen/antibody ratio also influence
the size of complexes, the degree of lattice formation,the pos¬
sibility of activating the complement cascade,of interacting with
platelets and of reacting with cells bearing Fc and C receptors.
Furthermore, differences in the specificity and sensitivity of the
various methods account for the discrepancies often found in the
results obtained with them.
A few collaborative studies were organized to compare different
methods. A WHO collaborative study for the evaluation of 18 methods
of detecting immune complexes in serum showed a considerable dif¬
ference in the pattern of reactivity of sera from diseases under
study in the various tests (Lambert et al,1978). The study suggests
that,for each disease,it is possible to select one or more tests most
likely to detect abnormal reactivity and to screen patients for
immune complexes.A parallel application of different methods,based on
different principles,is advisable.In another recent collaborative
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study,in which the author was involved, the conclusions were similar
(Celada and Migliorini,1982;Migliorini et al,1983).
Since immune complexes are polymorphic and since there is now
definitive evidence of variability in the quality of complexes from
disease to disease and in the same individual from stage to stage of
the disease,the attention of researchers is now focussed on the
possibility of purifying complexes and identifying the antigens in¬
volved in the immune complex formation.
At present antigen non-specific methods, possibly different
techniques based on different principles, are confined to screening
patients' sera or to following the same patient over a period of
time.
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A3.lb The Solid-phase Clq binding
test (Clq - SP)
a Preparation of immunological
reagents for Clq-SP
a.l Purification of Clq
The methodology described is that devised by Yonemasu and Stroud
(1971) with minor personal modifications.
* Reagents and equipment:
EGTA;Na2EDTA;NaOH;NaCl;Na acetate;acetic acidjKH^PO^
Na2HP04;
magnetic stirrer;ultracentrifuge (with a potential
load of at least 130ml);dialysis tubes
* Preparation of solutions:
bfl: 0.026 M EGTA in 2.2 litres of distilled water
(d.w.), reach pH 7.5 with concentrated NaOH
bf2: 0.75M NaCl;0.02M Na acetate;0.02M acetic acid;
0.01M Na2EDTA in 500ml of distilled water;
adjust to pH 5 with NaOH
bf3: 0.06M EDTA in 4 litres of d.w.
adjust to pH 5
bf4: 0.005M KH2P04;0.005M Na2HP04;0.75M NaCl,
500ml pH 7.5;0.01M EDTA,(8ml IN NaOH;
in 500ml of d.w.
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adjust to pH 7.5 with NaOH
bf5: 0.035M Na2EDTA
in 4 litres of d.w.
adjust to pH 7.5
bf6: 0.75M NaCl;0.02M Na acetate;0.02M acetic acid;
0.01M EDTA
in 500ml of distilled water
adjust to pH 7.5
Procedure for the purification of Clq:
The method is devised for 1 unit of serum ( 127ml).
For more than 1 unit, use adequate quantities of
buffers.
(i) first precipitation
- dialyze 1 unit of fresh human serum against
bfl, 1 litre, for 4 hr at 4°C
- continue dialysis against another litre of bfl
for lhr at 4°C
- spin at 10 OOOg for 15'
- wash precipitate with bfl, 50ml
- spin at 10 OOOg for 15'
- dissolve with bf2, 32ml




- dialyze the mixture against bf3, 4 litres, for
4 hr at 4°C
- spin at 10 OOOg for 15'
- wash precipitate with bf3, 50ml
- spin at 10 OOOg for 15'
- dissolve with bf4, 32ml
- spin at 5 OOOg for 5' to remove undissolved.
Keep the supernatant
(iii) third precipitation
- dialyze the mixture against bf5, 4 litres, for
5 hr at 4°C
- spin at 10 OOOg for 15'
- wash the precipitate with bf5, 50ml
- spin at 10 OOOg for 15'
- dissolve with B6, 16ml
- calculate the concentration, with a
spectrophotometer (OD 1=1.4mg)
- aliquot and store at -70°C
a.2 Radiolabelling of protein A (or anti human immunoglobulin
antibody)
The procedure is according to Dorval et al.(1975) with
minor personal modifications.
* Reagents and equipment:
125
I;Sephadex G.50 or G.25; protein A (or anti human
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immunoglobulin antibody); chloramin T;Na meta-
bisulfite; Bovine serum albumin;
chromatografic column 200 x 10mm; fraction collector
(if available)
* Preparation of solutions:
bfl: phosphate buffered saline (see part B)
bf2: chloramin T 0.8mg/ml in bfl
bf3: Na metabisulfite lmg/ml in bfl
bf4: BSA, 5% in bfl
* Procedure:
- prepare the chromatografic column with Sephadex G25
(or G50) in bfl
125
- add lmCi of I to 50ul of protein A, lmg/ml
- add bf2, 5ul and mix 1 min
- add bf3, 5ul and mix
- count the radioactivity
- add bf4, 250ul and mix
125 125
- separate I-protein A from I on the Sephadex
column collecting 1ml fractions
125
- pool the I-protein A peak (usually around the
3rd-5th fraction)
- divide into aliquots and store at -20°C till used
a.3 Preparation of immunoglobulin aggregates
* Reagents and equipment:
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human IgG;
thermostatic bath at 63°C
* Heat aggregation:
- dilute human IgG to a concentration of lOmg/ml and
divide into aliquots
- heat 20 min at 63°C
- store at -20°C
b. Preparation of other reagents
for ClqSP
b.l Buffers
bfl Phosphate buffered saline, pH 7.2, 0.15 M (quantities
for 10 litres):
Sodium chloride,80g;Potassium chloride,2g;




Gelatin powder,0.05% in bfl
bf3 Di sodium ethylene-diamino tetra-acetic acid, pH 7.5:
0.2M in d.w.adjust to the right pH with NaOH IN
bf4 PBS + Tween 20:
Tween 20 0.05% in bfl
bf5 PBS + Bovine serum albumin:
bfl + BSA 1%
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c. Procedure of Clq-SP
This procedure is a minor personal modification of those
described by Svehag (1975) and Hay et al.(1976).
c.l Coating tubes with Clq
- Clq is diluted to lOug/ml in bfl
- Diluted Clq (lOOul) is added to polysterene tubes
(Immulon, Dynatech, 250ul capacity tubes)
- incubate 3 days at 4°C
- wash 3 times with bf4
- fill tubes with bf2
- incubate 2h at room temperature (r.t.)
- wash 3 times with bf4
c.2 Complement inactivation of serum (13).
- add serum to be tested, lOul, to bf3, 20ul and mix
- incubate 30 minutes at 37°C
- transfer the mixture to an ice bath
c.3 Preparation of the standard curve
- dilute one aliquot of the immunoglobulin aggregates to
500, 250, 125, 62, 31, 16, 8, 4, ug/ml in normal serum
- include these dilutions in duplicate (or in triplicate)
in each experiment
c.4 Assay
- add the complement inactivated human serum (lOul) to
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Bfl.(90ul) and mix
- incubate 1 hour at 37° and 30 minutes at 4°C
- wash 3 times with Bf4
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- add I protein A, 25ng/ml in Bf5, lOOul
- incubate 1 hour at 37° and 30 minutes at 4°C
- wash 3 times with Bf4
- count in a gamma counter
c.5 Calculation of results
- use a semilogarithmic paper and put the absolute value
of aggregates on the semilog axis and the radioactivity
values (cpm) on the y axis
read the absolute values of aggregates for each test
serum
- taking into account the quantity and the dilution of
serum,give results in ug AHG equivalents/ml of serum.
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A3.lc The conglutinin binding radio¬
immunoassay (KgBt)
a. Preparation of immunological
reagents for KgBt
a.l Purification of conglutinin
The purification is performed according to the methods of
Lachmann ,1967,(Weir,1978) and Casali et al, 1977, with minor personal
modifications.
* Preparation of the yeast
i) Reagents and equipment:
baker's yeast;mercaptoethanol;iodoacetamide;NaCl;
KC1;Na2HP0^ jKl^PO^;sodium azide;
autoclave;centrifuge 4 x 500ml;incubator 37° C;
stirrer;pH meter
ii) Solutions:
bfl: phosphate buffered saline (see ClqSP)
bf2: mercaptoethanol 0.1M
bf3: iodoacetamide 0.02M;NaCl 8.5 g/1;
1/5 v/v of phosphate buffer 0.2M, pH 7.2
bf4: veronal buffered saline pH 7.2;NaCl 8.5 g/1
Barbitone 0.575 g/l;Soluble barbitone 0.185g/l;
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NaCl 8.5 g/l;MgCl2 0.168 g/1;
CaCl2 0.028 g/1
iii) Preparation of the yeast:
- 1 lb of baker's yeast is added to 21 of bfl
- autoclave for 30' at 120°
- centrifuge at lOOOg for 10'
- wash in bfl 3 times
- add 1.7ml of bf2 to 250ml of yeast in bfl
- incubate at 37° and stirring for 2 hrs
- centrifuge at lOOOg for 10'
- wash with bfl
- resuspend in 500 ml of bf4
- stir 2h at r.t.
- adjust pH to 7.2
- centrifuge at lOOOg and wash in bfl 3 times
- resuspend in 21 of bfl
- autoclave 30' at 120 °C
- centrifuge at lOOOg and wash extensively in bfl
- resuspend in 11 of bf5
- divide into 50ml aliquots
Purification of bovine conglutinin:
i) Reagents and equipment:
CaCl2;KH2PO^;NaCl;Na azide;Na2 EDTA;H3P04>
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Na 0H;HC1; dialysis tubes;
thermostated bath 56°;stirrer; centrifuge rotor 100ml
x 4 or rotor 500ml x 4;ultracentrifuge;DEAE column
ii)solutions
bfl: CaCl2 40g/dl
bf2: PBS (see above)
bf3: Na2EDTA 0.01M in PBS,adjust pH to 7.2
bf4: HoP0. 0.3 4 1M
bf5: Phosphat e buffer 0.01M, pH 5.4
bf6: mix 1/3 of phosphate b. 0.1M,pH8
1/3 of NaCl 0.2M
1/3 of Na2EDTA 0.02M, pH8
bf 7: mix 1/3 of phosphate b. 0.1M,pH8
1/3 of NaCl 0.1M
1/3 of Na2EDTA 0.02M,pH8
bf8: mix 1/3 of phosphate b. 0.1M,pH8
1/3 of NaCl 0.3M
1/3 of Na2EDTA 0.02M,pH8
bf 9: mix 1/3 of phosphate b. 0.1M,pH8
1/3 of NaCl 0.6M
1/3 of Na EDTA 0.02M,pH8
iii) initial purification
- centrifuge 101 of bovine blood ,2000g for 10' and
keep the serum
- heat the bovine serum at 56°C for 45'
- add 1 ml of yeast and 5 ul of bfl to 5 ml of bovine
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serum
- stir at 4°C for lh
- centrifuge at lOOOg for 10'
- wash 3 times with bf2
- resuspend in bf3 (0.5 ml for each 1 ml of yeast
previously added
- stir 10' at r.t.
- centrifuge at lOOOg for 10' and keep the
supernatant
- resuspend the precipitated yeast in bf3 (1 ml for
each 1 ml of yeast previously added)
- centrifuge at lOOOg for 10' and the supernatant
- pool the supernatants
- adjust to pH 5.4 with bf4
- dialyse 24h against bf5
- centrifuge at 5000g for 15'
- resuspend in 10 ml of bf6
iv) further purification
- use a DEAE chromatographic column 20x2 cm and a
fraction collector
- equilibrate the column with bf7
- carefully add the conglutinin to bf6
- use bf8 as the first gradient
- use bf9 as the second gradient
- collect 1ml fractions and measure the optical
density with a spectrophotometer
- the peak eluted by the second gradient contains the
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conglutinin
- check purity with an antiserum to conglutinin
a.2 Radiolabelling of protein A
(see Clq-SP)
a.3 Preparation of immunoglobulin aggregates
(see Clq-SP)
b. Preparation of other reagents
for K g B t
bfl carbonate Ca buffer 0.05M pH 9.6:
NaHC03,0.035M;Na2C03,0.015M;CaCl2,0.2mM;
Na azide,0.2g/l
bf2 VBS pH 7.2:
Barbital,0.575g,quantities for 1 litre;
Soluble barbital,0.185g;NaCl,8.5g;MgCl2,0.168g;
CaCl2,0.028g;Na azide,0.2g
bf3 VBS + Tween 20:
bf2 + Tween 20 0.05%
bf4 VBS + Bovine serum albumin:
bf2 + BSA 0.1%
c. Procedure of KgBt
c.l Coating tubes with conglutinin:
- Kg is diluted to 5ug/ml in bfl
101
- diluted Kg (lOOul) is added to polypropylene tubes
(Immulon.Dynatech, 250ul tubes)
- incubate 3h at 37°C
- leave 4°C until used
- wash 3 times with bf3
c.2 Preparation of the standard curve
- dilute one aliquot of the immunoglobulin aggregates to
250, 125,62, 31, 15, 8, 4 ug/ml in fresh human serum
- incubate 30min at 37°C
- keep at 4°C until used
c.3 Assay
- prepare the standard curve as indicated in A.3
- fresh serum (lOul) + Bf2 (90ul) are added to tubes
- incubate 2h 4°C
- wash 3 times in bf3
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- add 1-protein A, 5ng, in bf4 (around 30-50000 cpm)
- incubate 4h at room temperature
- wash 3 times in bf3
- count radioactivity in a gamma counter
c.4 Expression of results
(see Clq-SP)
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A3.Id The Raji cell radioimmune assay (RAJI)
The method is according to that of Theophilopoulos et al with
several personal modifications (Theophilopoulos et al,1976).
a. Preparation of immunological
reagents for RAJI
a.l Preparation of cells
For the culturing of cells see other general texts on
this topic
- prepare about 2 million cells for the assay
- wash cells in medium (RPMI 1640, Modified Eagles
medium,or others)
- count the cells and check the viability (for instance
by trypan blue exclusion)
- wash the right amount of cells for the assay and
resuspend in 50 ul of medium
a.2 Radiolabelling of protein A (or antihuman immunoglobulin
antibody (see Clq-SP)
a.3 Preparation of immunoglobulin aggregates
(see Clq-SP)




ml Modified Eagles medium (MEM)
m2 MEM + 1% bovine serum albumin
b.2 Buffers
bfl PBS (see Clq-SP)
c. Procedure for RAJ I
c.l Preparation of sera
dilute cells 1/4 in bfl, final volume 100 ul
c.2 Preparation of the standard curve
c.3 Assay
- add 25 ul of diluted serum (or standard) to RAJI cells
suspended in 50 ul of serum
incubate at 37°C for 45 minutes
- add 1 ml of "ml" to wash (spin 800 g, 10 minutes, room
temperature). Resuspend the pellet in 1 ml of "ml" and
repeat twice
125
- add 5-10 ug/tube of I-protein A in 50 ul of m2
resuspend the pellet
incubate at 4°C for 30 minutes
add 1 ml of m2 to wash (spin 800 g, 10 minutes, 4°C).
Resuspend the pellet in 1 ml of m2 and repeat twice
count the radioactivity
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c.4 Calculation of results
see Clq-SP
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A3 ■ Lc Technical notes
* Standardization,performance and sensitivity of the techniques as
assessed by aggregated Ig (AHG) binding. Fc receptor uptake of AHG by
Raji cells.
Aggregated Ig curves were included on all occasions assays were
performed. In terms of this standard the RAJI, Clq-SP and KgBt
techniques appear equally sensitive and more sensitive than the
Clq-FP. Each of the former assays detects less than 10 ug/ml of
aggregated Ig whilst the lower limit of detection for the latter
assay appears to be about 50-60 ug/ml. However, this comparison is
fallacious; the Clq-FP,for example,is more sensitive than the Clq-SP
technique in tests on rheumatoid arthritis sera (personal observa¬
tion) . Nevertheless, Clq-SP is a useful technique in other diseases
such as diabetes mellitus. In general terms very little variation was
seen in the binding of aggregated Ig in either Clq-SP or KgBt assays
over several months of use. Some variation in the background
non-specific precipitation of Clq in Clq-FP was evident from batch to
batch of Clq and also from day to day. Although this variation was in
the order of only 5-6% of Clq precipitated, it was sufficient to make
the interpretation of results between tests difficult. In practice,
because of the lack of binding of aggregated Ig in the Clq-FP
technique below about 50 ug/ml, it is difficult to express results as
equivalents of aggregated Ig in ug/ml and thus some form of internal
standardization, by including the same positive and negative sera in
every test, is a useful practice.This form of standardization is
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advisable for all the immune complex techniques. The poor binding of
Ig in the Clq-FP technique is probably related to the large size of
aggregates produced by heating Ig at 63°C. About 60% of Ig aggregated
by heating at 63°C has a molecular size of 1 million or greater and
the remainder is apparently monomeric Ig. Clq-FP does not appear to
detect such large complexes or aggregates as successfully as it
detects smaller molecular weight material.
In our hands the binding of aggregated Ig to Raji cells was
subject to quite marked variation over some months of use although
consecutive tests usually gave reproducible results. This variation
in apparent binding ability of Raji cells can usually be circumvented
by deriving serum binding values from aggregated Ig curves; in this
way sera tested several months apart gave reasonably correlative
results. Nevertheless, RAJI is by far the most technically demanding
of the four techniques we have used.
Although evidence exists that immune complexes are preferen¬
tially taken up by attachment to C3/C3d receptors on RAJI cells
(Theophilopoulos et al,1976), complement independent mechanisms may
be important for their attachment.Aggregated Ig,in the absence of
normal serum,is taken up equally well in the presence of complement.
The binding of aggregated Ig in heat inactivated sera is difficult to
assess because heat inactivation to destroy complement components
also induces aggregation of Ig (Zubler et al,1976) but some uptake of
Ig is evident. It has been sometimes found an unsatisfactory
correlation between RAJI and other complement dependent techniques
for complexes; when RAJI has been used,evidence of complexes, which
could not be confirmed with the Clq-SP, Clq-FP or Kg-B techniques,
has been found. Although differences in assay sensitivities may
account for these findings, the uptake of complexes onto RAJI cells
by complement independent mechanisms may well be a plausible expla¬
nation.
* Correlation between results obtained with different assays.
As some studies,including those presented here, have shown (see
below) the concordance rate among results of assays can be high. For
example, in tests of diabetic sera it has been found a good cor¬
relation between RAJI and Clq-SP. However, unsatisfactory cor¬
relations are sometimes apparent. Such unsatisfactory correlations
may be consequences of differences in the sensitivity of the assays
or may be reflections of the heterogeneity of physical and biological
characteristics of complexes found in disease. Even when the pre¬
valence of complexes detected in the same population by different
techniques is similar, the results for individual sera may not be in
accord. This was illustrated in a study of long-standing diabetic
patients (Chapter B3.2c) where the prevalence of detectable AgAb by
Clq-SP and KgBt was respectively 51% and 39% but the results of the
assays were in agreement in only 56% of sera tested. In this particu¬
lar example, the lack of correlation may be explained by differences
in the size of complexes which are detected by Clq and KgBt
techniques. From such examples it may be inferred that no single
technique is in itself sufficient to investigate the occurrence and
characteristics of immune complexes in disease.
108
* Expression of results and definition of positive immune complex
values.
It is widely accepted that quantitation in the described methods
may be achieved by reference of sample duplicates to the uptake of
serially diluted heat aggregated immunoglobulins and the results
expressed in micrograms of aggregate equivalents per millilitre of
undiluted serum (ugAHGeq/ml). As an alternative method, quantitation
may be referred to "in vitro" made complexes with a known antigen and
antibody in a prefixed ratio. Results may also be expressed as a
percent of the radioactivity added, calculating the ratio between the
radioactivity found in the sample and that added. Others prefer to
express results as a percent of the maximum bound, that is to say,
the ratio between the radioactivity found in the sample and that of
the highest fixed amount of aggregates in the standard curve.
The definition of the prevalence of immune complexes in disease
is obviously related to the values obtained for apparently normal
subjects in the assay used. Although some opinions suggest that
immune complexes are undetectable in healthy normal subjects, the
experience of the author indicates otherwise. About 10% of randomly
selected blood donors give moderatly raised binding values in Clq-SP,
Clq-FP and Kg-Bt assays (Figures A3.1/1, A3.1/2, A3.1/3). The
prevalence of complexes is related to age but not to the sex of the
subjects and may be a reflection of serum autoantibodies (Delespesse
et al,1980). In addition, gel filtration studies of normal sera show
"heavy" molecular weight IgG present and some variation in the levels
of complement fixing immune complexes can be shown during the day (Di
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Mario et al,1980). Some of this diurnal variation is perhaps due to
the formation of complexes after food ingestion. In the RAJI
assay,20-25% of blood donors may give raised binding values (Figure
A3.1/4) - an observation confirmed in other laboratories. This may be
related to the use of cultured cells as a matrix for the detection of
complexes; that is to say, some of the values obtained in RAJI may be
false positives due perhaps to the presence in the sera of antibodies
to cell surface membrane antigens or to antigens adsorbed onto the
cell during culture.
In conclusion, since the values of immune complexes in the
normal population show a positive peaked asymmetric distribution, the
90th percentile of the values of the normal population was chosen as
the limit of positivity for the Clq-SP and the KgBt techniques For
Clq-FP,the 90th percentile, the 95th percentile or the mean of the
controls plus 2 standard deviations of the mean may in practice make
little difference. However, in RAJI, because of the high values and
wide range Of values obtained for normal subjects, the author, along
with other researchers,has found it necessary to arbitrarily de¬
signate 20 mcg/ml of aggregated Ig equivalents as the upper limit of
immune complex negative. This value is usually the minimum quantity
of aggregated Ig which can be detected with confidence. As a function
of this wide variation of binding of normal sera to RAJI cells,and
the inter-test variability, necessitating expression of RAJI results
in terms of units derived from standard curves, the test may be
unduly influenced by the choice of serum used as a complement source
for the dilution of aggregated Ig.In studies with RAJI,for the
dilution of aggregated Ig sera derived from pools of normal sera or
sera with a binding value approximately equal to the mean of a large
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number of normal sera were used. Although this practice facilitates
the sensitivity of the test, it also delineates a number of normal
sera as apparently positive.
To reduce to a minimum the variability of the limit of posi-
tivity from test to test, it was decided to assay a very large group
of normal sera to be used as controls in the same experiment. Out of
these samples ten sera were chosen to statistically represent the
entire normal population studied, i.e. their median and interquartile
range were the same as the total group. Frozen aliquots of these ten
sera were included in each experiment and only an inter-assay
variability of less than 10% of their values was tolerated.
FIGURE A3.1/1
AgAb detected by Clq-SP in 80 normal subjects. Measurements
falling at or above the 90th percentile of the group are considered







AgAb detected by Clq-FP in 83 normal subjects. Measurements
falling at or above the 90th percentile of the group are considered




AgAb, as detected by KgBt, in 105 normal subjects. The dotted
line represents the 90th percentile. Measurements falling at or above
the 90th percentile of the group are considered positive. The limit of






















AgAb, as detected by RAJI, in 68 normal subjects. The limit of
positivity was chosen as 20 ug AHG eq/ml.
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A3.If Immune complexes in norma 1
subj ects
Since the methods presently available do not distinguish between
complexes related to specific disease processes and those found in
other more common conditions, e.g.,viral infections, it is not
surprising that circulating AgAb are also found in some apparently
healthy subjects. In evaluating the presence of AgAb in a particular
disorder it is necessary to compare the results with those found in
an apparently normal population. However, the limit dividing normal
from pathological values is arbitrary and may vary according to the
characteristics of the normal population,which have been chosen as
reference.
The presence of circulating AgAb in a clinically normal
population has been investigated using four methods based on
different principles: the solid phase Clq binding test (Clq-SP), the
fluid phase Clq radioimmune assay (Clq-FP).the Raji cell radioimmune
assay (RAJI) and the conglutinin binding test (KgBt) (Di Mario et
al,1980). With the first three methods, immune complex levels showed
a peaked asymmetric distribution with a positive tail including about
10% of subjects (Figures A3.1/1, A3.1/2, A3.1/3)) while with the
fourth method immune complex values were more widely spread (Figure
A3.1/4). No difference between immune complex values in males and
females was found. There was a significant trend for the prevalence
of immune complexes to increase with age when methods were used which
detected complexes through C3 binding. In subjects tested at regular
intervals during a period of 24 hours, using the fluid phase Clq
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binding assay,significant variations in immune complex levels were
found but no consistent pattern of variation at different hours of
the day or after meals could be seen (Figure A3.1/5). These
hour-to-hour variations are likely to pose a problem in the
investigation of small quantities of AgAb in individual subjects or
small groups of subjects. They may be compensated for by studying
considerable numbers of patients of a particular disease group and
comparing them with to age-matched controls, or by analysing multiple
samples obtained at different times from small groups of patients and
comparing them with to similar samples from control subjects.
FIGURE A3.1/5
AgAb in the serum during 24 hours in 13 normal subjects. The
figures are the means of the immune complex values for each of the
different time intervals. The standard deviations are shown.
B=Breakfast, L=Lunch, D=Dinner.
~I 1 1 1 1
11 14 17 20 hours 8
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A3.2 T CELL SUBPOPULATIONS
T cells and activated T cells were detected and evaluated by the
use of monoclonal antibodies (see below). Original technical develop¬
ments to facilitate the evaluation of T cell subsets (A3.2b) and of
class II MHC positive T cells (A3.2c) are described.
* T cell subset enumeration
T cell subsets have been enumerated by an indirect
immunofluorescence technique.
Purify lymphoid cells by density gradient centrifugation, check
the viability and count the cells;
- Add monoclonal antibody against T cell surface antigen (0.05ml
of the appropriate dilution to 5x10^ cells); incubate 30 minutes at
4°C and wash twice;
- add rabbit anti-mouse antibody conjugated with fluorescein;
incubate 30 minutes at 4°C and 2 washings;
- read under a fluorescence microscope.
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A3. 2a Monoclonal antibodies to
T cell surface antigens
Monoclonal antibodies defining regulator T lymphocytes
0KT3
This monoclonal antibody (Ortho Immune Diagnostics) is directed
against a T cell surface molecule of 20000 dalton present in all
mature T lymphocytes and a minority of thymocytes (Reinherz &
Schlossman,1980; Reinherz et al,1983). This antigen participates in
cell-mediated lysis by both of the major cytotoxic T lymphocyte (CTL)
subsets: in fact antibodies to this structure block killing by T4 and
T8 CTL. It seems that is closely linked to a recognition structure
for antigen. It was used here to enumerate T lymphocytes and as a T
cell cytotoxic antibody in the double staining technique (A3.2c).
0KT4
This monoclonal antibody (Ortho Immune Diagnostics) is directed
against a T cell surface molecule of 62000 dalton present on the
majority of thymocytes and on about 60% of peripheral T cells. This
antigen participates in cell-mediated lysis: antibodies to this
structure block killing by T4 CTL. T4 positive T cells are directed
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at class II MHC antigens on target cells. The T4 were shown to
provide inducer (helper) function in T-T and T-B cell interactions
(Reinherz & Schlossman,1980; Ballieux & Heijnen,1983).
Leu3a
This monoclonal antibody (Beckton & Dickinson) phenotypes the
helper/inducer T cell subsets (Ledbetter et al,1981). It is analogous
to the monoclonal 0KT4.
0KT8
0KT8 (Ortho Immune Diagnostics) is directed against a T cell
surface molecule of 76000 dalton present in the majority of
thymocytes apd on about 30% of peripheral T cells. This antigen
participates in cell mediated lysis: antibodies to this structure
block killing by T8 CTL. T8 positive T cells are directed at class I
MHC antigens on target cells. A number of studies have indicated that
the T cell subset defined by the T8 antigen is heterogeneous with
respect to function. It contains cytotoxic cells as well as cells
involved in the suppression of the immune response (Reinherz &
Schlossman,1980; Ballieux & Heijnen,1983) .
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UCHT4
This antibody is analogous to 0KT8 or Leu2a (Beckton &
Dickinson) monoclonal antibodies which phenotype the suppressor/
cytotoxic T cells (T8 positive T cells) (Beverley,1982).
Monoclonal antibodies defining activated T lymphocytes
The monoclonal antibodies used were: 4F2, 5E9, anti-Tac,
DA6.231, DA6.164, L243.
4F2
This monoclonal antibody is a IgG2a kappa immunoglobulin and
binds rabbit complement and protein A (Haynes et al,1981; Haynes,
1981). 4F2 antigen is a 120000 dalton protein present on haemato¬
poietic and non-haematopoietic cells. B and T lymphocytes bind
negligible amounts of 4F2 antibody, polymorphonuclear cells do not
bind the antibody whereas monocytes bind the 4F2 antibody. 70% of
concanavalin A activated T cells bind strongly the 4F2. The antigen
is newly synthesized by activated lymphocytes. The antigen is one of
the first antigens to be expressed on activated T cells.(The antibody
was kindly donated by DR GS Eisenbarth,Joslin Clinic,Boston,USA).
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5E9
This monoclonal antibody is a IgGl kappa myeloma protein which
binds neither complement nor protein A (Eisenbarth et al,1980; Haynes
1981). 5E9 antigen is a 87000 dalton protein but it may exists in
dimeric form with a molecular weight of 190000. The antigen has the
functional property of binding transferrin. It is present on all
rapidly dividing lymphoid or non-lymphoid cell lines. It is very
similar, or identical, to a monoclonal antibody termed 0KT9. B and T
lymphocytes, monocytes and polymorphonuclear cells do not bind this
antibody. About 50% of PHA activated lymphocytes bind 5E9 antibody.
5E9 is a useful marker of human cell activation. (The antibody was a
gift of Dr GS Eisenbarth, Joslin Clinic,Boston,USA).
anti-Tac (or TAC)
It is a monoclonal antibody that is reactive with human T cells
activated by phytohaemoagglutinin, pokweed mitogen, concanavalin-A,
streptolysin 0 and allogeneic cells. It does not react with fresh
peripheral blood T cells,B cells,monocytes, thymocytes and B cells
activated by pokeweed mitogen or Epstein-Barr virus (Uchiyama et al,
1981a; Uchiyama et al,1981b). The Tac antigen is expressed on T
cells, activated by pokeweed mitogen, that have the functions of help
and suppression. Two different kinds of helper T cells are present in
pokeweed-stimulated T cell cultures: the Tac+ helper T cells, that
are radioresistant, and the Tac- helper T cells, that are more
radiosensitive. Tac+ T cells, separated from peripheral blood
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mononuclear cells after in vitro allosensitization, showed specific
cytotoxic killer cell activity against allogeneic cells, whereas
Tac- cells did not have this function. Tac antigen seems different
from class II MHC antigens expressed on activated T cells: Tac+ and
class II- and Tac- and class 11+ leukemic T lymphocytes have been
reported. It seems that the Tac antigen is part of the T cell growth
factor receptor. In conclusion the anti-Tac monoclonal antibody can
define activated and functionally mature human T cells. The Tac
antigen is expressed on T cells not only after in vitro activation
but also after in vivo activation by specific antigens. In other
words it can be used to analyze the activation and the terminal
differentiation of T cells.
DA6.231
DA6.231 is an IgGl non-complement-fixing monoclonal antibody
directed to a framework determinant of human MHC class II molecules.
DA6.231 reacts with all homozygous typing cell lines representing the
common DR alleles (DRl-8). DA6.231 reacts with circulating peripheral
blood B lymphocytes and many B cell neoplasias. The DA6.231 deter¬
minant is expressing on >80% of peripheral blood monocytes and on
activated T lymphocytes. In in vitro assay systems of lymphoprolifer-
ation, DA6.231 blocks both DR and SB specific responses. DA6.23I does
not block the binding to cells of authentic anti-HLA-DC monoclonal
antibodies suggesting that it does not react with DC-encoded mo¬
lecules.When tested against a panel of mutant cell lines de-
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rived from DR1 and DR3 haploid parent cell lines, DA6.231 identifies
a determinant common to SB and DR molecules. The DA6.231 determinant
appears to be predominantly expressed on beta polypeptides (Van
Heyningen et al,1982; Guy et al,1982; Cohen et al, 1983).
DA6.164
DA6.164 is an IgGl non-complement-fixing monoclonal antibody
directed to a framework determinant distinct from that recognized by
DA6.231. DA6.164 reacts with all homozygous typing cell lines re¬
presenting the common DR alleles, with the exception of DR7 cell
lines. DA6.164 appears to have higher affinity for class II molecules
derived from DR3, DR5 and a subset of DRw6 cell lines than for
molecules from DR1, DR2, DR4 and some other DRw6 alleles. SB specific
responses are not blocked by DA6.164. With panels of deletion mutants
derived from DR1 and DR3 parent cell lines, DA6.164 identifies a
determinant present only on DR encoded antigens. The DA6.164 de¬
terminant is labile and does not react with isolated chains of class
II molecules. However the reaction of DA6.164 with cell lines is
invariably blocked by prior incubation of the cells with DA6.231
suggesting that the DA6.164 determinant is also on beta polypeptides.
DA6.164 is expressed on >80% of peripheral blood monocytes and is
present on activated T cells and normal and neoplastic B lymphoid
cells (Van Heynenegen et al,1982; Guy et al,1982; Cohen et al,1983).
(DA6.231 and DA6.164 monoclonal antibodies were a kind gift from
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Dr K Guy, MRC Clinical and Population Cytogenetic Unit,
Edinburgh,UK).
L243
This monoclonal antibody is directed against human class II MHC
molecules. It binds to human B cell lines but not to T cell lines in
normal conditions. The antigen is expressed on some activated T
cells. It precipitates 28000 and 34000 dalton chains from extracts of
B cell lines. It is cytotoxic for human cell lines (Lampson &
Levy,1980). (The antibody was donated by Dr GS Eisenbarth, Joslin
Clinic, Boston, USA).
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A3. 2b An original method to f a c i 1 i -
t a t e the evaluat ion o f
T-cell subsets
An important development in the characterization of cell surface
functional antigens has been the development of monoclonal anti¬
bodies.To date,more and more specificities are described in the
scientific literature and no doubt even more will be found in the
future. For example,accurate characterization of T and B lymphocyte
subclasses,K/NK cells and activated T cells requires at least 10
monoclonal antibodies per blood sample.If a fluorescence activated
cell sorter(FAGS) is available,the number of samples poses no pro¬
blem.At present,however, this is not the case and many researchers
find themselves,therefore,in the unenviable position of spending a
great deal of time on preparing a single slide for each monoclonal
antibody.
In this report an adaptation of existing equipment in order to
facilitate the workload is described.
Materials and Methods
The equipment consists of Medicell glass-bottomed plates
in conjunction with an inverted fluorescence microscope.The
plates, which are readily available(Medicell International LTD) since
they are routinely used for HLA-DR tissue typing,are made of a thin
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sheet of glass, subdivided into 60 flat circular areas by raised
rings, attached to a plastic frame with an inner ridge.The plates can
be covered with a transparent plastic cover which fits over the inner
ridge of the frame thus effectively reducing the rate of evaporation
of the cell samples. The latter are placed within the circular areas
where diffusion is prevented by the rings;alternatively the plates
can be moved along by hand.
The method described here is for blood mononuclear cells
although it can be applied to any other cell preparation.
- Isolate mononuclear cells by density gradient centrifugation
on Ficoll-Hypaque.
Wash cells three times in Phosphate Buffered Saline(PBS),pH 7.3,
and suspend them at a concentration of 2.0x10^ cell/ml in
RPMI 1640 medium containing 10% heat inactivated foetal calf
serum(complete medium).1.0 ml of this suspension is enough
for a panel of up to 10 monoclonal antibodies.
Divide the cell suspension into 0.1-0.2 ml aliquots in small
plastic centrifuge tubes(10x60mm).
- Spin tubes at 1,700 g for 1.5 min,preferably in a centrifuge
equipped with a fixed-angle rotor.Remove supernatant by tipping
tubes then add 50 ul of the appropriate monoclonal antibody.
Quickly vortex tubes to suspend cells and incubate for 30 min
in an ice-bath.
Wash cells three times with PBS at 1,700 g for 1.5 min then
add 50ul of the appropriate dilution of fluorescein conjugate
antimouse IgG antibody.Vortex tubes and incubate for 30 min
in an ice-bath.
Wash cells three times in PBS and finally suspend them in
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50ul of complete medium.
Place 5ul of each cell sample in a circular area of the Me-
dicell plate and leave for 3-5 min to allow cells to sink
to the bottom.
Count the proportion of rim fluorescence positive cells in the
inverted fluorescence microscope.
Comments
The length of time required to complete the characterization of
mononuclear cells from a single subject is a very acute problem in
all the laboratories. The method described has now been used for over
one year and has been found extremely useful. Many of the problems
connected with eye adaptation to dark room conditions are avoided
since the microscope reader does not need to leave the machine to
prepare single slides.
In addition to increasing the number of cell samples that can be
read at any given time, there is the bonus that the number of cells
required for each monoclonal antibody can be greatly reduced(0.2-
0.5x10"^ cells).This can be of considerable importance when pheno-
typing mononuclear cells from small blood samples, in particular
those from small children and difficult patients.
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A3.2c An original method to
evaluate class II antigen
positive T cells
Attention of investigators has recently been focused on that
subset of lymphocytes which expresses the class II (or DR) MHC
antigen on their surface. This class II antigen is a marker of T cell
activation and is normally absent on non activated or otherwise
uncommitted T cells. On the other hand, this antigen is normally
present on the surface of B cells. The fact that this surface antigen
is present in both B cells and in a few T cells creates some te¬
chnical difficulties.
Since the percentage of activated T cells is usually very low, a
method of easily and clearly identifing this T cell subset is needed.
Most investigators identify and isolate T cells on the basis of their
ability to form spontaneous rosettes when incubated with sheep red
blood cells (WHO Scientific Group Report,1977; Weir,1978; Hudson &
Hay,1981). This widely used technique is time consuming and not
accurate enough for the evaluation of activated T cells: some T cells
are lost - and a particular subpopulation of T cells may be
preferentially removed; on the other hand,some B cells still remain
in the rosette enriched T population,making it difficult to
discriminate the activated T cells from the contaminating B cells.
Other investigators use a double immunofluorescence staining - with
both fluoresceine and rhodamine - to label respectively the antibody
defining the DR antigen and that defining another antigen of either T
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or B cells. This technique is rather elaborate and tedious; the
immunofluorescence pattern is usually faint, the different cells need
to be read with different fluorescence microscope filters and the
results obtained are usually poorer than expected.
In order to overcome these difficulties, a straightforward
double staining technique using commercially available monoclonal
antibodies has been devised.
Methods
a) immunological or other specific reagents needed: anti-class
II antigen monoclonal antibody (this antibody should not be cyto¬
toxic), anti-total T cell monoclonal antibody (for instance Leu
la.Becton- Dickinson or 0KT3,0rtho Diagn.),ethidium bromide,fresh
rabbit complement,rabbit anti-mouse antibody conjugated with fluor¬
escein.All the monoclonal antibodies are diluted in medium (RPMI
1640) plus 10% foetal calf serum.
b) procedure:
- purify lymphoid cells by density gradient centrifugation; check
viability of cells and count them;
- add anti-class II antigen monoclonal antibody (0.05 ml appropriate
dilution to 5x10^ cells); incubate 30 minutes at 4°C and
wash twice in medium;
- add rabbit anti-mouse antibody conjugated with fluroscein; incubate
30 minutes at 4°C and wash twice in medium;
- add a cytotoxic anti-T cell monoclonal antibody (0.05 ml
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appropriate dilution) and fresh complement (200 ul rabbit or
guinea pig complement after checking for spontaneous cyto¬
toxicity); incubate 30 minutes at 37°C;
- add ethidium bromide at a concentration of 50ug/ml and read with a
fluorescence microscope,fitted with a filter for fluorescein.
The B cells will appear green on the surface, the class II
negative T cells will appear red in the nuclei whereas
the class II positive T cells will show a red nucleus and a
green surface.
Comments
With the technique described, the difficulties found with the
other methodologies seem to be overcome. Under the fluorescence
microscope it is possible to see clearly the bright red of the nuclei
of the T cells, the green continuous linear fluorescence of the
surface of the B cells and a few cells with a red nucleus and a
fluorescent green surface, i.e. the class II MHC antigen positive T
cells. Both colours are read with the same filter,i.e. that for
fluorescein. The technique is fast: 3 or 4 hours are needed to
complete it. No significant amount of cells are lost with this
procedure which requires only washings but not separation of cells.




The methods to detect insulin antibodies are numerous and differ
in principle (Christiansen,1970; Andersen et al,1972; Mustaffa et al,
1977; Gerbitz & Dixon,1978; Kurtz et al,1980). Two methods were
chosen to measure insulin antibodies in this study. Serum insulin
binding capacity was evaluated by the method described by Andersen et
al,1972, as developed by Mustaffa et al,1977, with minor
modifications and by the method described by Christiansen,1970.
A3.3a Andersen's method
a. Reagents
Guinea pig anti insulin serum (Wellcome), diluted 1:8000; rabbit
anti guinea pig serum (Wellcome), dilute 1:60; normal guinea pig
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serum, diluted 1:50; bovine I-insulin, at a working dilution
of 20uU/ml; charcoal suspension 5g/100ml; Sodium-phosphate
buffer 0.04mM/l; albumin solution 5g/l
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1st day
Add guinea pig anti insulin serum, 100 ul, to phosphate
buffer, 100 ul,
add rabbit anti guinea pig serum, 100 ul
mix and incubate overnight at 4 °C
2nd day
add to the mixture the serum to be tested, 100 ul
add radiolabelled insulin, 100 ul of the working dilution
mix and incubate at 4°C
3rd-5th day
leave to incubate at 4°C
6th day.
add normal guinea pig serum, 100 ul
- mix and incubate at 4 °C
7th day
centrifuge at 2800 rpm at 4°C for 45 minutes
keep the precipitate
add the charcoal suspension to the supernatant
mix for 5 minutes
- centrifuge at 2800 rpm at 4°C for 30 minutes
keep the supernatant
count the first precipitate and the second supernatant
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c. Expression of results
Insulin antibody levels are calculated as follows:
supernatant / precipitate x [guinea pig antiserum titre] x 10




Agarose (Litex Agarose.Denmark); anti-human-immunoglobulin
125




- add 50 ul of the serum to be tested to 50 ul of buffer
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- add 1-insulin to the mixture
- leave to incubate overnight
2nd day-
heat 50 ml of buffer, diluted 1/2 in distilled water, plus
Ig of agarose for a few minutes
- pour 13.5ml of the agarose solution in 20ml tubes inside a
thermostatically controlled bath at 52 °C
add 1.5 ml of anti-human-immunoglobulin antibody to each of
the tubes containing agarose
pour gently one tube of the agarose-antibody mixture in a
lOcmxlOcm glass slide, pre-heated with a Bunsen burner
leave the agar mixture to cool
make 12 wells into the agar gel
- put 5 ul of the test serum-radiolabelled insulin mixture in
each of the wells
fill the electrophoretic baths with 1/3 of buffer and 2/3
of distilled water
put dialysis paper on the anodic side of the glass
switch on the electricity
- leave antibodies to migrate for 18 hours
3rd day
cut the precipitation rings around the wells
put the strips in tubes with 1 ml of distilled water
count the radioactivity
Expression of results
Insulin antibody levels are calculated as follows:
cpm of tested serum - cpm mean of normals / total cpm added
x (uU of insulin added)
Results are expressed in mU/ml
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A3.4 INSULIN-ANTI-INSULIN COMPLEXES
The method used is a development of the methods described by
Jayarao et al,1973, and Virella et al,1980.
The method is based on the assumption that when bound and the
free radiolabelled insulin are separated at neutral pH with one of
the numerous of different ways, after having added radiolabelled
insulin to a serum containing insulin antibody, only free insulin
antibodies are measured. On the other hand, when the pH of the medium
is below three, insulin antibodies are dissociated from the antigen
and the measurement of insulin binding capacity at that point re¬
flects the total amount of insulin antibody. The difference between




prepare glycine 0.2N 31 and HC1 1 1
add 684 ml of HC1 0.2N to 31 of glycine,
reach pH 3
Barbital buffer
Na barbital 14.7g and Na acetate 9.7 g in 500 ml of d.w.
add 1800ml of NaCl 0.85g/100ml and 100 ml of HC1 0.1N
reach pH 7.4
Dextran charcoal
Charcoal norit A 5g/100ml in barbital buffer
Dextran 80 0.5g/100 ml
Mix equal volume of charcoal suspension and dextran
solution
Acid dextran charcoal
As above in glycine-HCl buffer
Albumin solution
Albumin 3% in barbital buffer
Procedure
- split the serum to be tested into two aliquots.
dialyse one aliquot overnight in buffer glycine-HCl (pH3),
- add serum to dextran-charcoal in glycine-HCl,
incubate for 30 minutes at room temperature,
- centrifuge at 2800rpm for 20 minutes
- dialyse the supernatant versus barbital buffer, pH 7.4.
add radiolabeled insulin to this mixture
add radiolabeled insulin also to the other aliquot, ade¬
quately diluted (1:10)
incubate for two hours at 37°C,
add dextran-charcoal
centrifuge at 2800 rpm for 20 minutes
count the supernatant and the precipitate.
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c. Expression of results
The insulin-anti-insulin complexes are calculated as the dif¬
ference between the "total" antibody and the "free" antibody. The
"total" and the "free" antibodies are calculated as follows: 100 -
(cpm in the precipitate -cpm in the supernatant/total cpm) x 100 -
background.
Positive values are above the mean + 2 SD of normal values and
are expressed in percentage (i.e. >10%). Positive values of Ins/iAb
are above the mean + 2 SD of values found in normal controls (i.e.
>7). The sensitivity of this technique in assaying the sole presence
of insulin antibodies is slightly different from Andersen's method.
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A3.5 ORGAN SPECIFIC AUTOANTIBODIES
A3.5a Islet cell antibodies
a. Reagents
Fresh human sharply frozen pancreatic tissue
Anti-human-immunoglobulin serum conjugated with fluorescein
b. Procedure
prepare unfixed 5nm cryostat sections of group 0 frozen
human pancreas
add.patient's undiluted serum to pancreas sections
incubate 30 minutes at 37°C
wash for two 15 minute periods in neutral buffer
rinse in buffer
incubate with anti-human-immunoglobulin antiserum
conjugated with fluorescein at appropriate dilution
for 30 minutes at 37°C
wash as above
read under a fluorescence microscope
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A3. 5b Complement fixing islet cell
antibodies
a. Reagents
Fresh human sharply frozen pancreatic tissue
Fresh normal human serum as source of complement
Anti-human-C3 antiserum conjugated with fluorescein
b. Procedure
- add patient's undiluted serum to pancreas slices as above
- incubate for 30 minutes at 37°C
add fresh normal human serum as a source of additional
complement
- wash for 2 15-minute periods in neutral buffer
- add anti-human-C3 conjugated with fluorescein
- incubate 30 minutes at 37°C
- wash as above
- read under a fluorescence microscope
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A3.6 CIRCULATING ISLET CELL ANTIGENS
The search for circulating specific antigens has been done by
the use of monoclonal antibodies reacting with human pancreatic islet
cell antigens.
A3. 6a Monoclonal antibodies reacting
with pancreatic islet cell
antigens
Overview on anti-islet monoclonal antibodies
The monoclonal antibodies reacting with islet cells antigens so
far produced (Eisenbarth et al,1984) can be grouped as follows:
1. Heterospecific monoclonal antibodies which initially were pro¬
duced to neurons or malignant cells.
2. Murine heterospecific monoclonal antibodies produced following
immunization of mice with rat islet cells (A4A11), a rat islet cell
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tumor line (5D6.A1D2), human islets and human insulinoma tissue (HISL
1 to 19)
3. Rat monoclonal autoantibodies produced by fusing spleen cells
from a diabetic prone BB rat (A1G12, BB-TECS).
4. Human monoclonal autoantibodies produced by fusing circulating
lym- phocytes from a child with type I diabetes with a human myeloma
cell line (B6).
In addition to anti-islet antibodies two monoclonal antibodies
which react with subsets of thymic epithelial cells have been re¬
cently described. These antibodies, BB-TECS (made by fusing spleen
cells of a diabetes prone BB rat) and DM-TECS i (made by fusing
circulating lymphocytes from children with type 1 diabetes with a
human myeloma line) react with the endocrine portion of the thymus
and their existance may indicate that the autoimmunity of type I
diabetes extends to the thymus.
mcAb Type Antigen Cells
A2B5 Mouse CQ ganglios. Islet,neuron & neuroend. tiss
3G5 Mouse Ganglioside Islet,neuron & neuroendocrine
Tet. Tox.+3D8 Mouse GD,GT gangl. Islet,neuron & neuroendocrine
4F2 Mouse 120K glycopr.Islet,monoctyte, act.T cell
LC7/2 Mouse 120K glycopr.Islet,tumor line
A4A11 Mouse Unknown " Islet
5D6 Mouse Unknown Islet,fibroblast
A1D2 Mouse 24K glyco Islet
B6 Human Unknown A cells
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A1G12 Rat-Mouse Unknown "Nuclear"islet
BB-TECS Rat-Mouse Unknown Thymic endocrine,islet
DMTECS 1 Human Unknown Thymic nonendocr. epithelium
HISL 1 to 17 Mouse Unknown Islet cells frozen pancreas
HISL 19 Mouse 64K Islet cells frozen pancreas
* Anti-islet monoclonal antibodies used in this study
Among the monoclonals described above, four anti-islet
monoclonal antibodies were chosen to be used in this study.
These two monoclonal antibodies have been very recently raised
in mice after immunization with human frozen pancreatic islet cells.
A number of monoclonal antibodies were produced in this way in Dr GS
Eisenbarth laboratory and sequentially numbered. The monoclonal
antibody HISL-19 reacts with a 64000 dalton molecular weight protein
present on the human islet. It is not known the molecular weight of
the antigen relative to the monoclonal HISL-5. These two monoclonal
antibodies give a bright staining of human pancreatic frozen sections




This monoclonal antibody was initially produced following
immunization of mice with chicken retina neurons (Eisenbarth et
al,1979). Studies of the antigenic material extracted from brain
revealed that this monoclonal antibody reacts with cQ gangliosides,
complex gangliosides with four sialic acid residues. Such complex
gangliosides are predominantly found in neuronal and in neuro¬
endocrine tissues, including pancreatic islets. A2B5 reacts
specifically with human pancreatic islets on frozen sections and
gives an indirect immunofluorescence staining identical to that of
islet cell autoantibodies.
3G5
3G5 is a monoclonal antibody that reacts with complex neuronal
gangliosides present in neuronal and in neuroendocrine tissues, such
as pancreatic islet cells. This monoclonal antibody does not react
with a solid phase ganglioside preparation from rat brain, with which
antibody A2B5 reacts. Thus its receptor is a ganglioside different
from antibody A2B5 (Eisenbarth et al,1984).
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A3.6b Techniques t o detect
circulating islet cell
antigens
The identification of soluble pancreatic antigens was performed
by the use of monoclonal antibodies in fluid phase. The monoclonal
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antibody is radiolabeled with I; the serum to be tested and the
radiolabeled monoclonal antibody are left to incubate; the free
monoclonal antibody and the complexed form are separated by
precipitation with polyethyleneglycol (PEG).
* Reagents
Monoclonal antibodies A2B5 (10 mg/ml), 3G5 (4mg/ml), HISL-5 (8
1 2 5
mg/ml), .HISL-19 (10 mg/ml), I, PEG 6000 12%, phosphate
buffer, bovine serum albumin
* Iodination of monoclonals
The chloramine T method was used (see chapter A3.1)
* Procedure
add 50 ul of serum to 200 ul of phosphate buffer with
bovine serum albumin 3%
add 50 ul of iodinated monoclonal antibody (approximately 2
ng/tube)
incubate 1 hour at 37 °C
add 300ul of the PEG solution
mix accurately at 4°C
spin at 3000 rpm for 20 minutes
count the supernatant and the precipitate
Expression of results
Results are expressed as in percent as follows:




IMMUNOLOGICAL FACTORS IN THE PATHOGENESIS OF TYPE 1 DIABETES
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Chapter B1 IMMUNOLOGICAL FACTORS IN THE PATHOGENESIS
OF TYPE 1 DIABETES
Bl.l Experimental design of the studies on the pathogenesis
of type 1 diabetes
B1.2 Earlier studies by the author
Bl.2a Soluble immune complexes in newly diagnosed
diabetics: a preliminary observation
B1.2b Autoimmunity and HLA antigens in type 1
diabetes
B1.2c Immune complexes in newly diagnosed type 1
diabetics: a pilot study
B1.2d Immune complexes in type 1 diabetics with
persistent islet cell antibodies
Bl.3 Immunological events in insulin dependent diabetics at
diagnosis and follow up
Bl.3 Aim of the study
B1.3b Materials and methods
Bl.3c Results
B1.3d Discussion
B1.4 Immunological events in diabetics not requiring insulin
at diagnosis and follow up
B1.4a Aim of the study




B1.5 Search for circulating specific antigens in the early
stages of type 1 diabetes by monoclonal antibodies
B1.5a Aim of the study





Bl.l EXPERIMENTAL DESIGN OF THE STUDIES ON THE PATHOGENESIS OF
TYPE 1 DIABETES
The prevailing concept of the aetiopathogenesis of most cases of
type 1 diabetes is that in genetically susceptible individuals a
combined process of an exogenous aggression and autoimmune reaction
determines the destruction of insulin producing cells. However most
of the pathogenetic mechanisms are still obscure (For details and re¬
ferences see chapter A1.3).
Four observations are highlighted here.
Circulating immune complexes, activated T cells, killer cells
and antibodies to islet antigens are present in the early stages of
type 1 diabetes.
- Circulating immune complexes are presently detected with methods
that do not give information on the antigen(s) involved in their
formation. Some types of complexes seem to be increased at diagnosis
in diabetes and then to decline in parallel with islet cell anti¬
bodies.
- The presence of humoral immune factors, such as islet cell
antibodies, complement fixing islet cell antibodies, immune complexes
and other factors seem to be important prognostic markers not only in
insulin dependent diabetics but also in some other diabetics not
requiring insulin.
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- The selective destruction of the pancreatic islet beta cells may
continue for months or years before and after the clinical onset of
diabetes. It is possible that circulating islet antigens, either free
or complexed with antibody are in the circulation both before and
after the initial clinical manifestation of the disease.
Starting from the above observations the following studies have
been undertaken:
a) The following over a period of time of the main humoral immuno¬
logical factors suspected of having a role in type 1 diabetes, from
diagnosis up to a few years after, and to evaluate the possible
correlations between them.
b) The evaluation of the clinical prognostic value of different
immunological markers in diabetic patients not requiring insulin at
diagnosis.
c) The search for circulating pancreatic antigens in newly diagnosed
type 1 diabetics.
In the study described in chapter B1.3, the humoral immune
response in type 1 diabetics has been investigated at diagnosis and
thereafter. When the study was done, no other similar investigation
on a large group of diabetics had been reported by others. Islet cell
antibodies, complement fixing islet cell antibodies, viral anti¬
bodies, different types of immune complexes, insulin antibodies and
HLA types were evaluated in a group of about 150 newly diagnosed type
1 diabetics. In the majority of them a regular follow up till 3 years
after diagnosis has been carried out.
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In chapter B1.4 a study of some immunological events in
diabetics not requiring insulin at diagnosis is described.The
presence of immune complexes and of islet cell antibodies have been
evaluated in newly diagnosed diabetics treated with diet or oral
agents. Those diabetics not requiring insulin at diagnosis and who
showed islet cell antibodies in their sera have been followed over a
period of time. The clinical prognostic value of islet cell
antibodies, complement fixing islet cell antibodies and immune
complexes has been evaluated.
An attempt to find possible specific circulating islet cell
antigens in early stages of type 1 diabetes and to relate them to the
pathogenetic events is described in chapter B1.5. Since the auto¬
antibodies to islet cells so far described do not seem to have a
direct correlation with islet damage, the detection of islet cell
antigens released in the circulation in parallel with islet cell
damage might provide a invaluable marker of the pathogenetic
events in type 1 diabetes. No investigation on circulating islet cell
antigens has been reported so far.
Patients have been included in these studies as a result of col¬
laboration with the Diabetic Department, Royal Infirmary, Edinburgh,
Uk, the Diabetic Unit, University of Rome, Italy, and the Joslin
Clinic, Boston, USA.
Viral antibodies have been assayed in the department of Bac¬
teriology, Edinburgh University,UK.
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HLA studies have been done in part in the Nuffield Department of
Surgery, University of Oxford and in part in the Endocrine Unit/-
Immunology Laboratories, Royal Infirmary,UK.
Part of the the islet cell antibody evaluations in study B1.3,
and the autoantibodies to gastric parietal cells and to thyroid cell
cytoplasm, have been done routinely in the Endocrine Unit/Immunology
Laboratories, Royal Infirmary, Edinburgh,UK.
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B1.2 EARLIER STUDIES BY THE AUTHOR
Bl. 2a Soluble immune complexes in
newly diagnosed diabetics;
a preliminary observation
The presence of immune complexes in the sera of newly diagnosed
insulin-dependent diabetics, compared to that in controls, and their
association with the occurrence of antibodies to islet cells and
viruses, are reported and discussed.
Materials and methods
Sera were obtained between October and March from thirteen newly
diagnosed diabetics.Control sera for these patients were obtained
during the same period from age- and sex-matched healthy subjects,
including hospital personnel. All sera were stored in 500 ul ali-
quots at -40°C.
The Raji cell radioimmunoassay as described by Theofilopoulos et
al (1976) was used. The amount of soluble immune complexes in each
test serum was espressed as being equivalent to so many ug aggregated
human gamma globulin (AHG) per ml serum (Chapter A3.1).
Islet cell antibodies (ICA) and other organ-specific auto¬
antibodies were detected by the indirect immunofluorescence test
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(Chapter A3.5;Irvine et al, 1977). Sera that were positive for ICA
when tested neat were titrated using doubling dilutions.
The sera of the thirteen newly diagnosed insulin-dependent
diabetics and their age- and sex-matched controls were screened and
titrated for the following viral antibodies: to Coxsackie virus Bl-5
by a metabolic inhibition test; to Epstein-Barr virus by an indirect
immunofluorescence test; and to rubella virus using a haemaggluti-
nation inhibition test. Sera were screened and titrated for com¬
plement fixing antibody to the following antigens: influenza A,B and
C; parainfluenza type 1; measles; mumps S and V; respiratory syn¬
cytial virus; adenovirus; cytomegalovirus; varicella zoster; Herpes
simplex; Coxiella burneti phase 2; Chlamydia group B and Mycoplasma
pneumoniae.
All analysis were done using Fisher's exact test, except where
indicated.
Results
Seven out of the 13 patients were positive for immune complexes,
6 of these 7 were were islet cell antibody positive whereas none of
the complex negative showed ICA in their serum. Three immune complex
positive and three complex negative patients showed also circulating
viral antibodies. The occurrence of soluble immune complexes in the
sera of seven out of thirteen newly diagnosed insulin-dependent
diabetics clearly correlated with the presence of ICA (P<0.01), but
not with the presence or titres of antibodies to Coxsackie B4. The
prevalence and titres of antibodies to the other viruses investigated
were similar in the diabetics and in the age- and sex-matched con¬
trols. There was no correlation between the occurrence of soluble
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immune complexes in the serum and the presence of ketosis or the
level of the blood sugar.
Discussion
The close correlation between the presence of soluble immune
complexes and ICA in the serum, and the absence of such a correlation
with viral antibodies and other autoantibodies, suggests that the
antigens involved in these immune complexes may be derived from islet
cells. This would suggest that in such patients there has either been
a recent release of islet cell antigens or that such antigens are
being continually released after the onset of clinical diabetes of
the insulin dependent type. The fact that the symptoms of diabetes
before diagnosis were present for as long as 4 months in patients
with immune complexes at diagnosis suggests the latter, and this
would accord with the observation that some B cells of the islets
persist after the clinical onset of this type of diabetes, as
evidenced by their ability (albeit diminished) to produce C peptide
(Heding & Rasmussen,1975). Moreover, ICA reacts with all cells in
the islets, although it is only the B cells that are markedly af¬
fected in Type I diabetes (Doniach,1974;Egeberg et al,1976) .
Soluble immune complexes comprising islet cell antigen and
antibody could be important in relation to antibody-dependent cell-
mediated cytotoxicity, whereby K cells may be specifically armed by
such complexes in antibody excess.If so, the question remains why it
is that the B cells are selectively destroyed, unless A and D cells
have greater powers of regeneration. Alternatively, immune complexes,
in relation to islet cell antigens, may simply be a consequence of
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islet cell damage and not be involved in producing further islet cell
damage.
160
B1.2b Autoimmunity and HLA antigens in type 1 diabetes
The present study was undertaken to analyse in greater depth
which, if any, of the three HLA groups in linkage disequilibrium with
B8, B15 and B7, respectively, could be shown to be correlated with
the autoimmune aspects of type I diabetes.
Materials and methods
Type I diabetics were selected from those attending the Out-
Patient Diabetic Departement of the Royal Infirmary, Edinburgh, and
divided in three groups. Group I included 101 recently discovered
insulin dependent (type 1) diabetics, with no other associated clinic
autoimmune disease. 50 patiens had ICA detectable in the serum within
1 month of diagnosis (group 12) while 51 did not show islet cell
antibodies (Group lb). The mean age at diagnosis was respectively
22.3(+1.8) and 25.2(+ 1.8) years respectively in group la and lb pa¬
tients. Group II consisted of 39 insulin dependent (type 1) diabetics
who had ICA detectable in their sera at least three years after dia¬
gnosis. Their mean age at diagnosis was 25.1 (+2.4) and they did not
show any clinical sign of autoimmune disorders. The diabetics in
group III showed clinical manifestations of organ specific autoimmune
disorders and were subdivided into group Ilia if they were ICA
positive at 3 or more years after diagnosis and group 111b if they
were ICA negative within 3 years of diagnosis. The mean age at
diagnosis was 41.1 (+3.7) years respectively in group Ilia and 111b
patients. 300 healthy Caucasians from the Oxford area served as
HLA-typing controls.
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ICA was detected by the indirect immunofluorescence test as
previously described (chapter A3.5). Antibodies to thyroid cytoplasm
and gastric parietal cells were also detected by indirect immuno¬
fluorescence and antibodies to thyroglobulin by tanned cell haemag-
glutination (a titre of 1:25 or more being taken as positive)(Irvine
et al,1970).
HLA typing was performed to study the following 37 antigens.A
series: 1,2,3,11,25,26,28,28 and W23,24,30,31,32,33. B series:5,7 ,8,
12,13,14, 15,17,18,27,37,40 and 21,22,35,38,39,41. C series:Wl,2,3,4,
5 (Morris et al,1976).
Statistical analysis used the chi-squared test (with Yates'
correction when indicated) (C) and Student's t-test (S) as shown.
Results
Diabetics without clinical evidence
of associated autoimmune disease
An increased prevalence of HLA-B8 was found in patients in
groups Tb (47%), 13 (61%) and II (73%) when compared with the control
population (28%). Apart from the increased prevalence of Al in group
II patients (67% vs 35% in the normal population, p<0.001), there was
no significant difference in any of the other HLA types tested,
particularly B7, B15,B18,B40 and CW3, between the groups and the
controls. There was no tendency for B15 to be increased in group II
patients (Figure Bl.2/1).
There was a significantly higher prevalance of B8 in those in
whom ICA persisted (group II) compared to those in whom ICA was
negative (group lb). Although there was a higher prevalence of B8 in
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ICA positive compared to ICA negative patients within group I, this
did not reach statistical significance.
The prevalence of thyroid and gastric autoantibodies was signi¬
ficantly increased in patients in group la and in group II when
compared with those in group lb. While patients who had thyroid and
gastric antibodies in their sera tended to have A a higher
prevalence of B8, this did not reach statistical significance.
There was no difference in the sex distribution nor in the mean
age at diagnosis in patients who were ICA positive (group la), ICA
negative (group lb) or in whom ICA persisted for more than 3 years
(group II) .
Diabetics with clinical evidence
of other autoimmune diseases
In patients in group III the prevalence of B8 (81%) and of A1
(59% vs 35% in the normal population, p<0.025) were significantly
higher when compared with those found in the normal population while
the prevalence of B15 did not show any tendency to be increased.
Moreover the frequency of B8 was significantly higher in diabetics in
group III, either ICA positive after 3 years or ICA negative within 3
years of diagnosis (78% and 89%, respectively), in comparison with
ICA negative patients in group lb (47%).
There was a significantly increased prevalence of thyroid and/or
gastric autoantibodies in group III patients compared to those in
group lb. Again the occurrence of these autoantibodies was not
significantly associated with B8.
In the 46 patients within group III there was a significantly
higher prevalence of females and the mean age at diagnosis was
greater than for patients in group I or II.
FIGURE B1.2/1
The prevalence (in %) of B8, B15 and B7 in diabetics in groups I,
II and III. The level 0 represents that found in the normal
population.
• p 0.0005
O p < 0. 025 ^ (C) compared to control population
* p 0.05 (C) compared to group lb
-** P °-ni I
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Discussion
This piece of research has demonstrated that in type I diabetics
without other clinical autoimmune disease, HLA-B8 is significantly
correlated with the persistence of ICA in the serum. This, together
with the observation that B8 is also significantly increased in
diabetics with other overt autoimmune diseases irrespective of their
ICA status, suggests that in type 1 diabetes B8 is associated with
autoimmunity either in terms of persistence of ICA or of clinical
autoimmune disease. Moreover, the presence, and particularly the
persistence, of ICA in the serum is significantly associated with the
occurrence of thyroid and/or gastric autoantibodies. These findings
contradict the reports by Lendrum et al(1975;1976) but substantiate
the trends reported previously by the Edinburgh Group (Irvine et
al,1977;Morris et al,1976).While an increased prevalence of thyroid
and/or gastric antibodies was to be expected in diabetics with poly-
endocrinopathy, its occurrence in group la and especially in group II
patients indicates that the presence of ICA is associated with a
diathesis towards organ-specific autoimmunity in general. However, no
significant correlation could be shown between B8 and the occurrence
of thyroid and/or gastric antibodies in the serum, which is in
agreement with other studies on patients with clinical autoimmune
thyroid disease (Irvine et al,1978) and with pernicious anaemia or
subclinical autoimmune atrophic gastritis (Mawhinney et al,1975).
The younger age and lower female prevalence of ICA positive
diabetics without other clinical autoimmune disease (groups la and
II) compared to diabetics with other immunological disease (group
III) suggests that the subclinical organ-specific autoimmunity in the
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former may progress in some with time to overt clinical disease
especially in females.
The fact that, apart from B8, the only HLA antigen of the A, B
and C series to have a significantly increased prevalence in groups
II and III was AI, suggests that only the HLA group A1, B8 and DR3 is
associated with the autoimmune aspects of type I diabetes. Intere¬
stingly, B15 showed a higher prevalence in group I patients but
tended to show a lower prevalence in groups II and III. Although
these trends did not reach statistical significance, they indicate a
lack of involvement of the second linked group of HLA antigens in
autoimmunity in diabetes. On the other hand, this second HLA group as
indicated by BI5 and CW3 is associated with the tendency to mount a
higher humoral immune response to heterologous insulin, but the
opposite tends to be the case in the presence of A1/B8 (Bertrams et
al,1976; chapter B2.2b).
The third HLA group, A3, B7 and DR2, is protective against the
development of type I diabetes (Ludwig et al,1976), although it is
not known whether this is achieved through a resistance to auto¬
immunity or to pancreatotropic viral infection (or other exogenous
reagent). B7 has been shown to be associated with a high response to
flagellin (Morris et al,1977). In diabetics with B7 a significantly
increased incidence of cutaneous allergic reactions to heterologous
insulin has been described (Bertrams & Gruneklee, 1977). However,
neither the production of antibodies nor the occurrence of cutaneous
allergic reactions to heterologous insulin is concerned with auto¬
immunity in the pathogenesis of type I diabetes. Thus, while all
three of the HLA groups associated with type I diabetes may be linked
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with different immune response genes, only the HLA group which
includes B8 is related to organ specific autoimmunity.
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B1.2c Immune complexes In newly
diagnosed type 1 diabetics:
a pilot study
Evidence is accumulating that in type I diabetes,immunopatho-
logical mechanisms may contribute to islet cell damage.In chapter
B1.2a the finding of soluble immune complexes (AgAb), detected by the
Raji cell assay,in a small group of newly diagnosed insulin dependent
diabetics has been reported. A correlation between the presence of
AgAb and islet cell antibodies (ICA) in the serum was found. To con¬
firm this preliminary report AgAb and ICA have been here studied in a
larger group of IDD patients at diagnosis and at intervals up to one
year following diagnosis.Immune complexes were detected by two sensi¬
tive techniques differing in principle because of possible heteroge¬
neity of AgAb in diabetes and the known discriminating ability of
available techniques for different types of AgAb(Lambert et al,1978).
Materia Is and methods
110 newly diagnosed insulin dependent diabetics attending the
Out-Patient Diabetic Department of the Royal Infirmary, Edinburgh
were studied. Serum from each patient was obtained within one week of
diagnosis and from 37,33,33 and 37 patients of the same group at 1,
3,6, and 12 months respectively after diagnosis. One hundred and
thirty blood donors of comparable age and sex distribution were used
as a control group.
Solid phase Clq radioimmunoassay (Clq-SP): Clq was isolated from
fresh human serum by the method of Yonemasu and Stroud (Yonemasu &
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Stroud,1971). The assay was carried out as a minor modification of
the method described by Hay et al,(Hay et al,1976)which is based on
the method of Svehag (1975). The sera were pretreated with EDTA ac-
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cording to Zubler et al(1976). I-labelled Staphylococcal protein A
was used to detect AgAb bound to Clq coated tubes. Protein A was
labelled according to Uorval et al. (1975) (see chapter A3.1).
Raji cell radioimmunoassay (RAJI): was used to detect AgAb by a
minor modification of the technique of Theofilopoulos et al(1976).
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Raji cell bound AgAb were detected by the addition of I-labelled
Staphylococcal protein A.
For the expression of results and definition of positivity see
chapter A3.1
ICA was detected as previously described (chapter A3.5).
The Chi squared test (C) , with Yates' correction where indi¬
cated, and Fisher's exact test (F) were used as shown.
Results
AgAb were found in 43 out of 110 (39%) IDD at or within a week
of diagnosis using Clq-SP. The presence of AgAb was significantly
higher in comparison with the control population (10% positive)
(p<0.0001, "C") . 52 subjects of the same group were also tested by
RAJI and 26 (50%) were positive compared to the control population
(20% positive)(p<0.005,"F").31(60%) of these 52 patients were
positive by one or both methods.
AgAb, studied in IDD at increasing intervals from diagnosis by
Clq-SP, were found in 9 patients out of 37 after 1 month of diagnosis
(p<0;05, "C" vs control population) and in 4 out of 37, 3 out of 33,
FIGURE Bl.2/2
The prevalence of AgAb in the serum of newly diagnosed type 1
diabetics as detected by ClqSP and by RAJI or by either method cor¬





























3 out of 37 respectively after 3,6,12 months from diagnosis (not
significant versus control population).
45 out of 110 IDD tested for ICA within a week of diagnosis were
positive(41%).Of the same patients studied for immune complexes after
diagnosis 41%,36%,27% and 24% remained ICA positive at 1, 3,6, and 12
months, respectively.
Using Clq-SP, 30 of the 45 (67%) ICA positive patients at
diagnosis had AgAb whereas only 13 out of 65(20%) of the ICA negative
patients were AgAb positive(p<0.0001,"C").Using RAJI, 17 out of
25(68%) of ICA positive and 9 out of 27(33%) of ICA negative patients
at diagnosis had immune complexes in their sera (p<0.02, "F").
Combining the results of both methods 84% of ICA positive and 37% of
ICA negative patients at diagnosis had immune complexes
(p<0.0001,"F") (Figure Bl.2/2).
At 1 month from diagnosis 47% of ICA positive and 9% ICA ne¬
gative diabetics had AgAb (p<0.025, "F"). At 3,6, and 12 months from
diagnosis the differences in prevalence of AgAb between the ICA
positive and negative patients did not reach statistical signifi¬
cance .
The results of tests for AgAb in diabetic patients were con-
cordantly positive or negative in 71% (p<0.01, "F") of the 52 sera
tested.
Discussion
The high prevalence of circulating AgAb in newly diagnosed
insulin-dependent diabetics and the close correlation between AgAb
and ICA, which it has been previously reported in a small number of
patients(see B1.2a),has been confirmed by the present study, using
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one of the same methods (RAJI) for detecting AgAb and also using a
second method (Clq-SP) based on a different principle. Although
neither method gives any indication of the nature of the antigens
involved, the correlation at diagnosis with the presence of ICA and
the comparable decline of the prevalence of both ICA and AgAb with
time following diagnosis strongly suggest that islet cell antigen-
antibody may well contribute substantially to the AgAb that occur in
the sera of type I diabetics at diagnosis and shortly afterwards. The
prevalence of AgAb declines to control levels after 6 months in ICA
positive patients, while control values are reached before 1 month in
ICA negative patients.
AgAb consisting of islet cell antigen-antibody may arise as a
consequence of islet cell damage caused by some chemical or virus but
it is also conceivable that such complexes may have a primary role in
the pathogenesis of islet cell failure.lt would appear that the
situation pertains at diagnosis, and we surmise also during the early
stages of type I diabetes, in which islet cell antigen-antibody
complexes exist in the presence of antibody excess. The islet cell
antigens involved may well include cell surface antigens (Lernmark et
al,1979) as a correlation has been demonstrated between the presence
of cytoplasmic and cell surface islet cell antigens (Freedman et al,
1979).Such complexes could conceivably "arm" K-cells (Calder et
al,1973) to render them specifically cytotoxic to islet cells.
Alternatively the presence of AgAb within the islets may activate the
complement system with the generation of its biologically active
components. The transient nature of lymphocytic infiltration in type
I diabetes, which is only observed within the islets during the first
month following diagnosis (Gepts,1979), could fit with the transient
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nature of ICA (Irvine et al, 1977;Lendrum et al,1976) and of AgAb at
this stage of the disease in most type I diabetics.
Impaired clearance of AgAb from the circulation of the reticulo¬
endothelial system may also contribute to their presence in the
circulation as it has been shown that phagocytic function is sub¬
normal during metabolic decompensation in diabetes(Badgage,1976).AgAb
in the serum of diabetics at diagnosis and shortly after are probably
quite different in the majority of patients from the immune complexes
that may be detected sometime after diagnosis in either insulin or
OHA treated diabetics and which may be contributory to diabetic
microangiopathy (Chapter B3).
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B1.2d Immune complexes in type 1
diabetics with persistent
islet cell antibodies
In this study the prevalence of AgAb in diabetics remaining ICA
positive at 3 or more years after diagnosis (ICA persisters) in
comparison whith ICA negative patients of comparable duration of
diabetes has been examined. In addition,the correlation between AgAb
and insulin antibodies, HLA antigens and thyroid/gastric cytoplasmic
antibodies in ICA persisters has been studied.
Materials and methods
A total of 102 type I (insulin dependent) diabetics were stu¬
died. The first group comprised 33 patients with persistent ICA (ICA
persisters):that is, patients with detectable ICA in their sera at
least three years after diagnosis. The second group comprised 68
diabetics without detectable ICA in their sera at the time of study.
The duration of diabetes was comparable in these two groups: the mean
duration for ICA persisters was 13.5 + 9.6 yr (s.d.) and for the
second group was 15.3 + 8.0 yr. Patients with associated clinical
autoimmune disease or severe microangiopathy were excluded from the
study. Sera from 105 blood donors were included as controls for
immune complex measurements.
The indirect immunofluorescence method was used to detect ICA as
previously described (chapter A3.5).
The solid phase Clq binding techinique of Svehag(1975).adapted
by Hay et al(1976) was used to reveal immune complexes.Results were
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expressed as ug/ml of aggregated Ig equivalents by reference to
preparations of heat aggregated Cohn fraction II immunoglobulin.
Those results falling above the 90th percentile of the blood donor
controls were considered positive (chapter A3.1).
The method of Ortved Andersen(1972) as modified by Mustaffa et
al(1977) was used to detect and titrate insulin antibodies(chapter
A3.3).
HLA typing was performed as previously described in B1.2b and
for the same range of antigens (Morris et al,1976).
Thyroid and gastric cytoplasmic antibodies were detected by the
indirect immunofluorescence technique as previously described
(chapter A3.5).
Fisher's exact test and Kendall's test were used as appropriate.
•<
Results
17 (52%) of 33 sera from ICA persisters were found to be
positive for AgAb in comparison with 13 (19%) of 69 sera from dia¬
betics without ICA more than 3 years from diagnosis (p<0.001) and 10%
of normal blood donors(p<0.0005).
16 (67%) of 24 ICA persisters typed for HLA were B8 positive.
AgAb were found in 9 (56%) of those 16. In the remaining 8 HLA -B8
negative patients 3 (38%) were positive for AgAb. The difference in
the prevalence of AgAb between the B8 positive and B8 negative ICA
persisters did not reach statistical significance with the small
numbers studied.
There was a significant negative correlation between AgAb values
and insulin antibody titres in the sera of 24 ICA persisters tested
(p<0.05).
FIGURE Bl.2/3




Thyroid and/or gastric cytoplasmic antibodies were found in the
sera of 16 of 33 ICA persisters (48%). These autoantibodies were
present in 7 of 17 AgAb positive patients (41%) and 9 of 16 AgAb
negative patients(56%)(not significant).
Discussion
Previous studies on type I diabetics have shown a correlation
between circulating AgAb and ICA at the time of clinical presentation
of the disease and during the following few months (Chapters B1.2a,
B1.2c). In most patients AgAb decline quite rapidly after diagnosis.
The prevalence of ICA declines at a more gradual rate so that after
about 5 years only 15-20% of diabetics are ICA positive (Lendrum et
al,1976;Irvine et al,1977). In ICA persistently positive diabetics
there is an increased incidence of the HLA-B8 antigen compared to ICA
negative patients, a difference which is not readly apparent at
diagnosis(Irvine et al,1977;Morris et al,1976; chapter B1.2b).
Moreover, in ICA persisters lower insulin antibody titres were
reported in comparison with insulin dependent diabetics without
persistent ICA (Chapter B2.2b).
In this study it is reported that ICA persisters also have an
increased prevalence of Clq binding AgAb when compared to normal
subjects or to ICA negative diabetics of comparable duration of
disease. These findings re-emphasise the hypothesis formulated for
newly diagnosed type I diabetes: that these complexes may be composed
of pancreatic antigens, or that ICA and AgAb are immunologically
unrelated but that their formation is related and linked to factors
yet unrecognised.
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Among ICA persisters the prevalence of AgAb was higher among
those who were HLA-B8 compared to those who were not, although the
increase was not found to be statistically significant in the small
number of patients studied.
In ICA persisters, high insulin antibody titres were not asso¬
ciated with significat amounts of AgAb; a result found also in other
insulin treated diabetics selected at random (Chapter B2.4). Indeed,
when insulin-anti-insulin complexes are formed in antibody excess
their small size (dictated by the bivalency of insulin) would not
facilitate Clq activation and hence they may be detected poorly by
the Clq-SP technique.
An association between AgAb and thyroid/gastric antibodies was
not found in the present study. This is in keeping with the lack of
an association between these antibodies and the presence of AgAb as
detected by the Raj i assay in patients with autoimmune thyroid
disease (Al-Khateed & Irvine,1978).This suggests that either thyroid/
gastric cytoplasmic antibodies are different from ICA in terms of
immune complex formation, or that the ratio of antibodies to antigens
in thyroid autoimmune disease is different from that in insulin
dependent diabetes with corresponding differences in relation to the
tendency to form AgAb.
At present the biological significance of persistent ICA and
AgAb formation is unknown, but persistence of autoantibodies in the
serum is characteristic of the "classical" organ-specific autoimmune
disorders; e.g. autoimmune Addison's disease(Irvine & Barns,1975) and
pernicious anaemia (Irvine et al,1965).This is perhaps a reflection
of the nature of corresponding immune response genes, rather than any
major differences in residual beta cell function of the islets, as
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there is no detectable difference in the amount of C-peptide secreted
by insulin dependent diabetics with or without ICA (Theophanides et
al,1978;Rubenstein et al,1980a).
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B1.3 IMMUNOLOGICAL EVENTS IN INSULIN DEPENDENT DIABETICS
AT DIAGNOSIS AND FOLLOW UP
B1. 3a Aim of the study
In this study the aims have been to examine the humoral immune
response in 1DDM to endogenous and exogenous antigens such as islet
cells, heterologous insulin and viruses, and to investigate the
presence of antigen-antibody complexes. The relationship of these
factors with the HLA antigens was also considered. Therefore AgAb and
cytoplasmic islet cell antibodies, as detected by anti IgG (ICA),
have been evaluated in a large group of IDD's at diagnosis and pro¬
spectively at intervals up to 3 years following diagnosis. In view of
the possible heterogeneity of AgAb in diabetes, immune complexes were
detected by three different techniques: the solid phase Clq binding
test (ClqSP) , the Raji cell radioimmune assay (RAJI) and the con-
glutinin binding assay (KgBt).Complement fixing islet cell antibodies
(CF-ICA) at diagnosis and after 6 months, viral antibodies (VAb) at
diagnosis,insulin antibodies (InsAb) at 9 months after diagnosis and
HLA antigens B8 and B15 were also evaluated in a number of these
patients.
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B1. 3b Materials and methods
Patients
One hundred and fifty-three newly diagnosed, insulin dependent
diabetics (IDD) attending an adult clinic were studied within 2 days
of diagnosis and of these 88 consecutive patients were studied pro¬
spectively for up to 3 yr following diagnosis.Details of patients are
shown in Table Bl.3/1. ICA were evaluted in all diabetics at dia¬
gnosis and in 88,79,76,68,57,31 and 6 patients at 1,3,6,9,12,24, and
36 months after diagnosis respectively. AgAb (Clq) were also measured
in all patients at diagnosis but only in 52,58,51,58,53,29 and 5
patients at the above intervals. CF ICA were evaluated in 30
randomly selected diabetics both at diagnosis and after 6 months.
AgAb (Kg) and (RAJI) were studied at diagnosis in 34 and 50 insulin
dependent diabetics, respectively. A group of normal controls were
included in the AgAb studies for the detection of the limit of
positivity as described below. Viral antibodies were assayed in 30
insulin dependent diabetics at diagnosis and in 30 age and sex
matched normal controls residing in the same geographical region.
Samples from the matched pairs of subjects were obtained within 7
days of each other. Insulin antibodies were measured 9 months after
diagnosis in 35 diabetics treated with highly purified ("mono-
component") insulins from diagnosis. HLA B8 and B15, representing the
two HLA diabetogenic series, were evaluated in 115 insulin dependent
diabetics.
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Detection of Islet Cell Antibodies
ICA were detected by indirect immunofluorescence on human
pancreatic cryostat sections using antihuman IgG conjugated with
fluorescein isothiocyanate (Chapter A3.5).CF ICA were detected by an
indirect immunofluorescence test using fresh complement and anti C3
coniugated with fluorescein isothiocyanate (Chapter A3.5).
Detection of Immune Complexes
Solid phase Clq radioimmunoassay (ClqSP)
Clq was purified according to Yonemasu and Stroud (1971).The
assay was carried out as described by Hay(1976) with minor modifica¬
tions. 125-1 labelled Staphylococcal protein A was labelled according
to Dorval et al (1975).One hundred and eighty five blood donors were
included in the study for the detection of the limit of positivity as
described in chapter A3.1.
Conglutinin binding test (KgBt).
Conglutinin was purified and the test performed according to
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Casali et al(1977). I-labelled protein A was used to reveal con¬
glutinin bound complexes. One hundred and five blood donors were
tested for the evaluation of the limit of positivity (Chapter A3.5).
Raji Cell Radioimmunoassay (RAJI)
Raji cells were used to detect AgAb by a minor modification of
the technique of Theophilopoulos et al(1976).Raji cell bound AgAb
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were detected by the addition of I-labelled Staphylococcal protein
A. The limit of positivity was calculated to be 20 ug AHG (aggregated
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human immunoglobulin G) eq/ml on the basis of the results of 68 blood
donors (Chapter A3.5).
Detection of Virus Antibodies
Inactivated sera (56°C for 30min) were tested in microtitre
assay for complement fixing antibodies to clamydia and to a number of
viruses and viral antigens, namely coxsackie Bl-6,influenza A and B,
adenovirus,respiratory syncytial,measles.mumps S and V,herpes simplex
and varicella zoster.Sera were screened at a dilution of 1:32 with 3
HD50 guinea pig complement. Sera positive at 1:32 were titrated at
further two fold dilutions to 1:512.Antibodies to coxsackie viruses
Bl 6 were estimated in a quantal neutralisation test. 100 TCID 50 of
each virus was reacted with serum dilutions and inoculated into virus
cell cultures in tubes. End points were determined by low power
microscopy of the viral cytopathic effect. All sera were negative for
hepatitis B surface antigen by a reverse passive haemoagglutination
test.
Detection of Insulin Antibodies
InsAb was evaluated according to the method of Ortved Andersen
(1972) as modified by Mustaffa(1977)(chapter A3.3).
Statistical Analysis
The Chi-squared (2x2) test ("X") with Yates's correction,
Fisher's test ("F") and Cox's test for trend ("C") were used in the




ICA were found in 68 of the 153 insulin dependent diabetics
studied at diagnosis (table B1.3/1).Forty-four (50%) of the insulin
dependent diabetics studied prospectively were ICA positive at
diagnosis, the presence of ICA declining to 45,38,36,31,26,19 and 17%
at 1,3,6,9,12, 24 and 36 months after diagnosis respectively (table
Bl.3/2).
CF-ICA
CF-ICA were found in 30% of the diabetics at diagnosis and in
23% at 6 months. All patients with CF-ICA at diagnosis were ICA
positive whilst only 47% of patients with ICA also had CF-ICA in the
serum.
AgAb
ClqSP.AgAb (Clq) were found in 54 of the 153 insulin dependent
diabetics studied at diagnosis (p<0.001 vs. normals, "X").Twenty-nine
of the 65 insulin-dependent diabetics studied at diagnosis alone and
25 (28%) of the 88 studied prospectively had AgAb (Clq) in their
serum at diagnosis. In the prospective study the AgAb (Clq) posi-
tivity declined to 25% (p<0.01 vs.normals, "X"),22% (p<0.02,"X"),17%
(n.s.,"X"),19%,17%,17% and 0% after 1,3,9;12,24 and 36 months from
diagnosis respectively.
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KgBt.AgAb (Kg) were found in 12 of the 34 diabetics studied at
diagnosis (p<0.001 vs. normals,"X").
RAJ I
AgAb (RAJI) were found in 27 of 50 diabetics studied at dia¬
gnosis (p<0.002 vs. normals,"X"). Eighty-four patients were studied
at diagnosis by more than one AgAb method and of these 57% had at
least one positive AgAb result.
ICA vs.AgAb
A significant correlation between the presence of AgAb, as
detected by ClqSP, and the occurrence of ICA was found in IDDM at
diagnosis (p<0.001, "X")(Fig.B1.3/1).Fifty-four percent of the ICA
positive insulin dependent subjects and 20% of those without ICA
showed AgAb in their serum at diagnosis.AgAb (RAJI) were also signi¬
ficantly increased in ICA positive diabetics (p<0.02,"F") but there
was no significant correlation between AgAb (Kg) and ICA.
CF-ICA vs.AgAb (Clq).
There was no significant correlation between CF-ICAb and AgAb
(Clq) either at diagnosis or after 6 months ("X").
Viral Antibodies
There was no significant difference ("F") in the presence titre
of VAb between the diabetics and the controls studied(Fig.B1.3/2).No
correlation was fond between VAb presence and AgAb or ICA positivity
at diagnosis (Table Bl.3/3).
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Insulin Antibodies
The mean ( + S.D.) InsAb value was 33.6 ( +46.4) uU/ml. No cor¬
relation was found between the InsAb levels at 9 months after dia¬
gnosis and the presence, both at diagnosis and after 9 months, of ICA
or AgAb (table Bl.3/4).
HLA Antigens
Forty-six percent of the insulin dependent diabetics were HLA B8
positive and 15% were HLA B15 positive. No correlation was found
between these two diabetogenic, series and the presence of ICA, AgAb
or VAb at diagnosis. HLA B15 positive patients tend to form signi¬
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TABLEBl.3/4
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TABLEBl.3/5
HLAB8and15correlatedwithserumlev lsfIC ,Ag b,VAbanns No.ofHLAB8+15 patientstientspatients
HLAvs.ICAICat+5223(44%)6(1 ) diagnosis-6331(49%)117 After12+6(50%)3(25 ) months-3621(58%)6(17 ) HLAvs.AgAbAgAb(Clq)+3918(46%7(1 ) atdiagnosis-7635(46%)10(13 ) AgAb(Clq)+84(50%1( 2.5%) after12months-402(5 %)7(17.5%) AgAb(Kg)+73(43%)00 atdiagnosis-188(44%)21 ) AgAb(RAJI)+191(58%210 atdiagnosis148(57%)214 7 HLAvs.VAbCox ackieBtitrestdiagnosis <3242(50%)) 32-64124(33%)17 _>12894(44%)111 HLAvs.InsAbInsAb(uU/ml) <10169(56%)2(12 ) 10-5007(70%)33 >500(0)3(60%)
FIGURE B1.3/1
A comparison of the results of ICA and AgAb (Clq) studies in
insulin dependent diabetics at diagnosis and during the 12 months
following diagnosis.
FIGURE Bl.3/2
A comparison of the serum viral antibody titres in 30 insulin



















































































The increased presence of circulating immune complexes in Type 1
diabetics at diagnosis is confirmed by this large study. Immune
complex positivity tends to decline rapidly following diagnosis and
within only a few months their prevalence is similar to that found in
the normal population. The methods used to assay AgAb differ in
principle and detect different types of complexes. However, with all
techniques employed, the increased prevalence of complexed immuno¬
globulins is similar and complexes are detected that can lead to
tissue damage by activating the complement system and by binding to
cells with Fc or C3 receptors on their surface. Thus, it has been
shown that a heterogenous group of potentially harmful complexes is
present at the time of diagnosis of Type 1 diabetes.
ICA were found in approximately half of our newly diagnosed
diabetics. This prevalence is lower than that reported by other
workers (Lendrum et al,1975;Bottazzo et al, 1976).The older age of
patients in this study and the decision to consider as negatives all
doubtful results may account for this apparent discrepancy. There is
a need to standardize the detection of ICA since differences in the
substrate and in the methodology have sometimes resulted in poorly
reproducible findings.
It has been reported that antibodies to certain viruses are
increased in Type 1 diabetics at diagnosis (El-Hagrassy et al,1980).
However, in epidemiological studies, where the parameter being
investigated is also present in the normal population, there is often
difficulty in selecting an appropriate control group. In these viral
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studies, each diabetic has been matched with a normal subject of the
same age and the sex who resided in the same geographical area. The
diabetic and the control subjects were sampled within the same 7 day
period to exclude differences resulting from the seasonal variation
of viral infections in the community. Although the antibody posi-
tivity to certain viruses appeared high in the diabetic patients,
there was no significant difference from the results obtained in the
control group (Cudworth,1981) and the findings simply reflect the
viruses prevalent at the time of sampling.
This finding is not unexpected since it is likely that only in a
very few cases does an overwhelming viral infection produce rapid
beta cell necrosis. In other cases, a viral infection of the islets
may trigger an autoimmune reaction against the islets which in turn
produces beta cell damage and leads to the development of diabetes
months, or even years, after the initial infection. However, viral
antibodies, which represent a positive reaction by the body against
an aggressive, agent, may not be the most appropriate phenomena to
study since our aim is to determine why the host fails to cope
adequately with a viral attack and thereby sustains beta cell damage.
Insulin antibody levels generally increase slowly from the time
insulin therapy is commenced and assume a steady level after several
months.InsAb levels were normal or only modestly elevated in patients
studied despite their estimation 9 months after diagnosis. This
finding can be explained by the use of purified insulins alone in the
patients studied. Furthermore, a correlation between AgAb (Clq) and
InsAb was not expected since AgAb presence tends to decline after
diagnosis in contrast to InsAb levels. AgAb seem to reflect other
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phenomena occurring at diagnosis more than the presence of cir¬
culating antibodies to insulin and viruses (see chapter B2).
This study has demonstrated a tendency for 1ILA B15 positive to
form significantly higher IBC levels than B15 negative patients
(Chapter B2). This genetic predisposition for some patients to
produce higher amounts of insulin antibodies is in accordance with
previous work(Bertrams et al, 1976). It is well recognised, at least
in animals, that the major histocompatibility genes are very close to
genes that regulate the immune response and in particular, the T-cell
mediated response. In patients studied this genetic influence was ap¬
parent only in the response towards therapeutic insulin since there
was no correlation between AgAb, ICA and VAb measured at diagnosis
and HLA types. The lack of correlation between ICA at diagnosis and
HLA types confirms previous findings (Chapter B1.2b).
Immune complexes (Clq, RAJI) were correlated with the occurrence
of ICA at diagnosis but not with the other antibodies studied. Thus,
it would appear that AgAb and ICA are related and that the presence
of AgAb at diagnosis does not simply reflect a recent viral infec¬
tion. This is supported by previous reports of a strong correlation
between ICA and immune complexes in insulin-dependent diabetics with
persistent ICA (Chapter B1.2d) and in newly diagnosed non-insulin
dependent diabetics (Chapter B1.4). In the present context,the CF-ICA
studies did not provide any additional information regarding the
immunological mechanisms which are operative at, and soon after, the
onset of IDDM.
It is possible that AgAb and ICA have separate roles in the early
stages of Type 1 diabetes or that they may be involved together,
either primarily or secondarily. Complexes may reflect damage to the
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islets and be present near the clinical onset of the disease together
with other immune phenomena such as ICA. Medium or large size
antigen-antibody complexes, that fix complement and react with cells
having surface receptors for Fcor C3, may produce cell damage either
directly or by interacting with specific T-cell subpopulations. AgAb,
if present in antibody excess, may arm K cells against a specific
antigen(s) in or the pancreatic islets and thereby result in the
development of diabetes mellitus. The correlation between the pre¬
sence of AgAb and ICA in the serum, at the time IDDM is diagnosed,
suggests that some of the AgAb may be comprised of islet cell Anti¬
body/islet cell Antigen.
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B1.4 IMMUNOLOGICAL EVENTS IN DIABETICS NOT REQUIRING
INSULIN AT DIAGNOSIS AND FOLLOW UP
B1. 4a Aim of the study
In this study,the presence of soluble AgAb in diabetic patients
who did not require insulin at the time of clinical diagnosis has
been investigated. Among them, particular attention was focused on
the minority who did not have ketonuria but showed ICA in the serum
at diagnosis. In this relatively uncommon group of patients, ICA,
complement fixing islet cell antibodies (CF-ICA) and AgAb were tested
at diagnosis and at regular intervals thereafter. Clinical and
subclinical associations with other autoimmune phenomena were also
studied. Aims of this study were to highlight the presence of AgAb in
patients who were ICA-positive but not ketotic, the modifications
with time of ICA, CF-ICA and AgAb and the correlation between the
presence of ICA, CF-ICA or AgAb at diagnosis and in the following
months with the tendency to progress to insulin dependency.
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B1.4b Materials and Methods
Patients
Over a period of more than a year, most patients newly diagnosed
at a few Edinburgh Diabetic Clinics as non-insulin dependent diabetic
subjects, according to the National Diabetes Data Group Classifica-
tion(1979), were tested for ICA at their first attendance. Two
hundred and sixty patients were tested and 106 of these were included
in the study: all those(17) who were found to be ICA-positive,
together with 89 who were randomly selected from the newly diagnosed
ICA-negative diabetic patients.
In the ICA-positive group, there were five males and 12 females
with a mean age at diagnosis of 55.4 + 16.1 years. In the ICA-
negative group, 42 were male and 47 were female and the mean age at
diagnosis was 61.6 + 12 years. Two of the 17 ICA-positive and two of
the 89 ICA-negative patients had other associated autoimmune di¬
seases, (Hashimoto's thyroiditis, pernicious anaemia and primary
hypothyroidism). Almost all the 17 ICA-positive patients could be
considered Type 2a patients(National Diabetes Data Group,1979),the
median of the ideal body weight percent being 98.5 (interquartile
range 89.8, 104.5).No other substantial difference in the symptoms
preceding diagnosis or in the clinical and metabolic signs at the
onset of overt diabetes was noticed between ICA-positive and ICA-
negative patients.
All the patients were followed clinically for approximately 3
years. ICA titres tend to decline after clinical diagnosis and there
have so far been no reports of ICA-negative diabetic patients later
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becoming ICA-positive, attention has been focussed on the 17 initi¬
ally ICA-positive patients. They were also followed serologically at
regular intervals for approximately 1 year from diagnosis and serum
antibody studies were performed twice between 2 and 4 months after
diagnosis and 10 or more months after diagnosis.
The clinicians did not know the result of the ICA test, at least
in the first months, and in any case the ICA status was not among the
parameters taken into account when the decision to put patients on
insulin was taken.
Immune complexes
AgAb were evaluated by the solid phase Clq radioimmunoassay
according to Hay et al(1976), with minor modifications. Details of
the technique used,the limit of positivity,the expression of results
and the reproducibility of the test have been described previously
(chapter A3.1).
Autoantibodies
ICA, thyroid cytoplasmic and gastric parietal cell antibodies
were determined by indirect immunofluorescence using fresh frozen
cryostat sections (Chapter A3.5). CF-ICA were evaluated with the
addition of fresh normal serum as source of complement, and of
fluorescein conjugated anti C3 antibody (Chapter A3.5).
Statistical evaluations
Statistical evaluation was done by chi squared test, with Yates'
correction when appropriate, and by the two tailed Cox's test for




In the ICA-positive patients, ICA were still present in 14 out
of 17 between 2 and 4 months after diagnosis and in 10 out of 16
after 1 year or more of clinical diabetes (Fig.B1.4/1).
Immune complexes
AgAb were found in eight of the 17 ICA-positive diabetic pa¬
tients (p<0.01 versus normal subjects) and in 16 of the 89 ICA-
negative patients (NS versus normal subjects, p<0.02 versus ICA-
positive patients), both groups being studied at diagnosis.
Complement fixing islet cell antibodies
CF-ICA were found in 11 of the 17 ICA-positive diabetic pa¬
tients. At the end of the first 3 months, ten were positive. Five
were still positive 10 months or more from diagnosis (Fig.
B1.4/1).None of the CF-ICA-negative patients at diagnosis became
CF-ICA positive with time.
Thyrogastric antibodies
Autoantibodies to thyroid or to gastric parietal cells, studied
in all the patients at diagnosis, were found in five of the 17
ICA-positive and in 16 of the 89 ICA negative diabetic patients (NS).
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ICA,CF-ICA,AgAb and clinical tendency
to progress to insulin dependency
Ten of the 17 ICA positive and two of the 89 ICA-negative
diabetic patients required insulin within 3 years of diagnosis
(p<0.0001) either because of the presence of ketonuria and/or because
of a metabolic derangement (glycaemia constantly > 12 mMol/1) non-
controllable with other therapy. When the patients were divided
according to tendency to progress to insulin dependency (Fig.-
Bl.4/2),five were still on oral hypoglycaemic agents more than 3
years from diagnosis, six went on to insulin after 20 months of
clinical diabetes, four between 6 and 10 months, and two died from
vascular complications after 5 and 21 months, respectively. There was
a significant trend for the presence of CF-ICA at diagnosis to be
associated with earlier development of insulin dependency (p<0.05).
The occurrence of AgAb and of thyro-gastric antibodies were not
correlated with the tendency to progress to insulin dependency.
FIGURE Bl.4/1
ICA (© ©), CF-ICA (19 83) and AgAb (A A) in
the 17 ICA-positive diabetic patients initially treated without
insulin, at diagnosis (A), between the second and the fourth month of









ICA (g.), CF-ICA (©:), AgAb (Hi) and tendency to progress to
insulin dependency. The horizontal lines within the rectangular frames
indicate the number of patients. Group 1 patients (n=5) were still on
oral hypoglycaemic agents 3 years fron clinical diagnosis, Group 2
(n=6) required insulin between 20 and 36 months from diagnosis, Group
3 (n=4) needed insulin within 10 months and the two Group 4 patients




While an increased prevalence of immune complexes has been shown
to be present in the serum at diagnosis of Type 1 diabetes (Chapters
B1.2a, B1.2c, B1.3), this is not the case here where a substantial
number of randomly selected Type 2 diabetic patients have been
studied at diagnosis and compared with control subjects. However, the
present study demonstrates that the prevalence of AgAb is increased
in the minority of diabetic patients who have ICA in the serum but do
not require insulin at diagnosis or during the first months of the
disease. A correlation between serum AgAb and ICA has also been
demonstrated in Type 1 diabetic patients close to diagnosis (Chapters
B1.2c, B1.3) and in those Type 1 diabetic patients in whom ICA
persists for some years (Chapter B1.2d). The correlation between
serum ICA and AgAb suggests that islet cell antigen-antibody com¬
plexes may be part of the AgAb detected in the subjects. Whether AgAb
are involved in islet cell damage in these patients has not yet been
established, but they could be involved in serum cytotoxic activity
or they could interact in several ways with cells which have re¬
ceptors for the Fc portion of immunoglobulins or for the third com¬
ponent of complement (WHO Scientific Group Report, 1977). As ICA-po-
sitive diabetic patients in this study, not requiring insulin at
diagnosis, were not ketotic, severe metabolic derangement would not
seem to be a major factor in the development of serum AgAb in these
subjects. Furthermore, hyperglycaemia is unlikely to be responsible
as an increased presence of AgAb was seen in ICA positive non-insulin
diabetic patients but not in the majority of Type 2 diabetes.
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The present study demonstrates that a small proportion of non
insulin dependent diabetic patients shows the same immunopathological
phenomena that occurr in classical Type 1 diabetes at diagnosis; i.e.
ICA, CF-ICA and AgAb. It has been demonstrated previously that the
presence of serum ICA in diabetic patients initially treated with
diet and/or oral hypoglycaemic agents is a useful marker for pre¬
dicting subsequent insulin dependency (Irvine et al,1977). The
findings of this study suggest that when serum CF-ICA are present,
the development of insulin dependency tends to occur earlier. A
similar predictive value for CF-ICA was recently shown by other
workers in different situations, i.e. Type I diabetes, relatives of
patients with Type 1 diabetes or patients with autoimmune disorders
(Bottazzo et al, 1980;Gorsuch et al,1981;Betterle et al,1980).
ICA-positive diabetic patients, not requiring insulin at dia¬
gnosis, who may also have CF-ICA and AgAb at diagnosis, clearly do
not fit logically into the broad clinical subdivision of the majority
of idiopathic diabetic patients according to the presence or absence
of insulin dependency (Gorsuch et al,1981).At clinical diagnosis,Type
1 diabetic patients are ketosis prone and have
islet cell autoimmunity. Type 2 diabetic patients classically have
neither of these characteristics. The small group of subjects in¬
cluded in the present study showed no ketonuria and did not require
insulin at diagnosis but had evidence of islet cell autoimmunity and
tended to progress to insulin dependency. The type of diabetes in ICA
positive non-insulin requiring diabetic patients should be regarded
as a subgroup of Type 1 diabetes, probably representing a stage
earlier in the same disease process (or group of disease processes)
that tends to culminate in classical Type 1 diabetes.
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B1.5 SEARCH FOR CIRCULATING SPECIFIC ANTIGENS IN THE EARLY
STAGES OF TYPE I DIABETES BY MONOCLONAL ANTIBODIES
Bl. 5a Aims of the study
The presence of circulating islet antigens, either free or
complexed with antibody, in the early stages of type 1 diabetes has
been investigated with monoclonal anti-islet cell antibodies. The
presence of such antigens, released into the circulation, might be a
good indicator of islet cell damage occurring in this form of dia¬
betes. Their presence was correlated to the occurrence of other
immunological factors, such as islet cell antibodies and different
types of complexes.
B1.5b Materials and methods
Patients
33 recently diagnosed type 1 diabetics, 18 patients with non-
immunological non-endocrine disorders and 26 normal controls were
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included in the study. 15 type 1 diabetics were studied at diagnosis,
10 within one mouth and 8 within 6 months of diagnosis.
The mean age of diabetic patients studied was 20.4 +8.3 years.
The 18 patients with non-immune and non-endocrine disorders suffered
from heart or gastrointestinal disorders and acted only as controls.
Circulating islet cell antigens
Circulating islet cell antigens, as detected by the monoclonal
antibodies A2B5, HISL5, HISL19 and 3G5, were investigated by a
fluid-phase technique as described in chapter A3.6.
Islet cell antibodies
Islet cell antibodies were detected with an indirect immuno¬
fluorescence test (Chapter A3.5).
Immune complexes
Circulating immune complexes were detected with two methods
differing in principle, the solid phase Clq binding test (Hay et al,
1976 with minor modifications) and the conglutinin radioimmune assay
(Casali et al 1977, with minor modifications) as described in details
in chapter A3.1.
Statistical analysis




The mean value of circulating islet cell antigens, as detected
by the monoclonal antibody HISL 19, in type 1 diabetics was 18.5% +
1.8 whereas in control patients and in normal controls the values
were 12.1% + 1.3 and 13.7% + 1.6 respectively (Figure Bl.5/1). The
difference in circulating islet cell antigens between type 1 dia¬
betics and control patients or normal controls was significant
(p<0.001 and p<0.001).
HISL 5
The mean value of circulating islet cell antigens, as detected
by the monoclonal antibody HISL5, in type 1 diabetics were 19% + 2.5
whereas in normal controls was 13.2% +1.4 (p< 0.001)(Figure Bl.5/2).
3G5
The mean value of circulating antigens, as detected by the
monoclonal antibody 3G5, was 17.2% + 2.8 in type 1 diabetics, 14.9% +
2.4 in control patients and 18.1% + 3.4 in normal controls. The
differences were not significant (Figure Bl.5/3).
A2B5
The mean value of circulating antigens, as detected by the
monoclonal antibody 3G5, was 22.9 + 2.9 in type 1 diabetics, 17.05 +
1.5 in control patients and 17.6 + 1.2 in normal controls. The
presence of A2B5 circulating antigens was significantly increased in
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type 1 diabetics in comparison with control patients and normal
controls (p<0.001 and p<0.001)(Figure Bl.5/4).
Circulating islet antigens
and islet cell antibodies
There was no significant difference in the values of circulating




There was no significant difference in the values of circulating
antigens between immune complex positive and negative sujects, both
when the Clq method and the conglutinin method were used (Table
Bl.5/1).
TABLEBl.5/1
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Circulating islet cell antigens, as detected by the monoclonal
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Circulating islet cell antigens, as detected by the monoclonal
antibody A2B5, in type 1 diabetics, in normal controls and in patients






























During the last decade a great deal of evidence has accumulated
to support the role of immunological phenomena in the pathogenesis of
insulin dependent (type I) diabetes mellitus (Chapter A1.3). Dif¬
ferent types of islet cell antibodies have been found in the cir¬
culation of newly diagnosed type 1 diabetics (Bottazzo et al,1974;
MacCuish et al,1974; Lendrum et al,1975). The author has been par¬
ticularly interested in circulating immune complexes since the
original report in 1977 of their increased presence in some insulin
dependent diabetics at diagnosis (Chapter B1.2a). The presently
available methods for the assay of immune complexes reveal different
types of complexes and the concordance between these techniques is
low. The above mentioned methods are antigen non specific and con¬
sequently do not differentiate between complexes related to specific
disease processes and those found in commoner conditions, such as
viral infections. The presence of Clq immune complexes was found to
correlate with the occurrence of islet cell antibodies at diagnosis
in type I diabetics, at least during the first year of the disease,
in type I ICA positive diabetics but not requiring insulin at least
in the first year of diagnosis (Chapters B1.2c, B1.3, B1.4). This
suggests that both islet cell antigens and their related antibodies
are in circulation in type I diabetes in the early stages following
diagnosis.
The pathologic hallmark of type I (insulin-dependent) diabetes
is the selective destruction of the pancreatic islet beta cells. In
the early stages of the disease the islets may be infiltrated by
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mononuclear cells (Gepts & LeCompte,1981). This phenomenon,"insu-
litis", has been found in a substantial proportion of newly diagnosed
cases and may be compatible with a recent viral infection or with a
cell mediated immune response causing beta cell destruction. It is
likely that islet cell antigens are released into the circulation as
a consequence of islet cell damage.
Prospective population studies have suggested that the initia¬
tion of the pathological processes may precede the abrupt clinical
onset of diabetes by several years (Gorsuch et al,1982). Anti islet
cell antibodies are found several years before the diagnosis. It is
also likely that antigens from the damaged tissues are slowly re¬
leased in circulation during this long prediabetic period. This has
important implications both for research and for possible future
prophylaxis. However there is no satisfactory investigation, so far,
on islet cell antigens, or on other antigens, possibly released in
circulation before and during the clinical onset of diabetes. Thus
this study was carried out with the attempt of filling this gap with
the development of methods to identify circulating antigens by the
use of monoclonal antibodies and the study of the role of these
humoral immune factors in the pathogenesis of type I diabetes. One of
the most important points in this kind of study is the availability
of a good panel of monoclonal antibodies. Only very few antibodies,
raised against antigens specific to the islets, have been reported
(Chapter A3.6). In this study two antibodies raised following immuni¬
zation of mice with human islets and two monoclonal antibodies raised
against other tissues but reactive with pancreatic islet cell de¬
terminants have been used.
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In this study an increase in the circulation of those antigens
detected by the monoclonal antibodies HISL5, HISL19 and A2B5, is
reported in the sera of recently diagnosed type 1 diabetics. This
finding seems to confirm that islet cell antigens do circulate after
islet damage.
Some aspects remain to be elucitaded.
The lack of correlation between islet cell antibodies and
circulating antigens, or immune complexes and circulating antigens
may be due to the relatively small number of patients studied.
However other immune factors also present in the early stages of the
disease,do not show a clear statistical correlation. For example
there is no clear correlation between islet cell antibodies and
abnormalities of k cells function or islet cell surface antibodies
and complement fixing islet cell antibodies.
The fact that the monoclonal antibody A2B5 was raised against
gangliosides and thus recognizes antigens in the neuroendocrine
system and not only in the islet, does not permit the conclusion that
the A2B5 antigen found in the circulation is of islet cell origin.
However, the increase in circulating antigens detected by this
antibody parallels that found with the two islet specific monoclonal
antibodies. Further more no increase in circulating A2B5 antigens was
found in other patients without immune or endocrine disorders.
The differences in circulating antigens, as detected by these
monoclonal antibodies, between diabetics and controls are clear but
not very large. In fact the islet cell antigens in circulation are
expected to be in rather small amounts. Future research must con¬
centrate on the development of highly sensitive techniques to reveal
very small quantities of pancreatic antigen released in circulation.
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The availability of sensitive techniques to study and monitor the
release and presence in circulation of islet antigens may be of
paramount importance to describe and follow with time the islet cell
damage in the early events of diabetes, to screen the normal subjects
at risk to develop diabetes, monitor the effectiveness of possible
pathogenetic antidiabetic treatment and to understand more clearly
the significance of several pathogenetic events in type I diabetes.
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B1.6 CONCLUSIONS
The results of humoral immune studies in the first stages of
type 1 diabetes suggest a number of conclusions.
Islet cell antibodies are present in about half of the newly
diagnosed diabetics at diagnosis and decline thereafter. In about 20%
of the patients these antibodies in the circulation can be found for
at least a few years following diagnosis.
The occurrence of complement fixing islet cell antibody, which
is found in about one third of the patients studied at diagnosis,
declines thereafter. All the patients who showed complement fixing
islet cell antibodies in their serum at diagnosis also had cir¬
culating islet cell antibodies.
Immune complexes, as detected by the Clq methods are increased
at diagnosis in type 1 diabetics. The decline in their occurrence
parallels that of islet cell antibodies but not of the other factors
studied. Other types of complexes, such as those detected by con-
glutinin binding assay or Raji cells assay, are also increased at
diagnosis.
Viral antibodies do not seem to be increased in newly diagnosed
type 1 diabetics when compared with matched normal controls.
Thus the pattern of the decline of the presence of islet cell
antibodies, complement fixing islet cell antibodies and Clq-immune
complexes seems to reflect the immunological events related to islet
cell damage.
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The second aim of the studies in this section was to evaluate
the possible presence and the clinical prognostic value of different
immunological markers in diabetic patients not requiring insulin at
diagnosis. Attention has been focussed on that minority of patients
who are initially treated with diet or oral agents but show islet
cell antibodies in their serum.
In most of the non insulin dependent diabetics studied, none of
the immunological factors evaluated were found to be increased. How¬
ever, immune complexes and complement fixing islet cell antibodies
were found to be increased in most of those rare islet cell anti-
body-positive, non-insulin dependent diabetics.
When islet cell antibodies and complement fixing islet cell
antibodies are both found in the circulation of diabetic patients not
requiring insulin at diagnosis, this is valuable prognostically as an
index of early insulin dependency.
In conclusion the type of diabetes in islet cell antibody
positive patients patients not requiring insulin at diagnosis has
strong immunological and clinical similarities to classical type 1
(insulin dependent) diabetes.
The search for circulating pancreatic islet in newly diagnosed
type 1 diabetics lead to the detection in serum of some antigens
present also in the pancreatic islet. The potential value of this
finding is high. An islet cell antigen in the circulation may be a
good marker to monitor the pathogenetic events in diabetics and, more
interestingly, in subjects at risk to become diabetics.
The production of specific anti islet cell monoclonal antibodies
and the development af highly sensitive techniques to study and
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monitor the release and presence in circulation of islet antigens may
be of paramount importance:
- to describe and follow with time the islet cell damage in the
early events of diabetes.
- to screen the normal subjects at risk of developing diabetes
- to monitor the effectiveness of possible pathogenetic anti¬
diabetic treatment
- to better understand the significance of several pathogenetic
events in type I diabetes correlating the antigens studied
with other immunological and genetic parameters.
CHAPTER B 2
IMMUNOLOGICAL CONSEQUENCES OF INSULIN TREATMENT
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Chapter B2 IMMUNOLOGICAL CONSEQUENCES OF INSULIN TREATMENT
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B2.1 EXPERIMENTAL DESIGN OF THE STUDIES ON THE CONSEQUENCES OF
INSULIN TREATMENT
It is well known that the administration of heterologous insulin
induces an immune reaction in most patients. The best known immu¬
nological conseguence is the formation of insulin antibodies. These
antibodies are a consequence of impurities present in the prepa¬
rations, of differences of the aminoacid composition and spatial
configuration of heterologous insulin molecule and of physico-chemical
changes of the molecule before or after injection.
It is also known that the formation of insulin antibodies is not
the only immunological consequence of the insulin treatment. An
immediate-type and a delayed-type hypersensitivity are likely to
occurr in some patients at the site of insulin injection. However
other humoral immune reaction are also present. Insulin-anti-insulin
complexes have been proved to be present in several insulin treated
patients, and data on these complexes will be presented in chapters B3
and B4. It is mentioned elsewhere (chapter A2 and B2.2) that increased
levels of circulating immune complexes are observed in some insulin
treated diabetics. It remains to be shown that there is a correlation
between this increase and the admnistration of insulin. (For details
and references see chapter Al).
Attention has been focussed in this study on two aspects. The
first is the relationship between insulin antibodies and immune
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complexes. In this way the consequences of exogenous insulin on immune
complex formation is indirectly investigated. The second is the
relative influence of impurities, of species differences and of
physico-chemical changes in the insulin preparations on the immuno¬
logical response.
The main variables that have been taken into account are : levels
of insulin antibodies, types of complexes, type of antidiabetic
treatment, purity of insulin preparations, species of exogenous
insulin, and the type of diabetes.
a) The types of immune complexes already found to be increased in
some diabetics have been studied in a large group of patients selected
at random to evaluate the influence of the antidiabetic treatment,
insulin or oral agents, on their formations (B2.3). Other variables
have also been considered.
b) The presence of the above studied types of immune complexes has
been correlated to the levels of insulin antibodies in insulin treated
diabetic patients selected at random (B2.4)
c) The types of complexes studied above and other types of complexes
have been assayed and correlated to the presence of insulin antibodies
in diabetics treated with insulins of different purity. To avoid the
interference of other variables, such as the duration of diabetes, the
type of diabetes and previous insulin treatment the study was done in
newly diagnosed type 1, diabetics who were regularly followed up for
one year after diagnosis (B2.5).
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d) Different types of complexes and the levels of insulin antibodies
have been studied in diabetics treated with human or heterologous
insulins. The investigation was performed in both type 1 and 2
diabetics who had never before been treated with insulin and the study
was done at the beginning of insulin treatment and for a 6 month
follow up period.
The clinical part of the studies was done in collaboration with
the Out-Patient Diabetic Department, Royal Infirmary, Edinburgh, UK
and with the Diabetic Unit, University of Rome, Italy.
HLA studies were performed in the NuffieLd Department of Surgery,
University of Oxford, UK.
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B2.2 EARLIER STUDIES BY THE AUTHOR




In the present study, the presence of antibodies to insulin and
the occurrence of immune complexes have been investigated in the sera
of treated diabetics and compared to those in controls. The signi¬
ficance of their possible correlation is discussed.
Materials and methods
63 diabetic patients have been included in the study. Sera were
obtained from thirty-two diabetics who had been treated with bovine or
porcine insulin for a mean duration of 16 years (range 2-42 years),
from thirty-one diabetics who had been treated with oral hypoglycaemic
agents (OHA) for a mean duration of 6 years (range 0-14 years), and
from eighty-four control subjects. All sera were stored in 500 ul
aliquots at -40°C.
The Raji cell radioimmunoassay as described by Theofilopoulos et
al,1976, was used. Purified human IgG, was diluted to 10 mg/ml in PBS
and then aggregated by heating at 63°C for 15 min. The amount of
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soluble immune complexes in each test serum was expressed as being
equivalent to so many ug aggregated human gamma globulin (AHG) per ml
serum. For the limit of detection of the assay and other details see
chapter A3.1.
Antibodies to insulin were estimated by a minor modification of
the method of Ortved Andersen et al,1972, according to Mustaffa et
al,1977. Insulin-binding of 10 uU/ml serum was regarded as indicative
of the presence of insulin antibodies. Insulin-antibody levels between
10 and 300 uU/ml were regarded as indicating moderate insulin antibody
titres, while binding of >300uU/ml was interpreted as being due to
high titres of insulin antibodies (chapter A3.3).
All statistical analysis were done using Fisher's exact test,
except where indicated.
Results
Immune complexes were found in seventeen out of thirty-two (53%)
2
insulin-treated diabetics (P<0.001; x test), in three out of thirty-
one (10%) patients requiring OHA (not significant); while in the
eighty-four normal age- and sex-matched control subjects immune
complexes were detected in five (6%) of them.
The sera of all the thirty-two diabetics treated with hetero¬
logous insulin had increased binding activity, indicating the presence
of antibody to insulin. The titres of insulin antibodies varied in
different patients from 26 to 586 uU/ml irrespective of the duration
of insulin therapy (between 2 and 42 years), dosage of heterologous
insulin used or sex.The sera of all the insulin-independent diabetics
were negative for insulin antibodies.Immune complexes occurred more
commonly in patients treated with insulin for 19 years or more
230
(sixteen out of twenty- three) than in those receiving insulin for
less than 10 years (one out of nine) (P<0.001). There was no
correlation between the presence or amounts of insulin antibodies, or
of immune complexes, with the patients' insulin requirements. All
patients with high titres of insulin antibodies (>300 uU/ml) had
soluble immune complexes.
When the insulin-treated diabetics were subdivided according to
whether they developed diabetes before or after the age of 30 years,
immune complexes occurred more frequently in the presence of moderate
titres of insulin antibodies in the early onset, compared to the late
onset diabetics (P<0.05). The mean duration of diabetes and of insulin
treatment in those diabetics with moderate iixsulin antibody titres
who developed diabetes before the age of 30 and in those who developed
diabetes after 30 were closely similar. When all the patients in each
of these two group were compared, there were no significant dif¬
ferences in the prevalence of immune complexes.
Discussion
Insulin antibodies were only detected in the insulin-treated
subjects, and their titres appeared to be a characteristic of the
patient rather than the dosage or duration of insulin therapy. Indeed,
it has been shown that patients who are HLA-B15 tend to have higher
titres of insulin antibodies consequent upon insulin treatment
(Bertrams et al,1976). A correlation was observed in the present study
between high titres of insulin antibodies and the presence of immune
complexes, suggesting that In these patients the antigen involved in
such complexes may be derived from heterologous insulin. The presence
of low or moderate titres of insulin antibodies did not show any
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correlation with the amount of complexes present. This may be due to
technical reasons, to the varying affinities that insulin antibodies
may have in different patients (Dixon, et al. 1975) or to the varying
rates at which immune complexes of different sizes are removed from
the circulation, or it may be that other antigens are involved in such
complexes. The possiblity exists that the late complications of
diabetes may be related, at least in part, to the production of immune
complexes, and it is therefore noteworthy that juvenile-onset
insulin-dependent diabetics tended to have more immune complexes in
relation to moderate or low titres of insulin antibodies than did
subjects who developed insulin-dependent diabetes after the age of 30
years, even although the duration of diabetes and of insulin treatment
was comparable in the two groups. Insulin-dependent diabetes
developing in young people is considered to be associated with a
greater risk for developing severe late diabetic complicatins over a
given time than diabetes developing later in life (Bradley & Ramons,
1971).
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B2. 2b Insulin antibodies in
relation to HLA antigens
in type 1 diabetes
Evidence is accumulating that the immune response against
exogenous insulin is under genetic control in animals as well as in
man(Keck,1975;Bertrams et al,1976).HLA antigens involved in the
regulation of the immune response towards heterologous insulin are
among those associated with type 1 diabetes(Bertrams et al,1976;
Ludvigsson et al,1977).To analyse this more closely the relationship
between insulin antibodies, ICA and the HLA types in insulin-treated
type I diabetics has been investigated.
Patients
Insulin binding capacity (InsAb) and islet cell antibodies (ICA)
were studied in 191 diabetics divided into three groups. Because in
most cases ICA persist for only a short period after diagnosis it was
decided to study only patients near diagnosis and patients with ICA
detectable at more than 3 years from diagnosis together with a
suitable control group.
Group I: 59 insulin dependent diabetics (age at diagnosis 21.8
yr,SD 9.2), of whom there was a specimen of serum available for ICA
detection sampled within a week of diagnosis, were studied for InsAb.
34 patients were found to be ICA positive (group la) and 25 ICA
negative (group lb). As InsAb titres show small variations with the
duration of insulin treatment,44 patients after a mean of 15 months
(SD 5.2) and 15 after a mean of 10.4 years (SD 2.3) from diagnosis
233
were tested for InsAb. None of these patients had any clinical
evidence of other organ specific autoimmune disease.
Group 11: Another 59 insulin treated diabetics (age at diagnosis
32.4 yr,, SU 19.9), who were ICA positive at more than 3 years from
diagnosis, were tested for InsAb. The 40 patients in group Ila (age at
diagnosis 27.5 yr,SD 16.4;interval from diagnosis when InsAb was
tested 13.6 yr, SD 8.6) did not show any clinical organ specific
autoimmune disease; 19 patients in group lib (age at diagnosis 41 yr,
Sd 22.9; interval from diagnosis when InsAb was tested 19 yr,SD 9.7)
had one of the following autoimmune diseases (AID): Addison's disease,
thyrotoxicosis, Hashimoto thyroiditis, primary hypothyroidism,
pernicious anaemia.
Group III: 73 insulin treated diabetics (age at diagnosis
29.9 yr, SD 15.2), in whom ICA was not detectable after 3 years of
diagnosis were studied for InsAb. These patients were matched as
closely as possible with patients of group II. The 51 patients in
group Ilia (age at diagnosis 26.6 yr,SD 15.9; interval from diagnosis
when InsAb was tested 14.2 years, SD 8.2), were without any AID; the
22 patients in group Illb (age at diagnosis 32.4 yr, SD 13.7; interval
from diagnosis when InsAb was tested 19.6 yr, SD 8.3) had one of the
above mentioned AID.
All these patients were Caucasians and were attending the same
clinic. None had been treated with highly purified insulin
preparations at the time of the study. No patient was in a remission
phase. 93 patients were recalled for HLA typing, 52 of group I and 41




Insulin binding capacity was estimated by a minor modification of
the method of Ortved Andersen,Brunfeldt and Albigard(1972) according
to Mustaffa, Dagget and Nabarro(1977)(chapter A3.3).Insulin binding of
more than 10 uU/ml of serum was regarded as indicative of the presence
of insulin antibodies. Insulin binding levels less than 100, between
100 and 300, and above 300 uU/ml were considered as indicating low,
medium and high levels of insulin antibodies respectively.
Islet cell antibodies were detected by the indirect immuno¬
fluorescence test as previously described(chapter A3.5).
HLA typing was performed as described by Morris et al,1976 for
the following 40 antigens:
A series: 1,2,3,9,10,11,25,26,28,29 and W 23,24,30,31,32,33.
B series: 5,7,8,12,13,14,15,17,18,27,37,40 and W 16,21,22,35,
38,39,41.
C series: W 1,2,3,4,5.
The chi-squared test ("C"), Wilcoxon's two sample test ("W") and
Cox's test for trend in proportins ("T") (Cox, 1970) were used as
indicated in the analysis of the results.
Results
In patients without other clinical autoimmune disease and tested
for ICA at more than 3 years from diagnosis, InsAb titres were signi¬
ficantly lower (p<0.05, "W") in the 40 patients who were ICA positive
(group Ila) compared to those in the 51 patients who were ICA negative
(group Ilia). No significant difference was found between InsAb titres
in patients in group Ila compared to those in patients in group 1 or
lb.
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There was no significant difference between the InsAb titres in
34 ICA positive patients in group la compared to the 25 ICA negative
diabetics in group lb. Again the InsAb titres were not significantly
different in ICA positive or negative patients in group I either after
15 months from diagnosis (InsAb median in ICA positive patients 191
uU/ml, interquartile range or IR 92-294; in ICA negative 89 uU/ml, IR
60-214) or after 10 years from diagnosis (InsAb median in ICA positive
94 uU/ml,IR 19-19; in ICA negative patients 80 uU/ml, IR 31-130).
There also no significant difference in InsAb titres in patients in
group II or III between those without (Ila, Ilia) and with (lib, Illb)
other clinical autoimmune disease.
The prevalence of HLA-A1 and B8 in the 93 diabetics HLA typed was
significantly increased in comparison with the normal population
(p<0.005 and p<0.0001 respectively, "C").
Diabetics who were B15 and/or CW3 positive showed significantly
higher titres of InsAb. The median of InsAb titres for the B15
patients was 233 uU/ml (interquartile range or IR 133-370) and for CW3
patients was 169 uU/ml (IR 98-305). These values are significantly
higher than those found in the total patients (107 uU/ml, IR 35-213)
(p<0.001 for B15, p<0.01 for CW3, "W")(Fig.B2.2/1). The difference in
InsAb levels in the B15 compared to the B8 patients was also stati¬
stically significant.
Dividing the patients into negative and low-,medium-, and high-
responder groups according to the levels of insulin antibodies, there
was a significant trend for B15 and/or CW3 positive patients to have
InsAb levels in the medium- and high-responder range (p<0.001 and p<
0.005, "t") and B8 and/or positive diabetics to have levels in the
negative and low-responder range (p<0.05 and p<0.02, "T"). There was
FIGURE B2.2/1
Insulin antibodies levels and HLA antigens in 93 insulin treated
type 1 diabetics.


















no significant correlation between the presence of B7 and InsAb
titres.
Discussion
The findings in the present paper emphasize that there are at
least two separate immune response (Ir) genes operative in type I
diabetes that are associated with HLA. It has previously shown(chapter
B1.2) that type I diabetics with what might be conveniently referred
to as Irl (and which is in linkage disequilibrium with A1, B8, DW3 and
DR3) tend to have persistent ICA or other clinical autoimmune
disorders. It has now been shown that such patients tend to form low
levels of insulin antibodies. However, type I diabetics with lr2
(which is in linkage disequilibrium with A2, B15, CW3, DR4) tend to
have high levels of insulin antibodies following treatment with
conventional heterologous insulin. The phenomenon of linkage
disequilibrium in relation to these two Ir genes is further
illustrated in that patients who are CW3 have similar insulin antibody
levels as those who are B15 and patients who are A1 have similar
insulin antibody titres as those who are B8.
The observation that insulin treated diabetics with persistent
ICA have lower insulin antibody levels than a matched group of ICA
negative diabetics confirms the difference in the immune response to
these endogenous and exogenous antigens. There is suggestive evidence
that patients who are B15 may have higher titres of antibody to
Cocksackie virus types B1-B4 (Cudworth et al,1977).
It would thus appear that Irl is concerned with organ-specific
autoimmunity, while Ir2 is concerned with the immune response to
certain exogenous antigens. This would indicate that the association
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of Irl with autoimmunity is not merely a manifestation of a heightened
immune response in general to all antigens, be they autoimmune or
otherwise.
Why B7, and presumably the HLA antigens A3, DW2 and DRW2 in
linkage disequilibrium with it, should be "protective" against the
development of type I diabetes is not understood.The observation that
B7 is associated with cutaneous allergic reactions to heterologous
insulin (Bertrams & Gruneklee,1977) and also the humoral response to
monomeric flagellin (Morris et al,1977) suggests that it is in linkage
disequilibrium with a third immune response gene Ir3. However, it must
be borne in mind that the HLA antigens mentioned above may also be in
linkage disequilibrium with other genes that are not related to immune
response.
Hopefully DR antigens will show even stronger associations with
the different type of immune response studied as illustrated by
persistent islet cell autoimmunity and high levels of insulin
antibodies in type I diabetics.
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B2.3 IMMUNE COMPLEXES IN RELATION TO THE TYPE OF TREATMENT,
DURATION OF DIABETES, SEX AND AGE IN DIABETIC PATIENTS
B2. 3a Aim of the study
In this study the influence of sex, age, duration of disease and
type of antidiabetic treatment (insulin or oral agents) on immune
complex levels has been investigated.
B2.3b Materials and Methods
Patients
Two hundred and seventy-six diabetics attending the Diabetic
Clinics of Rome and of Edinburgh were selected at random. One hundred
and forty-seven were males and 129 were females. Twenty-five diabetics
were less than 20 years old, 42 were in the third decade, 29 in the
fourth, 32 in the fifth, 53 in the sixth and 95 were more than 60
years old. In 67 patients the duration of diabetes was between 1 and 5
yr, whereas in 61, 62,42 and 44 patients the duration of diabetes was
between 6 and 10, 11-15,16-20 and over 20 yr, respectively. One
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hundred and forty-eight were treated with insulin at the time of the
study and 128 with diet or oral hypoglycaemic agents. Insulin treated
patients received ordinary commercial insulins (Lente, NPH,
crystalline).None of those was treated with purified insulins. One
hundred and thirty blood donors were included in the study as normal
controls.
Immune complexes
Circulating AgAb were assayed by the solid phase Clq binding test
according to Hay et al(1976) with minor modifications (chapter A3.1)
The limit of positivity was chosen as the 90th percentile of blood
donor values(Lambert et al,1978)
Statistical analysis





AgAb levels were above the limit of positivity in 65 out of the
total 276 diabetics studied and in 13 out of the 130 blood donors.
Therefore AgAb were significantly increased in the diabetics
(p<0.002).
AgAb and sex of patients
Among the diabetics, AgAb were present in 24.5% of males and in
22.5% of females.
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AgAb and age of patients
When the diabetics were divided according to age, there was no
significant difference in AgAb levels (Table B2.3/1).
AgAb and duration of diabetes
When the duration of diabetes was taken into account considering
all the patients together, there was no significant correlation
between AgAb and duration of disease (table B2.3/2).
AgAb and type of treatment
However, when patients were divided according to the type of
treatment, insulin treated diabetics showed a significantly higher
prevalence of AgAb compared to the non-insulin treated diabetics (30%
vs 16% p<0.005).The difference in AgAb positivity between insulin
preated diabetics and normal controls was highly significant
(p<0.0001),whereas the difference between non-insulin treated dia¬
betics and normals failed to reach statistical significance (x = 1.9).
Within the insulin treated group there is a statistically
significant peak in the prevalence of AgAb in diabetics of 11-20 years
duration (p<0.001)(Table B2.3/2)(Fig.B2.3/1),but there was no
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The prevalence of AgAb in diabetes. (A) The percentage positivity
for AgAb in recently diagnosed patients (see text). (B) The percentage
positivity in diabetics according to the duration of clinical
diabetes.
years at 05-1 1-5 6-10 11-15 16-20 >20
diagnosis
no of patients 110 70 36 32 24 26 30
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B2. 3d Discussion
In this study on a randomly selected population of diabetics,
AgAb were found to be increased in insulin treated diabetics in
comparison with non-insulin treated diabetics and normal controls.As
the nature of AgAb has not been analyzed in the present study it is
possible only surmise as to what the antigen components of these
complexes might be. This correlation between insulin treatment and
AgAb can be explained either as an intrinsic difference between type I
and type II diabetes or as the effect of heterologous insulin
administration. In some type I diabetics the increase in AgAb
positivity may be explained as a consequence of a genetically
determined increased immunoresponsiveness to exogenous agents present
in some insulin dependent diabetics (Chapter B2.2b;Scherthaner et
al,1979).On the other hand the administration of exogenous insulin may
induce the formation of insulin-anti-insulin complexes and several
clinical and experimental studies have already shown the presence of
these complexes in insulin treated subjects (Foiling,1976;Jayarao et
al,1974 chapter B3.4).
It is however by no means certain that insulin-anti-insulin com¬
plexes are detected by the Clq technique because of the immunological
characteristics of insulin. Considering the bivalency or insulin, most
insulin-anti-insulin complexes tend to be of very small size and so
are not detectable by the techniques which use complement to reveal
circulating AgAb.Only a small proportion of insulin-anti- insulin
complexes form polymers and aggregates of detectable size. Never¬
theless, in a randomly selected diabetic population it is possible
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that some of the complexes found may be a consequence of an increased
formation of such complexes induced by exogenous insulin.
This seems to be true especially when insulin-anti-insulin
complexes are formed in antigen excess, whereas in the presence of
antibody excess these complexes are not detected by the method
used.Indeed an inverse correlation has been found between increasing
levels of insulin antibodies and higher titres of AgAb in randomly
selected diabetics (chapter B2.4).
Within the insulin treated diabetics there is a pronounced peak
in the prevalence of AgAb in diabetics of ll-20yr duration. Thus in
insulin treated diabetics it is possible so far to describe two peaks
of AgAb positivity according to the duration of diabetes.The first
peak in AgAb levels is found within a few days of diagnosis with a
sharp decline in positivity thereafter (Fig.B2.3/1),as already
described in chapter B1.3. Since the techniques used to detect AgAb
are antigen non-specific it is likely that the two peaks in AgAb
positivity are due to different types of AgAb. AgAb in the first peak
seem to be part of the immunopathological phenomena occurring at
diagnosis and are statistically correlated with the presence of islet
cell antibodies (ICA). In the second peak, AgAb may be induced by
other factors even though in that minority of long standing insulin
treated diabetics with persistently positive ICA, AgAb were reported
to be increased (chapter Bl. 2d).While the highest titres of insulin
antibodies tend to occur at 9-12 months of insulin treatment, the
highest amounts of AgAb in the second peak (as detected by ClqSP)
occur at 11-20 yr. It is therefore likely that antigens other than
insulin are involved in the second peak of AgAb.
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This conclusion is also supported by the fact that, when severe
microangiopathy is present, AgAb are increased in insulin as well as
in non-insulin treated diabetics.This suggests that insulin-anti-
insulin AgAb may not be the main component of these complexes, but
that there may be a decreased clearance of miscellaneous types of
complexes resulting from an impaired phagocytic system (chapters B3.2b
B3.2c, B3.2d)
The decline in AgAb positivity in diabetics with more than 20 yr
of diabetes may be explained by the presence of milder complications
in this group of patients or by the presence of some insulin treated
type II diabetics. This study shows that the age of patients cannot
explain this decline.
These results, together with findings reported in other chapters,
suggest that a heterogeneous population of immune complexes is present
in diabetics. A careful selection of patients and the identification
of antigens involved in complexes are important to understand their
significance in diabetes.
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B2.4 INSULIN ANTIBODIES AND IMMUNE COMPLEXES IN RANDOMLY SELECTED
DIABETICS TREATED WITH CONVENTIONAL INSULINS
B2.4a Aim of the study
This study was planned to investigate the correlation between the
presence of insulin antibodies and the occurrence ut immune complexes
in randomly selected insulin treated diabetics. To detect
circulating immune complexes,a method detecting medium sized com¬
plexes in antigen excess through the Fc portion of complexed immuno¬
globulins was used.
B2.4b Materials and Methods
Patients
Ninety-seven randomly selected consecutive patients treated with
insulin for more than 1 year were included in the study 51 were males
and 46 females. Their mean age was 33.8 + 17.4. One hundred and




ClqSP as described by Hay, Nineham and Roitt (1976) with some
personal modifications (chapter A3.1) was used to detect immune
complexes. The characteristics of the methods, the limit of
positivity, the expression and analysis of the results for AgAb the
limit of positivity of IC have been discussed in chapter A3.1.
Insulin antibodies
Andersen's radioimmune assay (Orteved Andersen, Brunfeldt and
Albigard, 1972) as modified by Mustaffa, Dagget and Nabarro (1978) was
used to detect insulin antibodies. The results were expressed in uU/ml
of insulin binding capacity (chapter A3.3).
Statistical analysis
2
Fisher's exact test, the x test, Cox's test, the t-unpaired test





In randomly selected diabetics, immune complexes were found in 26
out of 97 patients (27%, P<0.01 vs normal population).
Insulin antibodies
In the same patients, InsAb, as evaluated by Andersen's method,
showed a mean value of 116.4+113.2 uU/ml.
Immune complexes vs insulin antibodies
When InsAb were correlated with Clq-IC values, an inverse
correlation was found between InsAb levels and Clq-IC values (P<0.02)
and patients with high levels of InsAb tended to be Clq-IC negative
(Fig.B2.5/1).
FIGURE B2.4/1
Immune complexes (AgAb), as detected by Clq-SP, and insulin
antibodies (IBC), as assayed by Andersen's method, in insulin treated
diabetics. The horizontal dotted lines divide insulin antibody levels
into negative low, medium and high levels. The vertical dotted line
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B2.4d Discussion
In insulin treated diabetics selected at random, when InsAb were
present in high amounts, immune complexes were not usually detectable.
Since ClqSP does not adequantely detect complexes in antibody excess
(Scullion, Balint and Whaley, 1979), in patients with high levels of
InsAb, insulin antibody complexes would not be expected to be
detected. It is conceivable that in patients with lower InsAb levels
some immune complexes may be related to insulin treatment. In fact,in
the study described in chapter B2.3, Clq-immune complexes were found
to be higher in randomly selected insulin treated patients than in
comparable diabetics not treated with insulin.
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B2.5 INSULIN ANTIBODIES AND IMMUNE COMPLEXES IN NEWLY DIAGNOSED
TYPE 1 DIABETICS TREATED WITH CONVENTIONAL OR MONOCOMPONENT
INSULINS : A ONE YEAR FOLLOW-UP
B2.5a Aim of the study
The aim of the present study was to attempt to correlate
circulating immune complexes (detected by Clq and conglutinin) and the
presence of insulin antibodies in type I diabetics during the first
year of disease bearing in mind the type and duration of the diabetes
and antigenicity of the insulin used in the treatment.The presence of
islet cell antibodies was taken into account.
B2.5b Materials and Methods
Patients
Forty-one newly diagnosed Type 1 diabetic patients, with age at
onset <30 years, were studied before insulin treatment was started.
Twenty of these patients (12 males and eight females, mean age 9
years, range 5-11 years) were treated with conventional insulins
(group 1), whereas 21 (15 males and 6 females, mean age 13 years,
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range 822 years) were treated with monocomponent porcine insulins
(group 2). Patients were randomly assigned to each group. Blood
samples were collected at diagnosis and 1,3,6 and 12 months later in
all patients.
A series of 189 blood donors was also studied to determine the
normal range of the immune complex assays.
Insulin antibodies
Anti-insulin antibodies, evaluated as insulin binding capacity,
were measured by an immunoelectrophoretic method (Christiansen 1972);
the sensitivity of the method is 0.05 mU/ml, the interassay variation
3%. (chapter A3.3).
Immune complexes
Immune complexes were determined by the Clq solid phase method
according to Hay et al. (Casali et al.). The characteristics of the
methods are described elsewhere(chapter A3.1).
Islet cell antibodies
Islet cell antibodies (ICA) were assayed by indirect immuno-
fluorenscence on cryostat sections of blood group 0 human pancreas.
The presence of islet cell antibodies was evaluated by two independent
observers using a Leitz Dialux microscope (Chapter A3.5).
Statistical analysis
2
The X test, Fisher's exact test, Cox's test, Student's t-test
for independent variables and the binomial test were used for stati¬




Anti-insulin antibodies were detectable after the first month of
treatment, being significantly higher in group 1 than in group 2 at
each stage of follow-up (table B2.5/1).
Immune complexes
Clq immune complexes were present in 19 of the 41 diabetic
patients at diagnosis (46%) and progressively decreased thereafter
(table B2.5/2). Prevalence at 12 months' follow-up was 12%. This
decrease was statistically significant (p<0.01). No difference was
found between groups 1 and 2. Conglutinin immune complexes were
present in 12 of the 41 diabetic patients at diagnosis (29%),
prevalence varying during follow-up from a minimum of 26% to a maximum
of 38% (NS). Although at 12 months the prevalence was 40% in group 1
and 20% in group 2, the differences between the two groups were not
significant.
Islet cell antibodies
Islet cell antibodies were detected in 19 of the 41 diabetic
patients at diagnosis (46%). During the follow-up period the
prevalence of ICA decreased progressively to 10% after 12 months. This
decrease was statistically significant (p<0.001). No difference in




Islet cell antibodies and Clq immune complexes showed similar
decreases in frequency from diagnosis to 12 months in all patients
together and in the two groups examined separately. Clq immune
complexes were detected in 58% of the 19 islet-cell-antibody-positive
subjects at diagnosis. The agreement between the two tests (both
positive and negative) was significant (1 month p<0.05, 6 months
p<0.001, 12 months p<0.001).
Islet cell antibodies and conglutinin immune complexes showed
different profiles during follow-up (Fig. B2.5/1). Analysis of the
relationship between these two immunological factors demonstrated a
difference in prevalence at diagnosis (46% versus 29%), and only four
out of the 19 islet-cell-antibody positive subjects also showed
conglutinin immune complexes. No significant agreement was found
between the two tests.
AgAb vs Insulin antibodies
No significant correlation was found between Clq immune complexes
and anti-insulin antibodies, either in the 41 diabetic patients or in
groups 1 and 2 considered separately. The presence of conglutinin
immune complexes, on the other hand, showed a tendency to parallel the
increase in anti-insulin antibody levels in the 41 diabetic patients
(p<0.001). This trend was still present when the two groups were
examined separately (p<0.001). However, whereas in group 1 the maximum
prevalence of conglutinin immune complexes (85%) was reached when
anti-insulin antibody levels were above 2 mil/ml (p<0.002), the maximum
(75%) in group 2 was reached at lower anti-insulin antibody levels
(0. 5-2mll/ml) (p<0. 002).
TABLEB2.5/1
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Prevalence of immune complexes assayed with Clq solid phase
method (© ©) and with conglutinin binding test (£ Q) and
of islet cell antibodies m—s) in 41 Type 1 diabetic patients at
diagnosis and during 1 year follow-up.
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B2. 5d Discussion
These results demonstrate a correlation between Clq immune
complexes and islet cell antibodies, and between conglutinin immune
complexes and anti-insulin antibodies, whereas no correlation was
found between Clq immune complexes and anti-insulin antibodies, or
between conglutinin immune complexes and islet cell antibodies.Indeed,
Clq and conglutinin detect different populations of immune complexes
(Chapter A3.1)
It is possible that islet cell antibodies and Clq immune com¬
plexes are present at the time of diagnosis independently of each
other and are different expressions of the immune response to the same
aetiological agent.On the other hand, the correlation between Clq
immune complexes and islet cell antibodies observed in the present
study suggests that the islet cell antibodies might circulate in the
form of soluble complexes bound to antigens of islet origin. In this
case immune complexes detected by Clq assay at diagnosis may be a
reflection of such a phenomenon.
Of interest in the present study is the relationship observed
between conglutinin-immune complexes and insulin binding capacity. A
relationship between this type of immune complex and insulin treatment
is described in chapter B3.2c: these complexes were significantly more
frequent in patients treated with insulin than in others. The present
data, showing the existence of a significant trend in the prevalence
of circulating conglutinin-immune complexes with increasing levels of
insulin binding capacity, appear to suggest that the conglutinin
method may detect some of the insulin-anti-insulin complexes present
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in diabetic patients following treatment. On the other hand, assay of
immune complexes using conglutinin could be affected by the anti-
insulin antibodies and by the aggregates of these antibodies. It is
more difficult to offer an explanation for the observation that the
relationship between conglutinin-immune complexes and the levels of
insulin binding capacity in patients treated with conventional in¬
sulins (group 1) differs from that in patients treated with mono-
component insulins (group 2). It would, in fact, appear that while the
former tend to produce immune complexes at high levels of insulin
binding capacity, the latter form these complexes at low or medium
levels of insulin binding capacity. This finding may be due to the
difference in immunogenicity of the two types of insulin. Even though,
because of their purity, monocomponent insulins produce low overall
levels of insulin-binding capacity, the antibodies induced may have a
relatively high affinity for insulin.In contrast, conventional in¬
sulins, which contain extractive polypeptides with a greater molecular
weight and immunogenic capacity than pure insulin, tend to produce
larger families of antibodies only some of which display marked
affinity for insulin, even though all may be detectable as insulin
binding capacity by Christiansen's method(Berson and Yalow,1959;Wehner
& Larsen,1969).It is thus possible that for the same insulin-binding
capacity level, patients treated with monocomponent insulin produce a
larger quantity of specific complexes than those using conventional
insulins.
In conclusion, the present findings confirm the presence of
circulating immune complexes in patients with Type 1 diabetes mel-
litus, some of which may be related to factors present at diagnosis,
others to anti-insulin antibodies. On the other hand conglutinin-
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immune complexes might provide a useful method with which to follow
the pathological events associated with circulating anti-insulin
antibodies.
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B2.6 INSULIN ANTIBODIES AND IMMUNE COMPLEXES IN TYPE 1 AND 2
DIABETICS TREATED FOR THE FIRST TIME WITH CONVENTIONAL,
MONOCOMPONENT AND HUMAN INSULINS : A SIX MOUNTH FOLLOW UP
B2.6a Aim of the study
Insulin antibodies and immune complexes vere studies in type 1
and 2 diabetics receiving insulin for the first time. A six mouth
follow up was carried out.
The aim of the present investigation was to study human mono-
component insulin and its biologic and immunologic activity,and to
draw a comparison with porcine monocomponent insulin and other
conventional types of insulin preparations.
B2.6b Materials and methods
Sixty-eight diabetic Patients receiving insulin for the first
time were examined.None of these patients had evidence of other
diseases likely to involve the immune system,and non exceeded 10% of
mean body weight values.No pregnant women were included in the series.
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Patients comparable for sex,age,and duration of disease were
divided into the following three groups according to the type of
insulin received.
Group I (15 subjects):
Eight men and seven women comprised group 1 (mean age,28,2 + 6.3 yr;
mean duration of diabetes, 4.4 + 2.1 yr). Ten were newly diagnosed
insulin-dependent diabetic patients (IDDM) and five had been treated
previously with oral antidiabetic drugs. Patients in this group were
treated with human monocomponent insulins; 5 received only the
Monotard (Novo Industri, Copenhagen,Denmark) preparation and 10 the
combination Monotard + Actrapid (Novo).
Croup 11(28 subjects):
Sixteen male and 12 female subjects comprised group 2 (mean age, 22.5
+ 3.3 yr; mean duration of diabetes, 2.6 + 1.2 yr) .Twenty-one were
newly diagnosed IDDM and seven had been treated previously with oral
antidiabetic drugs. Patients in this group were treated with porcine
monocomponent insulins; 10 received only the Monotard (Novo)
preparation and 18 the combination Monotard + Actrapid (Novo).
Group 111(25 subjects):
Fourteen male and 11 female subjects comprised group 3 (mean age, 21.4
+ 4.1 yr; mean duration of diabetes, 3.3 + 1.4 yr). Nineteen were
newly IDDM and five had been treated previously with oral antidiabetic
drugs. Patients in this group were treated with conventional insulins;
9 received only long-acting preparationes and 16 the regular plus
long-acting. Blood samples were collected before insulin treatment and
1, 2, 3 and 6 months after the beginning of insulin treatment. Serum
from blood samples was stored at -20.
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Insulin antibodies
Insulin antibodies were measured according to the immuno-electro-
phoretic method described by Christiansen 1970 (Chapter A3.3).
Immune complexes
Immune complexes were evaluated by two different methods : the
solid phase Clq method (Clq-AgAb) described by Hay et al 1976 with
minor modifications (chapter A3.1) and the conglutinin binding assay
(Kg-AgAb) described by Casali et al, 1977, with minor modifications
(chapter A3.1)
Islet cell antibodies
Antibodies to pancreatic islet cells were detected using the
indirect immunofluorescence technique (chapter A3.5)
Haemoglobin Al
Metabolic control was evaluated by assay of glycosylated haemo¬
globin (HbA^) with column chromatography using the Bio Rad kit
(Bio-Rad, Richmond, California). The upper limit of normal values in
our laboratory was 9%, intrassay variation was 0.3% (HbA^<7%) and 0.6%
(HbA^>7%), and interassay variation was 0.8% and 1.4%, respectively.
Statistical analysis
Student's test and Cox's trend test were used for statistical
evaluation of the data.
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B2. 6c Results
The prevalence of ICA at the beginning of the investigation was
comparable in the three groups of patients (52% in group 1, 57% in
group 2, and 52% in group 3). The metabolic control after 6 months of
treatment was similar in all three groups: the mean HbA^ was 9.4%,
9.2%, and 10.1%, respectively, in groups 1, 2, and 3. The insulin
requirement (table B2.6/1) was similar in all three groups 15 days
after the beginning of insulin treatment, whereas after 6 months a
progressive rise was observed from group 1 to group 3, but these
differences were not statistically significant.
Insulin antibodies
Anti-insulin antibodies (InsAb)(table B2.6/2) at 6 months were
significantly lower (p<0.05) in patients in group 1 than in group 2.
The levels were significantly higher (p<0.05-0.002) in group 3 than in
groups 1 and 2 from the end of the first month onward. No statistical
difference was found in insulin antibody levels between type 1 and 2
diabetics.
Immune complexes
The prevalence of Clq-AgAb was similar in the three groups of pa¬
tients before the beginning of insulin treatment; thereafter values
decreased progressively to reach, by 6 months values ranging between
13% and 16%(table B2.6/3).
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The prevalence of Kg-AgAb was similar in the three groups before
the beginning of insulin treatment (table B2.6/4).At 6 mo the presence
of Kg-AgAb remained practically constant in groups 1 and 2, and rose
significantly (p<0.001) from 24% at the beginning of treatment to 44%
at 6 months of observation in group 3.
The immune complex results were not statistically different
between type 1 and 2 diabetics.
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Before the beginning of insulin treatment the three groups of
patients displayed similar prevalence of ICA, Clq-AgAb and Kg-AgAb.
Two weeks after the beginning of insulin treatment,insulin requirement
was also comparable in the three groups. The present study confirms a
previous report (Schernthaner et al, 1983) indicating that human
monocomponent insulin produces a lower insulin antibody response than
porcine monocomponent insulin in subjects never treated previously
with insulin.
The observed differences may be due to the primary structure of
these insulins. However, it should be noted that the aminoacid in
position 30 of the B-chain, which differentiates human from porcine
insulin, does not appear to be directly involved in the immunogenic
activity of the hormone. On the other hand, since not only the primary
structure but also the steroisometric configuration define the
immunogenic characteristics of a polypeptide, the difference in only
one amino acid may result in differences in the three-dimensional
structures of proteins and alter the capacity to induce the
formation of specific antibodies.
The difference in insulin antibody formation between groups 1 and
2 could also be explained by a difference in the genetic background of
the diabetic population studied. Subjects with HLA.B15 and/or HLA-DR4
antigens produce more IgG insulin antibodies to animal insulin than
patients with other DR-types (chapter B2.2b; Schernthaner & Mayr,1981;
Bertrams,1981). Of interest,however,Schernthaner et al(1981) found a
high prevalence of HLA-DR3 in patients producing IgG insulin
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antibodies against human monocomponent insulin. The relevance of these
observations to the current study remains to be determined.
Circulating immune complexes assayed with Clq, which have been
previously shown to be correlated with the onset of type 1 diabetes
(chapter B1.2) and with the severe forms of microangiopathy in both
types of diabetes (chapter B3.2), do not appear to be influenced by
the type of insulin treatment employed. This observation would confirm
earlier findings indicating that insulin is not a substantial
component of Clq-AgAb (chapters B2.3,B2.3,B2.4,B2.5). The prevalence
of circulating immune complexes determined with the KgBt technique
appears, in contrast, to correlate with on the type of insulin
treatment used. This pattern is probably due to the positive
correlation between Kg-AgAb and anti-insulin antibodies demonstrated
elsewhere (chapter B3.5). However there is no definite evidence to
show that insulin is found among the antigens present in the Kg-AgAb
complexes.
Whatever mechanism is involved, human insulins injected into man
appear to induce less immune complexes in comparison with the levels
of immune complexes induced following administration of heterologous
conventional insulins.
The clinical importance of Kg-AgAb in diabetes mellitus still
remains to be defined, in as much as the presence of severe
microangiopathy has been shown to be correlated only with the
Clq-AgAb.
In conclusion, the present 6 month trial suggests that equivalent
glycemic control may be achieved with human monocomponent insulins at
similar doses to those required with porcine monocomponent insulins.
Furthermore, human insulin is the least immunogenic of the present
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available insulins. No evidence of undesired side effects of human
monocomponent insulin was found.
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B2.7 CONCLUSIONS
The first aim of these studies was to investigate the relation¬
ship between insulin antibodies and different types of complexes in
diabetes.
Some types of complexes have been found to be correlated, with
insulin antibodies.
The presence of immune complexes detected by conglutinin,
apparently medium-large size complexes with complement bound, pa¬
rallels that of insulin antibodies. This is confirmed also by other
studies described in chapters B1 and B3. The correlation of insulin
antibodies with this type of complexes was not hypothesized at the
beginning of the study. The complexes that insulin is likely to form
are expected to be of very small size with a scanty complement fixa¬
tion due to the characteristics of the antigen. On the contrary the
complexes detected by conglutinin are of a large size and have the
third fraction of the complement already bound. It is possible that
those complexes detected by conglutinin are related to the immuno¬
logical response induced either by polimers of insulin or by physico-
chemical modifications of the antigen that occurr in the insulin
preparations or in tissues following injection. Another likely pos¬
sibility is that conglutinin complexes are related to the impurities
present in the insulin preparations. This is substantiated by the fact
that conglutinin complexes were lower in patients treated with highly
purified or human insulins.
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The immune complexes detected by Clq, apparently of small-medium
size in antigen excess, do not seem to correlate with the levels of
insulin antibody. The Clq complexes appear to correlate with other
immune phenomena occurring in the early stages of type 1 diabetes,
namely with the presence of islet cell antibodies (chapter Bl).
Furthermore Clq complexes seem to be increased when severe signs of
microangiopathy are present, as will be discussed in chapter B3. The
higher presence of immune complexes, as dectected by Clq method, found
in insulin treated diabetics and described in the study B2.3 is
confined to those patients with a duration of diabetes of more than 10
years. In these patients it is possible that other factors, including
microangiopathic processes, may be operating.
The second aim of these studies was to evaluate the immuno-
genicity of insulins differing in purity and of homologous and hetero¬
logous insulin molecules.
Newly diagnosed type 1 diabetics, treated with highly purified
insulin, formed less insulin antibody after one year of treatment than
comparable diabetics treated with conventional insulins. The presence
of immune complexes, as detected by conglutinin, correlated with that
of insulin antibodies at one year of diagnosis.
Patients treated for the first time with human insulin showed
after six months a much smaller insulin antibody formation and lower
presence of complexes detected by conglutinin than patients in com¬
parable conditions and treated with conventional insulins. Even though
the humoral immunological factors studied were not significantly
different in patients treated with human insulins and in those treated
with insulins from animal sources but highly purified, it appeared
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that human insulin is the least immunogenic of the present available
insulins.
CHAPTER B 3
IMMUNOLOGICAL PHENOMENA IN DIABETIC VASCULAR COMPLICATIONS
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Chapter B3 IMMUNOLOGICAL PHENOMENA IN DIABETIC VASCULAR
COMPLICATIONS
B3.1 Experimental design of the studies on diabetic
vascular complications
B3.2 Earlier studies by the author
B3.2a Insulin antibodies,immune complexes and dia¬
betic microangiopathy: a preliminary
observation
B3.2b Immune complexes in diabetics with various
degrees of microangiopathy : a pilot study
B3.2c Immune complexes in diabetics with severe
microangiopathy: evaluation by two different
methods
B3.2d Immune complexes and phagocytic clearance in
diabetics with severe microangiopathy
B3.3 Insulin antibodies and immune complexes in patients with
and without microangiopathy
B3.3a Aim of the study
B3.3b Materials and methods
B3.3c Results
B3.3d Discussion
B3.4 Immune complexes, insulin antibodies,insulin-anti-insulin
complexes related to platelet and coagulation factors in
patients with proliferative retinopathy
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B3.4a Aim of the study
B3.4b Materials and methods
B3.4C Results
B3.4d Discussion
B3.5 Immune complexes and lymphocyte subsets in patients
with microangiopathy
B3.5a Aim of the study





B3.1 EXPERIMENTAL DESIGN OF THE STUDIES ON DIABETIC VASCULAR
COMPLICATIONS
Much controversy still exists regarding the mechanism and
factors involved in the pathogenesis of diabetic microangiopathy.
Whilst various processes have been shown to be involved in diabetic
microvascular lesions, certain findings appear to be of particular
interest: vascular lesions present in immune complex diseases share
morphological aspects with those observed in diabetes, diabetic-like
vascular lesions can be experimentally induced by immune mechanisms,
biochemical changes occurring in the vascular basement membrane
increase the binding or trapping of circulating macromolecules.
(For details and references see Chapters A1.5 and B3.2).
Circulating immune complexes have been described by the author
to be increased in diabetics with microangiopathy (B3.2a). After this
preliminary observation other studies in selected groups of patients
(B3.2b, B3.2c) have been conducted to confirm the increase of some
types of complexes in patients with microangiopathy and to determine
whether an impairment of the reticuloendothelial system coult result
in a decreased clearance of such complexes (B3.2d).
In diabetic patients with microagiopathy the influence of
insulin treatment on immune complex formation and on progression of
vascular lesions remained to be determined. The possible interaction
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between these complexes, with other factors or cellular systems, such
as platelets, coagulation factors and lymphocytes was considered to
be of interest. In fact, the presence of immune complexes in the
circulation or in the tissue "per se" may be simply a normal bio¬
logical phenomenon. The quantity, type and destructive potentiality
of these complexes, and the way in which the host deals with them,
are the main factors that give a pathological significance to the
presence of such complexes.
The aims of the studies on diabetic microagiopathy are :
a) To evaluate the presence of different types of complexes and the
levels of insulin antibody in patients with severe microangio¬
pathy and with no clinical sign of it.
b) To relate the presence of immune complexes, insulin antibodies
and insulin-anti-insulin complexes to the abnormalities of
platelet and coagulation factors in patients with proliferative
retinopathy.
c) To investigate the possible correlation between some types of
complexes, subsets of lymphocytes and the presence of micro¬
angiopathy.
Insulin treated diabetic patients were selected so as to have
patients in opposite conditions, i.e. with severe microangiopathy and
without any clinical signs of microangiopathy, and included in the
study B3.3. Two methods detecting immune complexes and differing in
principle and a method to detect insulin antibodies were used.
The presence of these immunological factors was correlated to the
presence of vascular lesions.
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Since several abnormalities of endothelial and platelet function
have been reported in diabetic microngiopathy, the interaction
between circulating immune complexes and platelets in particular
appears to be extremely interesting. Two main aspects deserve at¬
tention. On the one hand, immune complexes may activate platelet
function, while on the other, platelet factors may modify the de¬
position of complexes in the vessel walls. In the study B3.4 immune
complexes, insulin-anti-insulin complexes and insulin antibodies have
been evaluated and correlated to a number of coagulation and platelet
factors in patients with proliferative retinopathy. Patients without
retinopathy and normal subjects acted as controls.
It is known that lymphocyte bearing receptors for the Fc portion
of immunoglobulins or for complement may bind and remove some types
of complexes; in study B3.5, the presence of some types of complexes
was correlated to the relative presence of different subsets of
lymphocytes in patients with and without microangiopathy.
The clinical part of these studies was done in collaboration
with the Diabetic Clinic, Royal Infirmary, Edinburgh, UK and with the
Diabetic Unit, University of Rome, Italy.
Platelet and coagulation factors were assayed in the Blood
Transfusion Service, Royal Infirmary, Edinburgh, UK.
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B3.2 EARLIER STUDIES
B3.2a Insulin antibodies, immune
complexes and diabetic micro¬
angiopathy : a preliminary
observation
In the present study, the presence of antibodies to insulin and
the occurrence of immune complexes have been investigated in the sera
of treated diabetics and compared to those in controls.Their associa¬
tion with the occurrence of diabetic complications and their possible





Sixteen of the thirty-two insulin-treated diabetics had diabetic
complications that were clinically manifest,including diabetic
retinopathy (defined by the presence of more than 3 microaneurisms,
retinal haemorrhages, exudates or new blood vessel formation) or
diabetic nephropathy (defined by a permanent proteinuria with or
without abnormal kidney function). Twelve out of the sixteen had
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soluble immune complexes in the serum while only five of the re¬
maining sixteen patients did so. The presence of immune complexes in
the serum was associated with late diabetic complications only in
patients who had had diabetes for more than 13 years. Four of the six
patients with insulin antibodies in the serum in a titre of>300 uU/ml
had late diabetic complications and had had diabetes for 15 years or
more. In the other two the duration of diabetes was 2 and 13 years,
respectively.
Discussion
That immune complexes in relation to insulin may be implicated
in diabetic complications is suggested by the observation that renal
tissue from diabetics shows fine granular deposits on the basement
membrane, resembling those found in certain types of glomerulo¬
nephritis (Bloodworth, 1968), while the glomeruli in diabetic nephro¬
pathy have insulin-binding capacity and also contain immunologically
detectable insulin (Berns et al. , 1962). However, immuno-histopatho-
logical studies have shown that the basement membrane in diabetic
glomerulosclerosis contains not only insulin, IgG, IgM, and
components of complement, but also 'non-immunological' plasma
proteins deposited in a linear fashion (Westberg & Michael, 1972),
which suggests that there may be a non-specific lesion involving the
trapping (binding) of serum proteins. These two possible machanisms
for the production of diabetic complications may not be mutually
exclusive. While there was no clear correlation between the titres of
insulin antibodies and the late complications of diabetes, these
preliminary findings suggest that there is a tendency for immune
complexes to occur after prolonged insulin therapy and at a time when
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such complications are likely to become clinically common (i.e. after
10 years).
Clearly a long-term prospective study is required in order to
determine whether the development and persistence of soluble immune
complexes in insulin- dependent diabetes is correlated with the
development of late diabetic complications and whether the use of
monocomponent insulin will avoid the development of immune complexes,
and whether or not this will be associated with a reduction in late
complications.
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B3. 2b Immune complexes and insulin
antibodies in diabetics with
various degrees of microangio
p a t h y : a pilot study
The purpose of the present study was to investigate the pos¬
sibility that soluble immune complexes,not necessarily comprised of
insulin,may play a role in diabetic microangiopathy.Thus the levels
of complexes in circulation were assayed in groups of diabetics with
different degrees of microangiopathy.
Materials and methods
Ninety-three insulin or oral hypoglycaemic agent (OHA) treated
diabetics attending the same diabetic clinic of the University of
Rome were selected, and grouped according to the fluoroangiography
findings and the duration of diabetes.
The patients in groups A,B and C had had diabetes for many
years. Patients in group A were without any sign of diabetic retino¬
pathy and had no clinical evidence of other diabetic complications.
Patients in group B had non proliferative retinopathy with or without
other diabetic complications, while patients in group C had pro¬
liferative retinopathy with or without other diabetic complications.
The patients in groups D and E had had diabetes for only a few
years. Those in group E had developed retinopathy within 3 years of
diagnosis (precocious retinopathy) and they were compared with an
otherwise comparable group of diabetics without retinopathy (group
D).
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Fifty-three of the patients were treated with insulin while 40
were treated with OHA.None of the patients had laser treatment for
retinopathy.Diabetics with other AgAb associated diseases were not
included in the study.
One hundred and fifty blood donors were included as controls.
Because of the heterogeneity of AgAb two sensitive methods
differing in principle were used to detect AgAb:the solid phase Clq
binding test (Clq-SP) (Hay et al,1976) based on the method of Svehag
(Svehag,1975),and the Raj i cell radioimmune assay (RAJI) (Theofilo-
poulos et al,1976). Quantitation in both methods was obtained by
reference to the uptake of serially diluted heat aggregated human IgG
(AHG) in normal serum (EDTA inactivated in Clq-SP) and the results
were expressed in ug AHG equiv/ml undiluted serum. In the Clq-SP,
values greater than the 90th percentile of a series of 80 blood
donors were considered as positive.In the RAJI assay, values greater
than 20 ug AHG equiv/ml were considered positive. Further details of
the two methods for AgAb are given in the chapter A3.1.
Insulin antibodies, as measured by plasma binding capacity InsAb,
were detected and titrated by Christiansen's method (Christiansen,
1970)(see chapter A3.3).
Results
Considering all the patients together, the presence of AgAb was
significantly increased in diabetics compared to the control popula¬
tion using either Clq-SP (27% vs 10%) or RAJI (41% vs 24%). When the
results of the two tests were combined, 53% of the diabetics had
evidence for AgAb in their serum.
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In diabetics of more than 15 years duration (group A,B,C),
patients with proliferative retinopathy (group C) had a higher pre¬
valence of AgAb as detected by Clq-SP than did the control po¬
pulation, while those without retinopathy (group A) did not.The
prevalence of AgAb showed an increase in group B compared to group A
and in group C compared to group B. Applying the test for a trend in
proportions as proposed by Cox(1971),the trend for increased pre¬
valence of AgAb as detected by Clq-SP according to increasing se¬
verity of retinopathy is statistically significant at the 5% level
(normal deviate=2.13, p=0.03).
In diabetics with onset of retinopathy within 3 years of
diagnosis (group E) the prevalence of AgAb was higher than in the
control population but no such difference compared to controls could
be shown in diabetics of similar duration without retinopathy (group
D).
The prevalence of AgAb in group D and E can be summarized in 2x2
contingency table and analysis by means of Fisher's Exact Test gave
statistically significant differences at the 10% but not at the 5%
level for both Clq-SP and RAJI (using a two-tailed test) assessed
individually. When the same analysis was made in longer established
diabetics by comparing group C and A (ignoring B),the Clq-SP
technique also gave statistically significant results at the 10%
level, while no significant difference was obtained with RAJI.
A test for combining the information from two or more 2x2
contingency tables of the same type (e.g.group A vs C and D vs E) has
also been given by Cox(1971). Applying this to the data from the
Clq-SP technique gave a significantly higher prevalence of AgAb in
patients with severe or early retinopathy (normal deviate =3.25,
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p=0.001) compared to those without retinopathy,while with the RAJI
data, statistical significance at conventional levels was not found
(normal deviate=l.62, p=0.11).
Instead of using the prevalence, it is possible to apply non-
parametric tests of significance (randomization tests) which utilize
the levels of AgAb observed.Applying these tests gave precisely the
same conclusions that were obtained by considering prevalences.
There was no statistically significant differences in the
prevalence of AgAb when insulin treated and OHA treated diabetics in
groups A,B and C were compared using either Clq-SP or RAJI. Similar
negative results in relation to the form of treatment were found in
patients with or without precocious onset of retinopathy (groups
D,E), or when all the patients were considered together.
There was no statistical correlation between the titres of
insulin antibodies determined by insulin binding capacity and the
occurrence of AgAb in insulin treated diabetics.
Discussion
In the past, the detection of soluble immune complexes (AgAb)
was difficult because of the absence of a sensitive, reproducible and
simple method. In the seventies the methods for detecting circulating
AgAb were substantially improved (Lambert et al,1978), though they
are still antigen non-specific and do not differentiate true AgAb
from immunoglobulin aggregates.Methods based on different principles
detect soluble complexes with different characteristics (Lambert et
al, 1978), and it is therefore not surprising that the two methods
used in the present study, give somewhat different results although
showing the same overall trends(see chapter A3.1).
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Both methods indicate that AgAb are increased in treated dia¬
betics. This could be due to either an increased rate of production
of AgAb or to a decreased rate of clearance by the reticulo-endo-
thelial system. The composition of AgAb and change in phagocytic
function may influence the rate of clearance (Mannik et al,1974). The
methods used in the present study detect AgAb of medium to large size
and one would expect that such complexes would be rapidly removed by
a normally functioning phagocytic system (Mannik et al,1974). An
impairment of phagocytic function has been described in poorly
controlled diabetics (Badgage,1976) and a positive correlation
between poor metabolic control and microangiopathy in diabetes is
widely believed to exist (Colwell,1966;Job et al,1976). Conceivably,
therefore, poor metabolic control could lead to the accumulation of
AgAb in the circulation and this may contribute to the development of
microangiopathy.
The methods used for detecting AgAb in the present study do not
characterize the antigen(s) or the immunoglobulin(s) involved, but
only tell us that the immunoglobulin(s) belongs to lgGl,IgG2 or IgG4.
However it can be surmised that most of the AgAb detected would have
a medium/high degree of lattice formation, would be of medium/large
size, would activate the complement system and would react with cells
possessing Fc or C receptors (WHO Scientific Group,1977). AgAb with
these characteristics have the greatest pathogenic potential (WHO
Scientific Group, 1977) and they may act as harmful agents by com¬
plement activation and subsequent chemotaxis of leucocytes after
passive vascular trapping or binding.
Increased production and accumulation of AgAb may be due to
recurrent infections, which are likely to be related to poor
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metabolic control, irrespective of whether the patient required
insulin or not.
The presence of AgAb does not seem to be related to the type of
treatment or to insulin antibody titres.
It is probable that most AgAb related to diabetic retinopathy
are not comprised of insulin. Although a pathogenic role for insulin
anti-insulin complexes cannot be excluded, their involvement might
be a relatively minor one. Thus, on account of the bivalency of
insulin (Foiling,1976) , AgAb involving insulin would tend to have a
low degree of lattice formation and would therefore bind complement
poorly (Jaton et al,1976). Such complexes would be detected poorly by
the methods used in the present study and would not be expected to
have much pathogenic potentiality. These arguments would be in
keeping with the clinical observation that microangiopathy is present
with similar characteristics in insulin and non-insulin treated
diabetics.
In conclusion these preliminary findings suggest that the study
of soluble immune complexes provides a new approach to old and still
unsolved problem of the pathogenesis of diabetic microangiopathy.
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B3. 2c Immune complexes in diabe -
tics with severe microangio-
pathy:evaluation by two
different methods
In this study the presence of circulating immune complexes
(AgAb) in serum of diabetics has been investigated in order to
establish the correlation between AgAb and severe microangiopathy,
either proliferative retinopathy or advanced nephropathy. Attention
has been focused especially on patients with long standing diabetes
not presenting with microangiopathy. The influence of the type of
diabetes and of the antidiabetic treatment on AgAb levels was also
studied. Since AgAb are heterogenous and different methods detect
different types of complexes, two sensitive methods differing in
principle to detect them were used.
Materials and Methods
One hundred and fifty-one diabetics were selected according to
the presence of microangiopathy and the duration of disease. Since
many factors theoretically might influence the levels of AgAb in
diabetics, such as the duration of diabetes and the type of treat¬
ment, to minimize the interference of other variables, the relation
between the presence of microangiopathy and AgAb positivity was
studied in diabetics in two quite different, well defined and rather
uncommon conditions.
At first patients were studied who, after many years of dia¬
betes, showed no sign of diabetic complications and they were
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compared them with diabetics who, at the same time after diagnosis,
showed proliferative retinopathy or severe nephropathy. For this
purpose, 92 diabetics at more than 15 years after diagnosis were
studied(Group I):31 had no detectable sign of diabetic microangio¬
pathy whereas 30 showed proliferative retinopathy without marked
nephropathy, and 25 had severe nephropathy with various degrees of
retinopathy.
Thereafter diabetics with apparently a precocious onset of
severe retinopathy were studied and their levels of AgAb were
compared with those found in diabetics with no sign of diabetic
complications at a similar time from diagnosis, Fifty-nine patients
were assembled for this investigation(Group II):19 diabetics ma¬
nifested the onset of severe retinopathy within 3 years of diagnosis
whereas 40 had no sign of microangiopathy at comparable time from
diagnosis.
Diabetics presenting mild microangiopathy, or patients with
chronic disorders with primary or secondary immune aspects, were
excluded from the investigation.
Part of the patients were type I diabetics and the remainder
type II diabetics. Type II diabetics with an overweight of more than
20% of their ideal body weight were not included in the study in
order to minimize the number of variables.
One hundred and eighty-nine blood donors, age range 18-59, were
controls for the evaluation of the limit of positivity in AgAb
assays.
The presence and degree of retinopathy were assessed in all the
diabetics by retinal fluoroangiography and the results were evaluated
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by an ophthalmologist. Patients with severe retinopathy, included in
the study, showed either proliferative retinopathy or vitreal haemor¬
rhages. Nephropathy was evaluated on the basis of Blood Urea Nitrogen
(BUN) serum creatinine levels and proteinuria. BUN>50 mg/100 ml,
serum creatinine levels >2 mg/100 ml, and/or proteinuria > 2 g/1 were
considered as an index of kidney involvement.
The solid phase Clq binding test (ClqSP) (Hay et al. 1976) and
the conglutinin binding test (KgBt) (Casali et al. 1977) were used to
detect circulating AgAb(see chapter A3.1).
The selection of patients and the laboratory assays were done by
two independent researchers and so the sera were in a random order in
the experiments. If a difference of more of 10% in results from
duplicate tubes was found, the sample was re-tested. The same batch
of immunoglobulin divided in aliquots and aggregated at 63°C for 20
min, was used throughout the study. Values greater than 6 ug AHG
Eq/ml were considered above the limit of positivity in the ClqSP
whereas 4 ug AHG Eq/ml was the limit in the KgBt(chapter A3.1).
The chi square test (X), with Yates' correction when indicated
(Y), Fisher's exact test (F), Student's t-test (S) and Cox's test (C)
(Cox 1971) were used in the statistical evaluations of the results as
indicated. The quantities of AgAb were expressed as mean + SEM of
values.
Results
When the results in long standing diabetics (Group I) were
examined, the prevalence of AgAb, using ClqSP, was similar in
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patients without microangiopathy (16%) and in the normal population
(10%), whereas the prevalence of AgAb was significantly higher in
patients with severe microangiopathy (51%) than both in the normal
population (PC0.001, Y) and in the patients without complications
(P<0.005, Y).Also the quantities of AgAb in diabetics with severe
microangiopathy were significantly higher (P<0.01,S) when compared to
those found in patients without microangiopathy (17.7+3.2 vs 5.7+2.8
ug AHG Eq/ml).
There was a trend for severe microangiopathy to go with medium-
high levels of AgAb (PC0.002, C, performed on AgAb values divided as
indicated in Fig.B3.2/1).
The presence of AgAb studied by ClqSP, was not correlated vith
the type of diabetes. The AgAb prevalence in type I diabetics with
microangiopathy was 52% and in those without microangiopathy 20%. In
type II diabetics with microangiopathy the prevalence was 50% and in
those without microangiopathy 13%.
The prevalences and the quantities of AgAb were similar in pa¬
tients with proliferative retinopathy alone (50% and 21.3+6.3 ug AHG
Eq/ml, respectively) and in patients with nephropathy and various
degrees of retinopathy (52% and 15.2+3.2 ug AHG Eq/ml).
When the KgBt method was used in patients in Group I, an in¬
creased prevalence of AgAb was found both in patients with (39%) and
without microangiopathy (36%) in comparison with the normal po¬
pulation (P<0.0001 and P<0.0005,Y). Taking into account the type of
diabetes, AgAb presence detected by KgBt was higher in type I dia¬
betics (P<0.02,X). The AgAb prevalence in type I diabetics with
microangiopathy was 48% and in those without microangiopathy 47%. The
AgAb prevalence detected by KgBt in type II diabetics was
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respectively 25 and 19%, AgAb presence was the same in diabetics with
retinopathy alone (35%) and in those with nephropathy(35%).
When patients were examined a short time after diagnosis (Group
II),using ClqSP methodfor the analysis of AgAb, the prevalence of
AgAb appeared to be significantly higher in patients with early
retinopathy (63%) than in normal subjects (P<0.001,Y), or in dia¬
betics without microangiopathy (20%)(P<0.005,F). Also the quantities
of AgAb were different between diabetics with (15.5+4.2 ug AHG Eq/ml)
and without retinopathy (3.1+1.1 ug AHG Eq/ml) (p<0.001,S,and p<0.005
C, on AgAb values divided as previously described). Taking into
account the type of diabetes, the AgAb prevalence using ClqSP was 67%
in type I diabetics with microangiopathy and 25% in those without
microangiopathy, whereas in type II diabetics with and without
microangiopathy was respectively 62 and 15%. There is no difference
in AgAb prevalence using ClqSP between type I and II diabetics.
Using the KgBt method in patients in group II, differences in
the prevalence of AgAb in patients with early retinopathy (52%) and
in those without microvascular involvement (30%) were not stat¬
istically significant, though the prevalence of AgAb in all diabetics
(37%) was higher than in the control population (p<0.005,Y).No
difference in AgAb prevalence was found between type I and II dia¬
betics .
As previosly shown (Lambert et al,1978) the Clq-Sp and KgBt
techniques detect different types of AgAb and also in this work there
was not a significant concordance between AgAb values obtained by
these two methods:AgAb values were concordantly positive in 15% of
the cases and concordantly negative in 41%. 24% of sera showed an
AgAb presence only by ClqSP and 20% only by KgBt.
FIGURE B3.2/1
Immune complexes, detected by Clq-SP, in 31 long standing dia¬
betics without complications (o) and in 62 patients with micro¬
angiopathy (proliferative retinopathy and/or severe nephropathy ).
The horizontal line at 6 ug AHG Eq/ml represents the limit of po-
sitivity (see text). The heavy bars on the y-axis divide AgAb values































In aggreement with other reports (Kumar & Quismorio,1978; Kumar
et al, 1979;Ludwig et al,1979) circulating AgAb were found to be
increased in some diabetics. The presence of AgAb in several diabetic
conditions, namely type I diabetics at diagnosis (Chapters B1.2a,
B1.2c, BI.3) and long standing insulin treated diabetics (Chapters
B2.2a, B2.3, B2.4; Charlesworth et al,1979;Delespesse et al,1980),
has previously been described. In the present study an increase in
circulating AgAb was found in diabetics with severe microangiopathy.
AgAb detected by ClqSP are increased both in diabetics with
proliferative retinopathy and in those with severe nephropathy,
irrespective of the organ overtly damaged.
AgAb (ClqSP) are also increased in patients with early retino¬
pathy, including patients with the so-called malignant microangio¬
pathy (Andreani,1980), and long standing diabetics without micrangio-
pathy of comparable duration of disease.
The entity of microangiopathic changes, therefore, seems related
to AgAb levels and not to the duration of the illness.
In patients with severe complications, AgAb levels were in¬
creased irrespective of the type of anti-diabetic treatment; there¬
fore, in the presence of complications, the type of treatment seems
to be of no relevance.
All these findings suggest that increased levels of AgAb,
accumulated as a consequence of modification of the dynamics of
formation, clearance and tissue deposition of complexes, are related
to microvascular damage in proliferative retinopathy and diabetic
nephropathy, and probably also to the course of complications, being
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more marked in patients with rapid development of the pathological
changes.
Our selection of diabetics with extreme and unusual conditions,
i.e. severe retinopathy within a few years of disease and absence of
microangiopathy even after many years of disease, highlights the
correlation between AgAb and microangiopathy.This correlation is
perhaps not so obvious in less severe microangiopathy, and this may
explain the apparent discrepancy with other reports (Ludwig et
al,1979;Balestrieri et al,1979).
When KgBt method was used, a higher prevalence of AgAb in
diabetics was demonstrated, but partially discordant results were
found. Conglutinin and Clq bind different types of AgAb through
unrelated mechanisms.lt is likely that the AgAb present in diabetes
are heterogeneous and, from the characteristics of the two methods
used, it may be inferred that complexes associated with microangio¬
pathy are formed in antigen excess (Casali et al,1977), have a low
degree of lattice formation (Di Mario et al,1980), may be readily
trapped or bound in blood vessel walls and thus are potentially
harmful (WHO 1977).
Since only some diabetics with severe microangiopathy have an
obvious increase in circulating immune complexes, the true importance
of their presence remains to be established.
Nevertheless, this correlation between the presence of
circulating AgAb and the occurrence of severe microangiopathy should
be kept in mind when attempting to establish the pathogenesis of
diabetic microangiopathy.
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B3.2d Immune complexes and phagocytic
clearance in diabetics with
severe microangiophaty
The occurrence of circulating AgAb may conceivably be related to
the histologic abnormalities observed in diabetics with microangio¬
pathy. It was therefore considered of interest to study the mecha¬
nisms of the increase in AgAb in diabetics to throw some light on the
pathogenesis of late diabetic complications. AgAb may be increased in
the circulation either because of increased formation or decreased
clearance (or both). Since medium-sized AgAb are cleared from the
circulation by phagocytes,Mannik et al(1974) the function of these
cells in diabetics with various degrees of microangiopathy, utilizing
a colloid clearance test has been studied.The principle of the test
is that above a critical dose of colloid injected, the rate of its
clearance adequately reflects phagocyte activity (Mannik et
al, 1974;Biozzi et al,1958)
The relationship between colloid clearance rate and the presence
and concentration of AgAb was examined. Due to the heterogeneity of
circulating AgAb, two methods were used to detect them: the Clq-SP
and the conglutinin binding test (KgBT), which define different
populations of AgAb.
Patients and methods
Thirty patients with overt diabetes in whom informed consent for
the study was obtained, were the subjects of the study. Eighteen
patients were insulin-dependent (type I) and twelve were non-insulin-
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dependent (type II) diabetics. Of the latter, three were treated with
insulin and nine with sulfonylureas. To limit Some of the possible
variables, only patients not exceeding ideal body weight by more than
20% and with a fasting blood glucose (BG) ranging between 5 and 11 mM
before the test were included.
The patients were divided into three groups according to the
degree of microangiopathy. Retinopathy was chosen as an index of
microangiopathy because of easy assessment and quantification of the
lesions. Kidney function was also evaluated.
Twelve patients with severe (proliferative) retinopathy were
classified as group 1; seven of these also showed impaired kidney
function. Group 2 comprised seven patients with moderate (background)
retinopathy and five of these also showed impaired kidney function.
Group 3 consisted of 11 patients with no sign of retinopathy or
nephropathy.
The presence and the degree of retinopathy were established by
retinal fluoroangiography. The occurrence of nephropathy was assessed
by routine laboratory tests. Normality of kidney function was defined
as BUN (Blood Urea Nitrogen)<23mg/dl; serum creatinine<l.5 mg/dl, and
absence of proteinuria. Metabolic control was similar in all three
groups of patients during the 3 months before testing (as assessed by
glycosylated hemoglobin (HbA^), fasting BG, and glycosuria.
Forty normal volunteers (26 males and 14 females) were included
in the study as controls for the colloid clearance test. Their ages
ranged from 22 to 55 yr and all were more than 20% above ideal body
weight. In addition, the sera of 198 blood donors were studied as
normal controls in AgAb assays.
The colloid clearance test
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The colloid used for clearance studies was human serum albumin, which
was heat aggregated and iodinated according to the procedure
described by Ilio & Wagner(1963) and as modified by Drivas et
al(1975).The test, which has been used by various authors (Biozzi et
al,1958 and Drivas & Wardle,1978) was performed as follows. The day
before the experiment, thyroid uptake was blocked by the adminis¬
tration of Lugol's solution. The following day, after an overnight
fast, microaggregated human serum albumin (delta-HSA) was injected
intravenously, within 1 min, at a dose of 3.5 mg/kg body weight, to
saturate the function of fixed phagocytes. After 10 min, micro-
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aggregated and iodinated human serum albumin ( 1-delta-HSA), 3.5
mg/kg body weight, was injected intravenously within 1 min. Blood
samples were collected every 5 minute up to the 45th minute. Serum
radioactivity was measured in each sample to study the disappearance
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from the circulation of injected 1-delta-HSA. Radioactivity was
plotted semilogarithmically against time, and the half-life (t%) was
determined by graphic resolution of the straight line present between
8 and 20 min. Colloid clearance was considered reduced when the t%
values were greater than 2 standard deviations above the mean of the
values in normal subjects. Radioactivity was also measured in serum
after precipitation with 10% trichloroacetic acid (TCA) to detect the
presence of non-protein-bound radioactivity (free iodine) in the
125
supernatant. Possible phagocytosis of I-delta-HSA by circulating
leucocytes was examined in white cell buffy coat. BG,HbA^c> BUN,
creatinine levels, and AgAb were assayed in blood samples collected
immediately before the colloid clearance test.
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AgAb were measured in duplicate both by Clq-SP(Hay et al,1976)
and KgBt(Casali et al,1977). Quantitation of circulating AgAb was
obtained by reference to the uptake of serially diluted human ag¬
gregated immunoglobulins (AHG). Results were expressed as micrograms
of aggregate equivalents per ml of undiluted serum. Uptake greater
than the 90th percentile of the blood donor population assayed in the
same experiment was considered positive(see chapter A3.1).Patients
were selected and laboratory tests were performed by two independent
research workers. If a difference of more than 10% in duplicates was
found, the sample was retested. The same batch of immunoglobulin G,
divided into aliquots and aggregated at 63°C for 20 min, was used
throughout the study.Values greater than 6 ug AHG eq/ml were con¬
sidered above the limit of positivity in the Clq-SP, whereas the
limit in KgBt was 4 ug AHG eq/ml.
Cox's test for trend in proportion (C) and Fisher's exact test
(F) were used to evaluate the results.
Results
125
The half-life of I-delta-HSA was 23.4+8 min in group 1, 17.7
minutes + 5.3 in group 2, 17.9 minutes + 4.2 in group 3,and 15.2
minutes +2.4 in normal subjects.Ten of the 12 diabetics in group 1,2
of the 7 in group 2, and 2 of the 11 in group 3 showed reduced
clearance (Figure B3.2/2),suggesting a significant trend toward
125
reduced 1-delta-HSA clearance with increasing severity of micro¬
angiopathy (C - P<0.002). Radioactivity found in circulating phago¬
cytes up to the 45th min and the amount of free iodine in the super¬
natant after serum TCA precipitation up to the 25th min of the test
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were negligible. These findings confirm the absence of uptake by
circulating phagocytes or breakdown of migroaggregates.
Clq-SP revealed a 50% prevalence of AgAB in group 1, 28% in
group 2, and 18% in group 3. Using KgBt, AgAb positivity was 42%,
28%, and 36%, respectively.The prevalence of circulating AgAb both
with Clq-SP and KgBt was 10% in normal subjects.
No differences in BG and in HbA, concentrations were foundlc
between the threee groups of diabetics.
There was significant difference between type I and II diabetes
in the results of colloid clearance and AgAb.
Attempts were made to analyse a possible relationship between
the presence of circulating AgAb and phagocytic function.Using
Clq-SP, AgAb were found in 8 out of the 14 diabetics with reduced
125
I-delta-HSA clearance (a half-life of over 20 min), and in 2 out
125
of the 16 patients showing a I-delta-HSA half-life below 20 min.
AgAb prevalence was significantly higher in the former group
(F=P<0.05). Using KgBt, no significant correlation was found between
125
presence of circulating AgAb and reduced I-delta-HSA clearance
(43% vs. 31%, respectively).
Discussion
In the present study, impaired function of fixed phagocytes
(mainly Kupffer cells) was found in diabetics with severe micro¬
angiopathy. The colloid clearance test is one of the most reliable
It u
tests presently available to study phagocyte function in vivo and, as
the results therein show, is not affected by phagocytosis of micro¬
ti n
aggregates by circulating monocytes. It may be preferable to in vitro
assays of phagocytic function. The present study confirms the
FIGURE B3.2/2
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presence of increased concentrations of circulating AgAb in diabetics
with severe microangiopathy compared with diabetics who show no sign
of microangiopathy, and with normal subjects. The percentage of
diabetic sera found positive for AgAb in this investigation is
similar to that previously discussed (Chapters B3.2a, B3.2c). As in
these previous studies, differences in the prevalence of AgAb were
found when AgAb were measured using the Clq-SP and KgBt tests. As
stated previously, it should be stressed that these two methods
differ in principle and detect different types of complexes. As in
previous studies (Chapter B3.2c), only AgAb detectable by CTq-SP
appear to be correlated with the presence of severe microangiopathy.
The data confirm that AgAb are a population with differing biological
properties and suggest that only a part of them are related to the
microvascular damage.
Data in this study also confirm that the percentage of sera
positive for circulating AgAb is similar in type I and type II
diabetics when severe microangiopathy is present. Furthermore, the
data indicate that colloid clearance is similar in the two types of
diabetes.
The finding that the prevalence of circulating AgAb is signif¬
icantly increased in diabetics showing impaired fixed phagocyte
function is of considerable importance. Since the Clq-SP method
detects medium-sized AgAb,which are removed by fixed phagocytes, the
present data suggest that the increase in circulating AgAb may be a
consequence, at least in part,of a decreased clearance due to im¬
paired function of fixed phagocytes.
The reason for this impairment in diabetics with severe micro¬
angiopathy is presently not clear. Poor metabolic control over a
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prolonged period of time, which seems the most relevant factor
correlated with the occurrence of diabetic microangiopathy, could
influence the function of phagocytes. It has already been reported
that hyperglycemia impairs the function of circulating phagocytes
(Badgade,1976;Badgade et al,1978) and lymphocytes(MacCuish et al,
1974)in diabetics as well as in normal subjects(Pozzilli et al,1976).
High glucose concentrations, also influence circulating cell function
in diabetics and in normal subjects (MacCuish et al,1974; Pozzilli et
al,1976) , while lowering of the blood glucose reverses the ab¬
normalities (Badgade et al, 1972). Similar data are not available for
fixed phagocytes.
In the present investigation, metabolic control was similar in
patients with various degrees of microangiopathy; in previous studies
no correlation was found between metabolic control and circulating
AgAb concentrations (Di Mario et al,1979).Since the methods used here
to evaluate the metabolic control (BG and HbA. ) provide information
lc
only over relatively short periods of time, one cannot ignore the
suggestion that prolonged metabolic derangement not detectable by
these methods might have modified fixed phagocytic function.
In conclusion, this study suggests that impaired fixed phago¬
cytic function could contribute to long-lasting accumulation of AgAb
in plasma. It may be speculated that these AgAb are bound and trapped
in the vessel walls and contribute to the development of diabetic
microangiopathy.
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B3.3 INSULIN ANTIBODIES AND IMMUNE COMPLEXES IN PATIENTS WITH
MICROANGIOPATHY
B3.3a Aim of the study
This study was planned to investigate the correlation between
the presence of insulin antibodies and the occurrence of immune
complexes in patients with and without microangiopathy. Since there
are substantial differences in the results of different techniques
for the detection of circulating immune complexes, two methods were
employed, one detecting medium sized complexes in antigen excess
through the Fc portion of complexed immunoglobulins - the solid phase
Clq binding test(ClqSP) and the other detecting C3 binding complexes
near the equivalence point - the conglutinin radioimmune assay
(KgBt).
Patients were selected so as to have patients in opposite
conditions, i.e. with severe microangiopathy and without any clinical
signs of microangiopathy.
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B3. 3b Materials and methods
Patients
140 diabetics treated with insulin for more than 1 year were
selected according to the presence and degree of microangiopathy:58
showed severe microangiopathy, 82 had no sign of vascular lesions.The
clinical and personal data of the patients are shown in table B3.4/1.
One hundred and eighty-nine blood donors were used as the control
population in AgAb studies. The evaluation of the presence and degree
of microangiopathy was performed as follows: retinopathy was assessed
by retinal fluorangiography. Patients with proliferative retinopathy
or recidivant vitreous haemorrhages were considered to have severe
retinopathy and patients with the absence of any sign of retinopathy
were considered free of ocular complications. Patients with inter¬
mediate forms of retinal involvement were excluded from the study.
Blood urea >16 mmol/1, serum creatinine levels >2 mg/dl and/or
proteinuria >2 g/1 were considered the index of kidney involvement.
Immune complexes
ClqSP as described by Hay, Nineham and Roitt(1976) and KgBt
according to Casali et al.(1977), with some personal modifications,
were used to detect immune complexes; The characteristics of the
methods, the limit of positivity, the expression and analysis of the
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Clq-AgAb were found in 29 out of 58 patients with severe micro¬
angiopathy (50%, PC0.0001 vs normals) and in 20 out of 82 of those
without microangiopathy (24%, P<0.01 vs normals, P<0.001 vs comp¬
licated diabetics). Kg-AgAb were found in 21 out of 58 patients
without vascular lesions (36%, P<0.0001 vs normals) and in 20 out of
53 diabetics with severe microangiopathy (38%, PC0.0001 vs normals,
N.S. vs uncomplicated diabetics).
Insulin antibodies
Mean InsAb levels, as evaluated by Christiansen's method, were
1.33 mU/ml in group 2 patients. There was no significant difference
in InsAb levels between those with severe microangiopathy (1.27 +
1.47 mu/ml) and those without complications (1.38 + 1.88 mu/ml).
Immune complexes vs insulin antibodies
The correlation between Clq-AgAb and InsAb was significantly
different in patients with and without microangiopathy Figure B3.3/1.
In microangiopathic patients the positivity of Clq-AgAb did not vary
significantly at increasing levels of InsAb, whereas in patients
without microangiopathy, when InsAb levels were high, Clq-AgAb
positivity was significantly reduced in comparison with that found in
those with lower InsAb levels (P<0.05). Diabetics without microan¬
giopathy having medium/high levels of InsAb (>0.5 mU/ml) showed a
significantly reduced AgAb positivity in comparison with diabetics
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with microangiopathy showing similar InsAb levels. A different cor¬
relation was found between Kg-IC and InsAb Figure B3.3/2. In group 2
there was a positive trend for Kg-IC positivity to go with increasing
levels of InsAb (PC0.05). This trend was even more evident when only
patients without microangiopathy were considered (P<0.01; Figure
B3.3/2b).




Diabeticpatients withsevere58253349.5+16.18012 microangiopathy without8244387.8+16 7675 microangiopathy *R N R+N=proliferativeretinopathy; =advancednephropathy; =bothcomplications.
FIGURE B3.3/1
The association between AgAb, as detected by Clq, and insulin
antibodies (InsAb) in patients with (a) and without (b) complications
InsAb are indicated in the Y axis and divided into negative, low


































The association between immune complexes (AgAb), as detected by
conglutinin (Kg-IC), and insulin antibodies (InsAb) in patients with



























B3.3d D i s c u s s i o n
The relationship between InsAb and immune complexes is different
when Clq-AgAb or Kg-AgAb are studied.
In insulin treated diabetics selected at random, when InsAb are
present in high amounts, Clq-AgAb are not usually detectable. Since
ClqSP does not readily detect complexes in antibody excess (Scullion
et al,1979),in patients with high levels of InsAb, insulin antibody
complexes would not be expected to be detectable by Clq-SP. It is
conceivable that in patients with lower InsAb levels some immune com¬
plexes may be related to insulin treatment. In fact, in a previous
study, Clq-AgAb were found to be higher in randomly selected insulin
treated patients than in comparable diabetics not treated with
insulin (Chapter B2.3). Similar results were found in patients
without microangiopathy. It is interesting to note that when micro¬
angiopathy is. present, Clq-AgAb levels are much higher and not
correlated with the levels of InsAb. This study confirms the increase
in CTq-AgAb in diabetics with microangiopathy observed in previous
studies (Chapters B3.2b, B3.2c) . When microangiopathy is present,
some factors appear to modify the dynamics of formation and clearance
of medium-large sized complexes, leading to an increase in cir¬
culation of these macromolecules. These factors do not seem to be
directly related to insulin treatment since Clq-AgAb were increased
both in type I and in type II diabetics with microangiopathy (Chapter
B3.2c).It has been suggested that impairment of phagocytosis,
described in patients with microangiopathy (Drivas & Wardle,
1978;Bagdade,1976),might result in an increase of circulating
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macromolecules. Indeed in diabetic patients with an impaired phago¬
cytic clearance it has also been shown an increase in circulating
Clq-AgAb (Chapter B3.2d). It is suggested that in diabetics with
microangiopathy an impairment of the phagocytic system leads to an
increase in heterogeneous complexes, mainly in the range detected by
ClqSP, and masks any correlation between immune complexes and InsAb.
When Kg-AgAb results are evaluated, there is a trend for the
presence of Kg-AgAb to go with medium high levels of InsAb (especial¬
ly when microangiopathy is absent). An association between Kg-AgAb
and InsAb has been reported also in diabetics with less than 1 year's
diabetes (Chapter B2.5). Likewise, the prevalence pf Kg-AgAb is
higher in type I diabetics irrespective of the presence of micro¬
angiopathy (Chapter B3.2c). It appears that KgBt detects immune
complexes which are somehow related to the presence of InsAb rather
than to the occurrence of diabetic microangiopathy. The reason for
this correlation is not obvious. Kg-AgAb are usually large complexes
that fix complement and therefore are very different from most
insulin-anti-insulin complexes. It cannot be excluded that KgBt
reacts with some monomeric immunoglobulins, when present in very high
concentrations. The levels of InsAb in these patients were not
associated with the presence of microangiopathy. This is in keeping
with the lack of association between Kg-AgAb and microangiopathy.
In this study there is no clear evidence of the influence of
heterologous insulin treatment on diabetic microangiopathy. To some
extent this result might have been predicted. If insulin treatment
has any influence on the course of complications through immune
mechanisms (i.e. the formation of insulin-anti-insulin complexes),
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the insulin binding capacity is not the best tool for investigating
this problem. Insulin antibodies vary widely in avidity and may form
complexes with different pathogenetic significance. The methods for
detecting InsAb usually available, and particularly those used in
this investigation,give informationon the amount, and not the
avidity, of the antibody and measure mostly free antibodies. It is
therefore not surprising that the sole immunological phenomenon found
in association with the presence of severe diabetic microangiopathy
is related to two other questions: does insulin treatment give rise
to complexes of pathogenic significance, and do these complexes and
the Clq-AgAb - chronically accumulated and deposited in the small
blood vessels - play a role in aggravating local tissue damage?
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B3.4 IMMUNE COMPLEXES, INSULIN ANTIBODIES, INSULIN-ANTI-INSULIN
COMPLEXES RELATED TO PLATELET AND COAGULATION FACTORS IN
PATIENTS WITH PROLIFERATIVE RETINOPATHY.
B3.4a Aims of the study
In this study the relationship of soluble immune complexes,
insulin antibodies and insulin-anti-insulin complexes to platelet
function and coagulation has been investigated in two groups of Type
I diabetics chosen to represent the extremes of the retinopathy
spectrum, namely those with proliferative retinopathy and those
without retinopathy, and in non-diabetic controls.
B3.4b Patients and methods
Patients
20 Type I diabetics with proliferative retinopathy (mean age 35
+ 11 years, mean duration of diabetes 19 + 7 years), 20 Type I
diabetics without ophthalmoscopic evidence of retinopathy (mean age
34+9 years, mean duration of diabetes 21 + 7 years) and 20 healthy
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non-diabetic controls (mean age 35 + years), were studied. Subjects
in each group were individually matched for age, sex (12 male, 8
female) and, where applicable, duration of diabetes. All subjects had
a normal serum creatinine and absence of proteinuria on Albustix
testing. Two of the diabetics with retinopathy had signs and/or
symptoms of macrovascular disease.
A 2 hr post-prandial venous blood sample was withdrawn with
minimal venous stasis from resting subjects and analysed as follows:
Immune complexes
Soluble immune complexes (AgAb) were evaluated by a modification
of the conglutinin radioimmunoassay method (Casali et al,1977). The
technical aspects, limit of positivity and expression of results have
been described in chapter A3.1.
Insulin antibodies
Insulin antibodies (InsAb) were assayed according to the method
of Andersen et al,1972, as modified by Mustaffa et al,1977 (Chapter
A3.3).
Insulin-anti-insulin complexes
Insulin-anti-insulin complexes (Ins/iAb) were detected using a
modification (Chapter A3.4) of the techniques described by Jayarao et
al, 1973, and Virella et al,1980.
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Platelet and coagulation factors
Beta-thromboglobulin (beta-TG), platelet factor 4 (PF4), fi-
brlnopeptide A (FpA), fibrinogen (Factor 1), antithrombin III
activity (AT-III), and Factor VIII related antigen (VIII R:Ag) were
measured routinely by the Edinburgh Blood Transfusion Centre (Borsey
et al, 1984)
Statistical analysis
Parametric and non parametric tests were used in normally and
asymmetrically distributed data respectively. Student's t test,




Immune complexes were found in 12 out of the 20 patients with
retinopathy (p<0.05 vs the control group) and in 8 out of the 20
without retinopathy. There was no significant difference in immune
complex levels between non-retinopathic patients and controls or
patients with retinopathy.
Insulin antibodies
All the diabetics had detectable insulin antibodies but there
was no significant difference in insulin antibody levels between
patients with retinopathy (median 54 mu/ml, interquartile range o IR
20.5-135) and without retinopathy (median 117.5 mu/ml, IR 31.5-161.5)
(Figure B3.4/1).
Insulin-anti-insulin complexes
Ins/iAb were found in 7 out the 20 patients with retinopathy
(mean of the positive values 22.5% + 11.1) and in 10 (mean 21.8%,
8.3) out the 20 without retinopathy (Figure B3.4/2).
Immune complexes vs insulin-anti-insulin complexes
5 of the 7 retinopathic patients and 4 of the 10 non-retino¬
pathic patients with circulating Ins/iAb also had AgAb in their
serum.
Immune complexes vs insulin antibodies
There was no significant correlation between immune complexes
and insulin antibodies.
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Insulin antibodies vs insulin-anti-insulin complexes
There was no constant parallelism between the levels of detec¬
table Ins/iAb and levels of insulin antibodies. However patients with
retinopathy and detectable Ins/iAb in their serum showed levels of
insulin antibodies (median 137 mU/ml,IR 45-430) higher than in those
with Ins/iAb within the normal limits (median 42 mU/ml, IR 17-97).
When the non-retinopathic diabetics were likewise divided into those
with and without detectable Ins/iAb similar findings were observed
(median 161 mU/ml, IR 134-260 and median 31.5 mU/ml, IR 13-96
respectively).
Platelet and Coagulation Factors
Beta-TG and PF^ (Table B3.4/1) were higher in patients with
retinopathy than in the controls (p<0.01) and PF^ was also elevated
in the non-retinopathic patients compared to the controls (p<0.05). A
highly significant correlation between beta-TG and PF^ was seen in
each of the three groups (controls and retinopathic patients p<0.01,
non-retinopathic patients p<0.01).
Fibrinogen was elevated in non-retinopathic patients vs. con¬
trols (p<0.01), retinopathic diabetics vs. controls (p<0.001) and
retinopathic vs. non-retinopathic patients (p<0.05).
There was no significant difference in FpA levels between
groups, but FpA correlated with both beta-TG (p<0.05) and PF^
(controls and non-retinopathic patients p<0.05; retinopathic patients
p<0.01) within each of the groups.
AT-III was increased in retinopathic patients vs. controls
pCO.OOl; and in retinopathic vs. non-retinopathic patients p<0.01.
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Factor VIII R:Ag was higher in both the diabetic groups than in
the controls (p<0.001).
Immune factors vs Haemostatic Factors
In diabetics with proliferative retinopathy there was a signifi¬
cant correlation between positive values of AgAb and increased levels
of PF^ and beta-TG (Figure B3.4/3). In fact PF^ and beta-TG values
were higher in retinopathic patients with detectable complexes (PF^
mean 32.7, SD 16.7; beta-TG mean 72, SD 30.8) than in those without
complexes (PF4 mean 15.1, SD 11.4; beta-TG mean 45, SD 17.1) (p<0.05
and p<0.05 respectively).
Although there was no parallelism between the levels of insulin
antibodies and any of the haemostatic factors, the presence of
insulin-anti-insulin complexes was significantly correlated with
increased levels of beta thromboglobulin in the diabetics with
retinopathy (80. 1 + 26.1 vs. 50.6 + 25.3 in Ins/iAb negative pa¬
tients, p<0.05).
When retinopathic patients showing the presence of both com¬
plexes and insulin-anti-insulin complexes where compared to retino¬
pathic patients without any kind of complexes, a positive correlation
between complexes and abnormalities of platelet factors was apparent
in the former group (PF^ 38.7 + 14.7 vs. 13.1 + 10.1, p<0.02; beta-
TG 78.4 + 27.4 vs. 39.6 + 16, p<0.02) and also a correlation between
complexes and fibrinopeptide A became apparent (FpA 7 + 5.6 vs. 1.2 +
1 p<0.05). Significant correlations between immune and haemostatic
factors were not found in non-retinopathic patients and in controls.
TABLEB3.4/1Plateletndcoagulationfa tors(medi nr nge)ithhrest dygro p beta-TG PF4 Fibrinogen FpA AT-III VIIIR:AgDiabeticswi hiithoutNormalcontrol pr.retinopathy units ng/ml51.5(24.1-127.5)44 92.2-96.3)319 68.5) ng/rol19.6(6.7-63.7)5(8 5 72 6)0 4-52) g/12.93(1.85-5.70)4656-3.46)7004 2 93 ng/ml2.80(2.00-17.8). 2-16.6)1 646-19.2 %116(92-132)0428 19 %267(142-400)5226 6987 -14
FIGURE B3.4/1
Insulin antibody levels in patients with proliferative retino¬
pathy (Dl) and in those without any clinical signs of retinopathy
(D2).
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The relationship between AgAb and platelet specific proteins (PF4
and BTG) in diabetics with proliferative retinopathy.
Ag/Ab and platelet specific proteins

















In diabetic retinopathy the causes and the sequence of events
are still unclear. Metabolic abnormalities are thought to play a
major role in initiating the vascular lesions (Cudworth et al,1982).
Nevertheless, the metabolic derangement cannot explain many aspects
and steps in the development of microangiopathy. It is known that the
progression of retinopathy does not parallel the average degree of
the metabolic control in many patients: malignant retinopathy may
occurr soon after the clinical onset of the disease in patients with
acceptable metabolic control and with a mild form of the disease
(Andreani,1980). At least in microangiopathic lesions of the kidney ,
the metabolic control seems to have importance only in the first
phases of the disease (Cudworth et al,1982). Epidemiological studies
in diabetic twins and other genetic studies support the concept that
inherited constitutional factors influence the progression and the
severity of retinopathy (Leslie et al,1982;Bodansky et al,1982).
Furthermore a number of abnormalities of the immunological function
(Jayarao et al,1974; Virella et al,1980;Chapters B3.2c, B3.2d) and of
haemostasis (Jones et al,1981; Borsey et al,1984,Cudworth et al,1982)
have been already reported in patients with proliferative retino¬
pathy.
In this study the presence of both immune and haemostatic
abnormalities in diabetics with retinopathy have been confirmed.
Attention has been focussed on the role of factors, other than the
metabolic control, and in particular on the possible reciprocal
influence and modulation of immunological and haemostatic factors,
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trying to understand their significance in the general multifactorial
context.
In keeping with previous studies in which immune complexes were
evaluated by the conglutinin method (Chapter B3.2c) immune complexes
were significantly increased in diabetics with proliferative retino¬
pathy when compared with normal subjects. The finding of a similar
prevalence of insulin-anti-insulin complexes in diabetics with and
without retinopathy was not unexpected since it has been reported
that the frequency of insulin antibodies in these two groups does not
differ significantly (Chapter B3.3). Beta-TG, PF^, AT-III, VIII R:Ag
and fibrinogen were increased in the diabetics with retinopathy when
compared with the controls whilst fibrinogen and AT-III were also
significantly higher in the retinopathic than in the non-retinopathic
patients. Thus, platelet function and coagulation are deranged in
Type I diabetics and some of the abnormalities are more apparent when
retinopathy is present.
The finding of a correlation between humoral immune phenomena
and abnormalities of haemostasis in diabetics with retinopathy has
not been previously reported and raises many intriguing possibilities
as to the pathogenesis of microangiopathy. In these patients the
presence of immune complexes was significantly correlated with higher
levels of Beta-TG and PF^ and in immune complex- and insulin complex-
positive patients a significantly greater number of platelet and
coagulation factors were elevated. The platelet specific proteins
Beta-TG and PF^ are released together from alfa granules during
platelet aggregation and elevated plasma levels may reflect enhanced
in vivo platelet activation (Kaplan & Owen,1981). Immune complexes
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are removed from the circulation in different ways according to their
size: small complexes are eliminated by the kidney whereas the medium
and large complexes, such as those detected by the conglutinin
method, are cleared by reticuloendothelial cells (Mannik, 1974). When
phagocytic clearance is inefficient or when other factors, such as
the presence of vasoactive substances, intervene, complexes may be
deposited in the blood vessel walls. Platelets are the most likely
source of vasoactive amines since they are rich in both histamine and
serotonin. Previous work has shown that the deposition of microaggre-
gates is directly correlated with factors which favour increased
vascular permeability (Figure B3.4/4)(Williams,1980). Local immune
complex deposition is markedly diminished by agents which block the
effect of vasoactive amines and by platelet depletion. On the other
hand, immune complexes are among the factors favouring platelet
adhesion and aggregation and thereby may induce the release of
vasoactive substances and contribute to the vascular damage (Figure
B3.4/5). In fact in vitro studies have shown that Ins/Ab may activate
platelet aggregation in the blood of diabetic subjects (Virella et
al,1983).
This study shows a possibly interesting correlation between
immunological and haemostatic factors. Since the pathogenesis of
diabetic microangiopathy appears to be multifactorial, with an
individual variability on a genentic basis, our findings suggest that
an interaction between immune complexes or insulin-anti-insulin
complexes and platelets may aggravate the pathological events in the
development of diabetic retinopathy at least in some individuals or
at certain stages of the pathogenetic sequence.
FIGURE B3.4/4
Schematic representation of the interaction between immune
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B3.5 - IMMUNE COMPLEXES AND LYMPHOCYTE SUBSETS IN PATIENTS WITH
MICROANGIOPATHY
B3.5a Aim of the study
The percentage of peripheral lymphocyte subsets and the
occurrence of AgAb in diabetic patients of long duration has been
evaluated in order to investigate a possible relationship, in¬
dependent of the type of diabetes, between these two factors and the
presence of microangiopathy.
B3.5b Materials and Methods
Patients
The following subjects, attending the Rome University's Diabetic
Clinic, were randomly selected and included in the study:
- 19 Type 1 diabetic patients (11 males, 8 females, mean age: 45
yr.age range 27-63 yr, mean duration of disease: 16 yr, range:
12-45 yr);
- 17 Type 2 diabetic patients (10 males, 7 females, mean age: 57
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yr, age range: 42-70 yr, mean duration of disease: 16 yr,
range: 10-30 yr);
- 22 normal subjects (10 males, 12 females, mean age: 40 yr, age
range 24-62 yr) were included as a control group for
lymphocyte studies.
One-hundred and fifteen sera from normal volunteers were used as
controls in AgAb studies. In all patients, the presence of micro¬
angiopathy was evaluated by retinal fluoroangiography, albuminuria
and creatinine clearance.
T cell subsets
Peripheral lymphocytes were obtained by gradient centrifugation
of venous blood on Ficoll-Hypaque. The following monoclonal
antibodies defining antigens expressed on the surface of peripheral
lymphocytes were used: UCHT1 which reacts with 90% of E-rosetting
cells (T cells)(Beverley and Callard,1981); Leu 3a,which phenotypes
the helper/inducer T cells subset (T^) (Ledbetter et al,1981); UCHT4,
which identifies the suppressor/cytotoxic T cells (T8) (Beverley,
1982). The UCHT4 antibody is analogous to 0KT8 or Leu 2a monoclonal
antibodies which phenotype the T8+ cells(see chapter A3.2).
As total T cells have been reported previously to be normal in
patients with Type 2 diabetes (Cattaneo et al,1976), it was decided
in these patients to use only monoclonal antibodies phenotyping the
immunoregulatory lymphocytes (Leu 3a and UCHT4).
The indirect immunofluorescence technique using fluorescinated
rabbit anti-mouse antiserum was utilised for detecting positive
lymphocytes for each monoclonal antibody. The percentage of positive
cells was based on a minimum count of 300 cells.
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Immune complexes
AgAb were measured by two different techniques, the Clq solid
phase assay and the conglutinin binding method (Lambert et al,1978).
The limit of positivity of AgAb assays was evaluated as reported in
chapter A3.1.
Statistical analysis





In type 1 diabetic patients a significant decrease of total T cells
(P<0.01), T4+ cells (P<0.01) and a significant increase of T8+ cells
(P<0.05), were observed (Fig.B3.5/1). In patients with type 2 dia-
~f" "f"
betes, the percentages of T4 and T8 cells were not statistically
different from those of normal subjects (Figure B3.5/2). It can also
be assumed that in patients with type 2 diabetes, the percentage of
total T cells was not different from controls since the sum of T4+
and T8+ cells gave a result that was similar to that detected in
normal subjects. However, 5 out 18 patients with type 2 diabetes
-j-
showed a percentage of T8 cells which was at least 2 SD above the
mean percentage found in normal subjects.
Immune complexes
When the Clq assay was used, AgAb were found in 41% of type 1
diabetic patients and in 25% of type 2 diabetic patients (P<0.02)
whereas with the conglutinin binding method, the percentages were 63%
and 23%, respectively (P<0.01).
Relationship between
T cell subsets and immune complexes
There was no relationship between the presence of AgAb, as
measured by the Clq assay, and values for any of the lymphocyte
subsets. However, when AgAb were evaluated by the conglutinin binding
method, a relationship with the 1'8+ cells was observed (Table
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A3.5/1). Thus, in 11 patients with very high T8+ cells (2 SD above
the normal mean, i.e.>26%), AgAb were present only in one patient
(9%). By contrast, in 25 patients with T8+ cells within the normal
range, AgAb were present in 15 patients (60%) (Table B3.5/1).
Relationship between
T cell subsets,immune complexes and microangiopathy
Twenty-four patients (12 Type 1 and 12 Type 2) showed varying
degrees of retinopathy (background retinopathy n=16, including two
patients with nephropathy; proliferative retinopathy n=8, including
one patient with nephropathy). Twelve patients (7 Type 1 and 5 Type
2) had no signs of microangiopathy. Interestingly, the incidence of
microangiopathy was correlated with the level of T8+ cells and AgAb
as measured by the conglutinin method. Thus, 7 out of 11 patients
with raised T8+ cells (>26%) had no signs of retinopathy or nephro¬
pathy and only one was AgAb positive. By contrast, 20 out of 25
patients with T8+ cells within the normal range showed retinopathy
and 11 were also AgAb positive (Table A3.5/1).
TABLEB3.5/1herelationshipbetweenl v lofT8+ c ll(UCTH4positive)and circulatingimm necomplex sandretinopathy UCTH4(>26%)(n=ll) UCTH4(<26%)(n=25) Fisherexact probabilitytest:Immunecomplex s PositiveNegative 10 150 P=0.005
Retinopathy
PresentAbsent 4(3A,1B)S7 20(13A,7B)a5 P=0.014
£
A=backgroundretinopathy;Bproliferativereti opathy.Inati tsw thoutr i thy, nephropathywasalsbsent. RaisedlevelsofUCTH4positivelym hocytesarc ns der dth sexcee ing2SDm an observedinormalsubjects.
FIGURE B3.5/1
The percentages of total T cells (UCHT1 positive), T4 cells (Leu
3a positive) and T8 cells (UCHT4 positive) in 19 patients with Type 1
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The present findings suggest an inter-relationship among lympho¬
cyte subsets, immune complexes and the presence of microangiopathy.
The main feature consists of an increase of T8+ cells in diabetic
patients without immune complexes and no evidence of microangiopathy,
despite the long duration of disease. This concept is reinforced by
the opposite finding in patients with microangiopathy.
The other findings comprise a decrease of T4+ cells in type 1
diabetics with long duration of disease. As has been described herein
(chapter B3.2b),the presence of AgAb is closely related with the
presence of microangiopathic changes rather than with the duration of
the disease. Data are now accumulating to suggest that the presence
and persistence of AgAb are strictly dependent not only upon impaired
function of fixed phagocytes, but also upon the number of mononuclear
cells (Moretta et al,1978; Fridman et al,1981) which phenotypically
have the characteristics of T8+ cells and functionally could be
suppressor/cytotoxic cells (Beverley and Callard,1981). The latter
aspect, however, is still unclear and needs further elucidation.
The majority of cells with T8+ phenotype(defined by the UCHT4
antibody)possess receptors for the Fc portion of IgG (FcgammaR)
(Beverley and Callard,1981). Others have demonstrated that AgAb have
an affinity for the FcgammaR even greater than for native IgG
(Dickler,1976). This phenomenon is likely to be a consequence of the
multiple binding which occurs between FcgammaR and the Fc regions of
Ig when the latter are aggregated in an immune complex (Moretta et
al,1978). Therefore, as most of T8+ cells have FcgammaR, it is likely
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that these cells are capable of binding AgAb. On this basis, the
relative increase of T8+ cell subset could explain the absence of
detectable levels of circulating AgAb in some diabetic patients.
These cells may have a role in controlling the levels of at least
some types of AgAb by removing them from circulation and thus
preventing their deposition over the vessel walls.
An alternative hypothesis for a favourable role played by T8+
cells is based on their function as suppressor cells. Their increase
may contribute to a reduction in antibody formation by specific
suppressor factors (Fridman et al,1977), and thereby limiting the
formation of AgAb.
In the present study we have confirmed but also extended, using
different monoclonal antibodies, previous data indicating a decrease
of T4+ cells in patients with Type 1 diabetes of long duration have
been confirmed and extended (Mascart-Lemone et al,1982). As T4+ cells
represent the majority of the overall T lymphocyte population, the
significant decrease of these cells in type 1 diabetic patients with
long duration of disease may account for the reduction of total T
cells reported previously (Cattaneo et al,1976;Pozzilli et al,1979).
This suggests that the known susceptibility to infections in poorly
controlled diabetic patients could be partly due to a reduction of
T4+ cells.
A prospective study is now needed of lymphocyte subsets and of
circulating serum factors such as immune complexes or other macro-
molecules, in particular alpha-2-macroglobulin. The latterprotein is
increased in patients with microangiopathy (Aimer & Pandolfi,1976)
and it has been recently shown that alpha-2-macroglobulin can affect
lymphocyte responses in vitro (Miyanaga et al,1982). Future work
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should then highlight the role of these immune parameters in in¬
fluencing the appearance and evolution of diabetic microangiopathy.
B3.6 CONCLUSIONS
When selected groups of diabetics with microangiopathy have been
studied using a technique based on Clq properties, a correlation
appears between the presence of immune complexes and the occurrence
of severe microangiopathy. Immune complexes are increased in long
standing diabetics with severe microangiopathy and in those with a
precocious onset of retinopathy. Immune complexes found in patients
with severe microangiopathy do not seem to have any correlation with
the type of treatment and this finding is in keeping with the clini¬
cal observation that microangiopathy occurs irrespective of the type
of treatment. This enhancement of immune complex levels seems to be
due to a decreased rate of clearance by an impaired reticuloendothe¬
lial system in patients with severe microangiopathy.
Immune complexes detected by Clq correlated with the presence of
microangiopathy but not with insulin antibody levels. On the other
hand, insulin antibodies have been found to correlate with complexes
detected by conglutinin but neither of these two correlate with the
presence of microangiopathy.
A significant correlation between positive values of immune
complexes and increased levels of platelet specific proteins in
diabetics with proliferative retinopathy was found. This suggests
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that an interaction between platelets and complexes may have patho¬
logical relevance in the development of diabetic retinopathy.
Patients with very high levels of T8 positive cells did not have
detectable immune complexes and had no evidence of microangiopathy.
By contrast, patients with normal levels of these cells were found to
have raised immune complexes and showed retinopathy of varying
degree. This relationship between cells with the T8 phenotype, some
immune complexes and the presence of microangiopathy suggests that
the presence and persistence of complexes and their deposition or
prevention may be partly dependent upon the number of circulating
mononuclear cells with Fc or C receptors.
The immunological phenomena occurring in diabetic microangio¬
pathy are probably a limited aspect of the complicated multifactorial
events leading to vessel damage. Nevertheless, evidence accumulated
so far confirms that these phenomena form an important step in the
building up of microangiopathy (Figure B3.6/1). The deposits of
immunoglobulins, complement and complexes in microangiopathic vessels
are frequent and striking. Even though experienced only in animals,
immune mechanisms may well induce microangiopathic-like lesions.
Circulating, potentially lesive complexes are increased in diabetics
with microangiopathy and they are capable of interacting with the
complement, platelets and lymphocytes. An impairment of macromolecule
clearance is present in patients with severe complications.
Biochemical changes of the basement membrane present in diabetes with
microangiopathy may well favour the binding or trapping of
macromolecules. The pathogenetic relevance of these phenomena is
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still to be definitely determined. It is conceivable that immune
complexes of different types, chronically accumulated in small
amounts over a prolonged period of time secondarily to other events,
are likely to activate the complement and the coagulation cascade and
aggravate the local damage of blood vessel walls.
FIGURE B3.6/1
Possible pathogenetic involvement of circulating immune complexes
in the development of microangiopathy
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B4.5a Aim of the study





B4.1 EXPERIMENTAL DESIGN OF THE STUDIES ON DIABETIC PREGNANCY
Diabetic pregnancy is a useful model for the study of several
immune phenomena. The immune system in normal pregnancy is thought to
be in a state of "activation" rather than in a state of "depression".
In diabetes, several immunological abnormalities may be present and
these may be related to pathogenic events, metabolic derangement and
insulin therapy. In diabetic pregnancy, several immune phenomena may
be present temporarily as a consequence of both diabetes and pre¬
gnancy. Moreover, some abnormal immune factors can cross the placenta
and interfere with fetal metabolism and development (for a larger
discussion and references see chapter A1.6).
The author has planned to investigate humoral and cellular
immunological aspects in diabetic pregnant women and in some of their
neonates. Islet cell antibodies, organ specific autoantibodies,
immune complexes, insulin antibodies, insulin-anti-insulin complexes,
T cell subpopulations and activated T cells have been assayed.
The author had worked on the following hypotheses :
a) Humoral factors, in addition to metabolic events, might influence
the clinical course of pregnancy and neonatal complications.
b) Maternal insulin antibodies may easily cross the placenta and
reach the neonatal circulation. The fetal insulin that they face
is in several aspects different from the therapeutic insulin in
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the mother. Therefore the insulin-anti-insulin complexes formed
are likely to be different in the mother and in the foetus.
c) As the maternal immune system is "actively depressed", it is
conceivable that the T cell subpopulations are somehow different
in the diabetic pregnant woman in comparison with the normal
pregnant or the normal woman.
d) As the maternal immune system is informed of the presence of
the antigenically foreign fetus but does not reject, it is
possible that the activation of T lymphocyte either does not
occurr or is somewhere blocked.
Hypothesis "a" has been verified in the first study (Chapter
B4.2)
The study in a large group of insulin treated diabetic pregnant
women (118) has been in part cross sectional and in part prospective.
The immunological factors studied have been islet cell antibodies,
organ specific autoantibodies, insulin antibodies and immune com¬
plexes. The maternal metabolic control, the type of diabetes and the
type of insulin preparation have been taken into account.Both the
maternal metabolic control and the presence of immunological factors
have been correlated with the clinical complications in the mother
and in the neonate.
Hypothesis "b" was studied in the second research work (Chapter
B4.3)
The study was performed in 47 pregnant diabetic patients and in
23 neonates.Insulin antibodies and insulin-anti-insulin complexes
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were studied both in the mother during pregnancy and in the cord
blood.
Hypothesis "c" was investigated in the 3rd study (Chapter B4.4)
Monoclonal antibodies against an antigen common to all the T
cells, agains/cytotoxic/suppressor cells and to helper/ inducer T
cells were used to define T cell subpopulations in type 1, type 2 and
gestational pregnant diabetic women, in normal pregnant subjects and
in normal women.
Hypothesis "d" was analyzed in the 4th study (Chapter B4.5)
Monoclonal antibodies to T cell surface antigens present on
activated T cells which are related both to MHC class II antigens and
to other antigens, were used in T cell studies in type 1, type 2 and
gestational pregnant diabetic women, in normal pregnant subjects and
in normal women.
The monoclonal antibodies used in these study were produced in
the MRC Clinical & Popolation Cytogenetics Unit of Edinburgh.
The clinical part of these studies was done in collaboration
with the "Cattedra di Puericultura Prenatale" and with "Servizio
Stati Disendocrini e Dismetabolici", University of Rome, Italy.
B4.2 HUMORAL IMMUNITY IN DIABETIC PREGNANCY : ISLET CELL
ANTIBODIES, ORGAN SPECIFIC AUTOANTIBODIES, INSULIN ANTI¬
BODIES AND IMMUNE COMPLEXES.
B4.2a Aim of the study
This study was planned to examine the presence of islet cell an¬
tibodies (ICA), complement fixing islet cell antibodies (CF-ICA),
autoantibodies to thyroid, stomach, adrenal and ovary, insulin anti¬
bodies, and two different types of immune complexes in pregnant
diabetic patients , at the end of pregnancy and in some of the
patients regularly during pregnancy, taking into account the type of
insulin therapy and the maternal metabolic control. Furthermore, both
the presence of these immunological factors and the degree of me¬
tabolic control were correlated with the clinical characteristics of
patients, and with maternal or neonatal complications.
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B4. 2b Materials and methods
Patients
One hundred and eighteen diabetic pregnants attending the same
clinic were included in the study. All of them were treated with
insulin. Since the main aim of the work was the investigation of
immunological phenomena, patients were grouped according to the type
of diabetes and not to the White Classes.
Group 1 included 56 insulin dependent diabetic patients, already
treated withinsulin before pregnancy.
Twenty-three patients were included in Group 2;they were non-
insulin dependent, formerly treated with diet or oral hypoglycaemic
agents (OHA) and shifted to insulin at their first clinical control
in our clinic.
Group 3 was formed by 39 patients with gestational diabetes,
treated with insulin from their first control in pregnancy when
previously established clinical criteria (age of the patient >25
years, poor metabolic control, ketonuria) had been met.
In the first phase of the study (phase A) ninety-four patients
(42 in Group 1, 17 in Group 2, 35 in Group 3) were followed clini¬
cally during pregnancy and blood was collected at the end of pre¬
gnancy for a cross-sectional study (phase A).
In the second phase of the study (phase B), 24 patients were
studied prospectively (14 in Group 1, 6 in Group 2, 4 in Group 3) and
were sampled at regular intervals during pregnancy (phase B).
For the immunological study forty-two normal pregnants were
included as controls (mean age was 30+3; all subjects delivered
spontaneously at term).
The personal and clinical data of the normal and diabetic
subjects are shown in table B4.2/1.
For maternal and neonatal complications, 2000 consecutive non
diabetic deliveries were considered as a control group (table
B4.2/2).
The patients in phase A of the study were treated with standard
preparations of insulin and some of them, selected at random, were
transferred to purified mixed bovine and porcine insulin from the
first control in pregnancy. All patients in phase B were treated with
purified mixed bovine and porcine insulins. Rapid and long-acting
insulins were used, with the aim of maintaining blood glucose levels
within the most satisfactory levels without acetonuria and hypo-
glycaemic crisis.
Maternal metabolic control
Maternal metabolic control (MMC) was evaluated on the basis of
three times monthly blood glucose levels, four times daily gly¬
cosuria, the occurrence of hypoglycaemia and/or acetonuria. In
planning the study these criteria to evaluate the degree of maternal
metabolic control were chosen: A) absence of hypoglycaemia and
acetonuria, blood glucose levels never >7.7 mmol/1; glycosuria as an
exceptional event. B) Absence of hypoglycaemia and acetonuria, blood
glucose levels never >8.8 mmol/1; glycosuria as a rare event. C) Rare
hypoglycaemia and/or acetonuria; blood glucose levels often >8.8
mmol/1; glycosuria as habitual. D) Frequent hypoglycaemia and
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acetonuria, blood glucose levels often >10 mmol/1. Due to numerous
correlations,in the evaluation of results we considered only two
groups: good (A+B) and poor(C+D) maternal metabolic control. In
patients of phase B the metabolic control was also evaluated by the
glycoslated haemoglobin percentage (Bio-Rad Haemoglobin A1 column
test).
Clinical complications
The possible presence of diabetic complications and the oc¬
currence of other associated diseases were fully explored; the
duration and obstetric aspects of pregnancy and labour were care¬
fully examined in all the patients. In particular the occurrence in
the mother of hypertension,oedema and albuminuria in the last tri¬
mester of pregnancy were evaluated. The presence at least of two of
these signs was the diagnostic criterion for gestosis or toxaemia of
pregnancy (table B4.2/2).
The neonatal complications were also studied. Macrosomia (above
the 95th percentile in the Lubchenco charts), hypoglycaemia (blood
glucose <1.4 mmol/1 two hours after birth), hypocalcaemia (Ca < 1,7
mmol/1), hyperbilirubinaemia (> 171 umol/1), respiratory distress
syndrome, the Apgar index and the presence of malformations were
recorded in the all newborns (table B4.2/2).
Organ specific auto-antibodies
Organ specific autoantibodies, i.e. islet cell antibodies,
thyroid microsomal antibodies, antibodies to gastric mucosa, to
ovaries, to adrenal, were detected by indirect immunofluorescence.
Complement fixing islet cell antibodies (CF-ICA), with fresh normal
human serum used as a source of complement, were revealed by fluo-
resceinated anti C3 antibodies (Chapter A3.5).
Insulin antibodies
Insulin antibodies, as detected by insulin binding capacity,
were measured with two different methodological approaches:
Christiansen's method in phase A (Christiansen,1970) and Ortved
Andersen's method (Andersen et al,1972) as modified by Mustaffa et al
(1977) in phase B (Chapter A3.3). The results obtained with the
former method were divided into negative, low, medium and high when
values were < 0.05, 0.05-0.5, 0.51-2, >2 mU/ml; whereas those with
the latter when values were <10, 10-100, 101-300, > 300 uU/ml,
respectively.
Immune complexes
Immune complexes were studied by two different approaches:
small medium size complexes in antigen excess were detected by the
solid phase Clq binding (ClqSP) test (Hay et al,1976); C3 binding
medium-large size complexes near the equivalence point were detected
by the conglutinin radioimmunoassay (KgBt) (Casali et al,1976)
(Chapter A3.1). One hundred and forty three blood donor sera were
used to evaluate the limit of positivity in immune complex studies.
Out of these samples, aliquots of ten statistically representative
sera were included in all the experiment as reference sera. The
chosen limit of positivity was the mean plus 2 standard deviations
(SD) of normal values. Since the methods to detect immune complexes
are only semiquantitative, results were expressed as negative, low
(between mean plus 2 SD and mean plus 3 SD), medium (between mean
360
plus 3 SD and mean plus 4 SD) and high levels (above mean plus 4
SD).
Statistical analysis
Fisher's exact test,chi square test with Yates' correction when
applicable,Cox's test for trends in proportions and the unrelated t
test were used for the statistical evaluation of results.
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B4.2c Results
Islet cell antibodies and
other organ specific autoantibodies
At the end of pregnancy ICA were found in 12% of patients in
Group 1 and in 5% in Group 3. None of the Group 2 patients was ICA
positive. None of the sera were CF-ICA positive. In patients in phase
B, two out of the 14 patients in Group 1 showed autoantibodies to
thyroid and gastric mucosa; 1 of the 6 in Group 2 had antithyroid
antibodies and 1 out of the 4 in Group 3 presented with antibodies to
gastric mucosa.
Insulin antibodies
Insulin antibodies, studied at the end of pregnancy, were found
in 67% of Group 1 patients, in 73% of Group 2 and in 25% of Group 3
(Figure B4.2/.1) .There was no significant difference in insulin
antibody levels between patients treated with standard insulins
throughout pregnancy and those transferred to purified mixed
insulins. Insulin antibody levels in Group 1 diabetics followed
during pregnancy did not vary significantly from the first trimester
(mean 5.5 + 1.8uU/ ml) to the end of pregnancy (mean 15 + 5.5uU/ml).
Immune complexes
Immune complexes, as detected by ClqSP, were found to be
increased in diabetic pregnant women in comparison with normals
(p<0.001) (Figure B4.2/2). There was no significant difference in
immune complex levels between patients in Groups 1, 2 and 3. In the
patients followed throughout pregnancy there was a significant
increase in immune complex levels during the course of pregnancy
(Figure B4.2/3).
On the other hand, the presence of immune complexes, as detected
by KgBt, was not significantly different between diabetic and normal
pregnants. The positivity was 26% in Group 1 and 21% in Group 3. None
of Group 2 was positive.
Metabolic control
Data on the maternal metabolic control are shown in table
B4.2/3. The HbAl percentage, evaluated in the patients of phase B,
was found to be 7.5 + 0.3 %. These values were significantly higher
than in controls.
Correlation between
immunological parameters and clinical characteristics of patients
or maternal and neonatal complications
No correlation was found between the presence of organ specific
autoantibodies and clinical aspects of diabetic pregnancy.On the
contrary the levels of insulin antibodies were significantly cor¬
related with the occurrence of gestosis (p<0.05). There was a si¬
gnificant association between the levels of insulin antibodies and
the occurrence of neonatal hypoglycaemia (p<0.025), hypocalcaemia
(p<0.01) and respiratory distress syndrome (p<0.01) (Figure B4.2/4).
The presence of immune complexes detected by ClqSP was positively
correlated with the duration of diabetes, (p<0.05), whereas the
immune complexes detected by KgBt were correlated with the age of the
patients: the younger the patients the lower the complexes (p<0.01).
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Correlation between
metabolic control and maternal and foetal complications
A higher frequency of gestosis (p<0.02) and neonatal complica¬
tions (p<0.05) were found in those cases with a poor maternal meta¬
bolic control (table B4.2/3).
Correlations between
metabolic control,insulin antibodies and neonatal complications
In patients with comparable metabolic control, the presence of
insulin antibodies was significantly correlated with the occurrence
of neonatal complications (table B4.2/4).
TABLE B4.2/1



































* N : normal pregnant women
** GD: Gestational diabetes
TABLE B4.2/2
Maternal and neonatal complications of diabetic and normal pregnant
women.
Group
1 2 3 N*
Gestosis 20% 9% 13% 5%
Macrosomia 35% 18% 27% 12%
Hypoglycaemia 45% 48% 13% 0.6%
Hypocalcaemia 18% 22% 16% 1.8%
RDS** 10% 30% 8% 2.7%
Hyperbilirubinaemia 61% 74% 42% 16%
Apgar index (<7 at 5') 15% 31% 6% 8%
Malformations 4% 13% 0% 1.4%
* N : normal pregnant women
** RDS : respiratory distress syndrome
TABLE B4.2/3
Maternal metabolic control (MMC) and clinical data of 118 diabetic
pregnant women.
MMC GOOD POOR "p" value<
Number subjects 75 43
Age (years) 31.2 + 1.1 32.1 + 1.2
Mean gestational age
at delivery (weeks) 38,2 +0.3 37.5 + 0.2
Maternal complications(%):
gestosis 11 28 0.02
polyamnios 16 16 —
Neonatal complications(%):
total 53 75 0.05
macrosomia 35 42 —
hypoglycaemia 24 45 0.05
hypocalcaemia 8 20 —
RDS* 13 15 —
hyperbilirubinaemia 25 52 0.01
* RDS : respiratory distress syndrome.
TABLE B4.2/4
Maternal metabolic (MMC) and neonatal complications relation to the
presence of insulin antibodies (InsAb) in 118 diabetic pregnants.
MMC GOOD "p"< POOR "p"<
InsAb Absent Present Absent Present
Neonatal
complications(%) 54 89 0.01 88 93
macrosomia 33 38 — 31 44
hypoglycaemia 20 41 — 31 56
hypocalcaemia 3 15 — 12 30
RDS* 3 24 0.05 6 22
hyperbilirubinaemia 27 59 o•o 69 63
* RDS : respiratory distress syndrome
FIGURE B4.2/1
Insulin antibodies (InsAb) in all the diabetic pregnant women
studied at the end of pregnancy. Patients in phase A are indicated
with circles. The open circles indicate patients treated with com¬
mercial insulins; the closed circles those treated with highly pu¬
rified insulins. Patients in phase B are indicated with squares. For
further information on patients and methods used, see text.
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Group 1 Group 2 Group 3
FIGURE B4.2/2
Immune complexes (AgAb), as detected by ClqSP, in diabetic
pregnant women at the end of pregnancy in comparison with normals.
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studied at the end of pregnancy
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Immune complex levels (AgAb), as detected by ClqSP, during
pregnancy in phase B patients.
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The maternal and/or foetal pathological events in the diabetic
pregnancy could be the effect of several different pathogenic agents
including metabolic and immunological factors.
Immunological factors in pregnancy have not been adequately
investigated in the past. Therefore, the main concern in planning
this work was to reconsider the pathological events in the diabetic
pregnancy from this approach: the presence and the possible in¬
fluence of changes in the immunological aspect of the patients. The
results of the work have, in fact, substantiated this hypothesis.
The correlation between medium-high insulin antibody levels and
increased occurrence of maternal gestosis or neonatal hypoglycaemia,
hypocalcaemia and respiratory distress syndrome, suggests a possible
influence of these antibodies on the maternal and neonatal morbidity
in the diabetic pregnancy. This hypothesis is reinforced by the fin¬
ding that in patients with good metabolic control the presence of
insulin antibodies was still correlated with the occurrence of
neonatal complications. The presence of these antibodies may increase
the deleterious effect of hyperglycaemia.
Furthermore, the increased presence of circulating immune
complexes in diabetic pregnants, when compared to normal pregnants,
and their tendency to increase during pregnancy, reinforces the
concept of an involvement of immune factors; as it is frequently
observed only one type of complexes was found to be increased: those
of small-medium size, mostly in antigen excess,as detected by the
solid phase Ciq binding test.
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The presence of islet cell antibodies in a few gestational
diabetics, is in accordance with a few other similar reports (Steel
et al,1980;Tingle et al,1979).The presence of islet cell auto¬
antibodies suggests the occurrence of some damage of the islet cell
function, presumably sustained by immune factors, despite the clini¬
cal finding of only an impaired glucose tolerance. In this regard,
the report of the development of overt diabetes a few years after
pregnancy in islet cell antibody positive gestational diabetics is
relevant (Tingle et al,1979).
Of course, the finding of a statistical correlation between the
occurrence of immunological factors and pathological events does not
necessarily imply a cause-effect relationship. Nevertheless,the
finding herein and those of previous reports (Galbraith and Page
Faulk,1979), suggest that immunological factors may play a role in
the development of pathological events in diabetic pregnancies.
Although insulin does not cross the placenta in significant
amounts, insulin antibodies of IgG class do. Their presence in
the foetal circulation, buffering the foetal insulin, may well
increase the demand for insulin from the foetal pancreas (Heding et
al,1980); if this is the case, the higher the antibody levels, the
more likely is the occurrence of hypoglycaemia in the newborn. In
this respect a higher insulin and/or C-peptide level in the cord
blood of infants of diabetic mothers having elevated levels of
circulating insulin antibodies has been reported (Heding et al,-
1980;Fallucca et al,1980). This effete is evident even when
the influence of the maternal metabolic control has been taken into
account (Fallucca et al,1980).
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It is interesting that the switch from standard insulin prepara¬
tions to purified mixed bovine and porcine insulins did not substan¬
tially modify the correlations found. Bovine insulins, though purifi¬
ed, are still immunogenic to some extent (Chance et al,1976).
Noteworthy also is the correlation between insulin antibody
levels and the occurrence of infants' respiratory distress syndrome.
Although the pathogenesis of infants' lung distress syndrome is not
elucidated, the presence of immunological abnormalities in the
alveolar basement membrane has been suggested by previous studies
(Benatre et al,1974;Smith et al,1975). On the other hand, foetal
hyperinsulinism, indirectly induced by high insulin antibody levels,
appears to be a very important factor. Insulin has in fact an
inhibitory effect on lung surfactant factor production (Smith et
al,1975;Gajl-Perzalska,1964 ). More obscure is the possible re¬
lationship between high insulin antibody titers and neonatal hypo-
calcaemia. It is likely that other complicating conditions, such as
macrosomia and respiratory distress, both related to hyperinsu-
linaemia, may indirectly link, through an acidotic condition, the
presence of these antibodies to an impaired calcium and phosphate
homeostasis (Tsang et al,1972).
Other papers have reported a correlation between the presence of
circulating immune complexes and the occurrence of maternal gestosis
(Scott et al, 1978;Jenkins,1977;Gleicher et al,1978). The increased
presence of immune complexes in our diabetic pregnants failed to be
significantly correlated with the occurrence of gestosis, but a
correlation was found with the levels of insulin antibodies. It is
known that the increased presence of circulating macromolecules is
correlated with the presence of diabetic vascular lesions and that,
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in some diabetics, a deposition of immune materials and of macro-
molecules in placental blood vessels has been described (Galbraith
and Page Faulk,1979). Therefore, the possibility should be considered
that higher levels of insulin antibodies, and the consequent insulin
anti-insulin complex formation, contribute to increased deposition
of macromolecules and damage of blood vessels, leading to maternal
clinical manifestations.
In conclusion, the study of immunological parameters during
pregnancy in diabetics might give useful information on the pro¬
bability of the development of maternal complications and even
predict and somehow help in preventing the possible occurrence of
neonatal complications. Moreover an appropriate choice of highly
purified insulins, avoiding immunological phenomena connected with
insulin therapy, is a measure which will facilitate metabolic control
and may help to reduce the possibility of clinical complications.
B4.3 HUMORAL IMMUNITY IN DIABETIC PREGNANCY : INSULIN
ANTIBODIES AND INSULIN-ANTI-INSULIN COMPLEXES
B4.3a Aim of the study
In this study attention has been focused on assaying the posible
presence of insulin-anti-insulin complexes in the cord blood and on
the relationships of these complexes of the newborn with the maternal
insulin antibodies and insulin-anti- insulin complexes.
B4.3b Materials and methods
Patients
A total of forty-seven pregnant diabetic patients, all attending
the same clinic, were included in the study. Twenty-three of these
diabetic women were investigated together with their infants. All the
pregnant patients were sampled at the end of pregnancy and 27 also in
the first trimester of pregnancy. Twenty-six had type 1 diabetes, 14
type 2 and 7 gestational diabetes. All the patients were treated with
insulin; during pregnancy monocomponent insulins or semisynthetic
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human insulins were used, except in 2 cases, regardless of the type
of treatment previously used. The cord blood of the infants was
studied.
Insulin antibodies
Insulin antibodies, measured as insulin binding capacity
(InsAb), were evaluated according to the technique originally de¬
scribed by Ortved Andersen (1972) and modified by Mustaffa et al.
(1977) with a few other minor modifications (Chapter A3.3). Values
above 10 ull/ml were considered indicative of the presence of anti¬
bodies.
Insulin-anti-insulin complexes
Insulin-anti-insulin complexes (Ins/iAb) were measured according
to a modification (Chapter A3.4) of the techniques described by
Jayarao et al.(1974) and Virella et al.(1980). The insulin-anti-
insulin complexes are calculated as the difference between the
"total" antibody and the "free" antibody. The sensitivity of this
technique in assaying the sole presence of insulin antibodies is
slightly different from Andersen's method (Chapter A3.4).
Statistical analysis





InsAb were found at the end of pregnancy in 62% of the type 1
diabetic patients (median:15.5 uU/ml,interquartile range, or i.r.,
<10-45),in 71% of the type 2 (m.:26.5 uU/ml, i.r.<10-79) and in 43%
of the gestational diabetic patients (m.:<10 uU/ml,i.r. <10-13). No
significant difference was found when the levels of InsAb at the
beginning of pregnancy (median: 18 uU/ml,i.r.<10-43) were compared
with those at the end of pregnancy in the same type 1 diabetic
patient.
Neonates
InsAb were found in 48% of the newborn infants studied. InsAb
levels were similar in the newborns (m.:<10 uU/ml,i.r.<10-28) and in




Quantifiable Ins/Ab were found in 37% of the type 1 diabetic
patients studied at the beginning of pregnancy (m.:<7, i.r.<7-13.3)
and in 27% of the patients with the same type of diabetes studied at
the end of pregnancy (m.:<7, i.r. <7-7.1). Ins/iAb were also present
in 21% of type 2 diabetic mothers at the end of pregnancy (positive
values: 8,9.1,82.1) and in 14% of gestational diabetic patients
(p. v. : 7. 9).
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Neonates
Ins/iAb were found in infants of diabetic mothers (38% of
infants of type 1 and 43% of type 2 diabetic mothers) (Table B4.3/1).
There was a significant correlation between the presence of Ins/iAb
in newborn infants and the occurrence of these complexes in their
relative mothers; nevertheless, this correlation was much stronger
when the findings in newborns were correlated with those found in
mothers in the first trimester of pregnancy (p<0.0005) than at the
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B4.3d Discussion
Evidence has been attained in this study that insulin- anti-
insulin complexes are present in the circulation of a number of
infants of insulin-treated diabetic mothers.
The amount of complexed insulin antibody is not only related to
the total amount of the antibody but may be influenced by the af¬
finity and avidity of the maternal insulin antibody.
There is a strong correlation between the presence of insulin-
anti-insulin complexes in the cord blood and their presence in the
maternal circulation. Nevertheless, the presence of insulin-anti-
insulin complexes in the fetus does not merely represent a passive
transfer of the insulin antibodies from the mother to the fetus. The
levels of insulin-anti-insulin complexes in the newborn do not
reflect those of the mother at the end of pregnancy but appear to
correlate with the average of the levels of insulin- anti-insulin
complexes during pregnancy.
Indeed, even if insulin antibodies can easily cross the placenta
whereas insulin itself is not transferred in significant proportions,
when insulin antibodies reach the fetal circulation they face a
different situation. These antibodies react with an antigen slightly
different from the maternal one: fetal endogenous insulin and not
therapeutic heterologous insulin. The antigen/antibody molar ratio is
substantially different. While in the mother the antibody interacts
with massive doses of insulin, of high or low immunogenicity, ad¬
ministered in subcutaneous boluses twice a day on average, in the
fetal circulation the antibody reacts with a continuously produced
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pancreatic insulin. The amount of insulin itself produced by the
fetal pancreas varies tremendously from the first months until the
end of pregnancy, whereas the amount of insulin antibodies trans¬
ferred by the mother usually does not vary significantly during
pregnancy. From a situation very likely characterized by antibody
excess at the beginning of pregnancy, as the fetal pancreas produces
insulin in increasing amounts, the proportion between antigen and
antibody becomes more balanced. It is highly probable that both the
fate and the physiopathological significance of the fetal insulin-
anti-insulin complexes are different from those of the mother.
The clearance of fetal insulin-anti-insulin complexes seems, to
some extent, slower than that of the mother. It is not known whether
insulin antibodies in fetal circulation may easily be retransferred
to the mother's circulation, but it is not probable that the com¬
plexes may be freely exchanged.
Whereas in the mother small medium-size complexes are rapidly
removed by the kidney and the reticulo-endothelial system(Mannik et
al,1974), in the fetus, the complex clearance mechanisms are not so
efficient, especially in infants of diabetic mothers in whom the
normal duration of pregnancy is usually shortened. This could explain
why in those few cases in which the insulin antibody levels are high
in the mother at the beginning of pregnancy and low at the end, the
insulin-anti-insulin complex levels in the fetus are comparable to
those found in the mother in the first months of pregnancy.
A few research works, among which the previous chapter of the
thesis, have already described a correlation between the presence of
insulin antibodies and a few neonatal clinical complications (Martin
et al,1975;chapter B4.2))
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On the other hand, the possible damage induced by the deposition
and presence of immune complexes is well known both in diabetic
patients (Jayarao et al,1974;chapter B3) and in pregnant women with
clinical complications (Theophilopoulos et al,1981;Vazquez-Escobosa
et al, 1983). Moreover, it is well known that the injection of
insulin antibodies may induce a diabetic-like syndrome in normal
animals (Wrigth,1961). The presence of insulin-anti-insulin complexes
in detectable amounts may be theoretically associated with the
occurrence of defects in the circulation of the small blood vessels
of the placenta, some clinical complications in the newborn and, in
particular, with the macrosomia and the neonatal hypoglycemia neu¬
tralising or abruptly releasing substantial amounts of newborn
insulin.
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B4.4 CELLULAR IMMUNITY IN DIABETIC PREGNANCY:
T CELL SUBSETS
B4.4a Aim of the study
The aim of this study was to investigate the T cell sub-
populations in diabetic pregnant patients and to compare the findings
with those in normal pregnant subjects and in normal women. The type
of diabetes has been taken into consideration. The total number of T
cells, the proportion of T helper and of T cytotoxic/suppressor
lymphocytes and to ratio of T helper to T cytotoxic-suppressor cells
have been analyzed.
B4.4b Materials and Methods
Patients
37 diabetic pregnant patients, 16 with type 1 , 10 with type II
and 11 with gestational diabetes were studied together with 22 normal
pregnant subjects and 20 normal women. All the pregnant women were
attending the same Clinic. The medians of the age of type 1, type 2
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and gestational diabetic pregnants, of normal pregnants and of normal
controls were 25 (Range 22-34), 30 (R. 25-40),(R 21-31) and 26 (R
18-40) respectively. The duration of diabetes was 12 years (R 3-16)
in type 1 diabetics, and 10 years (2-16) in type 2 diabetics. 13 dia¬
betic patients were sampled at the end of pregnancy, 11 at the end of
the second trimester and 14 at the end of the first trimester of pre¬
gnancy.
T cell subsets
The monoclonal antibody 0KT3 (Ortho Diagnostic) was used to
count the total T cell population and 0KT4 to enumerate the helper/
inducer T cells. The antibody UCHT4, was used to detect the sup¬
pressor/ cytotoxic T cells. For details see chapter A3.2
Statistical analysis
Unpaired t testwas used to evaluate the results.
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B4.4c Results
Total T cell number
The total number of T cells as measured by 0KT3 was essentially
similar in type 1, type 2 , gestational diabetic pregnants, normal
pregnant subjects and normal women (Table B4.4/1).
Helper T cells (Th)
The percentages of helper/inducer T cells, as measured by 0KT4,
were found in 35.8% + 8.7 of type 1, 42.8 % + 9.2 of type 2, in 41.2
% + 8.7 of gestational diabetic pregnants, in 38.2 % + 7.3 of normal
pregnant subjects and in 41.5% + 6.4 of normal women (Table B4.4/1).
The reduction in T helper cells in type 1 diabetics in comparison
with normal subjects was statistically significant (p<0.01).
Suppressor/cytotoxic T cells (Tc/s)
The percentage of suppressor/cytotoxic T cells, as measured by
UCHT4, in type 1, type 2, gestational diabetic pregnants, normal
women were 19.% + 7, 13 % + 4.2,18.5 % + 3.8, 17.7 % + 5 and 19.8 % +
5.7 respectively (Table B4.4/1). The reduction in T cytotoxic-sup-
pressor cells in type 2 diabetics in comparison with normal subjects
was statistically significant (p<0.05).
Th/Tc-s ratio
When the ratio between the percentages of helper T cells and of
cytotoxic/suppressor T cells was calculated in type 1, type 2,
gestational diabetic pregnants, normal pregnant subjects and normal
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women the results obtained were 2.1 + 0.9, 3.4 + 0.9, 2.4 + 0.8, 2.4
+ 0.97 and 2.2 + 0.67 respectively (Table B4.4/1). The ratio was
significantly increased in type 2 diabetics in comparison to normal
pregnant women, gestational diabetics, type 1 diabetics and normal
subjects (p<0.02).
T cell subsets during pregnancy
The values of T cell subsets at the end of the 1st,2nd and 3rd
trimester of pregnancy in type 1, type 2 and gestational diabetic
pregnant women were as indicated below:
0KT3 0KT4 UCHT4
mean SD mean SD mean SD
type 1 pregnant d.
1st trim. 55.2 10.3 37.2 13.2 18.6 11.2
2nd trim. 56.1 5.5 35.1 5.9 21.2 3.6
3rd trim. 55.0 2. 1 35.3 3.6 18.3 3.9
type 2 pregnant d. 48.9 0.7 33.7 2.7 8.4 0.6
56.3 3.4 38.9 0.8 15.9 6.7
59.2 4.7 46.6 9.4 13 .5
gestational d. 57.9 4.6 42.6 9.1 18 2.2
54.9 5.1 41.6 5.5 16.3 2.2
51.9 0.7 36.6 0.9 27.5 0.8
Normal pregnancy
The percentages of total T cells, of helper/inducer T cells and
of suppressor cytotoxic lymphocytes were lower in normal pregnant
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women in comparison with normal controls. These differences were
clearer when the values at the end of the first trimester of
pregnancy were considered.
TABLEB4.4/1






































Changes in the relative proportions of T cell subsets, and in
particular in the balance between helper and suppressor T cells,
could be important in the maternal immune tolerance towards the
fetus. It is interesting to evaluate the possible changes in T cell
subpopulations especially in diabetic pregnancy where immune abnorma¬
lities related to diabetes may be superimposed on the modifications
related to pregnancy.
In normal pregnancy contradictory studies on the proportion of T
cell subpopulations have so far been reported. Absolute T cells
counts (Dodson et al 1977, Cornfield et al 1979), and the pro¬
portion of T cells (Scott et al 1978;Dodson et al 1977,Birkeland &
Kristoffersen,1977;Sumiyosshi et al 1981; Campion & Currey 1972;
Garewal et al 1978) are reported to remain unchanged in a few studies
whereas others report a marked fall in the first trimester
(Strelkauskas et al 1978) and a minor fall in the third trimester
(Baines et al 1977, Cornifield et al 1979; Bulmer & Hancock, 1977;
Vanderbeeken et al 1982). A decrease in T helper cells during pre¬
gnancy was reported (Vanderbeeken et al, 1982) in contrast with
others who did not find significant changes (Moore et al, 1983).
These contraddictory results may be explained by differences in the
methodology and techniques used and also by the relatively small
number of subjects investigated.
In this study a minor decrease in the percentages of total T
cells and helper T cells, especially at the end of the first
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trimester of pregnancy is in agreement with several of the above re¬
ported studies (Strelkauskas et al 1978; Vanderbeeken et al 1982).
Regular follow up of a large number of normal pregnant women and
studies with the use of standardized and accurate techniques to
evaluate the T cell populations are at present needed.
In diabetic pregnancy very few studies on cellular immunity are
reported (Galluzzo & Bompiani).
In type I diabetic pregnant women a significant reduction in
helper/ inducer T cells is observed. This reduction is observed also
in long standing type I diabetics (chapter B 3.5). Thus the reduction
in cells bearing the T4 phenotype seems to be related to the immune
abnormalities linked to diabetes more than to the events occurring in
pregnancy.
In type 2 diabetic pregnant women a significant increase in the
ratio of helper T cells/ cytotoxic-suppressor T cells is observed. In
long standing type 2 diabetes no significant modifications in the
percentage of.lymphocyte subsets was detected (chapter B 3.5).
This increase in the ratio of helper/suppressor lymphocytes seems to
be related to events occurring in pregnancy. The explanation of this
finding is not obvious. Since type 2 pregnant patients already
treated with diet or oral agents are at the beginning of pregnancy
and thereafter treated with heterologous insulin, this cellular
modification might reflect this event.
In gestational diabetic patients no significant difference in T
cell subsets in comparison with normal pregnant women has been found.
The modifications of T cell subpopulations reported above do not
seem to reflect adequately the complex and fascinating sequence of
immunological events occurring in pergnancy. The failure to respond
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of the maternal Immune system to the antigenically foreign feto¬
placental unit must involve complex immunological mechanisms. More
sophisticated techniques are needed to study cellular immunity in
pregnancy including monoclonal antibodies defining T cells during
activation and differentiation.
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B4.5 CELLULAR IMMUNITY IN DIABETIC PREGNANCY :
ACTIVATED T CELLS.
B4.5a Aim of the study
Aim of this study was to investigate the possible presence of
activated T cells in diabetic pregnant patients and to compare the
findings with those in normal pregnant subjects and in normal women.
The type of diabetes has been taken into consideration. The expres¬
sion of surface antigens such as the transferrin receptor, the T cell
growth factor, a protein of 120 k molecular weight linked to the
insulin receptor, and different determinants of class II MHC has been
analyzed.





4F2 positive cells (chapter A3.2a) were enumerated in all the
patients. Since 4F2 positive cells show a peaked asymmetric distri¬
bution in the normal population, the limit of positivity was chosen
as the 90th percentile of the values found in normal controls
Monoclonal antibodies 5E9 and TAC (see chapter A3.2a) have been
used to define activated T cells in some subjects.
The monoclonals 231, 164 and L 243 (see chapter A3.2a) were used
to reveal Class II antigens expressed on the surface of T lympho¬
cytes. A double staining method and Medicell chambers were used to
enumerate class II positive T cells (see chapter A3.2b&c)
Statistical analysis




Type 1 diabetic pregnants
4F2 positive cells, in numbers above the 90 th percentile of
values found in normal controls, were found in 75% of type 1 dia¬
betics (Figure B4.5/1).
Increased levels of 5E9 and TAC positive T lymphocytes were not
found in any of the patients.
DA6.231 positive/T3 positive lymphocytes were found in 42% of
this type of diabetics whereas DA6.164 positive/ T3 positive cells
were in 37% and L243 positive cells in 37% of type 1 diabetic pre¬
gnant women. The positivity for the antibodies 231, 164 and 243 was
defined taking as limit of positivity the mean + 2 SD of values found
in normals. 50% of the patients tested showed a class II MHC T cell
positivity with at least one of these 3 monoclonals. (Figure B4.5/2).
Type 2 diabetic pregnants
4F2 positive cells were present in 50% of type 2 diabetics
(Figure B4.5/1) whereas 5E9 and TAC positive cells were within the
normal range.
231 +/T3+ lymphocytes were found in 25% whereas 164+/T3+ and
243+/T3+ cells were within the normal range (Figure B4.5/2).
Gestational diabetics
4F2+ cells were present in 44% of patients (Figure B4.5/1)
whereas 5E9+ and TAC+ in none of them 231+/T3+ cells were present in
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20%, 164+/T3+ in 25% and 243+/T3+ cells in 30% of gestational dia¬
betic pregnants (Figure B4.5/2).
Normal pregnants
4F2 positive cells were found in 70% of subjects (Figure
B4.5/1).
DA6.231 +/T38 cells, DA6.164+/ T3+ and L243+/T3+ lymphocytes
were found in none of the normal pregnant women studied.
Normal women
The mean values for 4F2, 231, 164, 243 were 3.4 (2.2), 1.1
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B4.5d Discussion
In diabetic pregnancy, the immune phenomena occurring in
diabetes must be viewed against a background of immune events that
occurr in normal pregnancy. On the other hand the sum of the
immunological events related to diabetes and to pregnancy may
generate a particular immunological situation with possible effects
on the disease itself, on the course of pregnancy, on the placenta
and on the fetus.
In pregnancy there is an apparent failure to recognise fetal
antigenic components or an inability to generate an immune response
to the histoincompatible fetoplacental unit. Modifications in
cellular immunological processes are mainly responsible for this
immune adaptation to pregnancy. The proportions of T regulator and T
effector cells can be evaluated with accuracy by the use of mono¬
clonal antibodies (Chapter B4.4). More recently attention has been
focussed on the evaluation and presence of the significance of T
lymphocytes expressing antigens on their surface not present in the
resting state. The mitogenic or allogeneic stimulation of T lympho¬
cytes results in the appearance of activated T lymphocytes, i.e.
cells expressing surface determinants not present on resting cells.
According to some authors these antigens are expressed sequentially
in the process of activation: the 4F2 antigen being among the
earliest, the Tac among the last ones to be expressed whereas the
class II MHC molecules are among the best defined antigens expressed
on activated T lymphocytes (Cotner et al, 1983)
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To study activated T cells in diabetic pregnancy is of interest
for several reasons. Since the presence of activated T cells is a
marker for allogeneic stimulation, T cell activation would be ex¬
pected to be present in pregnancy but blocked or somehow modified, so
as to avoid an immune rejection of the fetus. Activated T cells have
been reported to be increased in type 1 diabetes ( Rowley &
Eisenbarth, 1982; Pozzilii et al, 1983). When diabetes and pregnancy
are concomitant the effects on T cell activation is not
obvious.
In this study activated T cells have been studied in diabetic
pregnant women and in normal pregnant subject by the use of a panel
of monoclonal antibodies.
A clear increase in 4F2 positive cells is present both in normal
and in diabetic pregnant women. There is an increase in MHC class II
positive lymphocyte in diabetic pregnant women but not in normal
pregnant subjects. The increase in class II positive T cells is
higher in type 1 pregnant diabetics. In those patients in whom Tac
and 5E9 antigen expression was examined, no increase of these anti¬
gens on T cells was found.
In normal pregnancy functionally mature and fully activated T
lymphocytes, namely those expressing class II, Tac and 5E9 antigens,
are not present. On the other hand the increase in 4F2 positive
cells is an interesting finding. It is conceivable that resting T
cells in normal pregnancy are activated or induced to enter the first
phase of the cell cycle (GO -> G1 transition) and that this coincides
with the expression of the 4F2 antigen at the cell surface . Further
progression into the cell cycle , leading to mitosis and expression
of the Tac antigen, class II antigens and functional maturity,
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apppears to be blocked. This is in keeping with the modern concept
that pregnancy represents a state of immunoactivation and not of
immunodepression (Gleicher & Siegel, 1983). In other words pregnancy
seems to be a state in which immunosuppressive components are activa¬
ted. It cannot be excluded that the 4F2 positive mononuclear cells in
pregnancy are immature cells or fetal cells (Gleicher & Siegel,
1983).
In diabetic pregnancy, in addition to the increase in 4F2
antigen on mononuclear cells, the increase in class II positive T
cells in a number of type 1 diabetics, and in a few type 2 or gesta¬
tional diabetics is likely to reflect the immune abnormalities
preexistent to pregnancy. Fully funtionally mature and activated T
cells, namely those expressing Tac and 5E9 antigens have not been
found. This is in keeping with other reports in type 1 diabetes where
5E9 positive cells were not found to be increased (Pozzilii et
al,1983). As expected in diabetic pregnancy the cellular immune
factors are simultaneously influenced by phenomena related to dia¬
betes and to pregnncy.lt remains to be shown whether the the super-
imposition of diabetes upon normal pregnancy may represent an immuno¬
logical "final straw" with consequences for the fetus (Page Faulk et
al, 1980; Galbraith & Page Faulk,1981).
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B4.6 CONCLUSIONS
The hypotheses formulated in planning the work have been in¬
vestigated. The results reported in this chapter show that :
a) Humoral factors, in addition to metabolic events, seem to
influence the clinical course of pregnancy and neonatal com¬
plications .
Islet cell antibodies were found not to be correlated with
maternal or neonatal clinical complications. In particular it is
confirmed that neonates of islet cell antibody positive mothers
apparently do not suffer from any specific metabolic disorder.
Nevertheless the presence of islet cell antibodies in some gesta¬
tional diabetic pregnant women is evidence of a likely immunological
response damaging the islets, as confirmed by the reports of others
of an early insulin failure in a similar group of patients.
Insulin antibodies were found to be increased in a significant
proportion of pregnant diabetic patients who presented with gestosis.
The presence of maternal insulin antibodies was correlated with a
number of clinical complications in the neonates. Indeed,
theoretically, insulin antibodies may interfere, either directly or
indirectly, in a number of ways with the fetal metabolism and de¬
velopment. Some types of immune complexes were increased in pregnant
diabetics but their correlation with gestosis failed to reach sta¬
tistical significance.
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b) Insulin anti-insulin complexes are here proved to be present
also in neonatal circulation and they may have physiopathological
effects. Insulin-anti-insulin complexes in the neonate do not reflect
simply a passive passage from the maternal circulation. The clearance
of fetal insulin-anti-insulin complexes seems slower than that of the
mother.
Insulin antibodies in the mother and in cord blood show similar
levels. The differences in the antigens encountered may explain in
part the different levels of insulin complexes.
c) The absolute number of total T cells is not significantly
different in diabetic pregnant women and in normal pregnants.
Nevertheless T helper cells are significantly decreased in type
1 diabetic pregnant women.
An increase in the ratio T helper/T suppressor-cytotoxic cells
has been observed in pregnant diabetics in comparison with normal
women.
The expected difference in cellular immunological status in
diabetic pregnants, seems to be only marginally refected in va¬
riations of the absolute T cell subpopulation number.
d) Mononuclear cells expressing surface antigens not usulally
present in non-activated lymphocytes are increased in diabetic
pregnant women.
A clear increase in 4F2 positive cells is present both in normal
and in diabetic pregnant women.
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There is an increase in MMC class II antigen positive lympho¬
cytes in type 1 diabetic pregnant women but not in normal pregnat
subjects.
Antigens usually found in mature and activated lymphocytes were
not found in the subjects studied.
A population of aberted but not fully activated immunocomponent
cells seems to be increased in pregnancy.
In diabetic pregnancy T cell subsets are simultaneously in¬
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SUMMARY
The relationship between immune complexes and insubn antibodies was evaluated in 237
insulin treated subjects with a duration of diabetes of more than 1 year. Ninety-seven
diabetics were selected at random (group I) whereas 140 according to the presence of
diabetic microangiopathy (group 2). Immune complexeswere evaluated by the solid phase
Clq binding test in all patients and by eonglutinin radioimmune assay in most of them.
Insulin antibodies were determined by Christiansen's and Anderson's methods, immune
complexes as detected by the solid phase Clq method were found increased in group 1 and
there was an inverse correlation between these complexes and insulin antibody levels. In
group 2 patients with microangiopathy the amount of this kind of complex was
significantly greater than in those without microvascular lesions and there was no
correlation with insulin antibodies. Immune complexes as detected by conglutimn were
found increased in group 2 patients and these were significantly correlated w ith the level of
insulin antibodies. No increase in these immune complexes was found in patients with
microahgiopathy when compared with patients without microangiopathy. Insulin
antibodies were not correlated with the presence of complications. Overall, immune
complexes detected by Clq binding were significantly correlated with the presence of
microangiopathy. In patients with high insulin antibody levels the complexes formed were
not detected by Clq binding. The immune complexes detected by conglutinin are
correlated with insulin antibodies, but not with the presence of microangiopathy.
INTRODUCTION
Since insulin antibodies (InsAb) were first described, there have been numerous investigations olYhe
possible influence of prolonged heterologous insulin treatment on the course of diabetic
microangiopathy. This question is still unanswered.
So far there have been a few conflicting studies that have tried to correlate the level of insulin
antibodies w ith the severity of microangiopathy (Ortved Andersen. 1476; Page Faulk. Narain &
Fudenberg, 1471; lavicoli et al„ 1480). There have also been several contributions in animals
showing a direct pathogenic role ofexogenous insulin in microangiopathic lesions (Andreev, Ditzov
& Dashev, 1470; Zampa & Mancini, 1465; Mohos, Heningar & Fogelman. 1463). On the other
hand, it is well known that the lesions of small blood vessels are present in patients treated with both
insulin and oral agents, although differences have been described in the severity and frequency of the
lesions.
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II" insulin treatment has a role in aggravating blood vessel damage through immune
mechanisms, the formation and deposition of insulin anti-insulin complexes must be considered.
This is supported by the finding that in animals microangiopathy is induced only when insulin is
injected with Freund's adjuvant and insulin antibodies are formed (Wehner. Hubcr & Kronenberg.
197.1).
The study of insulin anti-insulin complexes is complicated by a few factors (Foiling. 1976).
Insulin is a weak antigen and is antigenically bivalent. Insulin complexes are usually small and
soluble both in antigen and in antibody excess. Only a small part of these complexes, near the
equivalence point, are large enough to be capable of triggering a sequence ofevents that can result in
tissue damage. So far there are no routine methods available to measure these different kinds of
complexes. When a few years ago circulating immune complexes (IC) were described in some
diabetic conditions (Di Mario. lavicoli & Andrcani. I9S0) and w hen more recently these complexes
were reported to be significantly increased in diabetics with severe microangiopathy compared with
those without complications (Irvine <7 at.. 1978a; Andreani <7 al.. 1982). it was natural to suppose
that part of the complexes found m patients with microangiopathy would be comprised of insulin.
This study was planned lo investigate the correlation between the presence of insulin antibodies
and the occurrence of immune complexes in patients with and without microangiopathy. Since
there are substantial differences in the results of different techniques aimed at determining
circulating immune complexes, two methods were employed, one detecting medium si?ed
complexes in antigen excess through the Fc portion of complexed immunoglobulins the solid
phase Clq binding test (ClqSP) and the other detecting C3 binding complexes near the
equivalence point the conglutinin radioimmune assay (KgBt).
Patients were selected using two different approaches: one group was composed of randomly
selected insulin treated diabetics and another group was selected so as to hav e patients in opposite
conditions, i.e. with severe microangiopathy anil without any clinical signs of microangiopathy.
PAT1FNTS AND MFTHODS
Patients. Two hundred and thirty-seven diabetics treated with insulin for more than I year were
selected for the study. Ninety-seven were randomly selected consecutive patients (group I) and 140
patients were selected according to the presence and degree of microangiopathy: 58 showed severe
microangiopathy. 82 had no sign of vascular lesions (group 2). The clinical and personal data of the
patients are shown in Table I. One hundred and eighty-nine blood donors were used as the control
population in IC studies. The evaluation of the presence and degree of microangiopathy was
performed as follows: retinopathy was assessed by retinal fiuorangiography—patients with






(mean ± s.d.) I II R N R + N
Group 1 97 51 46 118+ 17 4
Group 2
with severe 58 25 11 49 5+ 16 1 18 20 16 i: to
microangiopathy
without 82 44 18 17 8+ 16 7 67 IS
microangiopathy
* R - proliferative retinopathy: N advanced nephropathy. R + N - both compli¬
cations.
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proliferative retinopathy or recidivant vitreous haemorrhages were considered to have severe
retinopathy and patients with the absence of any sign of retinopathy were considered free of ocular
complications. Patients with intermediate forms of retinal involvement were excluded from the
study. Blood urea > 16 mmol/1, serum creatinine levels > 2 mg, dl and/or proteinuria > 2 g/1 were
considered the index of kidney involvement.
Methods ClqSP in group I and 2 patients as described by Hay, Nineham & Roitl (1976) and
KgBt in group 2 patients according to C'asali el til. (1977) with some personal modifications (Irv ine
ft al.. 197Xb) were used to detect immune complexes. Andersen's radioimmune assay (Ortvcd
Anderson. Brunfeldt & Albigard. 1972) as modified by Mustalla. Dagget & Nabarro (1978) and
Christiansen's eleclrophoretie method (Christiansen, 1970) were used to detect InsAb respectively
in group 1 and 2 patients. The results wereexpressed in /iu ml of insulin binding capacity 111 the first
method and 111 u ml in the second one. The characteristics of the methods, the limit ofpositivity. the
expression and analysis of the results for IC tests have been extensively discussed elsewhere
(Andreani et ah. 19X2; l)i Mario ct ah. 19X0). As in most studies on circulating IC. the limit of
positivity of IC was chosen as the 90th percentile of the \alues found 111 the normal population,
because of their peaked asymmetric distribution. In I 1 g. 2 IC \alues were also expressed in
percentage of radioactivity (i:sI-protein A) bound radioactivity added (Casali et ah. 1977; Irvine et
al.. l97Xa, 1978b; lavicoli et al., 19X2). f isher's exact test, the y test. Cox's test, the /-unpaired test
and Kendall's test were used for the statistical evaluation of the results.
RESULTS
Group I
Immune complexes. In randomly selected diabetics, Clq-IC were found in 26 out of 97 patients
(27"P< OOI i v normal population; Fig. I).
Insulin antibodies. In the same patients, InsAh, as evaluated by Andersen's method, showed a
mean value of 116-4+113-2 /iu/ml.
Immune complexes vs insulin antibodies. When InsAb were correlated with Clq-lC values, an
inverse correlation was found between InsAb levels and Clq-IC values (P < 0 02) and patients with
high levels of InsAb tended to be Clq-IC negative (Fig. 2).
Group 2
Immune complexes Clq-IC were found in 29 out of 58 patients with severe microangiopathy
(50"„, P < 0-0001 r.v normals) and in 20 out of82 of those without microangiopathy (24"„, P < OOI r.v
normals, /3<0-00l is complicated diabetics; Fig. I). Kg-IC were found in 21 out of 58 patients
without vascular lesions (36"„, P < 0-0001 is normals) and in 20 out of 53 diabetics with severe
microangiopathy (38"/><0-00()l r.v- normals, N.S. r.v uncomplicated diabetics).
Group I Group 2
with and without
microangiopathy
Fig. I. Immune complex positivity, as detected by CTq-SP(t'lq-IC), in group I and 2 patients The positivity ("„)
of Clq-IC is indicated in the V axis. The dotted line indicates the positivity in the control population 110*',,).
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(^<0-02 Kendall's test) % of ct/min added AgAb
Kig. 2. Immune complexes (AgAb), us detected by Clq-SP. and insulin antibodies (IBC), as assayed by
Andersen's method, in group I diabetics. The horizontal dotted lines divide insulin antibody levels into negative







Kig. 3. The association between CIq-lC (AgAb) and insulin antibodies (InsAb) in group 2 patients with (a) am
without (b) complications. InsAb are indicated in the V axis and divided into negative, low <0-05-0 5 mu ml)












Fig. 4. The association between immune complexes (AgAb). as detected b\ conglutmin (kg-IO. and insulin
antibodies (InsAb) in group 2 patients with (a) and without (b) complications. InsAb as in Fig. 3.
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Insulin antibodies. Mean InsAb levels, as evaluated by Christiansen's method, were 1-33 mu/ml
in group 2 patients. There was 110 significant difference in InsAb levels between those with severe
microangiopathy (1-27+ 1 -47 mu/ml) and those without complications (1-38 + 1 -88 mu'ml).
Immune complexes vs insulin antibodies. The correlation between Clq-IC and InsAb was
significantly dilferent in patients with and without microangiopathy (Fig. 3). In microangiopathic
patients the positivity ofClq-IC did not vary significantly at increasing levels of InsAb, whereas in
patients without microangiopathy, when InsAb levels were high, Clq-IC positivity was signifi¬
cantly reduced in comparison with that found in those with lower InsAb levels (P < 0-05). Diabetics
without microangiopathy having medium/high levels of InsAb (>0-5 mu/ml) showed a signifi¬
cantly reduced IC positivity in comparison with diabetics with microangiopathy showing similar
InsAb levels. A dilferent correlation was found between Kg-IC and InsAb (Fig. 4). In group 2 there
was a positive trend for Kg-IC positivity to go with increasing levels of InsAb (P< 0-05). This trend
was even more evident when only patients without microangiopathy were considered (P < 0-01; Fig.
4b).
DISCUSSION
As expected the correlation between InsAb and immune complexes is rather dilferent when Clq-lC
or Kg-IC are studied.
In insulin treated diabetics selected at random, when InsAb are present in high amounts, Clq-IC
are not usually detectable. Since ClqSP lacks complexes in antibody excess (Scullion. Balint &
Whaley, 1979), in patients with high levels of InsAb. insulin antibody complexes would not be
expected to be detectable. It is conceivable that in patients with lower InsAb levels some immune
complexes may be related to insulin treatment. In fact, in another study by our group. Clq-IC were
found to be higher in randomly selected insulin treated patients than in comparable diabetics not
treated with insulin (Andreani el al.. 1982). Similar results were found in group 2 patients without
microangiopathy. It is interesting to note that when microangiopathy is present. Clq-IC levels are
much higher and not correlated with the levels of InsAb. This study confirms the ecently reported
(Irvine el al.. 1978a: Andreani et al.. 1982) increase 111 Clq-IC in diabetics with microangiopathy.
When microangiopathy is present, some factors seem to modify the dynamics of formation and
clearance of medium large sized complexes, leading to an increase in circulation of these
macromolecules. These factors do not seem to be directly related to insulin treatment since Clq-IC
were increased both in type I and in type 11 diabetics with microangiopathy (Andreani et al.. 1982).
It has been suggested that impairment of phagocytosis, described 111 patients with microangiopathy
(Drivas & Wardle. 1978; Bagdade. 1976), might result in an increase ofcirculating macromolecules
Indeed it was recently reported that diabetic patients with an impaired phagocytic clearance also
has e an increase in circulating Clq-lC (Iavicoh et al.. 1982). It can be accepted that in diabetics with
microangiopathy an impairment of the phagocytic system leads to an increase in heterogeneous
complexes, mainly in the range detected by ClqSI*. and masks any correlation between Clq-IC and
InsAb.
When Kg-IC results are evaluated, there is a trend for the presence of Kg-IC to go with medium
high levels of InsAb (especially when microangiopathy is absent) An association between Kg-IC
and InsAb has been recently reported in diabetics with less than 1 year's diabetes (lavieoli et al..
1983). Likewise, Kg-IC are higher in type I diabetics irrespective of the presence ofmicroangiopathy
(Andreani el al.. 1982). It appears that KgBt detects immune complexes which are somehow related
to the presence of InsAb rather than to the occurrence of diabetic microangiopathy. The
explanation of this correlation is not obvious. Kg-IC are usually large complexes that fix the
complement and therefore very dilferent from most insulin anti-insulin complexes. It cannot be
excluded that KgBt reacts with some monomeric immunoglobulins, when present in a very high
concentration, as we have seen in experimental conditions (unpublished personal observations).
The levels of InsAb in these patrehts were not associated with the presence ofmicroangiopathy. This
is quite in keeping with the similar lack of association between Kg-IC and microangiopathy
In this study there is 110 clear evidence of the influence of heterologous insulin treatment on
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diabetic microangiopathy. To some extent this result was expected. If insulin treatment has any
influence on the course of complications through immune mechanisms (i.e. the formation of
insulin anti-insulin complexes), the insulin binding capacity is not the best tool for investigating
this problem. Insulin antibodies vary widely in avidity and form complexes with different
pathogenetic significance. The methods for detecting InsAb usually available, and particularly
those used in this investigation, give information on the amount, and not the avidity, of the
antibody and measure mostly free antibodies. It is not therefore surprising that the sole
immunological phenomenon found in association w ith the presence of severe diabetic microangio¬
pathy is the increase of immune complexes detected by the solid phase CI q radioimmunoassay. The
question as to whether heterologous insulin treatment might influence microangiopathy is related to
two other questions: does insulin treatment give rise to complexes ofpathogenic significance, and do
these complexes and the Clq-IC chronically accumulated and deposited in the small blood
vessels play a role in aggravating local tissue damage.'
We are indebted to C. Tiberti, I Ma//ei, and G Roinani for the skilful technical work and to P. Henley for the
excellent secretarial assistance.
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CIRCULATING IMMUNE COMPLEXES IN DIABETICS:
THE INFLUENCE OF SEX, AGE, DURATION OF DISEASE
AND TYPE OF TREATMENT
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lCattedra Endocrinoloyia, University o) Rome. Italy.
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SUMMARY The influence of sex, age, duration of diabetes and type of antidiabetic treatment on
soluble immune complexes levels was investigated in the sera of 276 randomly selected diabetics.
Immune complexes were detected by the solid phase Clq binding test.
The prevalence of immune complexes was significantly higher in insulin treated than in non-insulin
treated diabetics. Within the insulin treated group, the prevalence in diabetics of 11 20 yr duration was
significantly higher than in the remainder. No difference in immune complexes levels was found
between males and females. The age of the patients did not have any correlation with the levels of
immune complexes.
These findings suggest that some of the immune complexes detected in randomly selected diabetics
are related to insulin treatment, reflecting either differences in the type of diabetes or the effects of
heterologous insulin.
Introduction
Circulating immune complexes (AgAb) were reported
to be increased in diabetics, especially in those who are
type I insulin dependent near diagnosis (1) and patients
with severe microangiopathy (2). The role of immune
complexes in the disease and especially in relation to
the vascular and renal complications is still contro¬
versial and further studies are necessary. The techniques
presently available for the detection of AgAb do not give
information on the antigen(s) involved and do not differ¬
entiate between immune complexes involved in a specific
disease process and those present also in clinically normal
subjects. Thus it is relevant to study the influence of the
many variables and factors that could influence the levels
of AgAb and it is necessary to compare the results with
those of a large group of clinically normal subjects (3).
In this study we have investigated the influence of sex,
age, duration of disease and type of antidiabetic treat¬
ment (insulin or oral agents) on AgAb levels.
Materials and Methods
Two hundred and seventy-six diabetics attending the Diabetic Clinics
of Rome and of Edinburgh were selected at random. One hundred and
forty-seven were males and 129 were females. Twenty-five diabetics
Correspondence: U. Di Mario. Clinica Medica 2 (Endocrinologiu).
Policlinico Umberto 1.00161 Rome. Italy.
were less than 20 years old. 42 were in the third decade, 29 in the fourth.
32 in the fifth, 53 in the sixth and 95 were more than 60 years old. In 67
patients the duration of diabetes was between 1 and 5yr. whereas in 61.
62, 42 and 44 patients the duration of diabetes was between 6 and 10,
II 15, 16 20 and oxer 20yr, respectively. One hundred and forty-eight
were treated w ith insulin at the time of the study and 128 with diet or
oral hypoglycaemic agents. Insulin treated patients received ordinary
commercial insulins (Lente, NPH, crystalline). None of those was
treated with purified insulins.
One hundred and thirty blood donors were included in the study as
normal controls
Circulating AgAb were assayed by the solid phase Clq binding test
according to Hay el al. (4) with minor modifications (5). The limit of
positivity was chosen as the 90th percentile of blood donor values (6).
The Chi square lest w as used for the statistical analysis of the results.
Results
AgAb levels were above the limit of positivity in 65 out of
the total 276 diabetics studied and in 13 out of the 130
blood donors. Therefore AgAb were significantly in¬
creased in the diabetics (p < 0 002).
Among the diabetics, AgAb were present in 24-5 % of
males and in 22-5 °„ of females.
When the diabetics were divided according to age.
there was no significant difference in AgAb levels (table
1(A)).
When the duration of diabetes was taken into account
considering all the patients together, there was no signifi¬
cant correlation between AgAb and duration of disease
(table 2(A)).
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Table 1 The influence of age on AgAb
Age ufpatients (years)
<20 21-30 31-40 41-50 51-60 >60
(A)
No. of patients 25 42 29 32 53 95
AgAb positive 8 12 7 11 11 16
(B)
Insulin treated (no.) 25 37 26 16 24 20
AgAb positive 8 12 6 7 5 7
, Non-insulin treated (no.) 0 5 3 16 29 7S
AgAb positive 0 0 14 6 9
Table 2 The influence of the duration of diabetes on AgAb
Duration oj diabetes (years)
1-5 6-10 11-15 16-20 >20
(A)
No. of patients 67 61 62 42 44
AgAb positive 15 13 16 13 8
(B)
Insulin treated (no.) 36 32 24 26 30
AgAb positive 9 7 11* 12* 6
Non-insulin treated (no.) 31 29 38 16 14
AgAb positive 6 6 5 1 2
*
p < 0 001 vs the remainder.
However, when patients were divided according to the
type of treatment, insulin treated diabetics showed a
significantly higher prevalence of AgAb compared to the
non-insulin treated diabetics (30% vs 16%, p < 0 005).
The difference in AgAb positivity between insulin treated
diabetics and normal controls was highly significant
(p < 0 0001), whereas the difference between non-insulin
treated diabetics and normals failed to reach statistical
significance (x2 1 -9).
Within the insulin treated group there is a statistically
significant peak in the prevalence of AgAb in diabetics of
11-20 years duration (p < 0 001) (table 2(B), fig. 1(B)),
but there was no correlation with the age of patients.
Discussion
In this study on a randomly selected population of




no of patients 110 70
1-5 6-10 11-15 15-20 >20
36 32 24 26 30
Fig. I. The prevalence of AgAb in diabetes. (A) The
percentage positivity for AgAb in recently diagnosed
patients (see text). |B) The percentage positivity tn
diabetics according to the duration ofclinical diabetes.
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treated diabetics in comparison with non-insulin treated
diabetics or normal controls. As the nature of AgAb has
not been analyzed in the present study we can only
surmise as to what the antigen components of these
complexes might be. This correlation between insulin
treatment and AgAb can be explained either as an
intrinsic difference between type I and type II diabetes or
as the effect of heterologous insulin administration. In
some type I diabetics the increase in AgAb positivity may
be explained as a consequence of a genetically deter¬
mined increased immunoresponsiveness to exogenous
agents present in some insulin dependent diabetics (7,8).
On the other hand the administration of exogenous
insulin induces the formation of insulin -anti-insulin com¬
plexes and several clinical and experimental studies have
already shown the presence of these complexes in insulin
treated subjects (9,10).
It is however by no means certain that insulin anti-
insulin complexes are detected by the Clq technique
because of the immunological characteristics of insulin.
Considering the bivalency of insulin, most insulin anti-
insulin complexes tend to be of very small size and so are
not detectable by the techniques which use complement
to reveal circulating AgAb. Only a small proportion
of insulin-anti-insulin complexes form polymers and
aggregates of detectable size. Nevertheless, in a randomly
selected diabetic population it is possible that some of the
antigen-unknown complexes found to be increased may
be a consequence of an increased formation of such
complexes induced by exogenous insulin.
This seems to be true especially when insulin anti-
insulin complexes are formed in antigen excess, whereas
in the presence of antibody excess these complexes are
not detected by the method used. Indeed an inverse
correlation has been found between increasing levels of
insulin antibodies and higher titres of AgAb in randomly
selected diabetics (11).
Within the insulin treated diabetics there is a pro¬
nounced peak in the prevalence of AgAb in diabetics of
11—20yr duration. Thus in insulin treated diabetics it is
possible so far to describe two peaks of AgAb positivity
according to the duration of diabetes. The first peak
in AgAb levels is found within a few days of diagnosis
with a sharp decline in positivity thereafter (fig. 1(A)),
as already reported in Edinburgh insulin dependent
diabetics (5). Since the techniques used to detect AgAb
are antigen non-specific it is likely that the two peaks
in AgAb positivity are due to different types of AgAb.
AgAb in the first peak seem to be part of the immune-
pathological phenomena occurring at diagnosis and are
statistically correlated to the presence of islet cell anti¬
bodies (ICAb). In the second peak AgAb may be inducetj
by other factors even although in that minority of long
standing insulin treated diabetics with persistently
positive ICAb. AgAb were reported to be increased (12).
While the highest titres of insulin antibodies tend to
occur at 9-12 months of insulin treatment, the highest
titres of AgAb in the second peak (as detected by ClqSP)
occurs at 11-20 yr. It is therefore likely that antigens
other than insulin are involved in the second peak of
AgAb.
This conclusion is also supported by the fact that,
when severe microangiopathy is present, AgAb are in¬
creased in insulin as well as in non-insulin treated
diabetics. This suggests that insulin-anti-insulin AgAb
may not be the main component of these complexes, but
that there may be a decreased clearance of miscellaneous
types of complexes resulting from an impaired phagocytic
system (2, 13).
The decline in AgAb positivity in diabetics with more
than 20 yr of diabetes may be explained by the presence
of milder complications in this group of patients or by the '
presence of some insulin treated type II diabetics. This
study shows that the age of p;"ients cannot explain this
decline.
These results, together with our earlier findings, suggest
that a heterologous population of immune complexes is
present in diabetics. A careful selection of patients and
the identification of antigens involved in complexes are
necessary to understand their significance in diabetes.
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SUMMARY Cytoplasmic islet cell antibodies, as detected by anti-IgG (ICAb), and circulating
immune complexes (AgAb), detected by the solid phase Clq test (ClqSP), were evaluated in 153 insulin
dependent diabetics (IDD) at diagnosis and subsequently in 88 of these patients who were studied
prospectively at regular intervals for up to 3 yr. AgAb detected by the conglutinin (KgBt) and Raji cell
(RAJI) techniques were also studied at diagnosis in 34 and 50 diabetics respectively. Normal controls
were included in the AgAb studies. Complement fixing islet cell antibodies (CF-lCAb) were evaluated in
30 randomly selected diabetics both at diagnosis and after 6 months. Viral antibodies (VAb) were
measured in 30 IDD at diagnosis and in 30 matched controls. Insulin antibodies (IBC) were measured 9
months after diagnosis in 35 diabetics and HLA studies (B8 and B15) performed in 115 patients.
In the prospective study the ICAb positivity declined from 50% at diagnosis to 45, 38, 36, 31, 26, 19
and 17 % at 1, 3, 6, 9, 12, 24 and 36 months after diagnosis respectively. CF-ICAb were found tn 30 °0 of
the diabetics at diagnosis and in 23 % at 6 months. All patients with CF-ICAb at diagnosis were ICAb
positive whilst only 47% of patients with ICAb also had CF-ICAb in the serum. AgAb were found at
diagnosis in 35 % of patients by ClqSP (p < 0 001 vs. normals), in 35% by KgBt (p < 0 001) and in
54% by RAJI (p < 0 002). Eighty-four patients were studied at diagnosis by more than one AgAb
method and of these 57% had at least one positive AgAb result. AgAb by ClqSP declined to less than
20% within 6 months of diagnosis. AgAb, as measured by ClqSP and RAJI techniques, correlated with
ICAb at diagnosis whereas there was no correlation with VAb levels, IBC values, nor with the HLA
antigens. There was no correlation between AgAb (Clq) and CF-ICAb. HLA B15 positive patients
tended to form higher IBC levels than B15 negative patients. Thus, AgAb presence seems to parallel
that of ICAb in the early stages of diabetes and both phenomena may be primarily or secondarily
involved in the development of the disease.
Introduction
During the last decade a great deal of evidence has
accumulated to support the role of immunological
phenomena in the pathogenesis of insulin dependent
(Type 1) diabetes mellitus (IDDM) (1-4). Islet cell
damage may be produced by cytotoxic antibodies, harm¬
ful immune complexes, T cells or by K cells. We have
been particularly interested in circulating immune com¬
plexes (AgAb) since Irvine et al. reported, in 1977, their
increased presence in some lDD's at diagnosis (5).
Several sensitive techniques for the assay of AgAb are
presently available including those which utilise Clq,
Raji cells and conglutinin to bind complexes (6, 7). These
methods reveal different types of complexes: Clq detects
Correspondence: Dr. W. J Irvine, Department of Endocrinology/
Immunology, Royal Infirmary, Edinburgh, EH.t 9YW, U.K.
mainly medium sized AgAb in antigen excess through the
Fc portion of immunoglobulin aggregates, w hilst conglu¬
tinin and Raji cells detect large size AgAb near the equi¬
valence point, mostly through the third component of the
complement. The concordance between these techniques
is low (6). The above methods are antigen non-specific
and consequently do not differentiate between complexes
related to specific disease processes and those found in
commoner conditions, such as viral infections. The signi¬
ficance of AgAb in a particular disease must be assessed
following a comparison of the results with those found in
the normal population and the selection of an approp¬
riate limit of positivity (8). Several workers have con¬
firmed the increase of AgAb in different diabetic states
(9-12). The cross-sectional nature of these studies and
methodological differences in AgAb assay may be re¬
sponsible for some apparent discrepancies.
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In this study our aims have been to examine the
humoral immune response in IDDM to endogenous and
exogenous antigens such as islet cells, heterologous
insulin and viruses, and to investigate the presence of
antigen-antibody complexes. The relationship of these
factors with the HLA antigens was also considered. We
have therefore evaluated AgAb and cytoplasmic islet cell
antibodies as detected by anti-IgG (ICAb) in a large
group of IDD's at diagnosis and prospectively at
intervals up to 3yr following diagnosis. In view of the
possible heterogeneity of AgAb in diabetes, immune com¬
plexes were detected by three different techniques: the
solid phase Clq binding test (ClqSP), the Raji cell radio-
immune assay (RAJI) and the conglutinin binding assay
(KgBt). Complement fixing islet cell antibodies (CF-
ICAb) at diagnosis and after 6 months, viral antibodies
(VAb) at diagnosis, insulin antibodies (IBC) at 9 months
after diagnosis and HLA antigens B8 and B15 were also
evaluated in a number of these patients.
Materials and Methods
One hundred and fifty-three newly diagnosed, insulin dependent
diabetics attending an adult clinic were studied within 2 days of
diagnosis and of these 88 consecutive patients were studied prospec¬
tively for up to 3 yr following diagnosis. Details of the patients are
show n in Table I
ICAb were evaluated in all diabetics at diagnosis and in 88, 79. 76, 68.
57, 31 and 6 patients at 1, 3, 6, 9, 12, 24 and 36 months after diagnosis
respectively. AgAb (Clq) were also measured in all patients at diagnosis
but only in 52, 58, 51. 58. 53, 29 and 5 patients at the above intervals.
CF-lCAb were evaluated in 30 randomly selected diabetics both at
diagnosis and after 6 months. AgAb (Kg) and (RAJI) were studied at
diagnosis in 34 and 50 insulin dependent diabetics, respectively. A
group of normal controls were,included in the AgAb studies for the
detection of the limit of positivity as described below.
Viral antibodies were assayed in 30 insulin dependent diabetics at
diagnosis and in 30 age and sex matched normal controls residing in the
same geographical region. Samples from the matched pairs of subjects
were obtained w ithin 7 days of each other.
Insulin antibodies were measured 9 months after diagnosis in 35
diabetics treated with highly purified ("monocomponent") insulins
from diagnosis. Ill A B8 and B15. representing the two HLA diabeto¬
genic series, were evaluated in 115 insulin dependent diabetics.
Detection of Islet Cell Antibodies
ICAb were delected as previously described by indirect immuno¬
fluorescence on human pancreatic cryostat sections using antihuman
IgG conjugated with fluorescein isothiocyanate (13). CF-ICAb were
detected by an indirect immunofluorescence test using fresh comple¬
ment and anti C3 conjugated with fluorescein isothiocyanate (14).
Detection of Immune Complexes
Solid phase Clq radioimmunoassay (ClqSP). Clq was purified
according to Yonemasu and Stroud (15). The assay was carried out as
described by Hay (16) with minor modifications. '*!I labelled Staphy¬
lococcal protein A was used to detect AgAb fixed to Clq coated tubes.
Protein A was labelled according to Dorval et al. (17). One hundred and
eighty-five blood donors were included in the study for the detection of
the limit of positivity as described elsewhere (8, 18).
Cony/utinin hindiny test [KyBt). Conglutinin was purified and the
test performed according to Casali et al. (19). ,251 labelled protein A
was used to reveal conglutinin bound complexes. One hundred and five
blood donors were tested for the evaluation of the limit of positivitv 18,
18).
Ra/i Cell Radioimmunoassay [RAJI)
Raji cells were used to detect AgAb by a minor modification of the
technique of 1 hcoplulopoulos et al. (20). Raji cell bound AgAb were
detected by the addition of '-51 labelled Staphylococcal protein A. The
limit of positivtt> was calculated to be 20pg AHG (aggregated human
immunoglobulin GI eq ml on the basis of the results of 68 blood donors
(8).
Detection of I trus Antibodies
Inactivated sera (56°C for 30min) were tested in a microtitre assay for
complement fixing antibodies to chlamydia and to a number of viruses
and viral antigens, namely coxsackie B1 6. influenza A and B. adeno¬
virus. respiratory syncytial, measles, mumps S and V, herpes simplex
and varicella zoster. Sera were screened at a dilution of 1 32 with
3 HDjr guinea pig complement. Sera positive at 1 :32 were titrated
at further two-fold dilutions to 1:512. Antibodies to coxsackie viruses
Bl 6 were estimated in a quantal neutralisation test 100 TC!DS0 of
each virus was reacted with serum dilutions and inoculated into virus
cell cultures in tubes. End points were determined by low power micro¬
scopy of the viral cytopathic effect. All sera were negative for hepatitis B
surface antigen by a reverse passive haemagglutination test
Detection of Insulin Antibodies
1BG was evaluated according to the method ofOrtved Andersen (21)
as modified by MustalTa (22).
Statistical Analysis
The Chi-squared (2x2) test ("X") with Yates's correction. Fisher's
test ("F") and Cox's test for trend ("C") were used in the analysis of the
results.
Table 1 Details of the 153 insulin dependent diabetics studied
ICAb status So. of Sex Aye al diaynosis Assoc iated
Study al diaynosis patients ( °amale) [mean ± S.D.) years autoimmune disease*
Diagnosis and follow up Positive 44 63 6 25-6 ± 15-4 0
Negative 44 75 0 24 8 ± 14 5 2
Diagnosis alone Positive 24 417 19 4 ± 9 8 0
Negative 41 63 4 23 7 ± 12-0 0
10
* Thyroid disease in all cases.
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Table 2 Islet cell antibody status of the 88 insulin de¬
pendent diabetics studied prospectively from diagnosis
T ime ajler No. of No . ICAb
Diagnosis patients positive (%)
Diagnosis 88 44 (50%)
1 month 88 40 (45%)
3 months 79 30 (38%)
6 months 76 27 (36%)
9 months 68 21 (31%)
1 year 57 15 (26%)
2 years 31 6 (19%)
3 years 6 1 07%)
Results
ICAb
ICAb were found in 68 of the 153 insulin dependent
diabetics studied at diagnosis (table 1). Forty-four (50"„)
of the insulin dependent diabetics studied prospectively
were ICAb positive at diagnosis, the presence of ICAb
declining to 45, 38, 36, 31, 26, 19 and 17% at 1, 3, 6, 9, 12,
24 and 36 months after diagnosis respectively (table 2).
CF-lCAb
CF-lCAb were found in 30% of the diabetics at
diagnosis and in 23 % at 6 months. All patients with CF-
ICAb at diagnosis were ICAb positive whilst only 47 % of
patients with ICAb also had CF-ICAb in the serum.
AgAb
ClqSP. AgAb (Clq) were found in 54 of the 153
insulin dependent diabetics studied at diagnosis
(p < 0 001 vs. normals, "X"). Twenty-nine of the 65
insulin-dependent diabetics studied at diagnosis alone
and 25 (28%) of the 88 studied prospectively had AgAb
(Clq) in their serum at diagnosis. In the prospective
study the AgAb (Clq) positivity declined to 25%
(p < 0 01 vs. normals, "X"), 22% (p < 0 02, "X"), 17%
(n.s., "X"), 19%, 17%, 17% and 0% after 1, 3, 6, 9, 12, 24
and 36 months from diagnosis respectively.
KgBt. AgAb (Kg) were found in 12 of the 34 diabetics
studied at diagnosis (p < 0 001 vs. normals, "X").
RAJI. AgAb (RAJ I) were found in 27 of 50 diabetics
studied at diagnosis (p < 0 002 vs. normals, "X"). Eighty-
four patients were studied at diagnosis by more than one
AgAb method and of these 57 % had at least one positive
AgAb result.
ICAb vs. AgAb. \ significant correlation between the
presence of AgAb, as detected by ClqSP, and the occur¬
rence of ICAb was found in IDDM at diagnosis
(p < 0 001, "X") (fig. 1). Fifty-four percent of the ICAb
positive insulin dependent subjects and 20 % of those
without ICAb showed AgAb in their serum at diagnosis.
AgAb (RAJI) were also significantly increased in ICAb
positive diabetics (p < 0 02, "F") but there was no signi¬










Fig. I. A comparison of the results of ICAb and AgAb It'lql studies in insulin dependent diabetics at
diagnosis and during the 12 months following diagnosis.
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Fig. 2. A comparison of the scrum viral antibody titres in 30 insulin dependent diabetics at diagnosis and
in 30 matched controls.
CF-ICAb vs. AgAb (Clq). There was no significant
correlation between CF-ICAb and AgAb (Clq) either at
diagnosis or after 6 months ("X").
Viral Antibodies
There was no significant difference ("F") in the pre-
Table 3 Antibodies to Coxsackie B(l-6) correlated with AgAb (Clq)






No. ofpositivesT iires No. ofpatients
< 32 * 6 0 5
32 —64t 14 4 3
3= 128 ) 10 2 6
* Coxsackie B 1-6 titres all < 32.
t One or more of the Coxsackie B 1-6 titres — 32-64.
X One or more of the Coxsackie B 1-6 titres > 128,
sence or titre of VAb between the diabetics and the con¬
trols studied (fig. 2). No correlation was found between
VAb presence and AgAb or ICAb positivity at diagnosis
(table 3).
Insulin Antibodies
The mean (± S.D.) IBC value was 33 6 (±46-4)
pU/ml. No correlation was found between the IBC levels
at 9 months after diagnosis and the presence, both :
diagnosis and after 9 months, of ICAb or AgAb (table 4).
HLA Antigens
Forty-six percent of the insulin dependent diabetics
were HLA B8 positive and 15% were HLA B15 positive.
No correlation was found between these two diabeto¬
genic series and the presence of ICAb, AgAb or VAb at
diagnosis. HLA B15 positive patients tend to form signifi¬
cantly higher IBC levels than B15 negative patients
(p < 0 05, "C") (table 5).
Table 4 Insulin antibodies, measured 9 months after diagnosis, correlated with the presence of AgAb
(Clq) and ICAb in the serum at diagnosis and at 9 months after diagnosis
IBC AyAbiClq) ICAb
kUlues No. of At At At At
(pU/ml) patients diagnosis 9 months diagnosis 9 months
<10 17 7 3 7 6
to-50 13 7 4 8 6
>50 5 3 1 2 1
12 BORSEY tt at.
Table 5 HLA B8 and B15 correlated with serum levels of ICAb, AgAb, VAb and IBC
No. of HLA B8 HLA B15


















































































































The increased presence of circulating immune complexes
in Type 1 diabetics at diagnosis is confirmed by this large
study. Immune complex positivity tends to decline
rapidly following diagnosis and within only a few months
their prevalence is near to that found in the normal popu¬
lation. The methods used to assay AgAb differ in principle
and detect different types of complexes. However, with all
techniques employed, the increased prevalence of com-
plexed immunoglobulins is similar and complexes are
detected that can lead to tissue damage by activating the
complement system and by binding to cells with Fc or C3
receptors on their surface. Thus, we have shown that a
heterogenous group of potentially harmful complexes is
present at the time of diagnosis of Type 1 diabetes.
ICAb were found in approximately half of our newly
diagnosed diabetics. This prevalence is similar to that
which we have reported previously (13, 23) but lower
than that reported by other workers (24, 25). The older
age of our patients and our decision to define as negatives
all doubtful results may account for this apparent
discrepancy. There is a need to standardize the detection
of ICAb since differences in the substrate and in the
methodology have sometimes resulted in poorly repro¬
ducible findings.
It has been reported that antibodies to certain viruses
are increased in Type 1 diabetics at diagnosis (26). How¬
ever, in epidemiological studies, where the parameter
being investigated is also p sent in the normal popu¬
lation, there is often difficulty in selecting an appropriate
control group. In our viral studies, we matched each
diabetic with a normal subject of the same age and sex
who resided in the same geographical area. The diabetic
and the control subjects were sampled within the same 7-
day period to exclude differences resulting from the
seasonal variation of viral infections in the community.
Although the antibody positivity to certain viruses
appeared high in the diabetic patients there was no signi¬
ficant difference from the results obtained in the control
group (fig. 2) and the findings simply reflect the viruses
prevalent at the time of sampling.
This finding is not unexpected since it is likely that only
in a very few cases does an overwhelming viral infection
produce rapid beta cell necrosis. In other cases, a viral
infection of the islets may trigger an autoimmune
reaction against the islets which in turn produces beta cell
damage and leads to the development of diabetes
HUMORAL IMMUNITY IN TYPE 1 DIABETES MELLITUS 13
months, or even years, after the initial infection. However,
viral antibodies, which represent a positive reaction by
the body against an aggressive agent, may not be the
most appropriate phenomena to study since our aim is to
determine why the host fails to cope adequately with a
viral attack and thereby sustains beta cell damage.
Insulin antibody levels generally increase slowly from
the time insulin therapy is commenced and assume a
steady level after several months. 1BC levels were normal
or only modestly elevated in our patients despite their
estimation 9 months after diagnosis. This finding can be
explained by the use of purified insulins alone in the
patients studied. Furthermore, a correlation between
AgAb (Clq) and IBC was not expected since AgAb pre¬
sence tends to decline after diagnosis in contrast to IBC
levels. AgAb seem to reflect other phenomena occurring
at diagnosis more than the presence of circulating anti¬
bodies to insulin and viruses.
This study has demonstrated a tendency for HLA B15
positive patients to form significantly higher IBC levels
than B15 negative patients. This genetic predisposition
for some patients to produce higher amounts of insulin
antibodies is in accordance with previous work (27-29).
It is well recognised, at least in animals, that the major
histocompatibility genes are very close to genes that re¬
gulate the immune response and, in particular, the T-cell
mediated response. In our patients, this genetic influence
was apparent only in the response towards therapeutic
insulin since there was no correlation between AgAb,
ICAb and VAb measured at diagnosis and HLA types.
The lack of correlation between ICAb at diagnosis and
HLA types confirms our previous findings (30).
Immune complexes (Clq, RAJI) were correlated with
the occurrence of ICAb at diagnosis but not with the
other antibodies studied. Thus, it would appear that
AgAb and ICAb are related and that, the presence of
AgAb at diagnosis does not simply reflect a recent viral
infection. This is supported by previous reports of a
strong correlation between ICAb and immune complexes
in insulin-dependent diabetics with persistent ICAb (31)
and in newly diagnosed non-insulin dependent diabetics
(32). In the present context, the CF-ICAb studies did not
provide any additional information regarding the
immunological mechanisms which are operative at, and
soon after, the onset of IDDM.
It is possible that AgAb and ICAb have separate roles
in the early stages of Type 1 diabetes or that they may be
involved together, either primarily or secondarily. Com¬
plexes may reflect damage to the islets and be present
near the clinical onset of the disease together with other
immune phenomena such as ICAb. Medium or large size
antigen-antibody complexes, that fix complement and
react with cells having surface receptors for Fc or C3, may
produce cell damage either directly or by interacting with
specific T-cell subpopulations. AgAb, if present in anti¬
body excess, may arm K cells against a specific antigen(s)
in or on the pancreatic islets and thereby result in the
development of diabetes mellitus. The correlation be- :
tween the presence ofAgAb and ICAb in the serum, at the
time IDDM is diagnosed, suggests that some of the AgAb
may be comprised of I.C. Antibody/I.C. Antigen. '
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Summary. In 41 Type 1 (insulin-dependent) diabetic patients,
islet cell antibodies, anti-insulin antibodies, and immune com¬
plexes measured by two different methods (the Clq solid
phase assay and the conglutinin binding test) were studied at
diagnosis, and the influence of treatment with insulins of dif¬
ferent purity was investigated during the first year of treat¬
ment. Twenty subjects were treated with conventional insulins
(group 1) while 21 were treated with monocomponent porcine
insulins (group 2). The prevalence of islet cell antibodies sig¬
nificantly decreased during the 12-month study period in the
41 patients. From the first month anti-insulin antibodies were
always significantly higher in group I than in group 2. At diag¬
nosis the prevalence of both types of immune complexes in
the 41 patients was higher than in normal subjects. The im¬
mune complexes measured by the Clq solid phase method
showed a significant and progressive reduction during the fol¬
low-up period, whereas the immune complexes assayed by
conglutinin showed no significant variation in the same peri¬
od. The presence of Clq immune complexes was found to
correlate with the occurrence of islet cell antibodies both at di¬
agnosis and during the follow-up period. The presence of con¬
glutinin immune complexes, on the other hand, tended to par¬
allel the increase of anti-insulin antibody levels.
Key words: Type 1 diabetes, anti-insulin antibodies, islet cell
antibodies, immune complexes, Clq solid phase assay, con¬
glutinin binding test, monocomponent insulins.
Islet cell antibodies, anti-insulin antibodies and im¬
mune complexes have been demonstrated in the sera of
diabetic subjects. Islet cell antibodies have been found
in Type 1 (insulin-dependent) diabetic patients at diag¬
nosis and in non-diabetic patients with other autoim¬
mune diseases. The role of these antibodies in the pa¬
thogenesis of Type 1 diabetes remains to be elucidated
[1-3]. Anti-insulin antibodies are present in most insu¬
lin-treated diabetic patients. It has been established that
anti-insulin antibodies may play a role in the transient
complications of insulin treatment (i.e. allergic reac¬
tions, insulin resistance, etc.), whereas no influence on
late diabetic complications has yet been demonstrated
[4-9].
It has been suggested that the presence of islet cell
and anti-insulin antibodies in the circulation may re¬
flect the presence of circulating immune complexes [10,
11]. Circulating immune complexes have been des¬
cribed in a large percentage of Type I diabetic patients
at the time of diagnosis [12] and in some cases with se¬
vere complications [13]. Detection methods based upon
different principles have also revealed the presence of
heterogeneous populations of immune complexes [14,
15]. A correlation was recognized in some of these stud¬
ies between immune complexes detected by the solid
phase Clq binding test and the presence of islet ceil
antibodies [16], whilst in others a correlation appeared
to exist between immune complexes detected by con¬
glutinin binding assay and insulin treatment [ 17],
The present investigation was carried out in a group
of patients at the time of clinical diagnosis of Type I
diabetes. These patients were treated with either con- |
ventional insulin or monocomponent insulin and were
observed at regular intervals for one year.
The aim of the present study was to attempt to corre¬
late circulating immune complexes (detected by Clq '
and conglutinin) and the presence of islet cell and anti-
insulin antibodies, bearing in mind the type and dura¬
tion of the diabetes and antigenicity of the insuiin used
in the treatment.
Patients and Methods
Forty-one newly diagnosed Type I diabetic patients, with age at onset
< 30 years, were included in the study before insulin treatment was
started. Twenty of these patients (12 males and eight females, mean
0012-186X/83/0024/0026/S01.00
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Table I. Anti-insulin antibodies in Type 1 diabetic patients at diagno¬
sis and during 1 year's treatment
Duration of treatment (months)
1 3 6 12
Group 1
Group 2
0.8 ± 0.8a 1.7 ± 1.5h 1.8 ±1.9"
0.08 ±0.11 0.3 ±0.4 0.3 ±0.5
1.9 ± l.3h
0.2 ± 0.3
Results are presented as mean ± SD:'1/' < 0.02; h/> < O.CK) 1
Table 2. Immune complexes assayed with Clq solid phase method
and with conglutinin binding lest in Type 1 diabetic patients at diag¬
nosis and during 1 year's treatment
Duration of treatment (months)
0 t 3 6 12
Clq solid phase method
Group 1 9/20 5/17 4'16 2/18 3/20
Group 2 10, 21 6/19 3/15 3/19 2/20
Total . 19/41 11 '36 7/31 5/37 5/40
P < 0.01
Conglutin binding test
Group 1 6/20 6/17 6/17 7/19 8/20
Group 2 6/21 4/18 5/18 7/18 4/20
Total 12/41 10/35 11/35 14/37 12/40
Results are presented as positive/total subjects
age 9 years, range 5 11 years) were treated with conventional insulins
(group I), whereas 21 (15males and six females, mean age 13years,
range 8 -22 years) were treated with monocomponent porcine insulins
(group 2). Patients were randomly assigned to each group. Blood sam¬
ples were collected at diagnosis and I, 3, 6 and 12 months later in all
patients.
A series of 189 blood donors was also studied to determine the
normal range of the immune complex assays. Islet cell antibodies
were assayed by indirect immunofluorescence on cryostal sections of
blood groupO human pancreas. The presence of islet cell antibodies
was evaluated by two independent observers using a Leitz Dialux mi¬
croscope.
Anti-insulin antibodies, evaluated as insulin binding capacity,
were measured by an immunoelectrophoretic method (18); the sensi¬
tivity of the method is 0.05 mU/ml. the interassay variation 3'V
Immune complexes were determined by the Clq solid phase
method according to Hay et al. [19] and by the conglutinin binding
test according to Casali et al. (20). The characteristics of the methods
are described elsew here [21],
The x1 'est. Fisher's exact test. Cox's test. Student's t-test for inde¬
pendent variables and the binomial test were used for statistical evalu¬
ation of the results.
Results
Islet cell antibodies were detected in 19 of the 41 diabet¬
ic patients at diagnosis (46" n). During the follow-up pe¬
riod their prevalence decreased progressively to 10% af¬
ter 12 months. This decrease was statistically significant
(p < 0.001). No difference in occurrence of islet cell
antibody was found between the two groups of patients.
Anti-insulin antibodies were detectable after the first
month of treatment, being significantly higher in
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Fig. 1. Prevalence of immune comp'exes assayed with Clq solid phase
method (■ •) and with conglutinin binding test (• • ) and
of islet cell antibodies (•---•) in 41 Type 1 diabetic patients at diag¬
nosis and during I year follow-up
group I than in group 2 at each stage of follow-up
(Table 1).
Clq immune complexes were present in 19 of the
41 diabetic patients at diagnosis (46%) and progres¬
sively decreased thereafter (Table 2). Prevalence at
12 months' follow-up was 12%. This decrease was statis¬
tically significant (p < 0.01). No difference was found
between groups 1 and 2. Conglutinin immune com¬
plexes were present in 12 of the 41 diabetic patients at
diagnosis (29%), prevalence varying during follow-up
from a minimum of 26% to a maximum of 38"o (NS)
Although at 12 months the prevalence was 40% in
group 1 and 20% in group 2. the differences between the
two groups were not significant.
Islet cell antibodies and Clq immune complexes
showed similar decreases in frequency from diagnosis
to 12 months in all patients together and in the two
groups examined separately. Clq immune complexes
were detected in 58% of the 19 islet-cell-antibody-posi¬
tive subjects at diagnosis. The agreement between the
two tests (both positive and negative) was significant
(I month p < 0.05, 6 months p < 0.001, 12 months p <
0.001).
Islet cell antibodies and conglutinin immune com¬
plexes showed different profiles during follow-up
(Fig. 1). Analysis of the relationship between these two
immunological factors demonstrated a difference in
prevalence at diagnosis (46% versus 29%), and only four
out of the 19 islet-cell-antibody-positive subjects also
showed conglutinin immune complexes. No significant
agreement was found between the two tests.
No significant correlation was found between Clq
immune complexes and anti-insulin antibodies, either
in the 41 diabetic patients or in groups 1 and 2 consid¬
ered separately. The presence of conglutinin immune
complexes, on the other hand, showed a tendency to
parallel the increase in anti-insulin antibody levels in
the 41 diabetic patients (p < 0.001). This trend was still
present when the two groups were examined separately
(p < 0.001). However, whereas in group 1 maximum
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prevalence of conglutinin immune complexes (85%)
was reached when anti-insulin antibody levels were
above 2mU/ml (p < 0.002), the maximum (75%) in
group 2 was reached at lower anti-insulin antibody
levels (0.5-2 mU/ml) (p < 0.002).
Discussion
These results demonstrate a correlation between Clq
immune complexes and islet cell antibodies, and be¬
tween conglutinin immune complexes and anti-insulin
antibodies, whereas no correlation was found between
Clq immune complexes and anti-insulin antibodies or
between conglutinin immune complexes and islet cell
antibodies. Furthermore, Clq and conglutinin probably
detect different populations of immune complexes.
It is possible that islet cell antibodies and Clq im¬
mune complexes are present at the time of diagnosis in¬
dependently of each other and are different expressions
of the immune response to the same aetiological agent;
on the other hand, the correlation between Clq immune
complexes and islet cell antibodies observed in the pres¬
ent study suggests that the islet cell antibodies might cir¬
culate in the form of soluble complexes bound to anti¬
gens of islet origin. In this case immune complexes de¬
tected by Clq assay at diagnosis may be a reflection of
such a phenomenon.
Of interest in the present study is the relationship
observed between conglutinin-immune complexes and
insulin binding capacity. We have demonstrated previ¬
ously a relationship between this type of immune com¬
plex and insulin treatment [17]: these complexes were
significantly more frequent in patients treated with in¬
sulin than in others [21], The present data, showing the
existence of a significant trend in the prevalence of cir¬
culating conglutinin-immune complexes with increas¬
ing levels of insulin binding capacity, appear to suggest
that the conglutinin method detects insulin-anti-insulin
complexes present in diabetic patients following treat¬
ment. On the other hand, assay of immune complexes
using conglutinin could be affected by the anti-insulin
antibodies and by the aggregates of these antibodies.
It is more difficult to offer an explanation for the ob¬
servation that the relationship between conglutinin-im¬
mune complexes and the levels of insulin binding ca¬
pacity in patients treated with conventional ir.sulins
(group 1) differs from that in patients treated with mo-
nocomponent insulins (group 2). It would, in fact, ap¬
pear that while the former tend to produce immune
complexes at high levels of insulin binding capacity, the
latter form these complexes at low or medium levels of
insulin binding capacity.
This finding may be due to the difference in
immunogenicity of the two types of insulin. Even
though because of their purity, monocomponent insu¬
lins produce low overall levels of insulin-binding capac¬
ity, the antibodies induced have a relatively high affinity
for insulin. In contrast, conventional insulins, which
contain extractive polypeptides with a greater molecu¬
lar weight and immunogenic capacity than pure insulin,
tend to produce larger families of antibodies only some
of which display marked affinity for insulin, even
though all may be detectable as insulin binding capacity
by Christiansen's method [4, 8].
It is thus possible that for the same insulin-binding
capacity level, patients treated with monocomponent
insulin produce a larger quantity of specific complexes
than those using conventional insulins.
In conclusion, the present findings confirm the pres¬
ence of circulating immune complexes in patients with
Type 1 diabetes mellitus, some of which may be relat¬
ed to factors present at diagnosis, others to anti-insulin
antibodies.
On the other hand conglutinin-immune complexes
might provide a useful method with which to follow the
pathological events associated with circulating anti-in¬
sulin antibodies.
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Immune Abnormalities in Diabetic Patients
Not Requiring Insulin at Diagnosis
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Summary. Islet cell antibodies (ICA), complement fixing islet
cell antibodies, immune complexes and thyro-gastric auto¬
antibodies were studied in newly diagnosed diabetic patients
not requiring insulin at diagnosis. Particular attention was lo-
cussed on that minority of patients who are initially treated
with diet or oral agents but show K'A in their serum. One
hundred and six non-insulin-requiring patients were studied
at clinical diagnosis. Seventeen who had ICA in their serum
were compared with a control group of 89 who did not. The 17
ICA-positive diabetic patients were followed serologically for
approximately 1 year from diagnosis. Patients were followed
clinically for 3 years. Forty-seven percent of ICA-positive and
19% of ICA-negative patients had immune complexes in their
serum. Eleven of the 17 ICA-positive patients also had serum
complement fixing islet cell antibodies. Thyro-gastric anti¬
bodies were found in 29% of ICA-positive and 18% of
ICA-negative diabetic patients. ICA, complement fixing an¬
tibody and immune complex positivity declined with time.
Ten of the 17 ICA-positive and two of the 89 ICA-negative
patients required insulin within 3 years of diagnosis. There
was a positive trend for the presence of complement fixing
islet cell antibodies at diagnosis to be associated with the early
development of insulin dependency. The type of diabetes in
ICA-positive patients not requiring insulin at diagnosis has
strong immunological and clinical similarities to classical
Type 1 (insulin-dependent) diabetes.
Key words: Type 1 diabetes. Type 2 diabetes, islet cell antibod¬
ies, complement fixing islet cell antibodies, immune com¬
plexes, thyro-gastric autoantibodies.
Circulating immune complexes (AgAb) have been re¬
ported to be present in higher levels in newly diagnosed
Type 1 (insulin-dependent) diabetic patients and to be
correlated with islet cell antibodies (ICA) at and shortly
after diagnosis [1-3]. These circulating complexes may
have a pathogenic role or simply reflect the presence of
ketosis and metabolic derangement in the early phases
of clinical diabetes, which could modify the dynamics
of formation and clearance of AgAb [4],
In this study, we investigated the presence of soluble
AgAb in diabetic patients who did not require insulin at
the time of clinical diagnosis. Particular attention was
focussed on the minority who did not have ketonuria
but showed ICA in the serum at diagnosis. In this rela¬
tively uncommon group of patients, ICA, complement
fixing islet cell antibodies (CF-ICA) and AgAb were
tested at diagnosis and at regular intervals thereafter.
Clinical and subclinical associations with other autoim¬
mune phenomena were studied also.
Our aims were to highlight the presence of AgAb in
patients who were ICA-positive but not ketotic, the
modifications with time of ICA, CF-ICA and AgAb
and the correlation between the presence of ICA, CF-
ICA or AgAb at diagnosis and in the following months
with the tendency to progress to insulin dependency.
Subjects and Methods
Subjects
Over a period of a year most patients newly diagnosed at a few Edin¬
burgh Diabetic Clinics as Type2 (non-insulin dependent) diabetic
subjects, according to the National Diabetes Data Group Classifica¬
tion |5], were tested for ICA at their first attendance. Two hundred and
sixty patients were tested of whom 106 were included in this study: all
those who were ICA-positive (17), together with 89 who were selected
randomly from the newly diagnosed ICA-negative diabetic patients
In the ICA-positive group, there were five males and 12 femaies
with a mean age at diagnosis of 55.4 ±16.1 years. In the ICA-negative
group, 42 were male and 47 were female and the mean age at diagno¬
sis was 61.6 ± 12 years. Two of the 17 ICA-positive and two of the 89
ICA-negative patients had other associated autoimmune diseases
(Hashimoto's thyroiditis, pernicious anaemia and primary hypothy¬
roidism). Almost all the 17 ICA-positive patients could be considered
to have Type 2 a diabetes [5], the median of the ideal body weight be¬
ing 98.5%. No other substantial difference in the symptoms preceding
diagnosis or in the clinical and metabolic signs at the onset of overt
diabetes was noticed between ICA-positive and ICA-negative pat¬
ients.
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Since there are no reports of ICA-negative diabetic patients later
becoming positive, we concentrated our study on the 17 initially ICA-
positive patients; they were followed serologically at regular intervals
for approximately 1 year from diagnosis and serum antibodies were
tested twice, once between 2 and 4 months and again 10 or more
months after diagnosis.
This research was part of a more general study, so that the clini¬
cians did not know the result of the ICA test, at least in the first
months, and in any case ICA status was not among the parameters
taken into account when the decision to put patients on insulin was
taken.
Methods
AgAb were evaluated by the solid phase Clq radioimmunoassay ac¬
cording to May et al. [6), w ith minor modifications. Details of the tech¬
nique used, the limit of positivity, the expression of results and the re¬
producibility of the test have been published previously [1, 7). ICA,
thyroid cytoplasmic and gastric parietal cell antibodies were deter¬
mined by indirect immunofluorescence using fresh frozen cryostat
sections [8,9], CF-1CA were evaluated with the addition of fresh nor¬
mal serum as the source of complement and fluorescein conjugated
anti-C3 antibody [10].
Statistical evaluation was done by x2 test. w'lh Yates' correction




In the ICA-positive patients, ICA were still present in
14 out of 17 between 2 and 4 months after diagnosis and
in 10 out of 16 after 1 year or more of clinical diabetes
(Fig.l).
Immune Complexes
AgAb were found in eight of the 17 ICA-positive dia¬
betic patients (/><0.01 versus normal subjects) and in
16 of the 89 ICA-negative patients (NS versus normal
subjects, p< 0.02 versus ICA-positive patients), both
groups being studied at diagnosis.
Complement Fixing Islet Cell Antibodies
CF-1CA were found in 11 of the 17 ICA-positive diabet¬
ic patients. At the end of the first 3 months, ten patients
were positive; five were still positive 10 months or more
from diagnosis (Fig. 1). None of the patients who were
CF-lCA-negative at diagnosis became CF-ICA-positive
with time.
Thyro-gastric A n tibodies
Autoantibodies to thyroid or to gastric parietal cells,
studied in all the patients at diagnosis, were found in
five of the 17 ICA-positive and in 16 of the 89 ICA-neg¬






0 I I i
A B C
Fig. 1. ICA (• •), CF-ICA (■ ■ ) and AgAb ( A A ) in
the 17 ICA-positive diabetic patients initially treated without insulin,
at diagnosis (A), between the second and the fourth month of the dis¬
ease (B), and after 10 months or more of clinical diabetes (C)
ICA, CF-ICA. AgAb and Clinical Tendency to Progress
to Insulin Dependency
Ten of the 17 ICA-positive and two of the 89 ICA-nega¬
tive diabetic patients required insulin within 3 years of
diagnosis (p< 0.0001), either because of the presence of
ketonuria and/or because of a metabolic derangement
(glycaemia constantly >12mmol/l) non-controllable
with other therapy. When the patients were divided ac¬
cording to tendency to progress to insulin dependency
(Fig.2), five were still on oral hypoglycaemic agents
more than 3 years from diagnosis, six went on to insulin
after 20 months of clinical diabetes, four betw een 6 and
10 months and two died from vascular complications
after 5 and 21 months, respectively. There was a signifi¬
cant trend for the presence ofCF-ICA at diagnosis to be
associated with earlier development of insulin depend¬
ency (/? < 0.05). The occurrence of AgAb and of thyro-
gastric antibodies were not correlated with the tendency
to progress to insulin dependency.
Discussion
While an increased prevalence of immune complexes
has been shown in the serum at diagnosis of Type 1 dia¬
betes (1 -3], this is not the case here w here a substantial
number of randomly selected Type 2 diabetic patients
have been studied at diagnosis and compared with con¬
trol subjects. However, the present study demonstrates
that the prevalence of AgAb is increased in the minority''
of diabetic patients who have ICA in the serum but do
not require insulin at diagnosis or during the first
months of the disease. A correlation between serum Ag--
Ab and ICA has been demonstrated also in Type 1 dia¬
betic patients close to diagnosis [1-3] and in those
Type 1 diabetic patients in whom ICA persists for some
years [11]. The correlation between serum ICA and Ag¬
Ab suggests that islet cell antigen-antibody complexes
may be part of the AgAb detected in the subjects.















Fig.2. 1CA (□), CF-1CA ( Si AgAb (Q) and
tendency to progress to insulin dependency. The
horizontal lines within the rectangular frames indi¬
cate the number of patients. Group I patients
(n = 5) were still on oral h> poglycaemic agents 3
years from clinical diagnosis. Group 2 (n = 6) re¬
quired insulin between 20 and 36 months from di¬
agnosis, Group 3 (n = 4) needed insulin within 10
months and the two Group 4 patients died during
the follow-up study. A, B and C as in Figure 1
Whether AgAb are involved in islet cell damage in these
patients has not yet been established, but they could be
involved in serum cytotoxic activity or they could inter¬
act in several ways with cells which have receptors for
the Fc portion of immunoglobulins or for the third com¬
ponent of complement [12], As our ICA-positive diabet¬
ic patients not requiring insulin at diagnosis were not
ketotic, severe metabolic derangement would not seem
to be a major factor in the development of serum AgAb
in these subjects. Furthermore, hyperglycaemia is un¬
likely to be responsible as an increased presence of Ag¬
Ab was seen in ICA-positive non-insulin diabetic pat¬
ients but not in the majority of patients with Type 2
diabetes.
The present study demonstrates that a small propor¬
tion of apparent Type 2 diabetic patients show the same
immunopathologica! phenomena that occur in classical
Type 1 diabetes at diagnosis; i.e. ICA, CF-ICA and Ag¬
Ab. It has been demonstrated previously that the pres¬
ence of serum ICA in diabetic patients initially treated
with diet and/or oral hypoglycaemic agents is a useful
marker for predicting subsequent insulin dependency
[13], The findings of this study suggest that when serum
CF-ICA are present, the development of insulin de¬
pendency tends to occur earlier. A similar predictive
value for CF-ICA was recently shown by other workers
in different situations, i.e. Type 1 diabetes, relatives of
patients with Type 1 diabetes or patients with autoim¬
mune disorders [10, 14, 15].
ICA-positive diabetic patients, not requiring insulin
at diagnosis, who may also have CF-ICA and AgAb at
diagnosis, clearly do not fit logically into the broad clin¬
ical subdivision of the majority of idiopathic diabetic
patients according to the presence or absence of insulin
dependency [14], At clinical diagnosis. Type 1 diabetic
patients are ketosis prone and have islet cell autoimmu¬
nity. Type 2 diabetic patients classically have neither of
these characteristics. The small group of subjects in¬
cluded in the present study showed no ketonuria and
did not require insulin at diagnosis but had evidence of
islet cell autoimmunity and tended to progress to insu¬
lin dependency. As argued previously [16], the type of
diabetes in ICA-positive non-insulin requiring diabetic
patients should be regarded as a subgroup of Type 1
diabetes, probably representing a stage earlier in th,
same disease process (or group of disease processes)
that tends to culminate in classical Type 1 diabetes.
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Introduction
An important development in the characterization of cell
surface functional antigens has been the development of
monoclonal antibodies. To date more and more speci¬
ficities are described in the scientific literature and no
doubt even more will be found in the future. As an
example, for accurate characterization of T and B lympho¬
cyte subclasses, K./NK cells and activated T cells, at least
10 monoclonal antibodies per blood sample are required.
If a fluorescence activated cell sorter (FACS) is available,
the number of samples poses no problem. At present how¬
ever not man\ researchers can use this facility routinely
and therefore they find themselves in the unenviable
position of spending a great deal of time preparing just a
single slide for each monoclonal antibody.
In this report we describe an adaptation of existing
equipment to facilitate the load of work.
Mati rials and Mi thuds
The equipment consists of Medicell glass-bottomed plates (see lig. 11 in
conjunction with an inverted lluorescence microscope. T he plates, which
are readily available (midktii inti knationai i id. 339 Liverpool
Road, London NI Ilx. UK (since they are routinely used for HLA-DR
tissue typing, are made of a thin sheet of glass, subdivided into 60 Hat
circular areas by raised rings, attached to a plastic frame with an inner
ridge. The plates can be covered with a transparent plastic cover which
fits over the inner ridge of the frame thus effectively reducing the rate of
ev aporation of the cell samples. The latter are placed within the circular
areas where diffusion is prevented by the raised rings. The microscope
stage can be easily adapted to take the plates; alternatively the plates
can be moved along by hand.
The method described is for blood mononuclear cells although it can
be applied to any other cell preparation.
2. Wash cells three times in Phosphate Buffer Saline (PBS). pH 7 3. and
suspend them at a concentration of 2 0 x 10" cell ml in RPMI 1640
medium containing lit heat inactivated foetal calf serum (complete
medium). I I)nil ol this suspension is enough for a panel of up to
10 monoclonal antibodies
3. Divide the cell suspension in 01 0 2ml aliquots into small plastic
centrifuge tubes (10 x 60 mm |.
4. Spin tubes at l.700g for 1 5 nun, preferably in a centrifuge equipped




cells by density gradient ccntrifugation on
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add 50(il of the appropriate monoclonal antibody. Quickly vortex
lubes to suspend cells and incubate for 30min in an ice-bath.
5. Wash cells three limes with PBS at 1,700 g for 1 -5 min then add 50 pi
of the appropriate dilution of fluorescein conjugate antimouse IgG
antibody. Vortex tubes and incubate for 30 min in an ice-bath.
6. Wash cells three times in PBS and finally suspend them in 50 pi of
complete medium.
7. Place 5 pi of each cell sample in a circular area of the Medicell plate
and leave for 3 5 min to allow cells to sink to the bottom.
8. Count the proportion of rim fluorescence positive cells in the
inverted fluorescence microscope.
Comments
The problem of the length of time required to complete
the characterization of mononuclear cells from a single
subject was very acute in our laboratory where a family
follow-up study involved 3-5 subjects at a time with
8 10 monoclonal antibodies. The method described has
now been used for over one year and it has been found
extremely useful. Many of the problems connected with
eye adaptation to dark room conditions are avoided
since the microscope reader does not need to leave the
machine to prepare single slides.
In addition to increasing the number of cell samples
that can be read at any given time, there is the added
bonus that the number of cells required for each mono¬
clonal antibody can be greatly reduced (0-2-0-5xl05
cells). This can be of considerable importance when
phenotyping mononuclear cells from small blood samples,
in particular those from small children and difficult
patients.
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EVALUATION OF CLASS II ANTIGEN POSITIVE T CELLS:
A SIMPLE DOUBLE STAINING METHOD USING
MONOCLONAL ANTIBODIES
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Introduction
Attention of investigators has been recently focused on
that subset of lymphocytes which expresses the class II
(or DR) antigen on their surface. This class II antigen is
a marker of T cell activation and is normally absent on
non-activated or otherwise committed T cells. On the
other hand, this antigen is normally present on the
surface of B cells. The fact that this surface antigen is
present in both B cells and in a few T cells creates some
technical difficulties.
Since the percentage of activated T cells is usually very
low, a method to easily and clearly identify this T cell
subset is needed. Most investigators identify and isolate
T cells on the basis of their ability to form spontaneous
rosettes when incubated with sheep red blood cells (1-3).
This widely used technique is time consuming and not
accurate enough for the evaluation of activated T cells:
some T cells are lost—and a particular subpopulation of
T cells may be preferentially removed — and on the other
hand some B cells still remain in the rosetting-enriched
T population making it difficult to discriminate the
activated T cells from the contaminating B cells. Other
investigators use a double immunofluorescence staining—
using both fluoresceine and rhodamine—to label respec¬
tively the antibody defining the DR antigen and that
defining another antigen either of T or B cells. This
technique is rather tedious and elaborate; the immuno¬
fluorescence pattern is usually faint, the different cells
need to be read with different fluorescence microscope
filters and the results obtained are usually poorer than
expected.
We have devised a straightforward double staining
technique to overcome these difficulties using commer¬
cially available monoclonal antibodies.
Correspondence: Dr. Umberto Di Mario. Caltedra di Endocrinologia 1,
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Method
Immunological or Other Specific Reagents Seeded
Anti-class II antigen monoclonal antibody (this antibody should
not be cytotoxic), anti-total T cell monoclonal antibody (lor instance
Leu la, becton Dickinson orOKT3,orthoDUGNkeihidium bromide,
fresh rabbit complement, rabbit anti-mouse antibody conjugated with
fluorescein. All the monoclonal antibodies are diluted in medium
(RPM1 1640) plus 10",, foetal calf serum.
Procedure
Purify lymphoid cells by density gradient centrifugation;cheek viability
of cells and count them;
- add anti-class II antigen monoclonal antibody (0 05ml appropriate
dilution to 5 x 105 cells); incubate 30min at 4°C and wash twice in
medium;
- add rabbit anti-mouse antibody conjugated with fluorescein; incubate
30min at 4°C and wash twice in medium;
- add a cytotoxic anti-T cell monoclonal antibody (0 05 ml appropriate
dilution) and fresh complement (200pi rabbit or guinea pig com¬
plement after check ing for spontaneous cytotoxicity); incubate 30min
at 37°C;
- add ethidium bromide at a concentration of 50pg ml and read with
a fluorescence microscope, fitted with a filter for fluorescein.
The B cells will appear green on the surface, the class 11 negative
T cells will appear red in the nuclei whereas the class 11 positive T cells
will show a red nucleus and a green surface.
Comments
With the technique described, the difficulties found with
the other methodologies seem to be overcome. Under the
fluorescence microscope it is possible to see clearly the
bright red of the nuclei of the T cells, the green continuous
linear fluorescence of the surface of the B cells and a few
cells with a red nucleus and a fluorescent green surface,
i.e. the class II antigen positive T cells. Both colours
are read with the same filter, i.e. that for fluorescein. The
technique is fast: 3 or 4hr are needed to complete it. No
significant amount of cells are lost with this procedure
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which implies only washings but not separation of cells.
Furthermore the total number of B and T lymphocytes is
easily obtained.
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Semisynthetic Human Insulin:
Biologic and Immunologic Activity in Newly
Treated Diabetic Subjects During
a Six-month Follow-up
m. 1av1coli, m d., u. d1 mario, m.d., o. a coronel., m.d., a. m. dawud, m.d.. p. arduin1, m.d.,
and m. leonarpi, m.d.
Biologic arid immunogenic activities of semisynthetic human monocomponent insulins were examined
in insulin-dependent diabetic patients (group 1). Patients treated with porcine monocomponent (group
2) and conventional (group 3) insulins were studied for control purposes. The patients were examined
before the beginning of insulin treatment and for a 6-mo follow-up period. The data collected during
the study show that insulin antibody levels were significantly lower in group 1 than in groups 2 and
3. Furthermore, the prevalence of immune complexes assays with the Clq solid phase technique failed
to reveal any differences between the three groups. When the conglutinin binding test was used, the
prevalence of immune complexes showed a slight but not significant reduction in group 1 and a significant
increase in group 3. The metabolic control was similar in the three groups during follow-up and the
insulin requirement was lower, but not significantly, in group 1 than in groups 2 and 3. These data
suggest that with human monocomponent insulins equivalent glycemic control may be achieved at
similar doses than those.required with porcine monocomponent insulins. Furthermore, human insulin
is the least immunogenic of the present available insulins, diabetes care 7. 128-1 31, march-april i9Sa
The main problems arising in insulin treatment to¬day are the mode of administration and the typeof insulin to he used. Numerous studies haveshown that purified insulins considerably reduce
the complications occurring with insulin treatment, such as
allergies, lipodistrophy, and resistance.1-5 This improvement
has been attributed to a significant decrease in the amount
of antibodies produced after the injection of the purified
hormone.6 7
The benefits of purified insulin on late diabetic compli¬
cations, particularly those of a microangiopathic nature, are
not yet known. Marked prevalence of circulating immune
complexes in diabetic subjects with severe microangiopathy8
suggests, however, that immune factors may play a role in
the pathogenesis and/or in the evolution of microangiopathy.
The recent production of human insulins, the biosynthetic
human insulins9 and the semisynthetic monocomponent hu¬
man insulins,10 has made available new tools that should lead
to further insight into insulin treatment," especially con¬
cerning the rise in insulin antibodies.
The aim of the present investigation was to study human
monocomponent insulin and its biologic and immunologic
activity, and to draw a comparison with porcine monocom¬
ponent insulins and other conventional types of insulin prep¬
arations.
MATERIALS AND METHODS
Sixty-eight diabetic patients receiving insulin for the first
time were examined. None of these patients had evidence
of other diseases likely to involve the immune system, and
none exceeded 10% of mean body weight values. No preg¬
nant women were included in the series.
Patients comparable for sex, age, and duration of disease
were divided into the following three groups according to
the type of insulin received.
Group 1 (15 subjects). Eight men and seven women com¬
prised group 1 (mean age, 28.?. ± 6.3 yr, mean duration of
diabetes, 4-4 ± 2.1 yr). Ten were newly diagnosed insulin-
dependent diabetic patients (1DDM) and five had been treated
previously with oral antidiabetic drugs. Patients in this group
were treated with human monocomponent insulins; 5 re¬
ceived only the Monotard (Novo Industri, Copenhagen,
Denmark) preparation and 10 the combination Mono¬
tard + Acirapid (Novo).
Group 2(28 subjects). Sixteen male and 12 female subjects
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TABLE 1
Insulin requirement (U/kg/day) in 68 newly treated IDDM from 2 wk to 6 mo after the beginning of insulin treatment
Months
Type of insulin No. of subjects 0" I 2 3 6
Human 15 0.411 0.48 0.44 0.42 0.44
0.03$ 0.03 0.04 0.02 0.05
Porcine 28 0.42t 0.46 0.50 0.43 0.52
0.021 0.04 0.05 0.04 0.03
Consentional 25 0.40t 0.45 0.51 0.55 0.62
0.03$ 0.05 0.05 0.07 0.07
"Fifteen days after the beginning of insulin therapy.
tMean, tSEM.
comprised group 2 (mean age, 22.5 ± 3.3 yr; mean duration
of diabetes, 2.6 ± 1.2 yr). Twenty-one were newly diagnosed
IDDM and seven had been treated previously with oral an¬
tidiabetic drugs. Patients in this group were treated with
porcine monocomponent insulins; 10 received only the Mon-
otard (Novo) preparation and 18 the combination Mono-
tard + Actrapid (Novo).
Group 3 (25 subjects). Fourteen male and 11 female subjects
comprised group 3 (mean age, 214 — 41 yr; mean duration
of diabetes, 3.3 ± 1.4 yr). Nineteen were newly 1DDM and
five had been treated previously with oral antidiabetic drugs.
Patients in this group were treated with conventional insu¬
lins; 9 received only long-acting preparations and 16 the
regular + long-acting.
Blood samples were collected before insulin treatment and
1, 2, 3, and 6 mo after the beginning of insulin treatment.
Serum from blood samples was stored at — 25°C until assay
for (1) islet cell antibodies (ICAb) using the indirect im¬
munofluorescence techniques;12 (2) insulin antibodies (1BC)
following the immunoelectrophoretic method described by
Christiansen11 using a Novo Industri kit; (3) circulating im¬
mune complexes using the solid phase Clq method (CIq-
AgAb) described by Hay et al.14 with minor modifications;15
TABLE 2
Insulin binding capacity (mU/ml) in 68 newly treated IDDM from the first to the sixth month after the beginning of insulin therapy
Months
Type of insulin No. of subjects 1 2 3 6
Human 15 0.07" 0.1 0.1 0.05
0.03t 0.07 0.05 0.02
Porcine 28 0.07" 0.2 0.3 0.4
0.02t 0.08 0.07 0.09
Conventional 25 0.5" 0.8 1.2 1.7
0.2+ 0.2 0.3 0.3
H-P NS NS NS P < 0.05
H-C P < 0.05 P < 0.05 P < 0.025 P < 0.01
P-C P < 0.05 P < 0.002 P < 0.002 P < 0.005
H = human insulin, P = porcine insulin, C = conventional insulin. Statistical evaluation by Student's t test.
'Mean, tSEM.
and (4) circulating immune complexes using the conglutsnin
method (Kg-AgAh) described by Casali et a!.16 with minor
modifications.15
The determination of immune complexes and the char¬
acteristics and criteria used to establish positive limits of the
technique have been described elsewhere.8
Metabolic control was evaluated by assay of glycosylated
hemoglobin (HbA,) with column chromatography using the
Bio Rad kit (Bio-Rad, Richmond, California). The upper
limit of normal values in our laboratory was 9%, mtraassay
variation was 0.3% (HbA, < 7%) and 0.6% (HbA, > 7%),
and interassay variation was 0.8% and 1.4%, respectively-
Student's t test and Cox's trend test were used for statistical
evaluation of the data.
RESULTS
The prevalence of ICAb at the beginning of the investigation
was comparable in the three groups of patients (52% in group
1, 57% in group 2, and 52% in group 3). The metabolic
control after 6 mo treatment was similar in all three groups:
the mean HbA, was 9.4%, 9.2%, and 10.1%, respectively,
in groups 1, 2, and 3. The insulin requirement (Table 1) was
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TABLE 3
Prevalence of circulating immune complexes (Clq-AgAb) (%) in 68
newly treated 1DDM from the beginning of insulin treatment to the sixth
month of therapy
Months
Type of insulin No. of subjects 0 1 2 3 6
Human 15 40 40 27 20 13
Porcine 28 53 42 22 22 16
Conventional 25 46 33 25 25 14
similar in all three groups 15 days after the beginning of
insulin treatment, whereas after 6 mo a progressive rise was
observed from group 1 to group 3, but these differences were
not statistically significant.
Anti-insulin antibodies (1BC) (Table 2) at 6 mo were
significantly lower (P < 0.05) in patients in group 1 than
in group 2. The levels were significantly higher (P < 0.05-
0.002) in group 3 than in groups 1 and 2 from the end of
the first month onward. The prevalence of Clq-AgAb was
similar in the three groups of patients before the beginning
of insulin treatment, thereafter decreasing progressively to
reach, by 6 mo, values ranging between 13% and 16% (Table
3).
The prevalence ofKg-AgAb was similar in the three groups
before the beginning of insulin treatment (Table 4). At 6
mo the presence of Kg-AgAb remained practically constant
in groups 1 and 2, and rose significantly (P < 0.001) from
24% at the beginning of treatment to 44% at 6 mo of ob¬
servation in group 3.
DISCUSSION
Before the beginning of insulin treatment the threegroups of patients displayed similar prevalence ofiCAb, Clq-AgAb, and Kg-AgAb showing the sameimmunologic background. Two weeks after the be¬
ginning of insulin treatment, insulin requirement was also
comparable in the three groups. The present study confirms
a previous report" indicating that human monocomponent
insulin produces a lower insulin antibody response than por¬
cine monocomponent insulin in subjects never treated pre¬
viously with insulin.
The observed differences may be due to the primary struc¬
ture of these insulins. Howevet, it should be noted that the
amino acid in position 30 of the B-chain, which differentiates
human from porcine insulin, does not appear to be directly
involved in the immunogenic activity of the hormone. On
the other hand, since not only the primary structure but also
the steroisometric configuration define the immunogenic
characteristics of a polypeptide, the difference in only one
amino acid may change the spatial structure of a protein.
This modification may change the insulin capacity to induce
the formation of specific antibodies and to bind with them.
The difference in insulin antibody formation between groups
1 and 2 could also be explained by a difference in the genetic
background of the diabetic population studied. In effect,
subjects with HLA-D4 antigens produce more IgG insulin
antibodies to animal insulin than do patients with other HLA
antigens.Of interest, however, Schemthaner" found a
high prevalence of HLA-DR3 in patients producing IgG in¬
sulin antibodies against human monocomponent insulin. The
relevance of these observations to the current study remains
to be determined.
Circulating immune complexes assayed with Clq, which
have been previously shown to be correlated with the onset
of type 1 diabetes" and with the severe forms of microan¬
giopathy in both types of diabetes,8,20 do not appear to be
influenced by the type of insulin treatment employed. Tin-
observation would confirm earlier findings indicating tha
insulin is not a component of Clq-AgAb. The prevalence
of circulating immune complexes determined with the KgBt
technique appears, in contrast, to show a course dependent
on the type of treatment used. This behavior is probably due
to the positive correlation between Kg-AgAb and anti-in¬
sulin antibodies demonstrated elsewhere.21
Nevertheless, since there is no definite evidence to show
that insulin is to be found among the antigens present in the
Kg-AgAb complexes, we may only suspect that some anti-
insulin-insulin antibody immune complexes may be revealed
with KgBt. Whatever mechanism is involved, human insu¬
lins injected in man appear to induce a slight formation of
immune complexes when compared with the heterologous
insulins. The clinical importance of Kg-AgAb in diabetes
mellitus still remains to be defined inasmuch as the microan¬
giopathy processes have been shown to be correlated only
with the Clq-AgAb.
TABLE 4
Prevalence of circulating immune complexes Kg-AgAb (%) in 68 newly treated IDDM from the beginning of insulin treatment to the sixth month erf
therapy
Months
















* P < 0 001 (Cox's trend test).
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In conclusion, the present 6-mo trial suggests that equiv¬
alent glycemic control may be achieved with human mon-
ocomponent insulins at similar doses to those required with
porcine monocomponent insulins. Furthermore, human in¬
sulin is the least immunogenic of the present available in¬
sulins. No evidence of undesired side effects of human mon¬
ocomponent insulin was present.
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Insulin-anti-insulin complexes in diabetic women and their neonates
U.Di Mario, F. Fallucca, P.Gargiulo, C.Tibeni, A.Scardellato, P.Arduini, A. Pachi' and D.Andreani
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Summary, It is known that insulin does not cross the placenta,
whereas maternal anti-insulin antibodies do. We have there¬
fore investigated insulin antibodies and insulin-anti-insuim
complexes both in pregnant diabetic women during pregnan¬
cy and in umbilical cord blood from their ncw-bom infants.
Forty-seven diabetic pregnant women and 23 new-bom in¬
fants of these diabetic women were studied. All the pregnant
patients were studied at the end of pregnancy and, in 27, at
least on one other occasion during pregnancy. All the patients
were treated with insulin during pregnancy: 26 had Type 1 (in¬
sulin-dependent) diabetes, 14 Type 2 (non-insulin-dependent)
diabetes and seven had gestational diabetes. Insulin antibod¬
ies were found in 62% of the Type 1 diabetic patients, in 71%
of the Type 2 diabetic patients and in 43% of the gestational
diabetic patients. They were present tn 48% of the infants
studied. Insulin-anti-insulin complexes were found in 37% of
the women with Type 1 diabetes, in 21% of those with Type 2
diabetes and in 14% of those with gestational diabetes. Com¬
plexes were found in 38% of the new-born infants. The pres¬
ence of these complexes in the babies was more strongly
correlated with their occurrence in their mothers at the begin¬
ning than at the end of pregnancy. Insulin-anti-insulin com¬
plexes arc thus present in the neonatal circulation. They may
difTer from those in their mothers and they may have patho¬
physiological and clinical importance.
Key words: Insulin antibodies, insulin-anti-insulin complexes,
diabetic pregnancy.
Diabetic pregnancy is useful for the study of several im¬
mune phenomena. The immune system in normal preg¬
nancy is thought to be in a state of 'activation' rather
than in a state o&depression' [1], In diabetes, several im¬
munological abnormalities may be present and these
may be related to pathogenic events, metabolic de¬
rangement and insulin therapy [2].
In diabetic pregnancy, several immune phenomena
may be present ternporanly as a consequence of both
diabetes and pregnancy. Moreover, some abnormal im¬
mune factors can cross the placenta and interfere with
fetal metabolism and development. In particular, mater¬
nal antibodies to exogenous insulin may be transferred
to the fetal circulation, whereas maternal insulin does
not cross the placenta. The significance of insulin antty-
"^dies in fetal blood during the first months of fetal de¬
velopment and their possible pathophysiological effects
and interactions with fetal insulin are unclear and these
antibodies have not received the attention they merit.
In this study, we looked for the possible presence of
insulin-anti-insulin complexes in cord blood and ex¬
amined the relationships between these complexes in




\ total of 47 pregnant diabetic patients, all attending
.he same clinic, were studied. Twenty-three were in\esti¬
mated with their babies. All the pregnant patients were
ested at the end of pregnancy; 27 were also tested in the
first trimester of pregnancy. Twenty-six had Type 1 dia¬
betes, 14 Type 2 diabetes and seven gestational diabetes
All patients were treated with insulin, either monocom-
ponent or semi-synthetic human, except in two cases.
Infant cord blood was also studied.
Methods
Insulin antibodies, estimated as insunn binding capaci
ty, were evaluated by the method ofOrtved Andersen et
al. [3] as modified by Mustaffa et al. j4] with a few fur¬
ther minor modifications [5j. Values above lOmU/i
vere considered indicative of the presence of ant)bod- 4
tes.
Insulin-anti-insulin complexes were measured by a
modification of the techniques described by Jayarao et /
2
al. [6 ind Virella et al. [7]. Serum to be tested was split
into^aliquots. One aliquot was dialysed overnight in
buffer glycine-HCl (pH 3), added to dextran-charcoal
in glycine-HCl, incubated for 30 min at room tempera¬
ture, centrifuged and finally the supernatant was dia-
lyzed against barbital buffer, pH 774. To this mixture
and the other aliquot, adequately diluted, radiolabeled
insulin was added. After 2 h incubation at 37 CC, the ad¬
dition of dextrarycharcoal and centrifugation, the(su.-
pernatants and precipitates were counted.
The insulin-anti-insulin complexes were calcula*""1
as the difference between 'total' antibody and 'free"'ir>-:
tibody. 'Total' and 'free' antibodies were calculated as'
follows:^ 100— (cpm in the precipitate — cpm in the
•upernatant/total cpm) x 100 — background. Positive
. alues/were taken as>mean + 2SD of normal values
and are expressed as.a percentage (i.e.> 10%). Positive
values of insulin/anti-insulin complexes were>
mean -t- 2 SD of values found in normal subjects (i.e. >
'%). The sensitivity of this technique in assaying the
tole presence of insulin antibodies was slightly different
from Andersen's method [3] (Table 1).
Fisher's exact test was used for statistical evaluation.
Results
Insulin antibodies
Diabetic mothers: Insulin antibodies were found at the
end of pregnancy in 62% of the Type 1 diabetic patients
(median 15.5 mU/1, interquartial range^frlO-45 mU/1),
in 71% of the Type 2 diabetic patients (median
26.5 mU/1; interquartial range -^10-79 mU/1) and in
43% of the gestational diabetic patients (median
10mU/1, interquartial range -j^lO-13 mU/1). No signify
cant difference was found when the levels of insulin(an^
tibodies in the Type 1 diabetic patients at the beginning
of pregnancy (median 18mU/l, interquartial range
10-43 mU/1) were compared with those at the end of
pregnancy.
Aeonates: Insulin antibodies were found in 48% of the
neonates studied. Their levels were similar in the
neonates (median^ 10 mU/1, interquartial ranged
10-28 mU/ lj and in the mothers at the end of pregnan¬
cy (mediaf'mU/1, interquartial ranged 10-30mU/l;
Table 1). \
Insulin-anti-insuiin complexes
Mothers: Quantifiable insulin-anti-insulin complexes
were found in 37% of the Type 1 diabetic patients at the
beginning of pregnancy (median/^7%, interquartial
range $7-13.3%) and in 27% of the Type 1 diabetic pat¬
ients at the end of pregnancy (median£^7%, interquar¬
tial range ^7-7.1%). Complexes were also present in
21% of the Type 2 diabetic mothers at the end of preg¬
nancy (three patients: 8%, 9%, 82%) and in 14% of ges¬
tational diabetic patients (one patient: 8%).
Neonates: InsuJin-anti-insulin complexes were present
in the infants of diabetic mothers (38% of infants of
Type 1 and 43% of Type 2 diabetic mothers; Table 1).
There was a significant correlation between the pres¬
ence of the complexes in neonates and their occurrence
in their mothers, and this correlation was much stronger
when the data in neonates were correlated with data
from the mothers in the first trimester of pregnancy
(p <0.0005) than at the end of pregnancy (p <0.01).
Discussion
|
IThis study shows that insulin-anti-insulin complexes
■ are present in the circulation of some infants of Type 1
■ diabetic mothers. The amount of complexed anti-insu¬
lin antibody is related not only to the total amount of
the antibody, but is also related to the affinity and avid/7 /
■y of the maternal insulin antibody.
i There was a strong correlation between the presence
of complexes in cord blood and in the maternal circula-
Ition. However, their presence in the fetus does not
imerely represent passive transfer of insulin antibodies
across the placenta. The levels of the complexes in the
I neonate do not reflect those of the mother at the end of
: pregnancy, but the average complex levels throughout
I pregnancy.
j Insulin antibodies can easily cross the placenta,
whereas f insulinf is fnot f transferred Hnt significant
amounts. In the fetus, these antibodies react with a dif¬
ferent antigen, fetal endogenous insulin, rather than ex-
jogenous heterologous insulin as in the mother. The anti-
jgen/antibody molar ratio is substantially different. In
Ithe mother, the antibody reacts with massive doses of
jinsulin, of either high or low immunogenicity. adminis¬
tered in subcutaneous boluses, often twice a day, while
i in the fetus, it reacts with continuously produced pan¬
creatic insulin. The amount of insulin produced by the
I fetal pancreas varies greatly between the first months cj
'gestation until term, whereas the amount of insulin.-an-
tibodies crossing the placenta does not usually vary sig¬
nificantly during pregnancy. From a situation probably
characterized by antibody excess at the beginning of
pregnancy, the proportion between antigen and antiif>- .
i^dy becomes more balanced, as the fetal pancreas pro¬
duces increasing amounts of insulin.
It is likely that both the fate and the significance of
the fetal insulin-anti-insulin complexes are different
from those of the mother.
Clearance of fetal complexes seems slower than that
i in the mother. It is not known whether insulin antjbod- .
i ies in fetal circulation may be easily retransferred to the
; maternal circulation, but it is unlikely that the com¬
plexes are freely exchanged.
Whereas, in the mother, small to medium size com-
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plexes are rapidly removed by the kidney and the re(I-
"|ulo-endothe!ial system [8], in the fetus, clearance is not
as efficient, particularly in the infants of diabetic moth¬
ers in whom the duration of gestation is often short¬
ened. This could explain why, in those few cases in
which the insulin antibody levels are high in the mother
; at the beginning of pregnancy and low at the end, the
insulin-anti-insulin complex levels in the fetus are com¬
parable to those found in the mother in the first months
of pregnancy.
Our group and others have a correlation be¬
tween the presence of insulin antibodies and aTaek of
; neonatal complications [9-13]. On the other hand, the
possible damage induced by the deposition and pres¬
ence of immune complexes is well known, both in dia¬
betic patients [6, 14] and in pregnant women with clini¬
cal complications [15, 16]. Moreover, it is well known
that the injection of insulin antibodies may induce a
diabetic-like syndrome in normal animals [17]. The
presence of insulin-anti-insulin complexes may theoret¬
ically interfere with the placenta! circulation and ex¬
plain some of the neonatal complications of diabetic
pregnancy, in particular macrosomia and neonatal hy-
ipoglvcaemia with neutralising or abrupt release of sub¬
stantial amounts of neonatal insulin.
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